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ABSTRACT 
Background: Smoking in pregnancy is the most significant preventable cause of 
poor health outcomes for women and their babies and, therefore, is a major 
public health concern. In the UK there is a wide range of interventions and 
support for pregnant women who want to quit. One of these is nicotine 
replacement therapy (NRT) which has been widely available for retail purchase 
and prescribing to pregnant women since 2005.  However, measures of NRT 
prescribing in pregnant women are scarce. These measures are vital to assess 
its usefulness in smoking cessation during pregnancy at a population level. 
)XUWKHUPRUHHYLGHQFHRI157VDIHW\LQSUHJQDQF\IRUWKHPRWKHUDQGFKLOG¶V
health so far is nebulous, with existing studies being small or using 
retrospectively reported exposures.   
Aims and Objectives: The main aim of this work was to assess population-
level estimates of maternal smoking and NRT prescribing in pregnancy and the 
safety of NRT for both the mother and the child in the UK. Currently, the only 
population-level data on UK maternal smoking are from repeated cross-sectional 
surveys or routinely collected maternity data during pregnancy or at delivery. 
These obtain information at one point in time, and there are no population-level 
data on NRT use available. As a novel approach, therefore, this thesis used the 
routinely collected primary care data that are currently available for 
approximately 6% of the UK population and provide longitudinal/prospectively 
recorded information throughout pregnancy. The specific objectives for this 
thesis were: 
x To assess the quality of  smoking data recorded during pregnancy in primary 
care  
x To quantify annual NRT prescribing trends in and around pregnancy and 
describe the characteristics of mothers prescribed NRT 
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x To assess the association between NRT and smoking exposure during 
pregnancy and major congenital anomalies (MCAs), stillbirth,  low birth 
weight and mode of delivery 
Methods: All women aged 15-49 years, with pregnancies ending in live or 
stillbirth, were identified from The Health Improvement Network (THIN) primary 
care database (2000-2009). Medical Read codes related to smoking status and 
Multilex smoking cessation drug prescription codes were used to extract data on 
ZRPHQ¶VVPRNLQJVWDWXVDQG157SUHVFULSWLRQV. The proportion of pregnancies 
with a smoking status record was calculated and logistic regression was used to 
assess how this vDULHGE\ZRPHQ¶VFKDUDFWHULVWLFV. Women were categorised as 
being smokers or non-smokers during pregnancy based on the recorded Read 
codes. Where smoking data were missing during pregnancy, smoking status 
recorded before pregnancy (up to 27 months before pregnancy, ever before 
pregnancy) was used as a proxy for smoking status during pregnancy. Annual 
smoking measures from THIN were then compared to other national datasets. 
Pregnancies ending in early fetal losses were not included for calculating 
smoking prevalence, as these outcomes can go unrecognised or can be the first 
recognised sign of pregnancy, making early ascertainment of all pregnancies 
uncomprehensive; this was also broadly in line with pregnancy ascertainment in 
the other national datasets. Prescribing prevalence of NRT and patterns of 
prescribing in terms of frequency, timing and different form of NRT were 
DVVHVVHG/RJLVWLFUHJUHVVLRQZDVXVHGWRDVVHVVZRPHQ¶VOLNHOLKRRGRIUHFHLYLQJ
NRT prescriptions by maternal characteristics. Absolute and relative risks (99% 
Confidence Interval (CI)) for four birth outcomes (MCAs, stillbirth, low birth 
weight and mode of delivery) were calculated for women prescribed NRT 
(defined as the NRT group) and women who continued to smoke during 
pregnancy (defined as smokers) compared to women who did not smoke during 
pregnancy (defined as non-smokers) with appropriate adjustments for potential 
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confounders. To assess MCAs and birth weight in relation to NRT and smoking a 
restricted cohort of children was used who had maternal-child linked records in 
THIN. 
Results: There were 277,552 pregnancies in 215,703 women, of which 28% 
had a gestational smoking status record. In 2000, smoking status was recorded 
in 9% of pregnancies; 43% in 2009. Smoking estimates from THIN data did not 
completely agree with estimates from other sources. For example, in 2009 
smoking prevalence was 12.9% in THIN, compared to 19.5% in Child Health 
Systems Programme (CHSP) data. However, the use of smoking data recorded 
up to 27 months before conception increased the THIN prevalence to 22.9%, 
which was slightly higher, but compared better with the CHSP estimates. 
NRT was prescribed in 4,826 pregnancies for an average duration of 2 weeks 
(Interquartile range 1-2 weeks), which represented 2% of all pregnancies (11% 
in smokers). NRT prescribing prevalence before and after pregnancy was half the 
prevalence during pregnancy.  NRT prescribing increased with socioeconomic 
deprivation (Odds Ratio (OR) =1.33, 95% CI 1.14-1.52) for the most compared 
to the least deprived group). Prescribing was higher in pregnant smokers with 
asthma (OR=1.34, 95% CI 1.21-1.50) and mental illness (OR=1.29, 95% CI 
1.18-1.43) compared to smokers without these diagnoses.  
The absolute risk of MCA was 279/10,000 live births. Compared with non-
smokers the adjusted OR for MCA in the NRT group was 1.34 (99% CI 0.94-
1.91). No statistically significant increase in the risk of MCA for the NRT group 
was found when the reference group was changed to smokers (OR=1.35, 99% 
CI 0.94-1.93).The absolute risk of stillbirth was 4/1000 live and stillbirths. 
Compared with non-smokers the adjusted OR for stillbirth in the NRT group was 
1.19 (99% CI 0.47-3.01). In smokers, the risk of stillbirth increased by 27% 
compared to non-smokers (OR 1.27, 99% CI 1.01-1.60). The mean birth weight 
4 
 
was 3.41kg (standard deviation 0.59) and the absolute risk of low birth weight 
was 6.4%. Compared to non-smokers, the risk of women having low birth 
weight babies was 93% higher in the NRT group (OR 1.93, 99% CI 1.48-2.53). 
However, there was no statistically significant increase in the risk of low birth 
weight in the NRT group compared with smokers. There was no increased risk of 
assisted delivery or caesarean section in the NRT group compared to smokers. 
However the risk of assisted delivery decreased by 25% in the NRT group 
(Relative Risk Ratio 0.75, 99% CI 0.60-0.93) compared to non-smokers.   
Conclusion: The completeness of smoking status recording during pregnancy in 
primary care data is improving; however, under-recording of smoking status 
during pregnancy still results in unreliable estimates of the prevalence of 
smoking in pregnancy and needs improvement. Pre-conception smoking records 
are reasonably complete and it is possible that low recording in pregnancy is 
EHFDXVHDZRPDQ¶VVPRNLQJVWDWXVKDVQRWFKDQJHG or that increased 
interaction with other health services, such as midwifery, during pregnancy 
means women are less likely to be asked about their smoking by their primary 
physician and information on their smoking does not get relayed back to their 
primary care record. Nevertheless records should be updated in pregnancy to 
ensure comprehensive health care. NRT was most commonly prescribed in 
pregnancy for about two weeks, which may not be adequate time for effective 
smoking cessation. Nevertheless, prescribing was higher during pregnancy 
compared to the nine months before and after pregnancy, which makes 
establishing its safety during pregnancy even more crucial. The safety studies in 
this thesis did not find NRT to be any more harmful than smoking during 
pregnancy if not beneficial. Considering that smoking in pregnancy remains one 
of the largest public health problems in the UK, improvements of antenatal and 
postnatal smoking in primary care may not only help identify women for 
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preventive measures earlier but would be invaluable for safety studies 
considering the outcomes are rare yet severe. 
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1 INTRODUCTION 
1.1 HEALTH EFFECTS 
Smoking in pregnancy is the most significant preventable cause of poor health 
outcomes for women and their babies.1,2 Approximately one-third of all perinatal 
deaths in the United Kingdom (UK) are attributable to smoking.3 In the United 
States of America (USA) maternal smoking in pregnancy increases infant 
mortality by 40% and approximately 5% of infant deaths in the USA have been 
attributable to maternal smoking.4  It not only affects perinatal outcomes 
adversely but has also been related to problems in later childhood as discussed 
below.  
  
1.1.1 Obstetric and perinatal complications 
Maternal smoking during pregnancy causes a myriad of obstetric and perinatal 
complications. Some of the most important complications are discussed below.  
 
1.1.1.1 Placental complications  
Smoking during pregnancy reduces blood flow to the uteroplacental fetal unit 
and results in higher frequency of placental abruption.5 Additionally, it has been 
linked to placental enlargements and increased placental weight consequently 
increasing the risk of placenta previa.6 A meta-analysis of 13 published studies 
presented a pooled odds ratio (OR) of 1.90 (95% Confidence Interval (CI) 1.8-
2.0) for placental abruption associated with maternal smoking.7 Furthermore, 
data from the Swedish Medical Birth Registry including about 2 million births 
reported 53% greater risk of placenta previa in smokers compared to non-
smokers in a dose-dependent manner.8 Cigarette smoking during pregnancy is 
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also an independent risk factor for pre-term premature rupture of membranes 
(PPROM)9 with a 70% increase in the risk (OR 1.70, 95% CI 1.18-2.25).10  
 
1.1.1.2 Low birth weight 
In developed countries, maternal smoking is one of the major risk factors for low 
birth weight (a birth weight of  less than 2500g11).12 A proposed mechanism 
behind this is the reduced uterine blood flow and fetal hypoxia caused by 
smoking.13,14 A study including 5,166 live births occurring in Pelotas, Brazil found 
an increased risk of low birth weight associated with maternal smoking during 
pregnancy (OR 1.45, 95% CI 1.30-1.95).15 A case-control study from Boston 
based on 207 cases of low birth weight and 534 controls found the risk of having 
low birth weight babies to be twice as high in smokers compared to non-smokers 
(OR 2.1, 95% CI 1.2-3.7).16 Similar effect estimates were found in another 
study based on 6,284 singleton live births in Switzerland.17  Another cohort 
study from the UK using the Millenium Cohort data found similar risk of low birth 
weight associated with maternal smoking during pregnancy (OR 1.92, 95% CI 
1.60-2.29)18  More recent data from Johannesburg and Soweto report that the 
birth weight of infants with smoking mothers was 165g less than of infants with 
non-smoking mothers.19 Even more recent data from Sweden suggest a dose 
response relationship between maternal smoking and low birth weight such that 
for light smokers (1-9 cigarettes per day)  the birth weight of infants reduced by 
162g and for heavy smokers (> 9 cigarettes per day) birth weight reduced by 
226g compared to non-smokers.20  
 
1.1.1.3 Preterm birth 
In the 2010 report on global, regional and national causes of child mortality 35% 
of neonatal deaths were attributable to preterm birth,21 making it one of the 
most important contributors to infant deaths worldwide.22 Cigarette smoking 
during pregnancy is one of the few modifiable risk factors for preterm birth.23 A 
24 
 
systematic review of 20 prospective studies on maternal cigarette smoking and 
preterm birth reported 27% increased risk of preterm birth associated with 
gestational cigarette smoking.24 A more recent case-control study from Italy 
based on 299 cases of preterm birth found that the adjusted ORs were 1.54 and 
1.69 for preterm babies and 1.90 and 2.46 for early preterm babies for 1±10 
and more than 10 cigarettes/day respectively.25 Another case-control study from 
10 European countries found that the odds of preterm birth increased by 40% in 
smoking mothers (OR 1.39, 95% CI 1.20-1.60).26 
   
1.1.1.4 Ectopic pregnancy 
Ectopic pregnancy results when the fertilised egg is implanted outside the 
uterus.10 A meta-analysis of nine studies assessing adverse pregnancy outcomes 
in relation to maternal smoking reported a pooled OR of 1.77 (95% CI 1.31-
1.22) for ectopic pregnancy among smokers.10 A more recent case-control study 
from France including 803 cases of ectopic pregnancy and 1,633 deliveries found 
a dose response relationship with quadrupling riVNLQZRPHQVPRNLQJ
cigarettes per day compared to non-smokers.27  
 
1.1.1.5 Birth defects/ congenital anomalies  
Literature suggests an association between maternal smoking in pregnancy and 
several major congenital anomalies (MCAs). A systematic review based on 
173,687 congenital anomaly cases and 11.7 million controls demonstrated an 
increased risk of heart defects (OR 1.09, 95% CI 1.02-1.17), musculoskeletal 
defects (OR 1.16, 95% CI 1.05-1.27), limb defects ( OR 1.26, 95% CI 1.03-
1.73), orofacial clefts (OR 1.28, 95% CI 1.20-1.36), gastrointestinal defects (OR 
1.27, 95% CI 1.18-1.36) and other defects associated with maternal smoking 
but  no increase in the risk of all major anomalies combined (OR 1.01, 95% CI 
0.96-1.07).28 
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1.1.1.6 Stillbirth and miscarriage 
Cigarette smoking during pregnancy is known to cause fetal growth restriction 
leading to stillbirth. A recent meta-analysis of four studies found a 36% 
increased risk of stillbirth (OR 1.36, 95% CI 1.27-1.46).29  Another meta-
analysis of 25 observational studies reported the risk of miscarriage to be 32% 
higher in women who smoke during pregnancy compared to non-smokers 
(pooled O 1.32, 95% CI 1.21-1.44). 30 
 
1.1.1.7 Caesarean section 
Evidence of the relationship between maternal smoking and mode of delivery is 
inconclusive to date. A cross-sectional analysis of 170,254 pregnancies delivered 
in Schleswig-Holstein, Germany between 1991 and 1997 reported no statistically 
significant difference in caesarean delivery between non-smokers and smokers.31  
However, a recent study conducted in Israel, including approximately 6000 
pregnancies reported the risk of any operative or instrumental intervention to be 
higher in smokers  compared to non-smokers OR 1.24 (95% CI 1.01±1.52).32 
 
1.1.1.8 Sudden infant death syndrome (SIDS) 
Published data support a dose-response relationship between maternal smoking 
during pregnancy and SIDS. A systematic review of 31 studies on maternal 
smoking and SIDS reported a twofold increase in the risk of SIDS associated 
with maternal smoking (OR 2.06, 95% CI 1.83-2.38).33 Additionally, smoking in 
the postpartum period was also found to double the risk of SIDS (pooled OR 
1.94, 95% CI 1.55-2.34). More recent data from another meta-analysis of 35 
case-control studies reported similar risks for smoking during pregnancy (OR 
2.25, 95% CI 2.03-2.50) and in the postpartum period (OR 1.97, 95% CI 1.77-
2.19) .34 The effects of cigarette smoking on cardiovascular and respiratory 
systems are said to play a key role in predisposition to SIDS in infants.13  
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1.1.2 Problems in early childhood and adolescence  
Maternal smoking in pregnancy has also been linked to several problems for a 
FKLOG¶VKHDOWKLQHDUly childhood and adolescence. These problems are further 
aggravated by second hand smoke (SHS) exposure if the mothers continue to 
smoke or relapse after delivery. Some of these problems are discussed below. 
 
1.1.2.1 Respiratory problems 
Smoking during pregnancy has been shown to reduce lung function in children. 
A cohort study including 58,841 births in Finland reported 35% greater risk of 
asthma in in children under the age of seven whose mothers smoked more than 
10 cigarettes per day during pregnancy (OR 1.35, 95% CI 1.13-1.62) and 23% 
increased risk in children whose mothers smoked less than 10 cigarettes per day 
(OR 1.23, 95% CI 1.07-1.42) compared to children of non-smoking mothers.35 A 
meta-analysis of 79 observational studies assessing the association between 
prenatal and passive smoke exposure on asthma and wheezing found that 
maternal smoking during pregnancy increased the risk of asthma by 85% 
(pooled OR 1.85, 95% CI 1.35-2.53) and the risk of wheezing by 41% (OR 1.41, 
95% CI 1.19-LQFKLOGUHQ\HDUV([SRVXUHWRpostnatal maternal 
smoking was also associated with a 70% increased risk of wheezing in children 
\HDUV25&,-2.35) and a 21% increase in the risk of 
asthma (Hazard Ratio (HR) 1.21, 95% CI 1.01-1.45).36  
  
1.1.2.2 Cancer (Leukaemia, Central nervous system tumours, lymphomas) 
Leukaemia, central nervous system (CNS) tumours and lymphomas account for 
more than two-thirds of all cancers diagnosed in children.37 A meta-analysis of 
30 studies on the association between maternal tobacco use during pregnancy 
and childhood cancer suggested a 10% increase ( OR 1.10, 95% CI 1.03-1.19) 
in all cancers  however no significant associations were found for leukaemia and 
CNS tumours.38 A more recent meta-analysis including a total of 6,566 patients 
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from 12 observational studies also did not show a clear association between 
maternal smoking during pregnancy and development of brain tumours in 
children (Risk Ratio (RR) 1.05, 95% CI 0.90-1.21).39 However, another meta-
analysis exploring the association between childhood lymphoma and smoking 
during pregnancy found a 22% increase in the risk of non-Hodgkin lymphoma 
associated with maternal smoking during pregnancy (OR 1.22, 95% CI 1.03-
1.45, n=7 studies).40  
 
1.1.2.3 Obesity/ Overweight 
Childhood obesity has become a health concern in many countries including the 
UK and the US.41 Women who smoke during pregnancy are more likely to have 
EDELHVZLWKORZELUWKZHLJKW7KHVHLQIDQWVRIWHQVKRZJUHDWHUµFDWFK-XS¶JURZWK
resulting in childhood obesity.42 A meta-analysis of 17 observational studies 
found that babies of mothers who smoked during pregnancy were 64% more 
likely to develop childhood obesity compared to babies of non-smokers.43     
 
1.1.2.4 Ear infections 
A prospective study including 8,556 pregnant women and their babies found the 
prevalence of otitis media to be higher in children of mothers who smoked 
during pregnancy such that children of mothers who smoked 1-9 cigarettes 
during pregnancy were 60% more likely to develop acute ear infection in the 
first five years of life compared to children of non-smoking mothers. In 
comparison, odds ratio for developing acute ear infection is reported to be 2.6 
(95% CI 1.6-4.2) and 3.3 (95% CI 1.9-5.9) in children of mothers who smoked 
10-19 and more than 20 cigarettes during pregnancy respectively.44 Maternal 
smoking after pregnancy has also been shown to increase the risk of middle ear 
infections in children by 62% (OR 1.62, 95% CI 1.33-1.97) in a meta-analysis of 
20 studies.45   
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1.1.2.5 Cognitive and behavioural problems 
Prenatal smoking exposure in children has been associated with reduced 
cognitive abilities and academic achievements.46 A Swedish study on over 
375,000 adolescents found that children whose mothers smoked during 
pregnancy had an increased risk of poor school performance after controlling for 
maternal and birth characteristics (1-9 cigarettes per day OR 1.59, 95% CI 
1.55-FLJDUHWWHVSHUGD\25-1.98).47 A systematic 
review of studies conducted over a 30 year period between 1973 and 2002 
demonstrated a link between smoking during pregnancy and attention deficit 
hyperactivity disorder (ADHD) in children.48 The odds of developing antisocial 
behaviour in children with prenatal smoking exposure are shown to be 1.5-4 
times greater than unexposed children.49  Furthermore, children with prenatal 
tobacco exposure have also shown to have 30-40% higher risk of psychiatric 
hospitalisations for substance abuse.50 
 
1.1.2.6 Diabetes 
The British National Child Development Study examined the association between 
maternal smoking during pregnancy and the risk of diabetes in children and 
found that the risk of type 2 diabetes in children increased by 11% (OR 1.11, 
95% CI 0.31-4.04) for light smokers and quadrupled for heavy smokers (OR 
4.55, 95% CI 1.82-11.36).51  
 
  
1.2 ECONOMIC BURDEN 
Smoking during pregnancy also imposes a substantial economic burden on 
society. A report by the Public Health Research Consortium (PHR) in 2010 
suggested that costs to the UK National Health Services (NHS) related to 
maternal outcomes associated with smoking are estimated to be between £8 
million and £64 million per year based on different costing methodologies. 52 
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)XUWKHUPRUHFRVWVUHODWHGWRLQIDQWV¶LQFUHDVHGULVNRISUHWHUPGHOLYHU\low 
birth weight, SIDS, perinatal mortality, asthma, otitis media, and upper and 
lower respiratory infections are estimated to be between £12 million and £23.5 
million per year.52 A study conducted by Petrou and colleagues (2005) in the UK 
looking at the association between maternal smoking and hospital inpatient 
costs in childhood found that after adjusting for clinical and socio-demographic 
factors, the mean cost difference when comparing infants born to women who 
smoked at least 20 cigarettes per day to infants of non-smoking mothers was 
£462, over the first five years of life. When infants born to women smoking 10-
19 cigarettes per day were compared to infants of non-smoking mothers this 
difference was £307.53  
 
1.3 SMOKING IN PREGNANCY ± CURRENT PREVALENCE 
1.3.1 International picture 
Smoking in pregnancy has become a global public health issue, especially in 
developed countries. Despite the harms associated with maternal smoking 
during pregnancy the prevalence of smoking during pregnancy across developed 
countries still remains high with the prevalence ranging between 10-15% in 
USA, Canada, Australia and Japan.54-57 Within Europe, the prevalence figures 
vary from low figures of <5% in Lithuania and Sweden to as high as 17% in 
France.58  
 
1.3.2 National prevalence and trends over time in the UK 
1.3.2.1 Trends over time 
There are four sources in the UK which collect data on smoking in pregnancy. 
Some of these cover all pregnancies whilst others collect data on a sample of 
women to capture self-reported smoking status at one or more time points 
during pregnancy. The Infant Feeding Survey (IFS) 2010, which randomly 
samples births in the UK every 5 years and measures smoking at delivery 
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retrospectively at six to eight weeks postpartum in the UK showed that 26% of 
women smoked before or during pregnancy and 12% smoked throughout 
pregnancy.59  The Smoking at the Time of Delivery (SATOD) data, is collected in 
maternity wards by midwives  and  measure smoking behaviour at the time of 
delivery in England, reported 12.6% women to be smoking at the time of 
delivery in England in 2012.60 Data from the Scottish Morbidity Records (SMR) 
collected in antenatal clinics, which measure smoking at the time of first 
antenatal appointment report slightly higher prevalence compared to the other 
two data sources (19.3%).61  The Child Health System Programme Pre-School 
component (CHSP-PS) data collected by health visitors approximately 10 days 
postpartum from Scotland report similar prevalence of maternal smoking during 
pregnancy (17.1%) in 2012.61  
Figure 1-1 summarises the trends in smoking prevalence during pregnancy in 
the UK from 1985 to 2012 from the available data sources and the time at which 
smoking status was assessed in each of these data. Overall there has been a 
reduction in smoking prevalence during pregnancy in the past two decades and 
all the data sources reflect a downward trend in maternal smoking during 
pregnancy. The earliest measures of smoking during pregnancy are obtained 
from the IFS. According to the IFS, 39% of women smoked before pregnancy 
and 30% smoked during pregnancy in 198562 which has now reduced by over 
50% with about 12% women smoking throughout pregnancy.59  In addition to 
these routinely collected data and the IFS, the Health Education Authority (HEA), 
now part of the National Institute for Health and Clinical Excellence (NICE), also 
conducted a series of small surveys between 1992 and 1999 and found that the 
prevalence of smoking in pregnancy reduced from 26% in 1992 to 22% in 1998 
but then peaked at 30% in 1999 with small fluctuations in the prevalence during 
the entire seven year period. A potential explanation for this paradoxically high 
prevalence in 1999 and fluctuations in the prevalence could be the sampling 
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method for the survey. Women were selected using quota sampling as opposed 
to probability sampling and also the sample sizes for each of these surveys only 
ranged from 625-1100 pregnant women,63,64 which makes the findings less 
generalisable.   
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Figure 1-1- Trends in maternal smoking during pregnancy from available data 
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1.3.2.2 Smoking and socio-demographic characteristics 
Maternal smoking prevalence during pregnancy varies by age. According to the 
IFS 2010 35% of pregnant women in the younger age group (< 20 years) 
smoked throughout pregnancy compared to 9% of pregnant women in the older 
age group (> 35 years). Results from SMR data also indicate a similar trend 
where the prevalence of current smoking in pregnant women younger than 20 
years was 38.2% compared to 12.8% in pregnant women over 40 years in 
2010.  
There is also a marked social gradient in the prevalence of smoking during 
pregnancy. Data from IFS 2010 showed that 4% of pregnant women in the 
managerial/ professional group smoked throughout pregnancy in comparison to 
20% of pregnant women in the routine/manual group. 59  
 
1.4 SMOKING CESSATION DURING PREGNANCY 
1.4.1 Benefits of smoking cessation during pregnancy 
McBride and colleagues suggest that pregnancy may be a teachable moment for 
smoking cessation where there is an increased perception of risk which prompts 
strong emotional responses and triggers cessation.65 Therefore, a higher 
proportion of women stop smoking during pregnancy than at other times in their 
lives.65 Smoking cessation during pregnancy is associated with reductions in 
various maternal and fetal complications in addition to the general health 
benefits. A prospective cohort study conducted in New Zealand and Australia on 
2,504 pregnant women suggested that women who stopped smoking before 15 
weeks of gestation had similar rates of spontaneous preterm birth and small for 
gestational age infants as those in non-smokers, indicating that these adverse 
outcomes can be reduced by quitting early in pregnancy.66 Another study from 
Sweden using the Swedish Birth Register concluded that stopping smoking 
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between the first prenatal care visit and the 32nd week of gestation prevented 
smoking-associated deficits in birth weight, head circumference and brain-to-
body weight ratio.67 These findings are supported by another study from Taiwan 
using the Pregnancy Risk Assessment Monitoring System (PRAMS) data which 
found that the babies of mothers who quit smoking during the first trimester 
weighed 168 g more than the babies born to smokers and there was no 
difference in birth weight between babies born to women who quit and never 
smokers (p-value 0.63).68 A Cochrane review has shown that smoking cessation 
interventions reduce low birth weight by 17% (RR 0.83, 95% CI 0.73-0.95, 
n=16 studies) and preterm birth by 14% (RR 0.86, 95% CI 0.74-0.98, n=14 
studies).69 A study based on a USA 1995 birth cohort reported that using 
smoking cessation interventions to reduce maternal smoking during pregnancy 
would prevent 108 cases of SIDS annually, which equated to 3.5% of overall 
SIDS deaths in the USA.70   
Apart from these health benefits smoking cessation during pregnancy may also 
generate financial benefits for the NHS.  It is estimated that spending between 
£13.60 and £37 on smoking cessation interventions per pregnant smoker would 
yield positive cost savings for the NHS.52 A study conducted in the USA on 227 
pregnant smokers found that for every $1 spent on smoking cessation for 
pregnant women, as estimated $3 in neonatal intensive care costs can be 
saved.71 Another American based study found that an annual drop of a single 
percentage point in maternal smoking prevalence during pregnancy would 
prevent 1300 low birth weight live births and save $21 million in direct medical 
costs.72   
 
1.4.2 Smoking cessation interventions for pregnant women  
Given the harms of maternal smoking during pregnancy and benefits of 
cessation, the World Health Organization (WHO) recently produced guidelines for 
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the prevention and management of tobacco use and second-hand smoke 
exposure during pregnancy. These guidelines recommend all healthcare 
providers to ask pregnant women about their tobacco use as early as possible in 
the pregnancy and at every antenatal care visit and to offer advice and 
psychosocial interventions for tobacco cessation to all pregnant women who are 
smokers or recent quitters.73 No recommendations were made on the use of 
nicotine replacement therapy (NRT) during pregnancy due to the lack of 
evidence of the safety, efficacy and adherence to the treatments (see Section 
1.5 for further details). Other drugs that are licensed as smoking cessation aids 
for the general population (bupropion and varenicline) are not currently 
recommended for use during pregnancy. Table 1-1 summarises the different 
psychosocial interventions currently used/evaluated for smoking cessation in 
pregnant women and the evidence for effectiveness of each intervention. 
Currently financial incentivisation, counselling and self-help are shown to be 
effective for smoking cessation during pregnancy. There is mixed evidence on 
the effectiveness of other psychological interventions in pregnancy such as 
feedback and social support. 
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Table 1-1 ± Psychosocial interventions for smoking cessation in pregnant women and evidence for effectiveness 
Interventions Description Evidence 
Cognitive behavioural therapy x Scheduled face-to-face meetings between 
pregnant smokers and specialist adviser which 
may take place individually or in groups typically 
over a period of at least 4 weeks after the quit 
date74 
A systematic review of 86 trials assessing psychosocial 
interventions for smoking cessation reported that 
pregnant women provided behavioural counselling such 
as CBT or MI were 44% more likely to be abstinent in 
late pregnancy compared to pregnant women given 
usual care (RR 1.44, 95% CI 1.19-1.75) and women 
receiving less intensive interventions (RR 1.35, 95% CI 
1.00-1.82).75  
Motivational interviewing x Directive, client-centred counselling style for 
eliciting behaviour change, with a focus to help in 
exploration and resolution of ambivalence 
regarding smoking cessation.76  
x Aims to increase the likelihood of making an 
DWWHPSWWRFKDQJHDSHUVRQ¶VKDUPIXOEHKDYLRXU 
x ranges from brief 20 minutes face to face sessions 
to telephone and group consultations etc. 77 
Self-help materials x Written materials such as booklets but also 
includes videos or audiotapes78  
x Offered to pregnant women who are referred to 
Stop Smoking Services (SSS) 
x Women who opt-out of SSS are also offered these 
self-help materials79 
x May also be supplemented by telephone 
counselling or quit lines74 
x Wide-reaching as they can be easily disseminated 
x Low-cost 
A meta-analysis of 12 trials assessing self-help 
interventions for smoking cessation in pregnant women 
reported that pregnant women who were given self-
help material were 83% more likely to quit compared 
to women given usual care including brief intervention 
(pooled OR 1.83, 95% CI 1.23-1.73)80 
 
Interventions based on stages of change theory ± 
µWUDQVWKHRUHWLFDOPRGHO¶ 
x The core of the transtheoretical model of 
behaviour change and acts as a basis for 
behavioural counselling for smoking cessation81 
x Five stages of change i.e. pre-contemplation, 
contemplation, preparation, action and 
maintenance.82  
x Tool to develop individually tailored 
communications for smoking cessation in form of 
counselling and self-help materials etc. 
Mixed evidence regarding the success of interventions 
EDVHGRQCVWDJHVRIFKDQJH¶WKHRU\79  
Lumley and colleagues reported a pooled RR of 0.99 
(95%CI 0.97-1.00) for smoking cessation in late 
pregnancy for interventions based on `stages of 
FKDQJH¶WKHRU\69 Less emphasis was placed on `stages 
RIFKDQJH¶LQWKHXSGDWHGUHYLHZDQGWKHLQWHUYHQWLRQV
were broadly categorised as counselling interventions 
in the new review. 75 
 
Financial incentivisation x 7KRXJKWWRLQIOXHQFHLQGLYLGXDO¶VPRWLYDWLRQDQG
self-regulation and also increase health 
SURIHVVLRQDOV¶HQJDJHPHQWZLWKSDWLHQWV83. These 
include incentives such as gift and other vouchers 
Women who were offered incentives used the services 
more than women not incentivised. Furthermore, 
women from the incentivised group reported the 
experience motivating for their smoking cessation83  
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Interventions Description Evidence 
or payments75 The four trials with financial incentives as the main 
intervention compared to usual care showed a three-
fold increase in the abstinence in late pregnancy (RR 
2.95, 95% CI 1.55-5.63), however the trials included 
are from the USA75 
A Randomised Controlled Trial (RCT) is in progress in 
the UK to evaluate the effectiveness of this intervention 
in the UK84 
Feedback x Giving feedback to pregnant women on the effects 
of smoking on the child and their own health. This 
includes interventions such as ultrasound 
monitoring, carbon monoxide or urine cotinine 
measurements etc.75 
Chamberlain and colleagues reported a significant 
effect of feedback on abstinence only when compared 
with usual care and provided in conjunction with other 
interventions (RR4.39, 95% CI 1.89-10.21) however 
no significant effect was found when compared to less 
intensive interventions (approximate of usual care) (RR 
1.19, 95% CI 0.97-2.31).75 
Social Support x Including peer/partner support, or support from a 
healthcare professional 75 
In a recent meta-analysis, social support by peers was 
reported to increase the abstinence in late pregnancy 
by 49% (Pooled RR 1.49, 95% CI 1.01-2.19) however 
social support by partner was not reported to have a 
significant effect of self-reported abstinence (RR 1.02, 
95% CI 0.70-1.50).75 
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Reducing maternal smoking during pregnancy has been an NHS priority since 
the beginning of the last decade. In March 2011 the government published a 
white paper titled ³+HDOWKy lives healthy people: A tobacco control plan for 
(QJODQG´ which set out how tobacco control would be delivered in the context of 
new public health systems.   One of the aims of this plan is to reduce the rates 
of smoking throughout pregnancy from 14% to 11% or less by 2015.2 Currently 
in the UK there are interventions and support available for pregnant women who 
want to quit including self-help interventions, pharmacotherapy, specialist 
support and intensive interventions offered by the NHS Stop Smoking Services 
(SSS).85 These services came into place in 2000 following the 1998 tobacco 
control strategy86 and since 2001 provide individualised support to pregnant 
women in clinic settings, home settings and on the phone.85 Data from the NHS-
SSS suggest that about half (46%) of pregnant smokers who use these services 
quit at the 4 week follow-up.87 However, less than 14% of pregnant smokers 
access these services.88 Therefore, to improve the uptake of these smoking 
cessation services NICE formulated guidelines on stopping smoking during 
pregnancy and childbirth in 2010.79 These guidelines recommend all midwives to 
DVVHVVSUHJQDQWZRPHQ¶VVPRNLQJVWDWXVDWERRNLQJGRDFDUERQPRQR[LGH
(CO) breath test and refer them to the NHS-SSS. Other healthcare professionals 
such as general practitioners (GPs), practice nurses, family nurses, obstetricians, 
paediatricians, sonographers and others are recommended to use any 
appointment as an opportunity to assess smoking status and offer smoking 
cessation advice and an NHS-SSS referral to those who want to stop.79 Similar 
to the WHO guidelines, bupropion and varenicline are contraindicated for use 
during pregnancy in the UK. In light of the insufficient data on the safety and 
effectiveness of NRT, NICE recommends a discussion of the risks and benefits of 
NRT before prescribing and to only prescribe NRT if cessation without NRT fails.79   
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1,&(KDVDOVRUHFRPPHQGHGDQµRSWRXW¶UHIHUUDO pathway through which the 
details of all identified pregnant smokers should be passed on to the local 
smoking cessation service without the need for direct consent.85  Figure 1-2 
explains the detailed pathway for referrals from maternity services to NHS Stop 
Smoking Services.  
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 Figure 1-2 - Pathway for referrals from maternity to NHS Stop 
Smoking Services 
Adopted with permission from: National Institute for Health and Clinical 
Excellence (2010) Quitting smoking in pregnancy and following childbirth 
PH26. London: National Institute for Health and Clinical Excellence 
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1.5 NICOTINE REPLACEMENT THERAPY 
Nicotine replacement therapy (NRT) contains low doses of nicotine in different 
medicinal forms. Its use is indicated outside of pregnancy for abrupt cessation of 
smoking, or to reduce the amount of cigarettes smoked before completely 
quitting.89 It can also be used to minimise passive smoking, to treat cravings 
and reduce compensatory smoking after enforced abstinence in smoke-free 
environments.89 The main mode of action of NRT is the stimulation of nicotine 
receptors in the ventral tegmental area of the brain and the consequent release 
of dopamine in the nucleus accumbens. This combined with other peripheral 
actions of nicotine leads to a reduction in nicotine withdrawal symptoms in 
regular smokers who abstain from smoking.90 Use for smoking cessation during 
pregnancy serves two important purposes: firstly, it delivers nicotine without 
delivering other harmful chemicals and teratogenic products from tobacco smoke 
to pregnant women and secondly it reduces withdrawal symptoms including 
cravings.91   
The use of NRT for smoking cessation during pregnancy is now supported by 
many countries in the world. The guidelines for smoking cessation in the USA, 
Australia, and New Zealand recommend that NRT can be used by pregnant 
women.92-94 The Ontario Provincial Medical Association in Canada also 
recommends that NRT should be made available to pregnant women who are 
unable to quit using non-pharmacological methods.95 Similar policies are in place 
for NRT use during pregnancy in European countries like France and Germany.95  
In the UK, NRT was made available on NHS prescription in 2001; however, its 
use was contraindicated in pregnancy due to safety fears; for example, concerns 
about its potential vaso-constrictive properties and potential placental transfer. 
In 2003 guidance for NRT prescribing was revised such that NRT use in 
pregnancy was cautioned rather than contra-indicated.96  In November 2005 the 
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Medicines and Healthcare products Regulatory Authority (MHRA) conducted a 
comprehensive review on the safety of NRT during pregnancy and despite a lack 
of conclusive evidence for efficacy, indicated that NRT use was likely to be less 
harmful than smoking,97 consequently broadening the UK licensing 
arrangements for NRT to include pregnant women in December 2005.98 As a 
result NRT can now be prescribed in specialist settings such as the Stop Smoking 
Services for Pregnant women (SSSPs) as well as in primary care settings. NICE 
recommends initially prescribing 2 weeks of NRT for use to pregnant women 
from the day they agree to stop and providing further prescriptions based on re-
assessment.79 NRT is available both on NHS prescription and over-the-counter 
(OTC) in many different forms and strengths. Table 1-2 presents a detailed 
description of currently available NRT formulations in the UK which are also 
available to pregnant women in the UK. 
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Table 1-2- Nicotine Replacement Therapy formulations currently 
available in the UK89,90 
Formulation Available 
Strength 
Specific side-
effects 
Maximum 
recommended 
daily dose  
Additional 
information 
Nicotine 
chewing gum 
2mg, 4mg Increased 
salivation, 
irritation of the  
throat 
60 mg Treatment to 
continue for 
3 months for 
smoking 
cessation 
Nicotine 
inhalation 
cartridge 
10mg, 15mg Irritation of the 
throat, reversible 
atrial fibrillation 
12 cartridges of 
10mg/ 6 
cartridges of 
15mg 
Single 10mg 
cartridge 
lasts for 20 
minutes and 
15 mg 
cartridge 
lasts for 40 
minutes  
Nicotine 
lozenge 
1 mg, 
1.5mg, 
2mg, 4mg,  
Increased 
salivation, 
diarrhoea, 
constipation, 
dysphagia, 
oesophagitis, 
gastritis, mouth 
ulcers, bloating, 
flatulence, taste 
disturbance, 
thirst, gingival 
bleeding, 
halitosis, chest 
pain, rash, hot 
flushes  
15 lozenges Treatment to 
continue for 
6-12 weeks 
for smoking 
cessation 
Nicotine 
sublingual 
tablets 
2mg Dry mouth 40 tablets  Treatment to 
continue for 
3 months for 
smoking 
cessation 
Nicotine oral 
spray 
1mg/spray Arrhythmia, hot 
flushes, 
sweating, 
myalgia, chest 
pain, abdominal 
pain, flatulence, 
taste 
disturbance, dry 
mouth, 
paraesthesia, 
watery eyes, 
blurred vision 
2 sprays per 
craving 
episode, 4 
sprays every 
hour and 64 
sprays daily 
- 
Nicotine 
nasal spray 
500 mcg/ 
spray 
Coughing, nasal 
irritation, 
epistaxis, 
sneezing, watery 
eyes 
64 sprays daily, 
twice every 
hour for 16 
hours  
Treatment to 
continue for 
8 weeks for 
smoking 
cessation 
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 Nicotine 
transdermal 
patches 
5mg/16 hrs, 
10mg/16 
hrs, 
25mg/16hrs, 
7mg/24hrs, 
14mg/24hrs, 
21mg/24hrs  
Abnormal 
dreams, 
sweating, 
myalgia, 
arthralgia, 
arrhythmia, 
chest pain, dry 
mouth, minor 
skin irritation,  
25mg/16hrs >10 
cigarettes 
daily - high-
strength 
patch daily 
for 6±8 
weeks, 
followed by 
the medium-
strength 
patch for 2 
weeks, and 
then the 
low-strength 
patch for the 
final 2 
weeks 
<10 
cigarettes 
medium-
strength 
patch for 6±
8 weeks, 
followed by 
the low-
strength 
patch for 2±
4 weeks 
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1.5.1 Effectiveness of NRT for smoking cessation in pregnant women 
In non-pregnant smokers NRT is shown to increase quit rates by 1.5-2.0 times 
the rate of those trying to quit without NRT99 however, the evidence of 
effectiveness of NRT during pregnancy is inconclusive. A recent multicentre, 
double blinded, randomised, placebo-controlled trial on Smoking, Nicotine and 
Pregnancy (SNAP) enrolled 1050 pregnant women across England to evaluate 
the effectiveness of NRT patches for prolonged abstinence and found no 
significant difference in the rate of abstinence from quit date until delivery 
between the NRT and placebo group (OR 1.26, 95% CI 0.82-1.96).100 
Furthermore, a systematic review including this trial and five other randomised 
controlled trials on NRT and smoking cessation in pregnant women, including 
1745 women in total, found similar results with no difference for smoking 
cessation in later pregnancy for NRT in comparison to the placebo group (RR 
1.33, 95% CI 0.93-1.91).101 A potential explanation for reduced effectiveness of 
NRT during pregnancy is the increased metabolism of nicotine during pregnancy. 
Several studies have reported higher metabolism of nicotine and cotinine (the 
primary metabolite of nicotine) in pregnant women compared to non-pregnant 
population 102,103 such that the half-life of cotinine is reduced to nine hours in 
pregnancy compared to 17 hours in non-pregnant women.104 Dempsey and 
colleagues studied metabolism of nicotine and cotinine in 10 healthy pregnant 
smokers after intravenous administrations of nicotine and found that both 
nicotine and cotinine are metabolised more rapidly during pregnancy than in the 
postpartum period with nicotine clearance being 60% higher during pregnancy 
compared to outside pregnancy and cotinine clearance being 140% higher. The 
half-life of cotinine was also significantly higher during pregnancy compared to 
outside pregnancy (8 hours vs. 16 hours).104  Another study compared nicotine 
metabolism using segmental hair analysis during each trimester of pregnancy in 
a large cohort of pregnant women and observed a significant decrease in hair 
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nicotine concentrations from the first to third trimester among steady smokers, 
accompanied by a significant increase in hair cotinine concentrations as nicotine 
clearance increases during later pregnancy.105 
Another factor related to the low effectiveness of NRT during pregnancy may be 
low adherence to the prescribed doses of NRT with a median duration of NRT use 
to be about two weeks. 100,106-109 In the general population NRT use is 
recommended for 8-12 weeks for optimal effectiveness therefore two weeks of 
NRT may be very short to show any effectiveness.107,110 
 
1.5.2 Safety of NRT for pregnant women 
There is very limited evidence of the safety of NRT during pregnancy and to date 
the evidence remains inconclusive. A recent systematic review of randomised 
controlled trials found no differences in the risk of preterm birth (RR=0.85, 95% 
CI 0.57-1.26), neonatal intensive care unit (NICU) admissions (RR= 0.94, 95% 
CI 0.64-1.38), miscarriage (RR 1.24, 95% CI 0.37-4.17), and  neonatal death 
(RR 0.28, 95% CI 0.06-1.41) between NRT and placebo groups.101 Additionally, 
no increased risk of low birth weight (OR=1.66, 95% CI 0.64-4.27) and stillbirth 
(RR 1.98, 95% CI 0.55-7.07) was found in the  NRT group compared to the 
placebo group.101 In contrast, observational data from the PRAMS, USA found 
that the risk of low birth weight to be twice in mothers who use NRT during 
pregnancy (OR 1.95, 95% CI 1.10-3.46) compared to non-smokers.111 Studies 
using the Danish National Birth Cohort have found no significant association 
EHWZHHQ157XVHDQGFKDQJHVLQELUWKZHLJKWǃFR-efficient=0.25g per week of 
NRT use) (95% CI -2.31,2.81)112 or stillbirth (HR) 0.83, 95% CI 0.34-2.00).113    
Evidence of the association between NRT use and congenital anomalies is also 
inconclusive. The SNAP trial found no increase in the risk of congenital anomalies 
associated with NRT use in pregnant women (OR 0.70, 95% CI 0.30-1.66).100 
The Danish National Cohort Data however suggest an increased relative risk for 
congenital malformations associated with NRT use (RR 1.61, 95% CI 1.01-
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2.58).114 The rate of caesarean section deliveries associated with NRT use has 
only been assessed in the SNAP trial which found it to be 20.7% which was 
approximately 45% higher in the NRT group as compared to placebo group (OR 
1.45, 95% CI 1.05-2.01).100 
These studies will be discussed in detail in Chapter 6 and Chapter 7.  
  
1.5.3 Views and attitudes of pregnant women regarding NRT use in 
pregnancy 
The licensing arrangements for NRT have now been broadened to allow use as a 
smoking cessation medication during pregnancy in the UK. However, as 
highlighted above, the evidence around its safety and effectiveness is 
inconclusive. The attitudes and views of pregnant women and care providers 
vary with some favouring the use of NRT during pregnancy and some being 
sceptical about it. These views play a key role in the uptake of NRT during 
SUHJQDQF\DVWKHXVHDQGXSWDNHRI157PD\GHSHQGRQZRPHQ¶VSHUFHSWLRQV
on the usefulness and safety of the drug. In a small survey of 150 pregnant 
smokers, identified through antenatal clinics in South West London, 
approximately half of the pregnant smokers (45%) expressed interest in using 
NRT. Women who smoked >10 cigarettes per day showed more interest in using 
NRT than women who smoked <10 cigarettes per day (55.9% vs. 37.4%, 
p=0.03).115 Another survey was conducted in the UK after NICE guidelines for 
smoking cessation supported the use of NRT during pregnancy to aid quit 
attempts. This survey was based on 145 pregnant women in their third 
trimester, identified through obstetric case notes. Approximately 70%  of these 
pregnant women expressed interest in using NRT during pregnancy for smoking 
cessation.116 Similar figures are reported in an Australian study of 256 pregnant 
women in an antenatal clinic where 63% of pregnant smokers expressed interest 
in using NRT if it were provided free of charge.117 In a qualitative study to 
investigate the potential barriers to smoking cessation using NRT via focus 
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groups, the use of patches was considered to be acceptable to most of the 
women. Some patients with medical problems or history of obstetric 
complications expressed doubts about using NRT and some were even sceptical 
of the effectiveness of NRT.118 However, this study was conducted on a selective 
sample of women in in Australia therefore the results may not be applicable to 
other countries like the UK.  Additionally, this study was conducted before the 
guidelines on NRT use in pregnancy were formulated and the licensing 
arrangements for NRT were broadened, which may have caused a shift in 
ZRPHQ¶VSHUFHSWLRQVDERXW157XVHGXULQJSUHJQDQF\,QDPRUHUHFHQW
qualitative study on 10 pregnant women in a semi-rural area of England, 
patches were the preferred form of NRT.119 However, the biggest concern 
highlighted by these women was that nicotine would harm the baby. Some other 
concerns related to NRT patch use were the dislike of marks left by the patch 
and finding a safe unobtrusive place to wear them on the body. Nevertheless, 
some found the patch to be very discreet with the advantage that once it was 
worn they forgot about it.119  
 
1.5.4 Views and attitudes of health care professionals regarding NRT 
use in pregnancy 
Another important factor in general population prescribing of NRT is the 
perceptions of health care providers regarding NRT use in pregnancy which may 
influence their practices and attitudes towards NRT prescribing. In a small 
survey based on 61 obstetric and paediatric nurses, practitioners and physicians 
in six community health centres in Boston, USA in 2000, 92% of obstetric 
providers stated that they would prescribe NRT to pregnant women if safety data 
were available. However, only 44% of the total sample was prescribing NRT at 
the time of the study. 120  A more recent study based on 154 obstetricians/ 
gynaecologists in Ohio, USA reported that only 25% of these specialists 
prescribed NRT to pregnant women, 32% perceived it as being safe in pregnancy 
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and only 14% considered it to be effective. Obstetricians/ gynaecologists who 
perceived NRT to be safe, effective, had confidence in their ability to effectively 
prescribe NRT and had their colleagues prescribing NRT were more likely to 
prescribe NRT (OR 20.0, 4.7, 3.9, and 6.7 respectively).121 In a similar study by 
the same authors assessing perception of nurses and midwives 74% of the them 
believed that NRT would reduce the number of pregnant smokers however only 
26% were confident in their ability to prescribe/ recommend NRT to pregnant 
women.122 A postal survey of 780 health professionals including general 
practitioners (GPs) and midwives from New Zealand in  providing maternity care 
reported that only 24% of these GPs and midwives perceived NRT to be 
appropriate to be prescribed to pregnant women.123 Nevertheless, since NRT is 
more widely available now and its use is supported by several international 
guidelines 124-126 this proportion may have increased as a result. In a UK survey 
of 368 GPs working in four districts of Nottingham, 62% of GPs considered NRT 
to be effective in pregnancy and 70% considered it to be safer than smoking 
however only 45% believed NRT to be safe in pregnancy.127 Even after 
relaxation of licensing arrangements of NRT in the UK, allowing health 
professionals to prescribe NRT to pregnant women, NRT in pregnancy was 
identified as a controversial issue in a qualitative study of midwives and health 
visitors and midwives expressed concerns in suggesting NRT use to pregnant 
women.128 Some of these concerns were related to time-constraints, lack of 
training and definitive knowledge about the effectiveness of NRT and poor of 
compliance to NRT during pregnancy.128 
 
1.5.5 NRT prescribing and use in pregnant women 
Although NRT has been available in different forms for over a decade and 
pregnant women have been encouraged to use NRT for smoking cessation if 
smoking cessation without NRT fails, the literature describing trends in NRT 
prescribing and use by this group is very limited. Studies using the Danish 
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National Birth Cohort to investigate associations between NRT use and adverse 
pregnancy outcomes presented self-reported NRT use in pregnant women to be 
0.3% in the first 12 weeks of gestation and between 2 to 2.5% when NRT use 
was assessed until 17-27 weeks of gestation.112-114,129  A similar study from the 
USA, using the 2004 PRAMS data reported NRT use to be 4% among pregnant 
women.111 A more recent study from the USA based on 296 pregnant smokers 
enrolled in an RCT reported that 7.4% of these pregnant smokers used NRT 
during pregnancy.130  A small study based on 145 pregnant smokers in an 
antenatal clinic in the UK, before the changes in licensing arrangements took 
place, found that none of the women in this study were prescribed or counselled 
about NRT.116 Another study linking Scottish maternity records with dispensed 
prescribing data in Tayside, Scotland in 2007 found that 2.4% of the pregnant 
women were prescribed NRT during pregnancy.131 In contrast, a recent study 
conducted in 44 NHS Stop Smoking Services (SSS) across England reported NRT 
use to be as high as 85% in pregnant smokers attending these services.132 
However, women attending the SSS are more motivated to give up smoking 
than the general population and therefore these rates may not be true for the 
whole population. 
 
1.6 SUMMARY AND THESIS OBJECTIVES 
Smoking during pregnancy causes significant health and economic burden. 
Therefore, up-to-date estimates of smoking in pregnancy are not only important 
for monitoring trends but also important to assess the effectiveness of current 
interventions and policies to tackle this problem.  
 
Most drugs are contraindicated during pregnancy however NRT is licensed for 
use in pregnancy in many other countries. In the UK, it is widely available for 
prescribing for smoking cessation in pregnant women since 2005. However, 
estimates of the use and prescribing of NRT in pregnant women are scarce. 
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These measures are vital to assess the utilisation and uptake of NRT which is 
available on the NHS. Furthermore, evidence of NRT safety in pregnancy is 
inconclusive with most RCTs being too small to detect an effect and most 
observational studies using retrospective reporting of exposures making them 
prone to recall bias.  
 
Therefore, the main aim of the work presented in this thesis was to assess the 
overall prescribing and safety of NRT in pregnancy. In order to meet this aim, 
the following objectives were addressed: 
1. To assess the completeness of smoking status recording and cessation 
advice during pregnancy in THIN data 
2. To compare the prevalence of maternal smoking in pregnancy from THIN 
data with other available data sources in the UK 
3. To quantify annual trends of NRT prescribing in and around pregnancy in 
the UK 
4. To assess whether NRT prescribing during pregnancy varies with 
maternal characteristics 
5. To investigate the relationship between antenatal exposure to NRT, 
maternal smoking and major congenital anomalies among children 
6. To investigate the relationship between antenatal exposure to NRT, 
maternal smoking and other birth outcomes (stillbirth, low birth weight 
and mode of delivery) 
 
1.7 OUTLINE OF THESIS CHAPTERS  
 
Chapter 2 briefly reviews potential data sources to assess the objectives of this 
thesis and describes in detail the main data source chosen for the studies in this 
thesis (The Health Improvement Network data). 
 
52 
 
Chapter 3 assesses the completeness of smoking status recording during 
pregnancy in primary care data (Objective 1) 
 
Chapter 4 assesses the potential utility of these data to produce population-
level estimates of smoking in pregnancy (Objective 2) 
 
Chapter 5 quantifies the prescribing of NRT in and around pregnancy and 
describes trends and patterns using descriptive statistics as well as poisson 
models (Objective 3 and 4) 
 
Chapter 6 investigates the association between maternal NRT or smoking 
exposure and major congenital anomalies in the offspring (Objective 5) 
 
Chapter 7 assess the relationship between maternal NRT or smoking exposure 
and stillbirth, low birth weight and mode of delivery (Objective 6) 
 
Chapter 8 summarises the main findings of the work presented in this thesis, 
discusses the public health implications and suggests avenues for future 
research.
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2 POTENTIAL DATA SOURCES AND DESCRIPTION 
OF THE DATA USED  
This chapter briefly presents potential data sources that measure smoking, NRT 
and other covariates required for the studies in this thesis and then describes in 
detail the main data source used i.e. The Health Improvement Network primary 
care data. 
In the UK, there are a number of routinely collected data or 
annual/quarterly/quinquennial surveys which assess different parameters of 
smoking and NRT use. Table 2-1 compares these data sources on some of the 
attributes that were essential for the studies in this thesis.   
 
Table 2-1 - Potential data sources in the UK to measure smoking and 
NRT trends and safety 
Data source Smoking 
outside 
pregnancy 
Smoking 
in 
pregnancy 
NRT 
data 
Sociodemographic 
factors 
Birth 
outcomes* 
General Lifestyle 
Survey (GLF)133 
/Integrated 
Household Survey 
(IHS)134 
Yes No No Yes No 
Health Survey for 
England (HSE)135 
Yes  No No Yes No 
Office for National 
Statistics (ONS) 
Opinions Survey136 
Yes No No Yes No 
Smoking Toolkit 
Study (STS)137 
Yes No Yes Yes No 
Infant Feeding 
Survey (IFS)59,138,139 
No Yes No Yes No 
Smoking at Time of 
Delivery (SATOD)60  
No Yes No No No 
Child Health Systems 
Programme (CHSP)61 
No Yes No Yes No 
Scottish Morbidity 
Record (SMR) ± 
smoking at booking61 
No Yes No Yes No 
Commercial over-
the-counter NRT 
data140 
No No Yes No No 
Electronic Prescribing 
Analysis and Cost 
Tool (e-PACT)141 
No No Yes No No 
Data from the Stop 
Smoking Services142 
No No Yes Yes No 
Primary Care 
Data143-145 
Yes Yes Yes Yes Yes 
*congenital anomalies, birth weight, stillbirth, mode of delivery 
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Out of the 12 data sources listed in Table 2-1 only five sources assess smoking 
status specifically in relation to pregnancy and four sources assess NRT 
use/prescribing. However, the table above clearly highlights that compared to all 
the other potential data sources a large dataset of primary care data could 
potentially provide information on all the attributes required for this thesis 
including information on smoking status during and outside pregnancy, 
prescribing of NRT, sociodemographic factors and birth outcomes. In addition, it 
has other health information on women such as comorbidities. Therefore, these 
data have the potential to provide detailed information on smoking and NRT use 
in and around pregnancy, offering a large amount of data for a period of about 
20 years, without the costs and time involved in using some other bespoke 
studies. The Health Improvement Network (THIN) primary care database was  
chosen as the dataset to be used for this thesis over the Clinical Practice 
Research Datalink and QRESEARCH it had an established pregnancy cohort with 
mother-child linkages at the time of the study which is essential for assessing 
the effects of pregnancy exposures (e.g. smoking, NRT) on birth outcomes 
(stillbirth, congenital anomalies). Additionally, about half of the general practices 
that contribute to THIN also contribute to CPRD.143 
 
2.1 INTRODUCTION TO THE HEALTH IMPROVEMENT NETWORK DATA 
THIN is an electronic primary care database of anonymised patient records from 
general practices across the UK. It contains medical, prescription, lifestyle and 
socio-demographic information routinely collected by GPs. THIN was set up in 
November 2002 following collaboration between the Cegedim Strategic Data 
(CSD) Medical Research UK, formerly known as the Epidemiology and 
Pharmacology Information Core (EPIC), part of the group who developed the 
Clinical Practice Research Database (CPRD) formerly called the General Practice 
Research Database (GPRD) 146 and InPractice Systems (InPS) who developed the 
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Vision software 143,147  Data are collected prospectively for all the registered 
patients who are alive. Additionally, historical information is available for 
patients who have died or transferred out of the practices.  All practices 
participating in THIN use Vision software for their prospective data recording. On 
joining THIN an initial Full Data Collection (FDC) is conducted where all the 
retrospective data are collected. 143 Retrospective medical data are also available 
LQHDFKSDWLHQW¶VUHFRUGVDOWKRXJKJHQHUDOSUDFWLFHVmay have previously used a 
number of different software systems to record their data, mostly using the 
Value Added Medical Products (VAMP) system to enter patient data,148 which was 
used in the Clinical Practice Research Data link (CPRD) formerly known as the 
GPRD.  
THIN adds to existing data every quarter to update the dataset with a lag of 
three to eight months between data being entered and being available for 
research.149 With each new release of the dataset the number of practices 
contributing data to THIN increases as a result of recruitment of new practices, 
though a small number of practices also leave the scheme.   
 
2.2  DATA FORMAT OF THIN 
Information for each patient is split into four main files, which are linked 
together by a unique patient identification number. Figure 2-1  describes the 
structure and information contained in each of these files. In addition to these 
files, there is a Postcode Variable Indicators (PVI) file containing postcode linked 
area-level socioeconomic, ethnicity and environmental indices however ethnicity 
information was only available for <15% of the women for the version of data 
used for this thesis (85% missing, 11% European, 0.6% Asian, 0.6% Black, 
1.2% Other White, 1.1% Mixed race) and therefore ethnicity was not included as 
a covariate in the studies conducted in this thesis150 
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unique patient 
identifier  
 
Patient file 
basic patient information such as date of birth, gender, registration, health authority, transfer out date, 
date of death 
 
Postcode variable 
indicator file 
Area level socioeconomic, 
ethnicity and 
environmental indices Medical file 
Disease symptoms, 
diagnoses, investigations, 
procedures  
Additional health data 
weight, height, smoking, alcohol and other lifestyle information, lab values etc. 
Therapy file 
drug prescriptions, dose, 
quantity, frequency etc.  
Figure 2-1 - Structure of THIN data 
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Clinical information in the Medical and Additional Health Data (AHD) file is coded 
using medical Read codes, a coded thesaurus of clinical terms including signs, 
symptoms, diagnoses, investigations and procedures etc.151  The medical Read 
codes in the file are also complemented by the AHD codes in the AHD file which 
describe details of lab values and other anthropometric measurements. More 
detailed clinical information and comments are entered as free text; these data 
were not available for this work.150 Prescriptions are entered using multilex drug 
codes which are linked to the British National Formulary (BNF). 
 
2.3 VERSION USED FOR THIS PHD ± THIN 1009 
The version of THIN used for the studies conducted as part of this thesis 
contains anonymised data from 495 practices across England, Scotland, Wales 
and Northern Ireland with a total of 9.5 million patients and covers 
approximately 5.7% of the UK population. Of these over 3.46 million patients 
are currently registered with active practices and can be prospectively followed. 
Data are available from January 1990 to September 2010.143 However, data for 
2010 were only available for the first nine months of the year and, therefore, all 
the studies discussed in this thesis have only used data until December 2009. 
  
2.4 STRENGTHS AND LIMITATIONS OF DATASET IN RELATION TO THE 
PHD WORK 
Electronic primary care data such as THIN are a good resource for descriptive 
epidemiology. However, there are limitations to its use which are important to 
consider.  The relative strengths and limitations of THIN, particularly with 
reference to studying smoking and NRT prescribing in pregnancy are discussed 
below.  
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2.4.1 Nature of data recording 
THIN has information on smoking status, prescriptions, cessation advice and 
counselling recorded prospectively compared to retrospective data collection in 
other data sources such as IFS and SATOD, which minimises the potential for 
misclassification due to recall or reporting errors. In addition to the smoking 
information, it also contains other clinical information recorded prospectively 
which may affect the smoking behaviour and other outcomes under study. 
Furthermore, THIN is based on routinely-collected data and reflects real life 
situation rather than experimental settings. It is therefore also useful to study 
the effect of certain policy and guideline changes on patient behaviour in the 
general population. These data however present a picture of routine UK clinical 
practice and inevitably lack information on people who did not consult their GPs 
for medical problems, which needs to be kept in mind while interpreting the 
findings from any study using primary care data. Additionally, the recording of 
different covariates will vary in the population as these data are not collected at 
regular intervals. 
 
2.4.2 Size, representativeness and generalisability 
Small sample sizes are one of the biggest drawbacks of many research studies in 
pregnancy as they result in reduced statistical power and are much less likely to 
represent the target population. THIN is a large database with information on 
over nine million patients and approximately two million women in their 
childbearing years from approximately 500 practices around the UK. Utilising 
THIN to estimate the prevalence of smoking and NRT prescribing in pregnancy 
could potentially produce precise estimates based on routine data with no added 
costs to conduct any surveys.  
Most people in the UK are registered with a GP. General practices voluntarily 
contribute data to THIN and therefore may have a slight under-representation of 
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the most deprived socioeconomic group compared with the UK as a whole. 
Nevertheless, electronic primary care data have been shown to be generally 
representative of the UK population in terms of demographics, prevalence of 
major conditions and mortality rates.152 Therefore, estimates of the clinical 
burden of disease, drug prescribing and the utilisation of primary care resources 
can be reasonably generalised to the population of the UK. 
 
2.4.3 Validity and data quality of exposures/ outcomes of interest 
Independent studies have shown high validity for both common and rare 
outcomes in THIN, including fertility rates.152-154 THIN has also been previously 
validated for recording of smoking status at a national and regional level in the 
general population149,155 and prescriptions for smoking cessation medications.156 
Additionally, the prevalence of congenital anomalies in THIN is shown to be 
consistent with European Surveillance of Congenital Anomalies (EUROCAT) 
data157 and has been validated against written GP records.158 Other pregnancy 
outcomes, however, have not been validated but show similar estimates to 
national figures (e.g. stillbirth).159    
As these data are primarily not collected for research purposes, information on 
certain exposures and outcomes may be more complete in certain groups 
compared with the general population. For example, a GP is more likely to ask 
and update smoking status in smokers as smoking is an important risk factor for 
many other medical conditions. Additionally, GPs address an average of two to 
three different medical problems during a single consultation160,161 however, only 
the dominant topics of the visit may be coded.141, 142  Therefore the information 
FRQWDLQHGLQWKHVHGDWDKHDYLO\UHOLHVRQWKH*3V¶DVVHVVPHQWRIWKHH[WHQWDQG
importance of the problem. Behavioural factors such as smoking, alcohol, 
exercise and diet etc. may therefore not always be recorded. Initial inspection of 
THIN data demonstrated poor recording of smoking status before 2000. 
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Therefore, for the purposes of this thesis analysis was limited to data from 2000 
onwards.  
Additionally, some drugs such as NRT are available from multiple sources in the 
UK for example GPs, SSS and OTC. Therefore, THIN may only be able to give 
population-based estimates of prescribing in primary care and not from other 
sources.  NRT only became available on NHS prescription in 2001.162  Therefore, 
the studies in this thesis assessing NRT prescribing and safety only analyse data 
from 2001 onwards.  
 
2.4.4 Duration of follow-up 
The average follow-up time for each woman in the data is approximately 4.5 
years. This may be useful when assessing prevalence of smoking at a population 
level and comparing trends in smoking prevalence and NRT prescribing over 
time. Whilst this is a relatively short time in the context of a lifetime, it 
surpasses other available data where cross-sectional sectional surveys are used.  
 
2.4.5 Contemporaneous 
The version of THIN used for this thesis has data up to September 2010. 
However, THIN data are updated routinely and have a lag of only three to eight 
months before the data become available for research. Therefore, methods used 
in this thesis could be utilised to provide contemporaneous and timely estimates 
of smoking in future. 
 
2.5 MOTHER-CHILD LINK 
To assess the health effects of maternal exposures on children, the anonymised 
primary care records of mothers and their children in THIN version 1009 were 
linked to form a pregnancy cohort with maternal-child linked records. This was 
done by Dr Linda Fiaschi and Dr Laila J. Tata using unique household 
61 
 
identification numbers to find mothers and children within the same household 
DQGWKHQPDWFKLQJWKHPXVLQJWKHGHOLYHU\GHWDLOVLQWKHPRWKHUV¶SULPDU\FDUH
UHFRUGVDQGELUWKGHWDLOVLQWKHFKLOGUHQ¶VSULPDU\ care records. Approximately 
87% of the children registered within three months of birth are matched to their 
PRWKHUV¶UHFRUGV7KLVGDWDVHWZDVFUHDWHGLQGHSHQGHQWRIWKHZRUNLQWKLV
thesis and serves as a resource for several studies within the Division of 
Epidemiology and Public Health. This mother-child linked data was used for 
Objectives 5 and 6 (safety of NRT).  
 
2.6 ETHICAL APPROVAL 
All data are anonymised before leaving the practice such that individual patient 
identifiers such as the name, address, date of birth, hospital number and specific 
location of general practices cannot be identified by researchers.  THIN data 
collection was approved by the NHS South-East Multi-centre Research Ethics 
Committee (MREC) in 2003.163 Ethical approval for the use of THIN data for 
studies on smoking and NRT prescribing prevalence was obtained from THIN 
Scientific Review Committee (Ref.No 11-047). Ethical approval for the studies on 
NRT safety in pregnancy was obtained from the Medical Research Ethics 
Committee, administered and approved by the NHS MREC (REC Ref. 
04/MRE01/9). 
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3 COMPLETENESS OF SMOKING STATUS 
RECORDING DURING PREGNANCY IN THIN 
3.1 INTRODUCTION 
Current recommendations in the UK emphasise that all healthcare workers 
LQYROYHGLQDSUHJQDQWZRPDQ¶VFDUH (e.g. midwives, GPs, practice nurses and 
obstetricians) should assess the womaQ¶VVPRNLQJVWDWXVat the earliest possible 
stage of pregnancy and offer cessation advice and a referral to specialist stop 
smoking advisers for women who smoke.74,79,164-166  Documentation of a 
ZRPDQ¶VVPRNLQJVWDWXVLQKHUPHGLFDOUHFRUGVLVUHFRPPHQGHGWRHQDEOHKHU
healthcare team to offer appropriate support throughout the pregnancy. 165 
Midwives record these data on the handheld maternity records and GPs record 
this information in the electronic primary care data. In the UK women must be 
registered with a GP in order to receive antenatal care provided by the NHS and, 
although most antenatal contacts are with midwives, an estimated 77% of 
women see their GPs first for confirmation of pregnancy before attending an 
antenatal booking appointment with a midwife.167 This visit is therefore an ideal 
opportunity for the GPs to assess smoking status, communicate it to the 
healthcare team and provide advice on quitting, given the benefits of quitting 
early in pregnancy.66-68 Primary care is the central hub in the current UK health 
care system and the assessment and complete documentation of smoking 
status, amongst other health indicators, in primary care is important to increase 
opportunities for providing smoking cessation advice and interventions during 
pregnancy. However, the extent to which smoking status is assessed and 
recorded during pregnancy in primary care is currently unknown. Additionally, 
there are no measures on whether GPs provide smoking cessation advice to 
pregnant women and how well it is recorded. These are important questions not 
only to identify missed opportunities for smoking cessation in primary care but 
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also to assess the potential utility of these data to generate smoking estimates 
during pregnancy at a population-level.  
This chapter is aimed at addressing the very important questions highlighted 
above. It begins with a brief overview of the Quality and Outcomes Framework 
(QOF), a national scheme introduced to increase the recording of medical 
conditions and lifestyle factors, including smoking, in primary care data. This is 
followed by an investigation of the completeness of maternal smoking status 
recording during pregnancy in THIN data, assessing the annual proportion of 
pregnant women who have a record of their smoking status during pregnancy in 
their primary care data and how this varies with sociodemographic factors and 
maternal morbidities. This study was published in PLOS One in September 2013 
and is attached as Appendix 10.1.     
 
Appendix 10.2 presents the results of a study which assessed the completeness 
of recording of smoking cessation advice during pregnancy in primary care and 
variations in completeness with maternal factors. This study was conducted as a 
BMedSci project undertaken by Bethany Hardy and jointly supervised by myself 
and Dr Lisa Szatkowski. This paper was published in BMC Family Practice in 
February 2014 and it attached as Appendix 10.2.
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3.2 QUALITY AND OUTCOMES FRAMEWORK 
In April 2004, a new contract for GPs was implemented which introduced a 
number of pay-for-performance targets as part of the QOF.168 A set of indicators 
was developed under four main domains (clinical, organisational, patient 
experience and additional service) to measure the performance of GP practices 
using points. Approximately 7.5-8% of the QOF points (worth around £10,000) 
per year per practice are related to the recording of smoking status and delivery 
of smoking cessation advice.169-171 At the time of its introduction, the QOF 
required GPs to document the smoking status of patients with hypertension, 
diabetes, asthma and certain other smoking-related morbidities every 15 
months and have at least one record of smoking status in the absence of these 
morbidities. In 2006, this was slightly changed to require all GPs to document 
smoking status of all patients at least once every 27 months. The target was 
then changed in 2013 to every 24 months for the general population and every 
12 months for patients with chronic conditions.171 No rules however have been 
developed for the recording of smoking status or smoking cessation advice 
specifically during pregnancy. A detailed explanation of the QOF rules for 
smoking status recording in the general population from 2004 to date is given in 
Table 3-1.
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Table 3-1 - QOF requirements for recording of smoking status172,173  
  
2004-
2005 
2005-
2006 
2006-
2007 
2007-
2008 
2008-
2009 
2009-
2010 
2010-
2011 
2011-
2012 
2012-
2013 
2013-2014 
R
ec
o
rd
in
g
 o
f 
sm
o
ki
n
g
 s
ta
tu
s 
in
 t
h
o
se
  
w
it
h
 s
p
ec
if
ic
 c
o
n
d
it
io
n
s 
Hypertension 
  
The notes of patients with any one or combination of these conditions should contain a record of 
smoking status in the previous 15 months, except those who have never smoked where the smoking 
status need only be recorded once since diagnosis.  
  
 
The notes of 
patients with any 
one or combination 
of these conditions 
should contain a 
record of smoking 
status in the 
previous 12 
months, except 
those who have 
never smoked 
where the smoking 
status need only 
be recorded once 
since diagnosis. 
 
 
Coronary heart 
disease 
Diabetes mellitus 
COPD* 
TIA** or stroke 
Asthma 
Chronic kidney 
disease  
 
Schizophrenia, 
bipolar disorder 
or other 
psychoses 
 
 
Peripheral Artery 
Disease      
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2004-
2005 
2005-
2006 
2006-
2007 
2007-
2008 
2008-
2009 
2009-
2010 
2010-
2011 
2011-
2012 
2012-
2013 
2013-2014 
Recording of smoking 
status in all registered 
patients in the general 
population 
The notes of 
patients aged 15-
75 should contain 
at least one record 
of smoking status.  
 
The smoking status of 
patients aged 15+ 
should be recorded in 
every 27 months, 
except those who have 
never smoked where 
smoking status need be 
recorded only once.  
The smoking status of patients aged 15+ should be 
recorded every 27 months, except those who have 
never smoked where smoking status is to be checked 
annually until age 25. Ex-smokers are to be asked 
about smoking status on an annual basis until they 
have been a non-smoker for 3 years.  
 
 
The smoking status 
of patients aged 
15+ should be 
recorded every 24 
months, except 
those who have 
never smoked 
where smoking 
status is to be 
checked annually 
until age 25. Ex-
smokers are to be 
asked about 
smoking status on 
an annual basis 
until they have 
been a non-smoker 
for 3 years. 
Table adapted with permission, and updated from Szatkowski L (2011) PhD Thesis: Can primary care data be used to evaluate the effectiveness of 
tobacco control policies? Data quality, method developments and assessment of the impact of smokefree legislation using data from The Health 
Improvement Network. Nottingham: University of Nottingham. 
*COPD ± Chronic Obstructive Pulmonary Disease, TIA ± Transient Ischaemic Attack 
Shaded areas represent the time when there are no QOF recording rules in place for specific conditions
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The introduction of the QOF led to an improvement in the recording of clinical 
information in primary care medical records including the data on smoking 
status and smoking cessation advice. A study examining the impact of the QOF 
rules on the recording of smoking targets in primary care using THIN found that 
with the introduction of the QOF in 2004, the recording of smoking status in the 
general population improved such that the overall proportion of patients with a 
smoking status record within the last 27 months increased from 30% in 2003 to 
over 40% in 2004 and increased steadily over time such that in 2008 the 
proportion of patients with a smoking status record within the last 27 months in 
THIN was approximately 65%.174 Similar increases were seen for recording of 
smoking status in patients with chronic conditions where this proportion 
increased from 50% in 2003 to over 75% in 2004 and then plateaued.174 A 
similar study using the QRESEARCH primary care database, including 525 
general practices across the UK, reported similar results with a 33% increase in 
the recording of smoking status between 2001/2002 and 2006/2007 with large 
increases in the collection of smoking data after the implementation of the 
QOF.175  
 
3.3 JUSTIFICATION FOR THE STUDY 
In the general practice population as a whole the recording of SDWLHQWV¶VPRNLQJ
status is more complete after the introduction of the QOF.149,155 However, as 
discussed above the QOF set no specific incentives for the recording of smoking 
status in pregnant women. Having smoking status recorded in a pregnant 
ZRPHQ¶VPHGLFDOUHFRUGVLVQRWRQO\XVHIXOIRUFOLQLFDOPDQDJHPHQWEXWDOVR
increases opportunities for health professionals to provide smoking cessation 
interventions throughout pregnancy and afterwards. Additionally, a cohort of 
pregnant smokers was required as a denominator to calculate NRT prescribing 
prevalence and also as a comparison group to compare the safety of NRT in this 
thesis. Therefore, the primary aim of this study was to assess the completeness 
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of recording of smoking status during pregnancy in primary care medical records 
RYHUWLPHDQGLQYHVWLJDWHZKHWKHUFRPSOHWHQHVVYDULHGZLWKZRPHQ¶V
sociodemographic and health-related characteristics. Additionally, the secondary 
aim of this work was to investigate whether, despite having no specific targets 
for pregnancy, there was an increase in the completeness of smoking status 
recording during pregnancy in UK primary care after the introduction of the QOF. 
 
3.4 METHODS 
3.4.1 Study population 
For this particular study the population included all pregnancies recorded in THIN 
between 2000 and 2009 in women of reproductive age (15-49 years), as defined 
by the WHO,176 which resulted in either a live birth or a stillbirth. Pregnancies 
ending in spontaneous abortions and terminations were not included in the study 
population as these do not have comprehensive information on pregnancy-
related exposures and outcomes.  
 
3.4.2 Smoking status records 
Records of maternal smoking status during pregnancy were identified using Read 
codes.151 These included codes for current, never, and ex-smoking, codes 
indicating the type or number of cigarettes smoked, and codes indicating 
smoking cessation interventions delivered to patients. Code lists are attached as 
Appendix 10.5.  Women were also considered to be smokers if they had a 
prescription for a smoking cessation drug (nicotine replacement therapy, 
bupropion or varenicline) in their medical records during pregnancy.  Code lists 
are attached as Appendix 10.6. Further information was extracted using the 
smoking AHD codes in Appendix 10.7. This method of classifying smoking status 
in electronic primary care data to calculate smoking prevalence has been 
previously validated in general population.149  
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3.4.3 Maternal characteristics 
To investigate the factors that may be associated with the recording of maternal 
smoking status during pregnancy, data were extracted on the following maternal 
characteristics. Code lists for the morbidities discussed below are attached as 
Appendix 10.8. 
 
3.4.3.1 Age and socioeconomic status 
Age was considered as a categorical variable with five-year age bands 
progressing from 15 years through to 49 years with seven categories in total. 
Socio-economic status was assessed using quintiles of the Townsend index of 
material deprivation.177 The Townsend deprivation index measures area level 
deprivation based on four indicators: unemployment, house ownership, car 
ownership and overcrowding. This was derived using the 2001 Census data, 
converted into five equal quintiles and then matched to UK postcodes to give 
deprivation quintiles for each postcode, quintile 1 being the least deprived group 
and quintile 5 being the most deprived group.  
 
3.4.3.2 Diabetes 
For each pregnancy, women were said to have diabetes if there was a medical 
Read code for diabetes or a prescription of insulin or an oral hypoglycaemic 
agent documented in the therapy file or a diabetes record in the AHD file within 
27 months before conception until delivery. Although the QOF required the 
smoking status of patients to be recorded every 15 months in patients with 
diabetes and other comorbidities until 2013, for the general population smoking 
status needed to be recorded every 27 months.173 Since this thesis is focused 
around smoking in pregnant women (who represent a fairly healthy group from 
the general population) the period of 27 months was set as a cut-off point for 
extraction of diabetes and all other morbidities for consistency purposes. 
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3.4.3.3 Hypertension 
For each pregnancy, a woman was said to have hypertension if there was a Read 
code for hypertension recorded in the medical file or three or more readings of 
high blood pressure (BP) (systolic > 140mmHg with/ or diastolic >90mmHg) 
documented in the AHD file between 27 months before conception until delivery. 
   
3.4.3.4 Asthma 
Women were defined as having asthma if they had a medical code for asthma 
within 27 months before conception until delivery or if they had a medical code 
for asthma any time in their general practice record before delivery and a drug 
prescription for asthma within 27 months before conception until delivery to 
identify if women had active asthma in and around the time of pregnancy 
 
3.4.3.5 Mental illness  
This variable included five psychiatric conditions: depression, anxiety, bipolar 
disorder, schizophrenia and other psychoses. A woman was said to have a 
mental illness if there was a definitive diagnosis (based on International 
Classification of Diseases (ICD)-10 codes) of any of the above mental illnesses in 
DZRPDQ¶VSULPDU\FDUHUHFRUGEHWZHHQPRQWKVEHIRUHFRQFHSWLRQXQWLO
delivery. 
 
3.4.3.6 Pre-conception body mass index 
Body Mass Index (BMI) was extracted from the medical file using Read codes. 
Information on BMI was also extracted from the AHD file using the AHD 
information on weight. The most recent recording of BMI within 27 months 
before conception was considered to keep it consistent with the method of 
determining all other comorbidities.  
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BMI was then divided into four categories according to the WHO classification178: 
normal (18.5-24.9 kg/m2), underweight (<18.5 kg/m2), overweight (25-29.9 
kg/m2), obese (30 kg/m2). A separate category was created for missing BMI 
information.  
  
3.4.4 Statistical analysis 
The prevalence of smoking status recording during pregnancy was calculated for 
each year from 2000 to 2009 as the number of pregnancies with at least one 
recording of smoking status during the gestational period divided by the total 
number of pregnancies delivered in that year. These data were plotted 
graphically.  
For women who only had records of being a never smoker up to the age of 25 
and who did not have a record of smoking during a subsequent pregnancy, a 
never smoking record was imputed during gestation. Similarly, for women who 
had no smoking status records during gestation but who were recorded as ex-
smokers for three consecutive years before the conception an ex-smoking record 
was imputed during gestation. The annual proportion of pregnancies with a 
recording of smoking status during the gestational period was then recalculated. 
These imputations were based on the QOF rules discussed in Section 3.2. Since 
April 2006 the QOF has not required GPs to record  smoking status of patients 
after the age of 25 years if they have been a never smoker until that age.179 
After 2008, if a patient who once smoked has been recorded as an ex-smoker 
for three years*3VQHHGQRORQJHUFKHFNDQGXSGDWHWKHSDWLHQW¶VVPRNLQJ
status records.  
Logistic regresVLRQZDVXVHGWRFDOFXODWH25VIRUDVVRFLDWLRQVEHWZHHQZRPHQ¶V
characteristics and the recording of smoking status during pregnancy. All 
covariates that reached statistical significance (p<0.05) in the univariable 
analysis were initially included in the multivariable analyses and each covariate 
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was tested sequentially in the multivariable model. Covariates that reached 
statistical significance (p<0.05) in the multivariable analysis were retained in the 
final model.  As some women had more than one pregnancy during the study 
period that contributed to the analyses, this potential clustering of pregnancies 
within women was accounted for by calculating robust CIs around the odds 
ratios using the clustered sandwich estimator. The clustered sandwich estimator 
allows for intragroup correlation (i.e. more than more pregnancy for each 
woman).180,181  
Logistic regression was carried out for two separate time periods: before the 
implementation of the QOF (January 2000-April 2004) and after the 
implementation of the QOF (April 2004-December 2009). The introduction of the 
QOF incentivised the recording of smoking status in patients with smoking-
related chronic conditions therefore it was expected to be an effect modifier of 
the association between recording of smoking status during pregnancy and these 
morbidities.  
Visual comparisons of the magnitude, precision and statistical significance of the 
odds ratios for each maternal factor in the pre and post-QOF periods were made 
in order to assess whether the association between maternal factors and the 
recording of smoking status during pregnancy changed after the QOF was 
introduced.  
 
3.5 RESULTS 
3.5.1 Baseline characteristics 
A total of 215,703 women with pregnancies resulting in live births or stillbirths 
were identified between January 2000 and December 2009. Of these, 162,295 
(75.0%) had only one pregnancy, 46,062 (21.5%) had two pregnancies and 
7,346 (3.5%) had three or more pregnancies, giving a total of 277,552 
pregnancies. The mean age at conception was 29.5 years (standard deviation 
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(sd) 5.9) and the average length of pregnancy was 39.4 weeks (sd 2.2). Table 
3-2 describes the baseline characteristics of the study population in the pre-QOF 
and post-QOF time periods. The overall prevalence of diagnosed asthma, 
diabetes, hypertension and mental illness within the study population was 
approximately 8%, 2%, 2.5% and 9% respectively. Information on 
socioeconomic status (Townsend index) was missing for 6% of the total 
pregnancies and information on BMI was missing for 42% of pregnancies.  
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Table 3-2 - Baseline characteristics of the study population 
  Pre-QOF(January 2000- March 2004) Post-QOF (April 2004- December 2009) 
  Total pregnancies 
(n=98,373) 
Pregnancies with a 
gestational smoking record 
(n=12,381)** 
Total pregnancies 
(n=179,179) 
Pregnancies with a 
gestational smoking record 
(n=64,188) 
 n n %* n n %* 
Age at Conception       
15-19 years 5,529 953 (17.2%) 9,854 4,856 (49.3%) 
20-24 years 14,809 2,202 (14.9%) 29,323 12,607 (43.0%) 
25-29 years 25,732 3,175 (12.3%) 45,416 16,758 (36.9%) 
30-34 years 32,621 3,750 (11.5%) 54,574 17,437 (32.0%) 
35-39 years 16,614 1,944 (11.7%) 32,778 10,296 (31.4%) 
40-44 years 2,907 338 (11.6%) 6,868 2,123 (30.9%) 
45-49 years 161 19 (11.8%) 366 111 (30.3%) 
Townsend Score in 
quintiles 
      
 
Quintile 1 ± least deprived 24,760 2,850 (11.5%) 38,815 11,733 (30.2%) 
Quintile 2 19,288 2,277 (11.8%) 32,962 11,025 (33.4%) 
Quintile 3 18,592 2,317 (12.5%) 35,209 12,542 (35.6%) 
Quintile 4 17,128 2,279 (13.3%) 33,982 13,114 (38.6%) 
Quintile 5 - most deprived 13,252 1,964 (14.8%) 25,742 10,915 (42.4%) 
Missing 5,353 694 (13.0%) 12,469 4,859 (39.0%) 
Pre-conception Body 
Mass Index (kg/m2) 
      
Normal(18.0-24.9) 26,663 3,948 (14.8%) 59,267 21,209 (35.8%) 
Underweight(<18.0) 1,968 293 (14.9%) 4,355 1,714 (39.4%) 
Overweight(25-29.9) 11,923 1,867 (15.7%) 29,476 10,957 (37.2%) 
Obese(>=30) 7,125 1,240 (17.4%) 20,993 8,406 (40.0%) 
Missing 50,694 5,033 (9.9%) 65,088 21,902 (33.6%) 
Asthma 6,537 1,297 (19.8%) 16,807 8,911 (53.0%) 
Hypertension 2,372 377 (15.9%) 4,962 1,959 (39.5%) 
Diabetes 1,345 194 (14.4%) 4,864 1,857 (38.2%) 
Mental illness 8,717 1,439 (16.5%) 17,294 7,373 (42.6%) 
*pregnancies with a gestational smoking record in each sub-category divided by the total number of pregnancies in the respective sub-category  
** women had information on whether they were an ex/never/current smokers or had a smoking cessation prescription  
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3.5.2 Completeness of maternal smoking records 
A record of smoking status at any point during gestation was present in 76,569 
(28%) of the 277,552 pregnancies. Of the 76,569 pregnancies in which there 
was smoking status information, 913 (1.2%) only had a recording for smoking 
cessation drug prescription with no accompanying Read codes indicating 
smoking status.  In 56,605 (73.9%) pregnancies, women had their smoking 
status recorded only once during the gestational period, whereas in 19,964 
(26.1%) pregnancies, smoking status was recorded more than once. Figure 3-1 
shows the proportion of pregnancies with smoking status recorded during 
gestation from 2000 to 2009. In 2000, smoking status was recorded during the 
gestational period for only 1,943 (8.8%) of the total 22,111 pregnancies. This 
proportion increased steadily to 18% in 2003, with the proportion rising to 
32.3% in 2004. After 2004 it increased steadily on an annual basis such that the 
proportion of pregnancies with smoking status recorded during gestation in 2009 
was 43.3% (13,360 out of 30,880 pregnancies).  
When data for never smoking and ex-smoking were imputed based on the QOF 
rules, the overall proportion of pregnancies with a record of smoking status 
during gestation increased to 32.1%. In 2000, smoking status was recorded 
during gestation for only 11.0% of pregnancies which increased to 35.8% in 
2004 and 49.2% in 2009. 
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Figure 3-1 - Annual proportions of pregnancies in THIN with smoking status recorded during gestation (2000-2009) 
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3.5.3 Factors associated with recording of maternal smoking status 
during pregnancy 
Table 3-3 shows variations in the recording of smoking status during pregnancy 
by ZRPHQ¶VVRFLRGHPRJUDSKLF characteristics and morbidities in the pre-QOF 
and post-QOF time periods. Overall, the magnitude of effect of the associations 
between most maternal characteristics and recording of smoking status during 
gestation was higher in the post-QOF period compared to the pre-QOF period. 
The recording of smoking status during pregnancy varied with socioeconomic 
status such that pregnant women from the most deprived group (quintile 5) 
were 17% more likely to have their smoking status recorded during pregnancy 
than pregnant women from the least deprived group (quintile 1) before the 
implementation of the QOF (OR 1.17, 95% CI 1.10-1.25) and 42% more likely 
afterwards (OR 1.42, 95% CI 1.37-1.47). Similarly, pre-QOF pregnant women 
with a diagnosis of asthma were 63% more likely to have their smoking status 
recorded during pregnancy than pregnant women without asthma (OR 1.63, 
95% CI 1.53-1.74) and post-QOF pregnant women with asthma were over twice 
as likely to have their smoking status recorded during pregnancy (OR 2.08, 95% 
CI 2.02-2.15). Having a diagnosis of diabetes was not associated with the 
recording of gestational smoking status pre-QOF (unadjusted OR 1.17, 95% CI 
1.00-1.36), (p=0.290). However, post-QOF it was associated with a 12% 
increase in the odds of recording of gestational smoking status (OR 1.12, 95% 
CI 1.05-1.19). Recording of smoking status during pregnancy was also related to 
hypertension and mental illness. In both time periods the odds of a woman 
having her smoking status recorded during pregnancy were greater at younger 
ages compared with older ages and also greater in overweight and obese 
women. However, the magnitude of effects and corresponding CIs in the pre-
QOF and post-QOF periods overlapped.
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Table 3-3 - Odds of having smoking status recorded during gestation by women's characteristics pre-QOF and post-QOF 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UOR=unadjusted odds ratio, AOR=adjusted odds ratio, CI=confidence interval, QOF=Quality and Outcomes Framework, ۆ Diabetes not significant in the final model 
  Pre-QOF(January 2000- March 2004) Post-QOF(April 2004-December 2009) 
 UOR (95% CI) p-val AOR (95% CI) p-val UOR (95% CI) p-val AOR (95% CI) p-val 
Age at conception             
15-19 years 1.48 (1.37 - 1.60)  1.56 (1.44 - 1.70)  1.66 (1.59-1.74)  1.62 (1.54 - 1.69)  
20-24 years 1.24 (1.17 - 1.32)  1.22 (1.15 - 1.30)  1.29 (1.25-1.32)  1.24 (1.20 - 1.28)  
25-29 years 1 <0.001 1 <0.001 1 <0.001 1 <0.001 
30-34 years 0.92 (0.87 - 0.97)  0.95 (0.91 - 1.00)  0.80 (0.78-0.82)  0.84 (0.82 - 0.86)  
35-39 years 0.94 (0.88 - 0.99)  0.99 (0.93 - 1.05)  0.78 (0.75-0.80)  0.83 (0.80 - 0.85)  
40-44 years 0.93 (0.83 - 1.05)  0.99 (0.88 - 1.12)  0.76 (0.72-0.81)  0.80 (0.76 - 0.85)  
45-49 years 0.95 (0.59 - 1.53)  0.99 (0.61 - 1.60)  0.74 (0.59-0.93)  0.77 (0.61 - 0.97)  
Townsend Score         
Quintile 1 (least deprived) 1  1  1  1  
Quintile 2 1.03 (0.78 - 1.09)  1.01 (0.95 - 1.07)  1.16 (1.12-1.19)  1.12 (1.09 - 1.16)  
Quintile 3 1.09 (1.03 - 1.16) <0.001 1.03 (0.97 - 1.10) <0.001 1.28 (1.24-1.32) <0.001 1.18 (1.14 - 1.21) <0.001 
Quintile 4 1.18 (1.11 - 1.25)  1.07 (1.00 - 1.13)  1.45 (1.40-1.49)  1.26 (1.22 - 1.30)  
Quintile 5 (most deprived) 1.34 (1.25 - 1.42)  1.17 (1.10 - 1.25)  1.69 (1.64-1.75)  1.42 (1.37 - 1.47)  
Missing 1.14 (1.04 - 1.25)  1.06 (0.97 - 1.16)  1.47 (1.41-1.54)  1.34 (1.29 - 1.40)  
Body Mass Index (kg/m2)             
Underweight(<18.0)  1.01(0.88-1.14)  0.92 (0.81 - 1.05)  1.16 (1.10-1.24)  1.03 (0.97 - 1.10)  
Normal(18.0-24.9) 1  1  1  1  
Overweight(25-29.9) 1.07 (1.01-1.13) <0.001 1.06 (1.00 - 1.13) <0.001 1.06 (1.03-1.09) <0.001 1.05 (1.02 - 1.09) <0.001 
Obese(>=30) 1.21 (1.13-1.30)  1.16 (1.08 - 1.25)  1.19 (1.16-1.23)  1.11 (1.08 - 1.15)  
Missing 0.63 (0.60-0.66)  0.63 (0.60 - 0.66)  0.91 (0.89-0.93)  0.90 (0.88 - 0.92)  
Asthma 1.80 (1.69-1.92) <0.001 1.63 (1.53 - 1.74) <0.001 2.19 (2.12-2.25) <0.001 2.08 (2.02 - 2.15) <0.001 
Hypertension 1.32 (1.18-1.48) <0.001 1.26 (1.12 - 1.41) <0.001 1.17 (1.11-1.24) <0.001 1.19 (1.12 - 1.26) <0.001 
Diabetes 1.17 (1.00-1.36) 0.045 - ۆ -ۆ 1.11 (1.05-1.18) <0.001 1.12 (1.05 - 1.19) <0.001 
Mental illness 1.42 (1.34-1.51) <0.001 1.32 (1.24 - 1.41) <0.001 1.37 (1.33-1.41) <0.001 1.26 (1.22 - 1.30) <0.001 
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3.6 DISCUSSION  
3.6.1 Principal findings 
Using a large population-based dataset this study found that the recording of 
smoking status during pregnancy in primary care has improved with time such 
that the proportion of pregnancies with a recording of smoking status during 
gestation was 8.8% in 2000 rising to 43.3% in 20097KHRGGVRIDZRPDQ¶V
smoking status being recorded during pregnancy was related to age, 
socioeconomic deprivation, BMI and QOF-incentivised morbidities such as 
asthma, diabetes, hypertension and mental illness. This indicates that even 
though there are no QOF targets specific to pregnancy, the QOF has had an 
influence on the completeness of smoking status recording during pregnancy. 
 
3.6.2 Strengths and limitations  
This is the first study to assess the completeness of recording of smoking status 
during pregnancy in UK primary care medical records at a national level with 
over 200,000 pregnancies. The study is also novel in that it assesses the 
association between maternal characteristics and the recording of smoking 
status during pregnancy, taking into account the effects that the QOF had on the 
overall recording trends. Additionally, the code lists used to defined smoking 
status were quite exhaustive including medical Read codes, smoking cessation 
drug prescription codes and AHD codes related to smoking cessation advice, 
increasing the sensitivity to identify any smoking related recording in the 
ZRPHQ¶VSULPDU\FDUHGDWD+RZHYHURQO\HOHFWURQLFDOO\-coded data in primary 
care records were used and no free-text data (additional uncoded data that the 
*3VPLJKWDGGLQSDWLHQWQRWHVWRHODERUDWHRQWKHSDWLHQW¶VFRQGLWLRQ182 which 
may provide additional information on the smoking status of women , were 
available. 
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Due to the infrequency of smoking status recordings during pregnancy the 
recording of smoking status throughout pregnancy was assessed compared to 
smaller time windows during pregnancy such as in each trimester, which may be 
more appropriate given that smoking status can fluctuate during pregnancy.183 A 
potential explanation for a high proportion of pregnancies in which smoking 
status was not recorded could be that although this information is part of the 
hand-held maternity notes 184 (mandatory paper notes that women carry with 
them throughout pregnancy) it may not be transcribed onto the GP electronic 
records. Another reason could be WKDWLIDZRPDQ¶VVPRNLQJKDELWGLGQRW
change after she became pregnant, GPs may be less likely to re-enter this 
information into medical records as there is no specific financial incentive for 
assessing and recording smoking status in pregnant women. Furthermore, as 
the QOF does not require GPs to record the smoking status of µnever smokers¶ 
after the age of 25, there is no financial incentive for them to update smoking 
status in the medical records of women who have never smoked. Similarly, ex-
smokers need only be asked about their smoking status annually until they have 
been a non-smoker for three years. When smoking status was recalculated 
based on these rules, the annual trends in the completeness of smoking data 
during pregnancy did not vary much from the trends using the original data, 
however each woman only had 4.5 years of follow-up so for older women who 
had been non-smokers for life recording may be especially low. 
 
3.6.3 Comparison with current literature 
Overall, a steady improvement has been observed in the recording of smoking 
status during pregnancy in the primary care data. The proportion of pregnancies 
with a gestational smoking record in this study increased by approximately 2% 
per year between 2000 and 2002. Since the late 1990s there has been an 
increased focus on the harms of tobacco use in the UK, with, for example, the 
SXEOLFDWLRQRIWKH*RYHUQPHQW:KLWH3DSHUµ6PRNLQJ.LOOV¶LQZLWKD
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specific objective of offering help to pregnant women to quit86 and the 
establishment of NHS-SSS specifically tailored for pregnant women from 2001 
onwards.185 This changing tobacco control environment may have made these 
pregnant smokers more willing to approach their GPs for help to quit, and 
IRFXVHG*3V¶DWWHQWLRQRQHQFRXUDJLQJFHVVDWLRQLQWKHLUSDWLHQWVWKHUHE\
increasing the proportion of pregnant women with a smoking status record in 
their medical notes. The proportion of pregnancies with a recording of smoking 
status rose sharply from 18.0% in 2003 to 32.4% in 2004, after which it 
increased slowly until 2009. The most plausible explanation for this marked 
incUHDVHEHWZHHQDQGLV*3V¶DZDUHQHVVRIWKHLPSHQGLQJ
introduction of the 2004 GP contract. 186 Similar improvements in the recording 
of smoking status have been seen in the general population. A study using 
primary care data for over 300 practices throughout the UK found that, although 
UDWHVRIUHFRUGLQJRIVPRNLQJVWDWXVLQSDWLHQWV¶HOHFWURQLFPHGLFDOUHFRUGVKDG
been increasing gradually since the year 2000, the rate of improvement 
accelerated from 2003, with an 88% increase observed between the first quarter 
of 2003 and the same period in 2004, just before the introduction of the QOF.187 
This suggests that the introduction of the QOF resulted in better recording of 
smoking status in the general population which has spilled over into greater 
recording in pregnancy observed in this study.  
For socioeconomic deprivation, asthma and diabetes the magnitude of effect of 
the association with smoking status recording was observed to be stronger after 
the introduction of the QOF. Pre-QOF, pregnant women from the most deprived 
group were 17% more likely to have their smoking status recorded during 
gestation compared to 42% post-QOF. Smoking prevalence is generally higher in 
lower socioeconomic groups in both the general population as well as amongst 
pregnant women59 and the smoking status of smokers is more likely to be 
recorded than that of non-smokers 188-190, which likely explains more complete 
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recording in pregnant women from lower socioeconomic groups. Furthermore, 
low socioeconomic status is associated with a higher prevalence of chronic 
diseases such as hypertension, diabetes, asthma and depression. 191 The QOF 
encourages improved clinical management of these patients, who post-QOF may 
have had more frequent contacts with their GP and thus have had more chance 
of being asked about their smoking behaviour, increasing the gradient of the 
association between socioeconomic status and smoking status recording, 
reflecting that recording, and thus hopefully monitoring, is more complete where 
it is most needed. 192,193  Asthma is the most common pre-existing condition 
encountered during pregnancy 194 and can be exacerbated by smoking,195 which 
may explain the high magnitude of association between asthma and recording of 
smoking status compared to other conditions like diabetes (which affects 
approximately 2-5% women of reproductive age)196 and hypertension (0.6-2.7% 
during pregnancy).197 Women with a higher BMI have an increased risk of 
complications during pregnancy and therefore are more likely to visit their 
GPs.198  They are also more likely to be smokers199 which in turn makes them 
more likely to have a recording of smoking in their primary care record.  
The findings from this work are similar to those from a study in the general 
population which found that primary care patients with smoking-related chronic 
medical conditions and greater social deprivation were more likely to have a 
recent recording of smoking status or cessation advice in their medical 
records.174 However, the magnitude of effect in the general population study for 
all morbidities was much higher than what this study found, possibly because 
currently pregnancy is not a QOF-incentivised condition for recording of smoking 
and because the pregnant population are generally healthier and younger on 
average than the whole population in general practice.  
 
83 
 
3.7 CONCLUSIONS  
In conclusion, smoking status of women during pregnancy was found to be 
recorded in less than half of the study population. This clearly highlights a 
missed opportunity in primary care considering that over three-quarters of 
pregnant women see their GP early in their pregnancy.167 
In relation to the further work in this thesis, even for women with a recording of 
smoking status during pregnancy in primary care, data may not capture the 
changes in their smoking status accurately as over three-quarter of these 
women only had a single smoking related record during pregnancy. This makes 
it hard to establish if the women smoked throughout pregnancy or quit during 
the course of pregnancy. It would also mean that if a cohort of pregnant 
smokers was to be created using gestational smoking records, it may not include 
all women who may have smoked during pregnancy simply because no 
information was recorded. This raises questions on the utility of these data to 
generate population-level estimates on smoking during pregnancy which will be 
explored further in the following chapter. 
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4 COMPARISON OF SMOKING PREVALENCE 
ESTIMATES FROM THIN DATA TO OTHER DATA 
SOURCES 
4.1 INTRODUCTION 
As discussed earlier, reducing smoking in pregnancy to 11% or less by 2015 is 
one of the national goals set in the 2011 White Paper.2 Information on maternal 
smoking is therefore important to monitor the progress towards this national 
goal and also to assess the effectiveness of the interventions currently in place 
for smoking cessation (discussed in Section 1.4.2). Electronic primary care data 
are collected routinely and have the power to provide estimates for the whole of 
the UK as well as constituent countries.149 Therefore, these data such as THIN 
could potentially provide comprehensive and timely population-level data on 
smoking prevalence during pregnancy.  Findings from the previous chapter show 
that even in recent years, smoking status was recorded in less than 50% of 
pregnancies. However, the completeness of the smoking data were be improved 
approximately 8% by making various assumptions based on the QOF recording 
rules discussed in Section 3.2. The next step in the quality assessment of 
smoking status data during pregnancy in primary care is to examine whether the 
prevalence obtained using these recordings in THIN is representative of the 
population-level prevalence of smoking in pregnancy. This is important firstly to 
assess the potential utility of primary care data such as THIN in providing 
population-level estimates of maternal smoking during pregnancy and secondly 
to establish an appropriate cohort of pregnant smokers which can be used for 
further analyses in this thesis. Hence, this chapter compares the prevalence of 
maternal smoking during pregnancy in THIN with the smoking prevalence 
measures obtained from other available data sources in the UK, with certain 
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assumptions based on the QOF, to assess the validity of recorded maternal 
smoking prevalence during pregnancy in THIN. 
This study was published in the Journal of Public Health in October 2014 and is 
attached as Appendix 10.3. 
 
4.2 CURRENTLY AVAILABLE DATA SOURCES IN THE UK TO PROVIDE 
PREVALENCE OF MATERNAL SMOKING DURING PREGNANCY 
The UK currently has four data sources that provide population-level estimates 
of smoking during pregnancy. Each data source measures smoking differently, at 
different points in and around pregnancy and has its strengths and limitations.  
Table 4-1 presents the summary of the important characteristics of these data 
sources and their strengths and limitations. Annual estimates for maternal 
smoking during pregnancy, for these data and other individual studies are 
described in Appendix 10.9 and were shown in Section 1.3.2, Figure 1-1. Annual 
estimates of maternal smoking in pregnancy from each of these data will be 
compared to estimates from THIN in this study.
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Table 4-1 - Summary of available data sources to measure smoking during pregnancy in the UK 
Data source 
 
Data 
collectio
n 
interval 
Country Sampling 
frame and 
method 
Sample size 
ۆ (% of 
national 
births) 
Data 
collection 
method 
Time at 
which data 
on smoking 
in 
pregnancy 
are 
collected 
Definition of 
smoking 
Strengths Limitations 
Infant 
Feeding 
Survey59,138,13
9 
Every 5 
years 
UK 
(England
, 
Scotland, 
Wales, 
Northern 
Ireland) 
Random 
sample of 
live births in 
England and 
Scotland 
and all 
births in 
Wales and 
Northern 
Ireland in 
study period 
22,400 (2.7% 
of all births in 
the UK)159,200-
203 
Postal 
survey 
administere
d by the 
National 
Health 
Service 
Information 
Centre 
6-8 weeks 
after birth 
Several self-
reported 
measures 
available: 
smoking prior 
to 
pregnancy; 
ever smoking 
during 
pregnancy; 
quitting on 
confirmation 
of pregnancy; 
quit/cut down 
attempts 
during 
pregnancy; 
smoking at 
delivery.  
Smoking 
estimates 
for overall 
UK and each 
constituent 
country 
Smoking 
status 
presented 
by socio-
demographi
c factors 
Measures 
smoking 
cessation 
during 
pregnancy 
Data only 
collected at 5 
years intervals 
Retrospective 
reporting of 
smoking status 
Low response 
rates (approx. 
52%) 
Results published 
at least a year 
after survey 
completion 
Smoking 
Status at 
Time of 
Delivery 
(SATOD)60  
Collected 
continuall
y and 
reported 
quarterly 
England Aims to 
capture all 
live births 
and 
stillbirths 
359,763 
(52.1% of all 
births in 
England)159,200 
Midwife-
survey (in 
hospital 
maternity 
units) 
At delivery  Self-reported 
smoking 
status at 
delivery 
Data 
collected 
and 
reported at 
a  local level 
Limited to 
England 
Data collected 
postnatally 
No assessment 
of smoking by 
sociodemographi
c factors  
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ÁSample sizes for each wave vary therefore sample sizes for 2010 described in the table for reference 
Smoking Data 
collected as 
part of the 
Scottish 
Morbidity 
Record 
(SMR)61,203 
Collected 
continuall
y and 
reported 
by 
financial 
year 
Scotland All pregnant 
women 
attending an 
antenatal 
booking 
appointment 
(pregnancie
s may end 
in live birth 
or stillbirth) 
57,398 (100% 
of all 
maternities in 
Scotland)201,20
3 
Midwife 
survey (in 
hospital or 
community) 
First 
antenatal 
booking 
appointment 
(usually 
between 8-12 
weeks 
gestation) 
Self-reported 
smoking 
status at the 
time of 
booking  
Provides 
measures of 
never / ex 
smoking 
along with 
current 
smoking 
Provides 
annual rates 
by age and 
socio-
economic 
status 
 
Limited to 
Scotland 
Does not give 
estimates for the 
whole duration of 
pregnancy 
Pre-school 
component of 
the Child 
Health 
Systems 
Programme 
(CHSP)61 
Collected 
continuall
y and 
reported 
by 
financial 
year  
Scotland Aims to 
capture all 
live births  
51,746 (92% 
of all live 
births in 
Scotland)201,20
3 
Survey 
administere
d by public 
health nurse 
or health 
visitor 
Approximatel
y 10 days 
after birth 
Self-reported  
smoking 
status at the 
time of 
survey 
approximatel
y 10 days 
after delivery 
Provides 
data on 
smokers 
and non-
smokers by 
age and 
socio-
economic 
status 
Limited to 
Scotland 
Data collected 
postnatally only 
Does not 
specifically ask 
about smoking 
during pregnancy 
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4.3 METHODS 
The study population included all pregnancies recorded in THIN between 2000 
and 2009 in women of reproductive age. To prevent the risk of using the same 
pre-conception smoking status for women in their subsequent pregnancies if the 
smoking records were not updated only one random pregnancy per woman was 
chosen.  
   
4.3.1 Comparing the prevalence of smoking in pregnancy in THIN with 
other data sources 
For each woman all smoking status records in THIN before and during pregnancy 
and up to 10 days after delivery were extracted in a similar way as described in 
Section 3.4.2. A period of 10 days after delivery was included to allow 
appropriate comparisons with the Child Health Systems Programme (CHSP) data 
which collects smoking information approximately 10 days postpartum.61 Where 
a Read code did not clearly indicate current smoking (e.g. 137X.00 ± Cigarette 
consumption) further information on smoking status was assessed from the AHD 
and therapy files. This included the number of cigarettes smoked, or presence of 
prescriptions for smoking cessation medications. If no additional information was 
found, the recording was labelled as unknown smoking status.  
For each comparison, ZRPDQ¶VVPRNLQJVWDWXVZDVGHWHUPLQHGLQDVOLJKWO\
different way (Figure 4-1). The annual prevalence of smoking during pregnancy 
as recorded in THIN (as a proportion of all births in that year) was then 
compared against the prevalence measures from the Infant Feeding Survey 
(IFS), Smoking status at Time of Delivery (SATOD), Scottish Morbidity Record 
data (SMR) and CHSP data. Each comparison made in the study used a slightly 
different population of women from THIN and assessed smoking status at a 
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different point in time in pregnancy to reflect the nature of the data collection in 
the source being compared (Table 4-2).  
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Figure 4-1 - Example of a woman's smoking records in primary care and smoking status used for each comparison 
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Table 4-2 - THIN comparisons with the currently available data in the UK 
Survey Time at which 
survey assesses 
smoking 
prevalence 
Years 
compared with 
THIN 
THIN population used for 
comparison 
Timing of records considered to 
define smoking status in THIN 
Infant Feeding Survey 
(IFS) 
At delivery 2000, 2005 Data from all UK practices 
(n=495) 
Last smoking status recording between 
conception and delivery 
Smoking Status at 
Time of Delivery 
(SATOD) 
At delivery 2006-2009 Data from English practices 
(n=378) 
Last smoking status recording between 
conception and delivery 
Scottish Morbidity 
Record (SMR) 
At booking (8-12 
weeks gestation) 
2000-2009 Data from Scottish practices 
(n=63) 
First smoking status recording between 
conception and delivery 
Child Health Systems 
Programme (CHSP) 
10 days after 
delivery 
2001-2009 Data from Scottish practices 
(n=63) 
Last smoking status recording between 
conception and 10 days after delivery 
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Estimates of smoking prevalence from the IFS were derived from the raw 
GDWDVHWVRILQGLYLGXDOZRPHQ¶VVXUYH\UHVSRQVHVDYDLODEOHIURPWKH8.'DWD
Service.204 The IFS only asked about smoking status 6-8 weeks after birth so 
women were classified as smoking at delivery if they reported that they tried to 
give up smoking during pregnancy but started again before delivery, if they tried 
to cut down on the amount smoked during pregnancy, or if they did not try to 
cut down during pregnancy. Estimates of the prevalence of smoking from 
SATOD, SMR and CHSP were obtained from the published reports.60,61,203 
 
 
4.3.2 Imputing smoking status where women had no record during the 
gestational period 
Initially, only records of smoking status documented in THIN after the date of 
conception were used to determine smoking status during pregnancy. However, 
LIDZRPDQ¶Vsmoking status was not recorded during gestation, pre-conception 
records of smoking status were assessed to identify women who smoked before 
pregnancy and may have continued during pregnancy. Based on the QOF rules 
for the recording of smoking status in the general population, which from April 
2004 to March 2006 required the smoking status of patients aged 15 or over to 
be recorded at least once in primary care records, and since April 2006 have 
required records to be updated every 27 months, two cut-off points for including 
pre-conception information were used.172 Firstly, a cut-off of 27 months before 
conception was used and women were recoded as smokers if their last smoking 
record in the 27 months before conception indicated smoking. Finally, if a 
woman did not have her smoking status recorded either during pregnancy or in 
the 27 months before conception, any smoking information recorded in their 
primary care data since registration was included.  
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4.4 RESULTS 
4.4.1 Population of pregnancies in THIN 
The total study population consisted of 215,703 pregnancies from 495 practices 
across the UK; 177,010 of these women were registered with a GP in England 
and 20,188 were in Scotland. Out of the 495 practices contributing to THIN 378 
were from England and 63 were from Scotland. The mean age at conception was 
29.5 years (sd 5.9 years). 
 
4.4.2 Comparison with IFS data 
Figure 4-2 shows the prevalence of smoking at the time of delivery in women in 
THIN in relation to the corresponding measures in the IFS. Annual trends could 
not be compared as there were only two data points available. In 2000, none of 
the three prevalence estimates using THIN data were comparable to the IFS 
estimates. In 2005, smoking prevalence including data recorded up to 27 
months before conception from THIN was slightly higher than the IFS estimate 
(17.0% vs. 20.9% respectively) however THIN prevalence using gestational 
smoking records was approximately seven percentage points lower than the IFS 
estimate. The THIN estimates were only available until 2009 therefore 
comparisons for the 2010 estimates were not possible. However, the IFS 
prevalence of smoking at delivery decreased to 11.6% in 2010 which is in good 
agreement with the THIN prevalence of (10.2%) in 2009 using gestational 
smoking records.  
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Figure 4-2 - Comparison of maternal smoking prevalence during pregnancy from IFS and THIN 
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4.4.3 Comparisons with SATOD data 
When using smoking data recorded any time before delivery, the prevalence of 
smoking during pregnancy recorded in THIN was approximately seven 
percentage points higher than the SATOD estimates from 2006 to 2009. In 
comparison, the THIN prevalence considering data recorded up to 27 months 
before conception was approximately four to five percentage points higher over 
the four years of available data, while the THIN prevalence considering only 
records of smoking recorded during the gestational period was five percentage 
points lower than the SATOD estimates (Figure 4-3). 
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Figure 4-3 - Comparison of maternal smoking prevalence during pregnancy from SATOD and THIN 
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4.4.4 Comparisons with CHSP data 
Using only records of smoking status entered during the gestational period, the 
THIN prevalence of maternal smoking status was low until 2004 (e.g. 43% of 
the CHSP prevalence of 23.1% in 2004) (Figure 4-4). It was 12.9% in 2009, 
approximately seven percentage points lower than the corresponding CHSP 
prevalence of 19.5%. Using smoking information recorded in the 27 months 
before pregnancy, the prevalence in CHSP and THIN converged in 2005. After 
this the THIN estimates were slightly higher than the CHSP estimates, such that 
in 2009 the THIN prevalence using data recorded up to 27 months before 
pregnancy was 22.9% compared to the CHSP prevalence of 19.5%. The 
prevalence estimates using data recorded ever before delivery were only slightly 
higher than the estimates using the data recorded up to 27 months before 
conception.  
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Figure 4-4 - Comparison of maternal smoking prevalence during pregnancy from CHSP and THIN 
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4.4.5 Comparison with SMR data 
Using smoking status data recorded during the gestational period, the THIN 
prevalence was much lower than the SMR prevalence until 2004 (56% lower 
than the SMR prevalence of 23.8% in 2004, as shown in Figure 4-5). Prevalence 
in THIN was 13.8% in 2009 but was still 23% lower than the corresponding SMR 
prevalence of 18.1%. When including smoking information recorded up to 27 
months before conception the two lines converged in 2005; in 2009 smoking 
prevalence in THIN was 23.8% using data recorded up to 27 months before 
conception and smoking prevalence using data recorded any time before 
pregnancy was 24.5% compared to the SMR prevalence of 18.1%.   
100 
 
 
 
Figure 4-5 - Comparison of maternal smoking prevalence during pregnancy from SMR and THIN 
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4.5 DISCUSSION  
4.5.1 Principal findings  
With current levels of completeness of smoking data in primary care records, it 
is not possible to produce population level estimates of smoking prevalence 
during pregnancy that are directly comparable to those derived from the existing 
data sources. The convergence between THIN estimates and estimates from 
other data sources has, however, improved over time. The comparability of THIN 
data to the SMR and CHSP surveys can be improved by the additional use of 
smoking status data recorded in the 27 months before conception but these to 
an extent may reflect smoking in general female population. 
 
4.5.2 Strengths and limitations 
This is the first study to assess the potential of primary care data to provide 
population level estimates of smoking during pregnancy and compare it with 
other current data sources in the UK. As discussed earlier, fertility rates in THIN 
are comparable to national fertility rates153 and therefore the ascertainment of 
pregnancies is reasonably complete. However, like the other data sources under 
comparison, data on smoking status recorded in THIN are self-reported and 
women may not accurately report their smoking behaviour, particularly during 
pregnancy where there may be social stigma attached to smoking.205 
Underreporting of smoking during pregnancy may arguably be a particular 
problem in the IFS, where women are surveyed six to eight weeks after delivery.  
A potential limitation of this work is the inclusion of pre-conception smoking 
records to predict smoking status during pregnancy, which may not be an 
DFFXUDWHUHIOHFWLRQRIZRPHQ¶VVPRNLQJVWDWXVGXULQJSUHJQDQF\6WXGLHVZKLFK
have investigated smoking behaviour in early pregnancy indicate that many 
women attempt to quit when they find out they are pregnant or later during 
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pregnancy,206  so it is unlikely that the inclusion of pre-conception records 
resulted in an under-estimation of smoking prevalence during pregnancy.  It 
could however, lead to misclassification of some ex-smokers as smokers, 
resulting in an over-estimation of the prevalence of smoking during pregnancy in 
THIN. A substantial over-estimation is unlikely as approximately 35-50% of 
pregnancies in the UK are unplanned,207,208 which means that only some women 
are likely to make positive behaviour changes such as quitting smoking before 
attempting to conceive. It may, however, hold true for some women who quit on 
confirmation of their pregnancy.  
Another potential weakness of this study, and of primary care data, is that using 
primary care records it is difficult to determine the timing of smoking status 
ascertainment in relation to progress through gestation; this makes direct 
comparison with other data sources, obtained at booking or delivery, difficult. 
Lastly, smoking status during pregnancy is a complex and variable behaviour 
and it may fluctuate throughout pregnancy.183 Therefore, single measures of 
smoking such as smoking at booking or smoking at delivery captured in SATOD, 
SMR and CHSP data are limited in their usefulness. Although these single 
measures may give a snapshot of smoking behaviour at a certain time, they 
may not give a complete picture of smoking behaviour throughout pregnancy. 
Hence, these data sources may provide population-level prevalence of maternal 
smoking at different points relative to pregnancy but do not contain information 
RQFKDQJHVLQZRPHQ¶VVPRNLQJVWDWXVWKURXJKRXWSUHJQDQF\RUSRVWSDUWXP
period. IFS data assess smoking behaviour throughout pregnancy in more detail, 
albeit collected retrospectively. Nevertheless, these data are collected on a 
quinquennial basis and thus may become out of date quickly. A study with 
complete pregnancy follow-up and accurate assessment of smoking status and 
chanJHVLQZRPHQ¶VVPRNLQJEHKDYLRXUPD\EHUHTXLUHGIRUWKLV However, if 
smoking information was collected and recorded by GPs more frequently 
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throughout pregnancy, then primary care data may prove to be very useful to 
assess these changes in the smoking status of women during pregnancy but as 
shown in this study currently these data are not complete.    
 
4.5.3 Interpretation in light of the current literature 
To date, there are no studies assessing the validity of primary care data for 
quantifying the prevalence of smoking during pregnancy. A study comparing 
smoking prevalence recorded in THIN to smoking prevalence in the general 
population (measured by the General Lifestyle Survey (GLF)) found a good 
agreement between THIN and the GLF after 2008 and concluded that primary 
care data may provide an alternate means of monitoring national smoking 
prevalence.149 Despite the smaller sample sizes at regional level, primary care 
data have also been shown to be a good means of monitoring regional smoking 
prevalence in the general population.155  
The prevalence estimates of smoking during pregnancy from primary care do not 
accurately converge with other data sources because, at least in part, smoking 
status recording during pregnancy in primary care is incomplete.20 209 Potential 
reasons for this have already been discussed in Section 3.6.3. This was shown in 
the previous study in this thesis which found that from 2000 to 2009 smoking 
status was only recorded in primary care for 28% of pregnancies. Nevertheless, 
this is to an extent similar to conducting a survey on a selected group of 
pregnant women from the population where smoking information may only be 
available on the women surveyed out of the whole population, which in this case 
is only available for women who were asked about their smoking status during 
pregnancy out of the whole primary care population of pregnant women.  
Another possible explanation for the lower THIN prevalence could be that THIN 
over-represents general practices from more affluent areas of the UK. Since 
smoking prevalence is lower in women from more affluent groups, this may 
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slightly under-estimate the smoking prevalence generated using THIN data and 
account for some of the differences between THIN prevalence estimates and 
other data sources.  
Whilst THIN estimates using only gestational smoking records do not 
approximate closely to annual prevalence from other data sources, THIN 
estimates using gestational smoking status show a close converging pattern with 
the data from SMR (collected at booking) in 2009. This is sensible as women see 
their GPs for initial care in pregnancy and implies that primary care data may be 
most useful to provide adequate data on smoking prevalence early in pregnancy, 
when most women see their GPs for initial care, compared to the time around 
delivery, when most women will be cared for essentially in secondary care 
facilities.   
 
4.6 CONCLUSIONS  
All existing data sources that measure smoking during pregnancy have their 
strengths and limitations. Primary care data have a great potential to measure 
smoking status during pregnancy at a population level. Although recording of 
gestational smoking status in THIN is improving over time, it is not adequately 
complete to produce maternal smoking estimates at a population level with most 
women just having a single record of smoking status throughout the course of 
pregnancy. Periodic recording of smoking status during pregnancy is important 
to monitor changes in smoking behaviour throughout pregnancy and to maintain 
DQGLPSURYHZRPHQ¶VFDUHEHIRUHDQGDIWHUGHOLYHU\$OWKRXJKWKLVLQIRUPDWLRQ
may be recorded and updated in hand-held maternity notes, there is currently 
no centralised recording system and the information in these notes is lost after 
delivery. Better integration of recording systems in primary care and midwifery 
services is required to improve communication and relay of relevant medical and 
lifestyle information including smoking status.  
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In terms of the further work in this thesis, it means that a cohort of pregnant 
smokers developed using smoking data recorded during gestation may not be 
representative of the UK population of pregnant smokers and some assumptions 
including use of pre-conception smoking records may need to be made in order 
to capture more women who smoke during pregnancy. Using gestational 
smoking records to create a cohort of smokers for studying the trends in the 
epidemiology of NRT prescribing in pregnant women in the later chapters will 
result in an underestimation of smokers. Therefore, a more exhaustive approach 
is needed to define the denominator of smokers for further analysis in this 
thesis. Smoking records from 27 months before conception were therefore 
included where no gestational smoking records were available. The comparability 
of THIN measures with prevalence measures from other data sources increased 
by including smoking information recorded within 27 month before conception 
and therefore this will provide a more appropriate denominator for further 
analysis in the thesis especially after 2004 as the recording of smoking status 
improved after the introduction of QOF. Another important consideration which 
was highlighted in this chapter was that even when considering the smoking 
records from 27 months before conception, the comparisons for earlier years i.e. 
2000-2003 are not good, so it may be more appropriate to also use all pregnant 
women as a denominator for the later analysis in addition to pregnant smokers 
to rule out any bias that may arise due to the changes in smoking data quality 
over time.   
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5 PRESCRIBING OF NICOTINE REPLACEMENT 
THERAPY IN AND AROUND PREGNANCY 
5.1 INTRODUCTION 
As discussed in Section 1.5, NRT has been available on NHS prescription since 
2001; however, it was only in 2003 that the BNF changed its instructions for 
NRT use in pregnancy to a caution from a contraindication.96  The 2005 MHRA 
review concluded that despite a lack of conclusive evidence for efficacy, NRT use 
was likely to be less harmful than smoking,97 consequently broadening the UK 
licensing arrangements for NRT to include pregnant women in December 2005.98 
It is now widely available and recommended for smoking cessation in pregnant 
women in the UK, based on the theoretical notion that it is safer to use NRT 
during pregnancy than to smoke. The BNF clearly states that the use of NRT in 
pregnancy is preferable to the continuation of smoking but should be used only 
if smoking cessation without NRT fails.210  
NRT use is also recommended in guidelines for smoking cessation in pregnancy, 
where cessation without NRT fails.79,124 However, information on NRT prescribing 
and use in pregnant women is lacking worldwide.  In light of this, the  WHO 
recently recommended an urgent need for studies on surveillance of current use 
of NRT in pregnancy.73 Literature describing NRT use in pregnancy is limited to 
observational studies from the USA and Denmark assessing the association 
between NRT use during pregnancy and adverse birth outcomes. The prevalence 
of self-reported NRT used in the first 12 weeks of gestation was 0.3% 114, 2-
2.5% in 17-27 weeks of gestation in the Danish National Birth Cohort 112,113 and 
in the Pregnancy Risk Assessment Monitoring System (PRAMS) from four USA 
states it was 3.9% (2004).111 Since then, new NRT products have been 
introduced and international guidelines on gestational NRT use have changed. 
Thus far, only a limited number of studies in the UK have assessed prescribing 
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and uptake of NRT during pregnancy in the UK and these studies are either too 
small,116 providing local data 116,131 or only including prescribing taking place in 
the NHS-SSS.132 It is also important to know the NRT prescribing trends for 
pregnant women by different maternal factors as the prevalence of maternal 
smoking varies by different maternal factors (e.g. age, socioeconomic status 
etc.59). Therefore, investigation of factors related to NRT prescribing may give 
an insight on the characteristics of women who attempt to quit smoking during 
pregnancy and whether targeted interventions are needed for women with 
specific characteristics. However, none of these previous studies have assessed 
these in detail. The generalisability of the findings from the previous is therefore 
limited. Furthermore, none of the previous studies have assessed changes in 
prescribing after the relaxation of the licensing arrangements for NRT which is 
important to assess the effect of this change on the prescribing rules. Therefore, 
this chapter aims to assess the prescribing of NRT in and around pregnancy, 
using the UK primary care data. This will potentially provide population-based 
estimates for NRT prescribing in pregnant women which can be generalisable to 
the whole of the UK, which previous studies have failed to do. The specific 
objectives for the study discussed in this chapter are: 
1. To examine patterns of NRT prescribing before, during and after 
pregnancy 
2. To calculate annual prescribing prevalence of NRT before, during and 
after pregnancy to inform changes in relation to the MHRA relaxation  
3. To assess whether and how NRT prescribing varies by maternal 
characteristics  
This study was published in the British Journal of General Practice in September 
2014 and attached as Appendix 10.4. 
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5.2 METHODS  
5.2.1 Study population 
The study population for this analysis was restricted to all pregnancies between 
January 2001 and September 2009 in women of childbearing age (15-49 years) 
which resulted in either a live birth or a stillbirth, as NRT only became available 
on NHS prescription in 2001. 
 
5.2.2 Extracting smoking status, NRT prescribing and other covariates 
All prescriptions for NRT were extracted, using multilex drug codes for all the 
NRT formulations available in the UK according to the BNF (Appendix 10.6) 
which may be used by the GPs to prescribe NRT in primary care .210 To 
investigate the maternal factors that may be associated with NRT prescribing 
during SUHJQDQF\GDWDZHUHH[WUDFWHGRQZRPHQ¶VDJHDWFRQFHSWLRQ
socioeconomic deprivation as measured by quintiles of the Townsend Index of 
deprivation,177  pre-conception BMI and recorded diagnoses of medical 
conditions (hypertension, diabetes, asthma, and mental illness) as described in 
Section 3.4.3. These conditions are most prevalent in women of childbearing age 
and are closely related to smoking51,59,195,211,212 and therefore may also influence 
quit attempts made using NRT.  
 
5.2.3 Statistical analysis 
The overall and annual proportions of pregnancies with one or more NRT 
prescriptions before, during and after pregnancy were determined. This was 
repeated restricting the denominator to pregnancies in smokers only (making 
use of gestational smoking data and smoking information from 27 months before 
conception). A period of nine months before and after pregnancy was used to 
calculate prescribing prevalence, as this was similar to the average pregnancy 
length allowing for comparisons of period prevalence. There is no evidence of 
the time before and after pregnancy during which smokers are more likely to 
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attempt to quit. However, since nine months is a comparatively long time and 
smoking behaviours may fluctuate during this time, prescribing prevalence of 
NRT was also assessed in smaller three month windows before, during and after 
pregnancy. In addition, the use of different forms of NRT (patches, gum, nasal 
spray, lozenges, sublingual tablets, and inhalator cartridges) and combination 
NRT was also assessed. Oromucosal nicotine spray was first authorised for use in 
November 2010213 and therefore was not included in this analysis. 
Logistic regression was used to calculate ORs for associations between ZRPHQ¶V
characteristics and NRT prescribing to smokers during pregnancy, restricting the 
analysis to pregnancies delivered between January 2006 and December 2009 
since NRT was not licensed for use in pregnancy until December 2005 and 
therefore prescribing was not expected to be very frequent. Likelihood ratio tests 
(LRT) were used to assess the associations with categorical covariates and Wald 
p-values were used for binary covariates. All covariates that reached statistical 
significance (p<0.05) in the univariable analysis were initially included in the 
multivariable analyses and each covariate was sequentially dropped from the 
model to assess whether the associations were still significant. Covariates that 
reached statistical significance (p<0.05) in the multivariable analysis were 
retained in the final model. As some women had more than one pregnancy 
during the study period, this potential clustering of pregnancies within women 
was accounted for by calculating robust CIs around the odds ratios using the 
clustered sandwich estimator, 180,181  which is explained in Section 3.4.4. 
 
5.2.4 Sensitivity analysis 
In addition to calculating overall proportions, rates of prescriptions per 1,000 
person-years were also calculated as this allowed for better categorisation of 
time windows before, during and after pregnancy (nine months), controlling for 
possible fluctuations in smoking status. The study time was split into times 
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before, during and after pregnancy to accurately assess the rates of NRT 
prescribing for smokers in each of the three time periods. Smoking was treated 
as a time-YDU\LQJFRYDULDWHXVLQJOH[LVH[SDQVLRQLHZRPHQ¶VVPRNLQJVWDWXV
was allowed to change at every point of smoking status recording in their 
SULPDU\FDUHGDWDWRFDSWXUHZRPHQ¶VVPRNLQJHSLVRGHVPRUHDFFXUDWHO\Figure 
5-1 explains the step-by-step splitting of the follow-up time for each woman by 
pregnancy time and smoking status. The follow-up time was further split into 
times before and after the relaxation of NRT licensing arrangements in 
December 2005. The rates of NRT prescriptions per 1,000 person-years were 
calculated before, during and after pregnancy in two time periods (2001 to 2005 
and 2006 to 2009).  Finally, rate ratios and 95% CIs were calculated to compare 
prescribing in smokers before and after the relaxation of licensing arrangements 
in the three time periods, using poisson regression.
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Figure 5-1 - Step-by-step splitting of the study follow-up time by smoking status and pregnancy time 
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5.3 RESULTS 
5.3.1 Baseline characteristics 
A total of 201,465 women were identified with 255,411 pregnancies resulting in 
live births or stillbirths between January 2001 and December 2009, of which 
45,045 (18%) were pregnancies of mothers classified as smokers. The mean 
age at conception was 29.5 years (sd 5.9) and the average length of pregnancy 
was 39.4 weeks (sd 2.2). Table 5-1 GHVFULEHVZRPHQ¶VFKDUDFWHULVWLFVIRUDOO
pregnancies and pregnancies among smokers, and NRT prescribing prevalence 
according to these characteristics. In the whole population, asthma, diabetes, 
hypertension and mental illness affected 9%, 2%, 3% and 9% of pregnancies 
respectively. Only the prevalence of asthma and mental illness were higher in 
smokers. 
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Table 5-1 - Baseline characteristics of the study population 
*recorded as current smoker within 27 months before conception until delivery, **socioeconomic status 
 
 
 
 
 Total 
pregnancies 
(n=255,441) 
Pregnancies with an NRT 
prescription  (total n=4,826) 
Pregnant smokers* 
(n=45,045) 
Pregnant smokers with an NRT 
prescription (n=4,826) 
Age at Conception      
15-19 years 19,212 636 (3.3%) 6,716   623    (9.3%) 
20-24 years 43,569 1,227 (2.8%) 12,300 1196    (9.7%) 
25-29 years 69,159 1,237 (1.8%) 11,620 1223  (10.5%) 
30-34 years 78,034 1,103 (1.4%) 9,246 1086  (11.7%) 
35-39 years 38,764 527 (1.4%) 4,412 523  (11.9%) 
40-44 years 6,384 90 (1.4%) 712 89  (12.5%) 
45-49 years 319 6 (1.9%) 39 6  (15.4%) 
Townsend score in quintiles **   
Quintile 1 ± least deprived 57,859 486 (0.8%) 5,339 474     (8.9%) 
Quintile 2 47,841 586 (1.2%) 6,118 582     (9.5%) 
Quintile 3 49,670 921 (1.9%) 8,797 904   (10.3%) 
Quintile 4 47,292 1,315 (2.8%) 11,376 1,295   (11.4%) 
Quintile 5 - most deprived 36,103 1,188 (3.3%) 10,515 1,166   (11.1%) 
Missing 16,676 330 (2.0%) 2,900 325   (11.2%) 
Pre-conception Body Mass 
Index 
     
Normal(18.0-24.9) 80,003 1,502 (1.9%) 15,040 1,483     (9.9%) 
Underweight(<18.0) 5,871 152 (2.6%) 1,630 151     (9.3%) 
Overweight(25-29.9) 38,931 784 (2.0%) 7,306 771   (10.6%) 
Obese(>=30) 26,753 617 (2.3%) 5,500 603   (11.0%) 
Missing 103,883 1,771 (1.7%) 15,569 1,738   (11.2%) 
Asthma 21,884 678 (3.1%) 5,216 670 (12.8%) 
Hypertension 6,885 107 (1.6%) 966  107 (11.1%) 
Diabetes 5,971 114 (1.9%) 939 114 (12.1%) 
Mental illness 24,178 947 (3.9%) 7,166 937 (13.1%) 
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5.3.2 Patterns of NRT prescribing in and around pregnancy 
NRT was prescribed in a total of 4,826 pregnancies, which represents a 
prescribing prevalence of approximately 2% of all pregnancies and 11% of 
pregnancies in smokers. In comparison, the prescribing prevalence was 1% 
during both the nine months before and after pregnancy and approximately 5% 
in pregnancies in smokers. Figure 5-2 shows the prescribing prevalence in each 
three-month period before, during and after pregnancy in all pregnant women 
and Figure 5-3 shows the prescribing prevalence among pregnant smokers. 
Among smokers, NRT prescribing was more prevalent during the first and 
second trimester, with a prescribing prevalence of just over 5% in each  
compared to approximately 2.5% in the third trimester, which was similar to the 
periods before and after pregnancy.  
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Figure 5-2 - Proportion of all pregnancies with NRT prescription in each three month period, between 2001 and 2009 
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Figure 5-3 - Proportion of pregnant smokers with NRT prescription in each three month time period, between 2001 and 2009 
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Among the 4,826 women who were prescribed NRT during the nine months of 
pregnancy, over half of these (56%) were only issued one prescription for NRT.  
Another quarter of these women were prescribed NRT on two separate 
occasions. The maximum number of prescriptions issued during pregnancy was 
262QDYHUDJHZRPHQZHUHSUHVFULEHGDWRWDORIZHHNV¶ZRUWKRI157,45
1-2 weeks). The frequency of NRT prescribing nine months before and after 
pregnancy was similar to the pattern within pregnancy, with over half of the 
women receiving only a single prescription for NRT in each nine month period. 
In approximately two thirds of the pregnancies in which NRT was prescribed 
during gestation NRT prescribing was initiated only during pregnancy; there 
ZHUHQRUHFRUGVRI157SUHVFULSWLRQVLQWKHVHZRPHQ¶VSULPDU\FDUHGDWDSULRU
to the start of pregnancy.  The most common form of NRT used during 
pregnancy was transdermal patches (approximately 70% of all prescriptions), 
followed by inhalator cartridges (14%), gum (9%), lozenges (5%), sublingual 
tablets (3%) and nasal spray (0.5%). The distribution of NRT forms prescribed 
before and after pregnancy was very similar. Figure 5-4 describes the 
distribution of different forms of NRT prescribed before, during and after 
pregnancy. Prescribing of combination NRT was observed in 471 (10%) of the 
4,826 women where NRT was prescribed during pregnancy, 204 (8%) of 2,645 
mothers with NRT prescriptions before pregnancy and 273 (11%) of 2,410 
mothers with NRT prescriptions after pregnancy.
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Figure 5-4 - Use of different forms of NRT before, during and after pregnancy 
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5.3.3 Annual prescribing of NRT before, during and after pregnancy 
Figure 5-5 shows the annual proportion of pregnancies and Figure 5-6 shows the 
proportion of pregnancies in smokers between 2001 and 2009 where NRT was 
prescribed before, during and after pregnancy. In 2001, the prescribing 
prevalence of NRT during pregnancy, taking all pregnancies as the denominator, 
was 0.03% (0.7% in pregnancies in smokers). This increased to 2.6% (11.5% in 
pregnancies in smokers) in 2005 after which it remained stable such that in 
2009 the prescribing prevalence of NRT in all pregnancies was 2.6% (11.2% in 
pregnancies in smokers). The overall prescribing prevalence of NRT during 
pregnancy between 2001 and 2005 (i.e. before the relaxation of licensing 
arrangements) was 1.1 %( 9.6% in pregnancies in smokers) and increased to 
2.5% (11.1% in pregnancies in smokers) for the period of 2006-2009 (time 
after the relaxation of licensing arrangements). NRT prescribing prevalence in 
the nine months before and after pregnancy increased until 2005 after which it 
remained stable at around 1% (6% in smokers), with a slight decline after 2006. 
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Figure 5-5 - Annual prescribing prevalence of NRT in all pregnancies 
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Figure 5-6 - Prescribing prevalence of NRT in pregnant smokers 
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5.3.4 Prescribing of NRT by maternal characteristics 
Table 5-2 shows the maternal characteristics associated with prescribing of NRT 
within pregnant smokers between 2006 and 2009. Pregnant smokers from more 
deprived groups were more likely to receive an NRT prescription compared to 
pregnant smokers from less deprived groups (OR for Quintile 5 compared to 
Quintile 1= 1.33, 95% CI 1.14-1.52) and older pregnant smokers were more 
likely to receive NRT than younger smokers (OR for 30-35 years compared to 
25-30 = 1.21, 95% CI 1.09-1.35). Pregnant smokers with a diagnosis of asthma 
were 34% more likely to be issued an NRT prescription in primary care 
compared to pregnant smokers without asthma (OR 1.34, 95% CI 1.21-1.50). In 
addition, pregnant smokers with a diagnosis of mental illness were 29% more 
likely to receive a prescription for NRT during pregnancy compared to pregnant 
smokers without mental illness (OR 1.29, 95% CI 1.18-1.43).
123 
 
Table 5-2 - Prescribing of NRT during pregnancy in smokers by maternal characteristics between January 2006 and 
December 2009 
Demographic variables Pregnant smokers with one or 
more NRT prescriptions   
(n=3,160) 
Unadjusted  Odds Ratio 
(95% CI) 
p-value Adjusted Odds 
Ratio (95% CI)** 
p-value 
Age at conception      
15-20 years 430 (10.1%) 0.91 (0.80-1.02)  0.89 (0.78-1.00)  
20-25 years 833 (10.6%) 0.96 (0.86-1.06) <0.001 0.94 (0.85-1.04) <0.001 
25-30 years 801 (11.0%) 1  1  
30-35 years 692 (12.8%) 1.19 (1.07-1.32)  1.21 (1.09-1.35)  
35-40 years 337 (12.5%) 1.15 (1.00-1.32)  1.18 (1.03-1.35)  
40-45 years 63 (13.8%) 1.29 (0.98-1.69)  1.28 (0.97-1.69)  
45-49 years 4 (16.7%) 1.61 (0.55-4.73)  1.58 (0.53-4.71)  
Townsend score      
Quintile 1 (least deprived) 285 (9.4%) 1  1  
Quintile 2 384 (10.3%) 1.10 (0.94-1.30) <0.001 1.11 (0.94-1.31) <0.001 
Quintile 3 611 (11.0%) 1.20 (1.04-1.39)  1.23 (1.05-1.43)  
Quintile 4 880 (12.2%) 1.35 (1.17-1.56)  1.39 (1.20-1.61)  
Quintile 5 (most deprived) 766 (11.6%) 1.28 (1.10-1.47)  1.33 (1.14-1.52)  
Missing 234 (12.6%) 1.39 (1.16-1.67)  1.43 (1.21-1.76)  
Pre-conception Body 
Mass Index (kg/m2) 
     
Normal(18.0-24.9) 1,036 (11.1%) 0.89 (0.2-1.09)    
Underweight(<18.0) 104 (10.0%) 1 0.549 - - 
Overweight(25-29.9) 532 (11.3%) 1.02 (0.91-1.35)    
Obese(>=30) 433 (11.8%) 1.06 (0.94-1.19)    
Missing  1,055 (11.4%) 1.03 (0.94-1.13)    
Diabetes * 86 (13.5%) 1.23 (0.98-1.56) 0.078 - - 
Hypertension* 71 (12.2%) 1.09 (0.85-1.41) 0.476 - - 
Asthma* 477 (14.4%) 1.37 (1.24-1.53) <0.001 1.34 (1.21-1.50) <0.001 
Mental illness* 612 (13.9%) 1.34 (1.22-1.47) <0.001 1.29 (1.18-1.43) <0.001 
NRT ± Nicotine Replacement Therapy, CI ± confidence interval, * compared to women without the condition **all covariates 
mutually adjusted 
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5.3.5 Sensitivity analysis 
A total of 201,465 women contributed 669,230 person-years before pregnancy, 
927,952 person-years during pregnancy and 971,754 person-years after 
pregnancy giving a total person time of 2,568,936 years. The rate of NRT 
prescribing during pregnancy in smokers between 2001 and 2005 was  34.1 
prescriptions per 1000 person-years (95% CI 34.1-33.0), equating to 
approximately 3.4% of women annually. The rate of NRT prescribing in the nine 
months before and after in women during pregnancy was 30% lower  than the 
rates of prescribing during (RR 0.70, 95% CI 0.66-0.73) each. After the 
relaxation of licensing arrangements in December 2005 this rate of prescribing 
during pregnancy increased to 68.3 per 1000 person-years equating to 
approximately 7% of women annually. The gradient between prescribing during 
pregnancy and outside increased such that women were 45% less likely to 
receive an NRT prescription before pregnancy (RR 0.55,95% CI 0.52-0.58) and 
52% less likely to receive a prescription after pregnancy (RR 0.48, 95% CI 0.46-
0.50) compared to during pregnancy. 
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Table 5-3 - Time specific rates and rate ratios of NRT prescribing  
Exposure time  No. of Prescriptions Person-years Rate* 95% CI RR 95% CI 
2001-2005 
9 months before pregnancy 2,535 107,857 23.5 22.5-24.5 0.70 0.66-0.73 
During pregnancy 3,701 108,476 34.1 34.1-33.0 Reference 
9 months after pregnancy 1,994 84,671 23.6 22.5-24.6  0.70  0.66-0.73 
2006-2009 
9 months before pregnancy 2,107 561,373 37.5 35.9-39.2 0.55 0.52-0.58 
During pregnancy 5,594 819,476 68.3 66.5-70.1 Reference 
9 months after pregnancy 2,892 887,083 32.6 31.4-33.8 0.48 0.46-0.50 
*rate of NRT prescribing per 1000 person-years 
RR ± Rate Ratio, CI ± Confidence interval 
Total number of women=201,465 
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5.4 DISCUSSION  
5.4.1 Principal findings 
After NRT was made available  on NHS prescription in 2001 prescribing in and 
around pregnancy increased; by 2005 prescribing was twice as high during 
pregnancy as that in the nine months immediately before and after pregnancy, 
despite it being contraindicated for pregnant women. The December 2005 
licence relaxation to allow prescribing in pregnancy did not further increase 
these trends and the prescribing prevalence during pregnancy has remained 
stable at 2% (11% in smokers). Women with asthma or mental illness and those 
from more socio-economically deprived areas were more likely to receive 
prescriptions during pregnancy. However, 80% women received less than 2 
prescriptions, lasting two weeks on average. 
 
5.4.2 Strengths and limitations 
This study presents longitudinal and contemporaneous prescribing estimates; it 
is the first study of NRT prescribing during pregnancy in the UK primary care and 
the only study internationally to assess NRT prescribing trends. The 
ascertainment of NRT in this study is based on prescribing data rather than the 
self-reported NRT use, which women may under-report.112 Additionally, 
prescribing in the nine month periods immediately before and after pregnancy 
has also been assessed in this study, whereas other studies only report NRT use 
in trimesters 1-2.112-114,129 Therefore, the findings of this study are novel in that 
they present the first estimates of NRT prescribing around pregnancy, which 
provides some information on smoking cessation attempts pre-conception and 
postpartum.  
The data used in this study capture all NRT prescribing to pregnant women in UK 
primary care in practices registered in THIN. However, this may not include NRT 
prescribing in other settings such as local NHS Stop Smoking Services for 
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Pregnant women (SSSP) and NRT purchased over-the-counter or off the shelf. 
Only 3% of pregnant women use the SSSP on average each year214,215 and a 
survey of all SSSPs in England conducted between April 2010 and March 2011 
reported that almost half of the NRT provided by these services was issued 
through GPs.185 In terms of self-purchased NRT, this is expected to be infrequent 
for several reasons. Firstly, the prevalence of medication use without health 
professional consultation is lower during pregnancy than when women are not 
pregnant.216 Furthermore, all NRT packaging, clearly instructs women to consult 
a doctor before using this if they are pregnant. Lastly, in the UK women are 
entitled to free NHS prescriptions during pregnancy and the first year after 
delivery217  so they may be more likely to get free prescriptions through GPs 
than paying for NRT. Hence, this study is believed to capture the majority of the 
prescriptions of NRT issued. 
Some women may quit or relapse after delivery consequently leading to changes 
in the denominator of smokers and therefore the NRT estimates could be both 
over-estimated if more women relapse than are recorded and under-estimated if 
more women quit. Therefore, prescribing prevalence is also reported in all 
pregnancies in addition to smokers. Also, in these data over 75% of pregnant 
women who were classified as smokers during pregnancy and who had a 
recording of smoking status within the nine months after delivery were still 
recorded to be smokers. Hence, a substantial over-estimation or under-
estimation of NRT prescribing prevalence in smokers is unlikely. The rates of 
NRT prescribing were also calculated, treating both smoking and pregnancy as 
time-varying covariates, to take into account the changes in wRPHQ¶VVPRNLQJ
status over time. These rates were found to be slightly lower than the calculated 
NRT prescribing prevalence in smokers (~7% compared to ~11% after 2005). 
This is because although rates allow for more appropriate categorisation of time 
and exposure windows, the recording of smoking status during pregnancy is 
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incomplete as discussed in Chapter 3, masking the true reflection of smoking 
status changes over time and consequently limiting the advantage of using lexis 
expansion for this analysis. Nevertheless, the rate ratios using poisson 
regression were in concordance with the other results reiterating that NRT 
prescribing during pregnancy was almost double that of the prescribing before 
and after pregnancy in the post-relaxation period (RR 0.55 before pregnancy 
and RR 0.48 after pregnancy). 
Another potential limitation of the study is that prescriptions provide no 
measures of actual medication use, compliance to the drug therapy or successful 
quit attempts made and some of the prescriptions issued may not have been 
redeemed. However, a validation study comparing the recorded prescriptions for 
smoking cessation medications in THIN and the NHS dispensing data between 
January 2004 and December 2005 reported good comparability between the two 
data sources indicating that prescriptions recorded for smoking cessation 
medications in primary care data are collected by the patients.156  The only 
measures of compliance are available from trials. The SNAP trial reported low 
compliance rates in both treatment and placebo group (7.2% and 2.8% 
respectively using NRT for more than a month).100 However, the reasons for low 
compliance remain unexplored. A qualitative study conducted on pregnant 
smokers in Australia explored barriers to NRT use and found that women with 
medical problems or history of obstetric complications expressed doubts about 
using NRT and were sceptical about its effectiveness.118 However, specific 
reasons for low compliance rates to NRT during pregnancy have not been 
studied to date. Lastly, there were no measures available for nicotine 
dependence in the data. Assessing these measures of dependence (e.g. 
Fagerstrom Test for Nicotine Dependence) is difficult without surveying the study 
participants which would be limited by potential response biases and are rarely 
possible on the large population scale presented by the data in this study.   
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5.4.3 Comparison with current literature 
There are no studies internationally which have assessed the annual prescribing 
prevalence of NRT in pregnant women in detail. However data from nested case-
control studies from the USA and Denmark assessing associations between NRT 
use and adverse pregnancy outcomes report the overall prescribing prevalence 
of NRT in all pregnancies to range from 0.3 to 4%,111-113 which is very similar to 
the findings of this study. The findings of this study closely mirror that of the 
Scottish data linkage study where NRT was prescribed to 2.4% of all pregnant 
women131. In addition, NRT usage in pregnant smokers attending English SSSPs 
is reported to be 85%132 and considering that only 3% of pregnant women 
attend these services, this also equates to 2.5%. This implies that the uptake of 
NRT during pregnancy in smokers is quite high (~11% of smokers) despite the 
lack of evidence of its effectiveness and safety.   
The results of this study also demonstrate that the annual prescribing 
prevalence of NRT has been stable and not increased much since the changes in 
the licensing arrangements in December 2005, although overall prescribing in 
the years after the relaxation of licensing arrangements has almost doubled. The 
difference between the prescribing prevalence in pregnancy and the nine month 
periods immediately before and after pregnancy started widening after 2003. 
This may be attributed to the changes in prescribing indications for NRT use 
implemented in May 2003, when pregnancy was removed from the list of 
contraindications for NRT use and instead cautious use of NRT products in 
pregnancy was advised if smoking cessation without NRT failed.96 After the 
relaxation of licensing arrangements of NRT in 2005 prescribing of NRT during 
pregnancy was almost twice as high compared to the prescribing in the nine 
months immediately before and after pregnancy. This may also be related to the 
licensing of varenicline for smoking cessation in the general non-pregnant 
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population in December 2006, after which a reduction in prescribing of NRT and 
bupropion in the general population was seen.218 Alternatively, women may be 
more motivated to quit after finding out they are pregnant or may deliberately 
wait to quit until they get pregnant as they can get free NRT prescriptions during 
pregnancy.    
The prescribing prevalence of NRT was found to be the highest in the first two 
trimesters during pregnancy compared to the other time periods under study 
and the prescribing prevalence within the third trimester was very similar to the 
prescribing prevalence before and after pregnancy. In a survey of all SSSPs in 
England between April 2010 and March 2011 assessing delivery of smoking 
cessation support, 60% of the SSSPs reported that there was a difference in the 
proportion of pregnant women seeking help by the stage of pregnancy, with the 
most referrals given in the first two trimesters.185 This may be related to the 
level of motivation to quit smoking which has been shown to be higher during 
early pregnancy compared to late pregnancy resulting in more women seeking 
help at these times in pregnancy.219 A study using an online database containing 
data  on 3,880 pregnant smokers supported by one of the 44 regional SSS in 
England reported that 55% of all pregnant smokers (65% of pregnant NRT 
users) used combination NRT,132 which is very high compared of 10% as shown 
in this work. This is mostly likely related to different baseline populations i.e. 
data from specialist stop smoking services compared to data from primary care. 
Women voluntarily attending these specialist services will likely have a higher 
motivation to quit which may result in more quit attempts and more NRT being 
prescribed compared to women attending primary care. 
NICE recommends that pregnant women should initially be prescribed two weeks 
of NRT from their agreed stop date, with further NRT after re-assessment.79 The 
average duration of prescription for women in this study was two weeks and 
most women (80%) received two or less prescriptions. One reason for this may 
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be that compliance was low and women did not quit or use it to quit in which 
case no further NRT was prescribed. Some women may have bought NRT 
independently after the first prescription; however, considering that women are 
entitled to free prescriptions during pregnancy and NRT from retailers is 
reasonably expensive, this is unlikely. Studies in other populations have not 
reported the duration of NRT use in pregnancy. However, eight to twelve weeks¶ 
use is recommended for optimal effectiveness in the general population110 so it is 
unlikely that two weeks¶ use is effective for smoking cessation in pregnancy.  
A study conducted in four states of the USA, in 5,716 pregnant women between 
the ages of 18-45 years, found NRT prescribing to be lower in pregnant smokers 
younger than 35 years of age compared to pregnant smokers over the age of 
35.111 In comparison, prescribing was assessed within 5 year age bands between 
15-49 years in this study and the results were found to be similar, with NRT 
prescribing increasing with age; however the confidence intervals between the 
age categories overlapped. Advancing maternal age is associated with a higher 
risk for pregnancy complications 220 which may lead women to visit their GPs 
more often during pregnancy providing more opportunities to provide smoking 
cessation advice and prescribe NRT which may explain higher prescribing rates 
in these smokers compared to younger smokers. Low socioeconomic status is 
associated with a higher prevalence of chronic disease 191 and higher risk of 
adverse pregnancy outcomes221, which would explain why pregnant smokers in 
the deprived group would be prescribed more NRT than affluent groups. Asthma 
and mental illness are the most common conditions encountered during 
pregnancy194,222 and are closely related to smoking, which may explain a 
significant association with NRT prescribing compared to other conditions. 
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5.5 CHAPTER CONCLUSIONS 
In conclusion, this study shows that the prevalence of prescribing of NRT during 
pregnancy, especially after the relaxation of licensing arrangements in 2005, 
was almost twice the prevalence of prescribing in the nine months immediately 
before and after pregnancy. Although studies on NRT prescribing in pregnancy 
are lacking worldwide, these findings give insight into prescribing in and around 
pregnancy and highlight that the prescribing of NRT during pregnancy is quite 
high. These data also show that NRT was prescribed for an average of only two 
weeks during pregnancy which is unlikely to be effective.  
 
Prescribing was also found to be relatively lower before and after pregnancy, 
which are also important times when quitting has significant health benefits for 
the woman and her child. This is indicative of a possible missed opportunity to 
assist many young women in quitting smoking. Whilst interactions between 
health professionals and pregnant women should be used to discuss and offer 
interventions to promote smoking cessation, greater potential benefit would be 
derived from starting before pregnancy which should be a focus for women and 
health care providers. 
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6 NICOTINE REPLACEMENT THERAPY, MATERNAL 
SMOKING AND CONGENITAL ANOMALIES 
6.1 INTRODUCTION 
The findings from the previous chapter report that approximately 11% of 
pregnant smokers are prescribed NRT in primary care settings annually. In 
addition, some women may be getting their NRT directly from the SSSP and 
some, although a small proportion, may be buying it OTC which would make the 
proportions of pregnant smokers using NRT even higher. Whilst the use of NRT 
is now recommended for smoking cessation during pregnancy in both UK and 
European guidelines,79,124 the evidence concerning its safety in pregnancy is still 
lacking.  Therefore, the WHO has made a strong recommendation for more 
research on the safety of NRT in pregnant women.73 This chapter and the 
following chapter (Chapter 6 and Chapter 7) address this gap in the literature by 
assessing the safety of NRT use during pregnancy. This chapter focuses on 
investigating the relationship between antenatal NRT exposure or smoking, as 
recorded in primary care data, and the presence of congenital anomalies in 
children born to women exposed to these potential risks in early pregnancy and 
the following chapter will focus on other birth outcomes.  
The association between maternal smoking in pregnancy and congenital 
anomalies in infants seems to be biologically plausible. Compromised oocyte 
quality in mothers who smoke may be one of the possible mechanisms by which 
smoking causes congenital anomalies.223 Another possible mechanism is the 
chromosomal damage and epigenetic changes leading to subtle changes in the 
gene expression in babies of mothers who smoke.223 However, this association is 
currently not very clear in the literature. A large systematic review of 
observational studies published between 1959 to 2010 including 173,687 cases 
of congenital anomalies and 11,674,332 controls showed an OR of 1.01 (0.96-
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1.07) for all malformations combined in relation to maternal smoking during 
pregnancy. However, significantly increased risks of system-specific anomalies 
including heart defects (OR 1.09, 95% CI 1.02-1.17), musculoskeletal defects 
(OR 1.16, 95% CI 1.05-1.27), orofacial clefts (OR 1.28, 95% CI 1.20-1.36), limb 
defects (OR 1.26, 95% CI 1.15-1.39), eye defects (OR 1.25, 95% CI 1.11-1.40) 
and gastrointestinal defects (OR 1.27, 95% CI 1.18-1.36) were found.28 
Contrary to the systematic review, a newer study based on 1,676 cases and 
3,267 controls from a total of 44,732 live births in Rhode Island between 2007 
and 2010 found a significantly increased risk of congenital anomalies associated 
with maternal smoking (OR 1.27, 95% CI 1.05-1.55).224 Similarly, a more recent 
case-control analysis from the Baltimore-Washington Infant Study found no 
statistically significant association between maternal smoking and congenital 
heart defects (OR 1.07, 95% CI 0.80-1.45) however an increased risk was 
reported for specific anomalies e.g. pulmonary valve stenosis (OR 1.35, 95% CI 
1.05-1.74), truncus arteriosus (OR 1.90, 95% CI 1.04-3.45).225 Another study 
using the PRAMS data from nine states of the USA found no increased risk of 
congenital heart defects in relation to maternal smoking (OR 0.50, 95% CI 0.22-
1.10).226 In contrast, a study from Greece including 157 infants with congenital 
heart defects and 208 infant without congenital heart defects born between 
2006 and 2009 reported approximately a three-fold increase in the risk of 
congenital heart defects associated with maternal smoking during pregnancy 
(OR 2.75, 95% CI 1.66-4.48)227 and a systematic review including all studies 
between 1947 to 2011 on maternal smoking and congenital heart defect found 
the risk of congenital heart defects to be 11% higher in children of mothers who 
smoked compared to non-smokers (RR 1.11, 95% CI 1.02-1.21).228  Data from 
the National Birth Defects Prevention Study (NBDPS), USA showed no significant 
increase in the risk of neural tube defect in children in relation to active maternal 
smoking (OR 0.9, 95% CI 0.8-1.1).229 Hence, to-date the evidence of the 
association of maternal smoking and congenital anomalies is inconclusive. 
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The evidence of the teratogenic safety of NRT is only limited to two studies 
which have assessed the association between maternal use of NRT during 
pregnancy and congenital anomalies in the offspring. Table 6-1 describes these 
studies in detail.  
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Table 6-1 Summary of studies assessing congenital anomalies in relation to NRT use during pregnancy 
First 
author, 
year and 
location 
Study methodology Sample size 
(Inclusion/Exclusi
on) 
Exposure Assessment Outcome 
Assessment 
Results for NRT safety 
Coleman 
(2012), UK 
100 
Large, double-blinded, 
placebo-controlled 
multicentre RCT 
1050 participants 
between 16 to 50 
years with 
pregnancies of 12-
24 weeks of 
gestation smoking 
five or more 
cigarettes per day 
 
4 weeks supply of 
Standard nicotine patch 
(15mg/16 hrs)  versus  
visually identical placebo, 
started on the quit date 
Secondary outcome: 
Adverse pregnancy 
and birth outcomes 
including congenital 
anomalies 
OR for congenital anomalies 
associated with NRT use = 0.70 (95% 
CI 0.30-1.66) compared to placebo 
group. Estimates only based on 9 
cases in the treatment group and 13 
cases in the placebo group. 
Morales- 
Suarez-
Varela 
(2006), 
Denmark 
114 
Cohort study using 
Danish National Birth 
Cohort 
76,768 pregnancies 
between 1996 and 
2002 
Smoking and NRT during 
the first 12 weeks of 
pregnancy  
Congenital anomalies 
diagnosed at birth or 
during the first year of 
life, further classified 
based on EUROCAT 
criteria230 
OR 1.61 (95% CI 1.01-2.56) for 
congenital malformations in children 
born to non-smokers, who used 
nicotine substitutes compared to non-
smokers who did not use any nicotine 
substitutes. When restricted to major 
malformations the odds ratio was 
1.13(95% CI 0.62-2.07)  
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The SNAP trial found no association between the use of NRT during pregnancy 
and congenital anomalies in the offspring.100  Although the SNAP trial is the 
biggest trial of NRT patches in pregnancy conducted so far, the primary end 
point was abstinence from the date of smoking cessation until delivery and 
therefore all the safety analyses were underpowered, especially for the more 
rare outcomes like congenital anomalies. This finding was based on only 22 
children with congenital anomalies so this negative finding for the association 
between NRT use in pregnancy and congenital anomalies could be due to Type 2 
error (low statistical power) in the trial to detect any association with congenital 
anomalies. Another important point to consider is that the mean gestational age 
at the time of study enrolment in the trial was about 16 weeks indicating that 
most of the pregnant women in the trial were given NRT after the end of the first 
trimester, when most of the organ development had already taken place. By 
contrast, the study using the Danish National Birth Cohort (DNBC) found a 61% 
(95% CI 1.01-2.58) increase in the risk of congenital anomalies in the babies of 
mothers using NRT during pregnancy compared to non-smokers but no 
increased risk was found when restricted to only major congenital anomalies. 
Although the population-based nature of the study and prospective data 
collection minimised the potential for ascertainment and selection bias in the 
study, the data on smoking and NRT use were self-reported. Furthermore, this 
study was conducted over a decade ago (1997-2003) after which many new 
forms of NRT have been introduced to the market and the prescribing of NRT in 
pregnancy has increased.  In light of these limitations of the current literature, 
this chapter describes the relationship between antenatal exposure to NRT or 
maternal smoking described in primary care data and the presence of MCAs in 
children born to women exposed to these potential risks in early pregnancy.  
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6.2 METHODS 
6.2.1 Study population 
All live born children delivered between January 2001 and December 2009, with 
linked mother records were included in this analysis. The study population was 
limited to only live births because stillborn children are generally not registered 
with the GPs. Data before January 2001 was excluded as NRT only became 
available on NHS prescription in 2001.  
 
6.2.2 Exposure 
A variable indicating NRT exposure in early pregnancy (defined here as one 
month before conception until the end of the first trimester) and smoking was 
developed with four categories. The period of four weeks before conception was 
used to enable inclusion of drug prescriptions received immediately before 
pregnancy and potentially used around the time of conception. The first 
trimester of pregnancy is considered the critical period for the developments of 
congenital anomalies 231,232 and therefore only early pregnancy exposure was 
considered. The four exposure categories are described below: 
  
x Non-smoker: All women with Read codes for never smoking or ex-
smoking in their primary care records during the first trimester and within 
27 months before pregnancy, with no current smoking codes in this time 
were classified as non-smokers. 
x NRT group: All pregnant women with a drug code for NRT prescription 
during the first trimester of pregnancy or within four weeks before the 
estimated conception dates in their primary care records were classified 
as being prescribed NRT during early pregnancy. Similar to other drug 
safety studies, the period of four weeks before conception was included 
to enable the inclusion of NRT prescriptions immediately before 
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pregnancy and potentially used during very early pregnancy and around 
conception.233 
x Smoker: If any records of current smoking were found during early 
pregnancy or if the latest smoking status record within 27 months before 
pregnancy until the end of first trimesters indicated smoking, women 
were categorised as being smokers during that pregnancy.  
x Unknown: All women who did not have a recording of smoking status or 
NRT prescription during early pregnancy or where the smoking status 
records did not clearly indicate whether they were smokers or non-
smokers were included in this category. 
 
6.2.3 Outcome 
$OOLQIRUPDWLRQRQPDMRUFRQJHQLWDODQRPDOLHVUHFRUGHGDWDQ\DJHLQFKLOGUHQ¶V
primary care records was extracted using Read codes mapped to the EUROCAT 
classification system (Code list attached as Appendix 10.10).230  This system 
identifies all conditions classified as major congenital disorders coded by the Q 
chapter of the International Classification of Disease version 10 (ICD-10)234 and 
a small number of conditions in the other ICD-10 chapters and categorises them 
into subgroups.230  Minor congenital anomalies are not very well recognised and 
therefore not recorded very well in primary care. Therefore, epidemiological 
studies only focus on assessing major congenital anomalies and so do registries. 
Therefore, in line with the  EUROCAT classification, minor congenital anomalies 
(e.g. lip hypertrophy, congenital flat foot etc.) were excluded from the case 
definition.230 Children with medical codes for teratogenic anomalies (e.g. 
PK80.00 ± Fetal alcohol syndrome, PK84.00 Fetal valproate syndrome) were also 
excluded from the study population.  
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6.2.4 Potential confounders  
Maternal age, socioeconomic status and all other maternal morbidities described 
in Section 3.4.3 were considered to be potential confounders due to the 
associations of these conditions or their treatments with congenital anomalies 
and maternal smoking. 51,59,195,199,211,235-244 In addition, epilepsy was also deemed 
to be an important clinical confounder for this analysis as the medical treatment 
for epilepsy is strongly related to congenital anomalies245,246 and studies have 
shown epilepsy to be associated with smoking as well.247 Records of diagnosed 
epilepsy were extracted from both the Medical and AHD files and epilepsy 
medication prescriptions were extracted from the Therapy file. For the purpose 
of this study, pregnant women were said to have epilepsy if they had a 
diagnostic recording of epilepsy ever before delivery and had a recording of 
epilepsy prescription during pregnancy or within 27 months before conception. 
Medical code lists and prescription code lists are attached as Appendix 10.8.11 
and Appendix 10.8.12. 
 
6.2.5 Statistical analysis 
To estimate the disease burden of all major and individual system-specific 
congenital anomalies, absolute risks (per 10,000 live births) for the total 
population and each exposure group (i.e. non-smokers, smokers, NRT group and 
unknown group) were calculated. ORs for any major and each system-specific 
anomaly group were calculated for the NRT group and smokers using non-
smokers as the reference group in a logistic regression model. Some women had 
more than one pregnancy in the study period; this was accounted for by 
calculating robust CIs around the OR using the clustered sandwich estimator, 
180,181  which is explained in Section 3.4.4. In recognition of the fairly large 
number of exposure and outcome categories in this analysis, 99% CIs were 
calculated for each measure of association; exact p-values (to 3 decimal places) 
have also been presented for more transparent reader assessment of 
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associations potentially arising by chance. Adjustments were also made for 
potential confounders discussed above. Chi-squared tests were used to 
determine whether each of these confounders was associated with the exposure 
and with the outcome. Covariates with statistically significant associations at 5% 
level of significance were included in the multivariable model to obtain adjusted 
ORs. The reference group was then changed to smokers and ORs for MCAs in the 
NRT group were calculated. 
 
6.2.6  Sensitivity analysis 
6.2.6.1 Restricting to only singleton live births 
The absolute and relative risks of overall and individual system-specific 
congenital anomalies were calculated, restricting the study population to only 
singleton live born babies, as malformations are more likely to occur in multiple 
births compared to singleton births.248  
 
6.2.6.2 Reclassifying smokers and non-smokers based on gestational smoking 
status recording 
The definitions of smokers and non-smokers were restricted to only mothers 
who had a gestational smoking status record during early pregnancy indicating 
them to be a smoker or non-smoker respectively. This was done because some 
women who were documented to be smokers in the 27 months before 
conception may have given up smoking before pregnancy and therefore the 
definition of smokers and non-smokers during early pregnancy may result in 
some misclassification between these two exposure categories. The absolute 
risks of overall and system-specific MCA groups were calculated using only 
smokers and non-smokers, based on gestational records and ORs (99% CI) for 
MCAs in children with maternal NRT exposure during early pregnancy were 
calculated.   
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6.2.6.3 Exposure window changed to 2nd/3rd trimester 
The exposure period was changed from early pregnancy to 2nd/3rd trimester and 
all women with NRT prescriptions in early pregnancy were excluded from the 
analysis. Although most of the organogenesis takes place in the first trimester, 
consequently increasing the risk of structural defects, some periods in the 
second and third trimester are also slightly sensitive for the development of 
congenital anomalies.249  These include defects of the eye, ear, teeth, central 
nervous system and genitalia. 250 Therefore, the absolute and relative risks of 
overall and system-specific MCA groups for NRT group and smokers, compared 
to non-smokers were calculated based on 2nd/3rd trimester exposure.   
 
6.2.7 Sample size calculation 
Previous literature suggests the prevalence of MCAs to be 2.7%251 and the 
prescribing prevalence of NRT during pregnancy has been found to be 
approximately 2%.252 Based on these numbers, a sample size of 138,064 
children with maternal NRT prescriptions in early pregnancy was needed in this 
study to detect an OR of 1.50 with 80% power at a 1% level of significance. The 
sample size to achieve this power for system-specific anomalies was much 
higher (e.g. 301,082 children with maternal NRT prescriptions for heart defects). 
Similarly, a sample of 19,041 children with smoking mothers was needed to 
detect an OR of 1.50 for the association between maternal smoking and 
presence of CAs, with 80% power at a 1% level of significance. Sample size 
calculations were performed in PASS 12 (Power Analysis & Sample Size 
Software).253  
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6.3 RESULTS  
6.3.1 Baseline characteristics 
A total of 232,242 live born children were included in the study population out of 
whom 6,480 had at least one major congenital anomaly (279 per 10,000 live 
births). Out of these 232,242 children 0.7% were born to mothers who were 
prescribed NRT , 16% to mothers who smoked during pregnancy and 49% to 
mothers who did not smoke during.  Table 6-2 shows the baseline maternal 
characteristics in children with and without MCAs. The distribution of maternal 
age at conception, socioeconomic status and pre-conception BMI was very 
similar in women whose children had any MCA and women whose children did 
not have any MCA. The prevalence of maternal morbidities particularly epilepsy 
(0.4% vs. 0.7%), was found to be higher in the MCA group. Similarly, multiple 
births were more common in children with congenital anomalies compared to 
children without congenital anomalies (3.6% vs. 5.2%). 
 
Table 6-3 presents the maternal and birth characteristics by smoking and NRT 
exposure. Women in the NRT group and smokers were more likely to be from 
socioeconomically deprived groups compared to non-smokers. Additionally, the 
NRT group had a higher prevalence of asthma (14.4%) compared to smokers 
and non-smokers (11.1% and 10.3% respectively). Similarly, mental illness was 
found to be most prevalent in the NRT group (20.8%) and epilepsy was found to 
be the highest in smokers (0.7%), followed by the NRT group (0.6%). The 
distribution of other morbidities was very similar across the exposure groups.  
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Table 6-2 - Maternal and birth characteristics of the study population 
 All children Children without 
MCAs 
Children with 
MCAs 
N=232,242 n=225,762 n=6,480 
n % n % n % 
Age at conception       
15-19 years 12,037 5.2% 11,692 5.2% 345 5.3% 
20-24 years 36,003 15.5% 34,999 15.5% 1,004 15.5% 
25-29 years 59,203 25.5% 57,624 25.5% 1,579 24.4% 
30-34 years 73,844 31.8% 71,822 31.8% 2,022 31.2% 
35-39 years 42,477 18.3% 41,262 18.3% 1,215 18.7% 
40-44 years 8,341 3.6% 8,046 3.6% 295 4.5% 
45-49 years 337 0.1% 317 0.1% 20 0.3% 
Townsend score in 
quintiles 
      
Quintile 1 (least deprived) 53,916 23.2% 52,430 23.2% 1,486 22.9% 
Quintile 2 43,850 18.9% 42,653 18.9% 1,197 18.5% 
Quintile 3 45,280 19.5% 43,986 19.5% 1,294 20.0% 
Quintile 4 42,696 18.4% 41,490 18.4% 1,206 18.6% 
Quintile 5 (most deprived) 31,884 13.7% 30,963 13.7% 921 14.3% 
Missing  14,616 6.3% 14,240 6.3% 376 5.8% 
Pre-conception Body 
Mass Index (kg/m2) 
      
normal(18.5-24.9) 73,002 31.4% 71,019 31.5% 1,983 30.6% 
underweight(<18.5) 5,225 2.2% 5,071 2.2% 154 2.4% 
overweight(25-29.9) 35,625 15.3% 34,626 15.3% 999 15.4% 
obese(>=30) 24,594 10.6% 23,876 10.6% 718 11.1% 
missing 93,796 40.4% 91,170 40.4% 2,626 40.5% 
Asthma 19,932 8.6% 19,335 8.6% 597 9.2% 
Hypertension 6,392 2.8% 6,165 2.7% 227 3.5% 
Diabetes 5,490 2.4% 5,268 2.3% 222 3.4% 
Mental illness 22,154 9.5% 21,507 9.5% 647 10.0% 
Epilepsy 1,036 0.4% 994 0.4% 42 0.7% 
Multiple birth 8,373 3.6% 8,038 3.6% 335 5.2% 
MCAs = major congenital anomalies
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Table 6-3 - Numbers and proportions of maternal and birth characteristics by NRT exposure and smoking  
 NRT group* Smokers** Non-smokers*** Unknown 
n= 1,594 n= 37,141 n=114,254 n= 79,253 
n % n  % n % n % 
Age at conception 
        15-19 years 110 6.9% 3,918 10.5% 4,044 3.5% 3,965 5.0% 
20-24 years 354 22.2% 9,885 26.6% 14,895 13.0% 10,869 13.7% 
25-29 years 443 27.8% 10,005 26.9% 29,888 26.2% 18,867 23.8% 
30-34 years 400 25.1% 8,127 21.9% 38,695 33.9% 26,622 33.6% 
35-39 years 236 14.8% 4,335 11.7% 22,230 19.5% 15,676 19.8% 
40-44 years 49 3.1% 846 2.3% 4,330 3.8% 3,116 3.9% 
45-49 years 2 0.1% 25 0.1% 172 0.2% 138 0.2% 
Townsend score in quintiles  
        
Quintile 1 (least deprived) 152 9.5% 4,573 12.3% 29,060 25.4% 20,131 25.4% 
Quintile 2 219 13.7% 5,120 13.8% 23,056 20.2% 15,455 19.5% 
Quintile 3 339 21.3% 7,281 19.6% 22,382 19.6% 15,278 19.3% 
Quintile 4 438 27.5% 9,303 25.0% 19,090 16.7% 13,865 17.5% 
Quintile 5 (most deprived) 338 21.2% 8,524 23.0% 12,731 11.1% 10,291 13.0% 
Missing  108 6.8% 2,340 6.3% 7,935 6.9% 4,233 5.3% 
Pre-conception BMI (kg/m2)         
Normal (18.5-24.9) 495 31.1% 12,535 33.7% 44,568 39.0% 15,404 19.4% 
Underweight (<18.5) 49 3.1% 1,277 3.4% 2,733 2.4% 1,166 1.5% 
Overweight (25-29.9) 262 16.4% 6,011 16.2% 21,472 18.8% 7,880 9.9% 
Obese (>=30) 223 14.0% 4,553 12.3% 14,369 12.6% 5,449 6.9% 
Missing 565 35.4% 12,765 34.4% 31,112 27.2% 49,354 62.3% 
Asthma 230 14.4% 4,116 11.1% 11,764 10.3% 3,822 4.8% 
Hypertension 36 2.3% 793 2.1% 3,731 3.3% 1,832 2.3% 
Diabetes 45 2.8% 746 2.0% 3,324 2.9% 1,375 1.7% 
Mental illness 331 20.8% 5,882 15.8% 9,095 8.0% 6,846 8.6% 
Epilepsy 9 0.6% 248 0.7% 497 0.4% 282 0.4% 
Multiple birth 47 2.9% 1,290 3.5% 4,021 3.5% 3,015 3.8% 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, *** No smoking in early pregnancy
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6.3.2 Absolute risks of major and system-specific congenital anomalies 
 
Table 6-4 presents the numbers and absolute risks of any major and system-
specific congenital anomalies in the total population and also stratified by 
maternal exposures.  The absolute risk of MCAs in the NRT group was higher 
than non-smokers (364/10,000 live births compared to 273/10,000 live births). 
Similar increases in the risk were seen in the most common anomaly groups in 
the NRT group like heart, limb, genital and urinary defects. The absolute risks of 
MCAs in smokers were found to be very similar to the non-smokers with slightly 
higher risk in the more rare anomalies such as abdominal anomalies (5/10,000 
live births in smoking group compared to 1/10,000 live births in the reference 
group). 
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Table 6-4 - Absolute risks of major congenital anomalies by NRT exposure and maternal smoking  
 All children NRT group* Smokers** Non-smokers*** Unknown 
 N= 232,242 n= 1,594 n= 37,141 n=114,254 n= 79,253 
 n ۆ  n/10,000 n n/10,000 n n/10,000 n n/10,000 n n/10,000 
All MCAs combined 6,480 279 58 364 1,009 272 3,121 273 2,292 289 
Heart 2,021 87 15 94 327 88 999 87 680 86 
Limb 1,243 54 11 69 183 49 623 55 426 54 
Genital system 1,077 46 12 75 158 43 507 44 400 50 
Urinary system 622 27 6 38 89 24 304 27 223 28 
Chromosomal 438 19 3 19 53 14 216 19 166 21 
Musculoskeletal 416 18 5 31 64 17 196 17 151 19 
Oro-facial cleft 348 15 2 13 57 15 158 14 131 17 
Digestive system 347 15 5 31 44 12 174 15 124 16 
Nervous system 359 15 3 19 58 16 170 15 128 16 
Other malformations$ 316 14 2 13 45 12 150 13 119 15 
Eye 256 11 1 6 32 9 120 11 103 13 
Respiratory system 188 8 10 63 32 9 89 8 57 7 
Genetic 176 8 0 - 21 6 82 7 73 9 
Abdominal wall 61 3 0 - 20 5 17 1 24 3 
Ear, face & neck 41 2 0 - 8 2 15 2 18 2 
MCA = Major Congenital Anomalies  
ۆ each case may have more than one system anomaly, therefore total of all system-specific anomalies may vary 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, *** no smoking in early pregnancy 
$ e.g. Asplenia, conjoined twins etc.  
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6.3.3 Relative risks of major and system specific congenital anomalies 
Table 6-5 shows the adjusted ORs for overall and each system specific major 
congenital anomaly comparing the NRT group and smokers to non-smokers. The 
OR for MCAs in the NRT group was 1.34 (99% CI 0.94-1.91, p-value 0.034) 
compared with non-smokers. There was no increased risk of MCAs in smokers 
compared to non-smokers (OR 0.99, 99% CI 0.89-1.09, p-value 0.819) 
compared to non-smokers. The ORs for system-specific anomalies were broadly 
similar to the overall findings. At 99% confidence interval, odds ratios showed 
no increased risk of any system specific congenital anomaly in the NRT group 
compared to non-smokers except respiratory system anomalies (OR 7.61, 99% 
CI 2.93-19.74, p-value <0.001). However, this was based on a very small 
number of exposed cases (10 cases of respiratory system anomaly) as shown in 
Table 6-4. 
 
Table 6-6 presents the ORs for major congenital anomalies in the NRT group 
compared to smokers. The relative risk of major congenital anomalies in NRT 
group was not appreciably altered when the reference group was changed to 
smokers (OR 1.35, 99% CI 0.94-1.93 for overall MCAs). 
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Table 6-5 - Adjusted odds ratio for major congenital anomalies by maternal NRT and smoking exposure 
 NRT group*¥ Smokers**¥ Unknown¥ 
 n= 1,594 n=37,141 n= 79,253 
 AORۆ (99% CI) p-value AORۆ (99% CI) p-value AORۆ (99% CI) p-value 
All MCAs combined 1.34 (0.94-1.91) 0.034 0.99 (0.89-1.09) 0.815 1.06 (0.98-1.15) 0.032 
Heart 1.08 (0.55-2.13) 0.757 1.02 (0.86-1.21) 0.787 0.99 (0.87-1.13) 0.861 
Limb 1.31 (0.59-2.88) 0.380 0.94 (0.75-1.17) 0.487 0.99 (0.84-1.16) 0.847 
Genital system 1.66 (0.78-3.55) 0.082 0.92 (0.72-1.18) 0.411 1.14 (0.96-1.36) 0.047 
Urinary system 1.43 (0.49-4.16) 0.385 0.92 (0.67-1.26) 0.511 1.05 (0.83-1.34) 0.523 
Chromosomal 1.03 (0.23-4.64) 0.961 0.85 (0.56-1.28) 0.313 1.09 (0.83-1.42) 0.424 
Musculoskeletal 1.89 (0.58-6.16) 0.166 1.03 (0.70-1.52) 0.826 1.13 (0.85-1.49) 0.268 
Oro-facial cleft 0.86 (0.14-5.37) 0.828 1.05 (0.69-1.58) 0.748 1.20 (0.88-1.64) 0.123 
Digestive system 2.01 (0.62-6.49) 0.125 0.76 (0.49-1.19) 0.118 1.02 (0.75-1.38) 0.873 
Nervous system 1.17 (0.26-5.24) 0.792 0.98 (0.65-1.47) 0.904 1.13 (0.83-1.53) 0.314 
Other malformations$ 0.96 (0.15-6.02) 0.952 0.92 (0.59-1.44) 0.654 1.14 (0.83-1.56) 0.296 
Eye 0.56 (0.04-7.47) 0.567 0.77 (0.45-1.30) 0.197 1.23 (0.87-1.75) 0.121 
Respiratory system 7.61 (2.93-19.74) <0.001 1.07 (0.62-1.86) 0.745 0.93 (0.60-1.44) 0.683 
Genetic - - 0.85 (0.44-1.65) 0.532 1.26 (0.83-1.92) 0.150 
Abdominal wall - - 2.27 (0.94-5.44) 0.016 1.87 (0.81-4.30) 0.053 
Ear, face & neck - - 1.62 (0.49-5.37) 0.300 1.68(0.68-4.14) 0.138 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, ¥Reference category = non-smokers 
during early pregnancy, ۆ adjusted for maternal age at conception, Townsend score, maternal hypertension, diabetes and epilepsy, $ e.g. Asplenia, 
conjoined twins etc.  MCAs= Major Congenital Anomalies, AOR = Adjusted Odds Ratio, CI = confidence interval 
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Table 6-6 - Adjusted odds ratio for major congenital anomalies in the 
NRT group compared to smokers 
 NRT group*  
 n=1,594 
 AOR ¥ۆ (99% CI) p-value 
All MCAs combined 1.35 (0.94-1.93) 0.032 
Heart 1.06 (0.54-2.11) 0.813 
Limb 1.39 (0.62-3.10) 0.292 
Genital system 1.80 (0.83-3.90) 0.051 
Urinary system 1.55 (0.52-4.61) 0.297 
Chromosomal 1.20 (0.26-5.61) 0.750 
Musculoskeletal 1.83 (0.55-6.06) 0.195 
Oro-facial cleft 0.81 (0.13-5.18) 0.774 
Digestive system 2.63 (0.78-2.11) 0.041 
Nervous system 1.19 (0.25-5.47) 0.770 
Other malformations$ 1.04 (0.16-6.68) 0.962 
Eye 0.73 (0.05-10.01) 0.759 
Respiratory system 7.10 (2.60-19.38) <0.001 
Genetic - - 
Abdominal wall - - 
Ear, face & neck - - 
¥Reference category ± smokers during early pregnancy 
* NRT=nicotine replacement therapy prescription in early pregnancy  
ۆ adjusted for maternal age at conception, Townsend score, maternal hypertension, 
diabetes, epilepsy, $ e.g. Asplenia, conjoined twins etc.  
MCAs= Major Congenital Anomalies, AOR = Adjusted Odds Ratio, CI = confidence 
intervals 
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6.3.4 Sensitivity analysis 
6.3.4.1 Restricting to only singleton live births 
Table 6-7 shows the absolute risks of all major and system specific congenital 
anomalies in singleton live-born children by NRT and smoking exposure. Similar 
to the main results, the absolute risk of MCAs was higher in the NRT group 
compared with non-smokers (356/10,000 live births compared to 270/10,000 
live births). Similar increases in the risk were seen for the most common 
anomalies in the NRT group like heart, limb, genital and urinary defects but the 
absolute risk differences were very small.  
Table 6-8 shows the adjusted ORs for overall and each system specific major 
congenital anomaly group in singleton live-born children comparing the NRT 
group and smokers to non-smokers. The effect estimates remained unaltered 
with no increased risk of congenital anomalies in the NRT group and smokers 
compared with non-smokers.  
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Table 6-7 - Absolute risks of major congenital anomalies by NRT exposure and maternal smoking in singleton live borns 
 All children NRT group* Smokers** Non-smokers*** Unknown 
 N= 223,869 n= 1,547 n= 35,851 n=110,233 n= 76,238 
 n ۆ  n/10,000 n n/10,000 n n/10,000 n n/10,000 n n/10,000 
All MCAs combined 6,145 274 55 356 959 267 2,973 270 2,158 283 
Heart 1,868 83 14 90 307 86 927 84 620 81 
Limb 1,199 54 11 71 177 49 604 55 407 53 
Genital system 1,020 46 12 78 152 42 482 44 374 49 
Urinary system 597 27 6 39 85 24 296 27 210 28 
Chromosomal 425 19 3 19 51 14 208 19 163 21 
Musculoskeletal 398 18 5 32 62 17 187 17 144 19 
Oro-facial cleft 333 15 2 13 54 15 149 14 128 17 
Digestive system 330 15 5 32 44 12 166 15 115 15 
Nervous system 347 16 3 19 56 16 163 15 125 16 
Other malformations$ 306 14 2 13 44 12 144 13 116 15 
Eye 241 11 1 6 30 8 114 10 96 13 
Respiratory system 176 8 8 52 28 8 86 8 54 7 
Genetic 168 8 - - 19 5 81 7 68 9 
Abdominal wall 55 2 0 - 19 5 15 1 21 3 
Ear, face & neck 41 2 0 - 8 2 15 1 18 2 
MCA = Major Congenital Anomalies, NRT = nicotine replacement therapy 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, *** no smoking in early pregnancy 
ۆ each case may have more than one system anomaly, therefore total of all system-specific anomalies may vary 
$ e.g. Asplenia, conjoined twins etc. 
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Table 6-8 - Adjusted odds ratio for major congenital anomalies by maternal NRT and smoking exposure in singleton live-
born children 
 NRT group*¥ Smokers**¥ Unknown¥ 
 n= 1,547 n=35,851 n= 76,238 
 AOR*ۆ (99% CI) p-value AOR*ۆ (99% CI) p-value AOR*ۆ (99% CI) p-value 
All MCAs combined 1.31 (0.91-1.87) 0.053 0.98 (0.89-1.08) 0.684 1.06 (0.98-1.15) 0.038 
Heart 1.07 (0.53-2.15) 0.797 1.02 (0.86-1.22) 0.708 0.98 (0.85-1.12) 0.660 
Limb 1.33 (0.61-2.94) 0.340 0.94 (0.75-1.18) 0.465 0.98 (0.83-1.15) 0.699 
Genital system 1.73 (0.81-3.68) 0.063 0.93 (0.73-1.19) 0.451 1.13 (0.94-1.35) 0.079 
Urinary system 1.46 (0.50-4.24) 0.359 0.90 (0.65-1.25) 0.423 1.03 (0.81-1.29) 0.757 
Chromosomal 1.07 (0.24-4.80) 0.909 0.85 (0.56-1.28) 0.312 1.11 (0.85-1.45) 0.319 
Musculoskeletal 1.97 (0.611-6.36) 0.135 1.05 (0.71-1.55) 0.742 1.13 (0.85-1.51) 0.265 
Oro-facial cleft 0.91 (0.14-5.74) 0.900 1.07 (0.70-1.62) 0.677 1.25 (0.91-1.70) 0.066 
Digestive system 2.07 (0.64-6.69) 0.110 0.79 (0.51-1.24) 0.182 0.99 (0.73-1.36) 0.966 
Nervous system 1.21 (0.27-5.44) 0.745 0.98 (0.65-1.48) 0.923 1.15 (0.84-1.56) 0.244 
Other malformations$ 0.98 (0.16-6.18) 0.983 0.94 (0.59-1.47) 0.709 1.16 (0.84-1.59) 0.244 
Eye 0.59 (0.04-7.81) 0.596 0.76 (0.44-1.30) 0.186 1.21 (0.84-1.73) 0.168 
Respiratory system 6.36 (2.43-16.63) <0.001 0.99 (0.56-1.76) 0.977 0.92 (0.59-1.44) 0.644 
Genetic - - 0.78 (0.40-1.53) 0.350 1.19 (0.78-1.82) 0.285 
Abdominal wall - - 2.25 (0.90-5.59) 0.022 1.83 (0.76-4.39) 0.074 
Ear, face & neck - - 1.75 (0.55-5.60) 0.213 1.69 (0.66-4.40) 0.151 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy  
¥Reference category = non-smokers during early pregnancy, ۆ adjusted for maternal age at conception, Townsend score, maternal hypertension, 
diabetes and epilepsy      MCAs= Major Congenital Anomalies, AOR = Adjusted Odds Ratio, CI = confidence interval 
$ e.g. Asplenia, conjoined twins etc.
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6.3.4.2 Reclassifying smokers and non-smokers based on gestational smoking 
status recording 
When the smoker and non-smoker groups were reclassified to women with a 
gestational smoking status recording in their primary care data indicating such 
behaviour only 3% were classified as smokers and 8% as non-smokers. The 
absolute risk of CAs in smokers was now higher compared to the risk using a 
broader definition (298/10,000 live births compared to 272/10,000 live births). 
However, the association between NRT exposure, smoking during early 
pregnancy and MCAs remained unchanged with no significant association 
between NRT exposure and smoking compared to non-smokers apart from 
respiratory anomalies where the risk of MCAs was over six times higher in the 
NRT group compared to definitive smokers during early pregnancy (OR 6.49, 
99% CI 2.35-17.87, p-value <0.001). Table 6-9 presents the absolute risks of 
congenital anomalies by each exposure group and Table 6-10  presents adjusted 
ORs for NRT and smoking exposure, based on a restricted definition of smokers 
and non-smokers.   
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Table 6-9 - Absolute risks of major congenital anomalies by NRT exposure and maternal smoking, using only gestational 
smoking records 
 All children NRT group* Smokers** Non-smokers*** Unknown 
 N= 232,242 n= 1,594 n= 198 n=547 n= 205,602 
 n ۆ  n/10,000 n n/10,000 n n/10,000 n n/10,000 n n/10,000 
All MCAs combined 6,480 279 58 364 198 298 547 297 5,677 276 
Heart 2,021 87 15 94 116 84 330 91 1,560 86 
Limb 1,243 54 11 69 73 53 192 53 967 54 
Genital system 1,077 46 12 75 57 41 172 48 836 46 
Urinary system 622 27 6 38 31 22 97 27 488 27 
Chromosomal 438 19 3 19 21 15 70 19 344 19 
Musculoskeletal 416 18 5 31 24 17 59 16 328 18 
Oro-facial cleft 348 15 2 13 29 21 50 14 267 15 
Digestive system 347 15 5 31 21 15 60 17 261 14 
Nervous system 359 15 3 19 27 19 51 14 278 15 
Other malformations$ 316 14 2 13 26 19 35 10 253 14 
Eye 256 11 1 6 9 6 42 12 204 11 
Respiratory system 188 8 10 63 16 12 33 9 129 7 
Genetic 176 8 0 - 7 5 28 8 141 8 
Abdominal wall 61 3 0 - 5 4 9 2 47 3 
Ear, face & neck 41 2 0 - 2 1 5 3 34 2 
MCA = Major Congenital Anomalies, NRT = nicotine replacement therapy 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, *** no smoking in early pregnancy 
ۆ each case may have more than one system anomaly, therefore total of all system-specific anomalies may vary 
$ e.g. Asplenia, conjoined twins etc. 
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Table 6-10 - Adjusted odds ratio for major congenital anomalies by maternal NRT and smoking exposure using only 
gestational smoking records 
 NRT exposed group*¥ Smokers**¥ Unknown¥ 
 n= 22,814 n=1,113 n= 19,038 
 AORۆ (99% CI) p-value AORۆ (99% CI) p-value AORۆ (99% CI) p-value 
All MCAs combined 1.22 (0.84-1.77) 0.156 1.00 (0.80-1.25) 0.978 0.93 (0.82-1.04) 0.096 
Heart 1.04 (0.52-2.06) 0.886 0.92 (0.69-1.23) 0.485 0.96 (0.81-1.12) 0.506 
Limb 1.34 (0.59-2.98) 0.353 1.03 (0.72-1.48) 0.817 1.00 (0.82-1.23) 0.543 
Genital system 1.56 (0.72-3.38) 0.138 0.84 (0.56-1.26) 0.265 0.98 (0.79-1.22) 0.788 
Urinary system 1.42 (0.48-4.21) 0.408 0.85 (0.49-1.45) 0.435 1.00 (0.76-1.34) 0.951 
Chromosomal 1.00 (0.22-4.62) 0.996 0.86 (0.45-1.66) 0.566 0.98 (0.70-1.38) 0.901 
Musculoskeletal 1.99 (0.59-6.70) 0.145 1.09 (0.58-2.07) 0.710 1.13 (0.78-1.63) 0.396 
Oro-facial cleft 0.86 (0.13-5.57) 0.842 1.44 (0.78-2.68) 0.127 1.07 (0.71-1.62) 0.661 
Digestive system 1.85 (0.56-6.18) 0.185 0.90 (0.46-1.75) 0.692 0.86 (0.59-1.25) 0.314 
Nervous system 1.26 (0.27-5.81) 0.700 1.30 (0.69-2.44) 0.279 1.12 (0.76-1.66) 0.447 
Other malformations$ 1.31 (0.20-8.61) 0.707 1.95 (0.98-3.92) 0.013 1.45 (0.91-2.30) 0.041 
Eye 0.52 (0.04-6.97) 0.512 0.52 (0.20-1.34) 0.075 0.98 (0.63-1.52) 0.907 
Respiratory system 6.49 (2.35-17.87) <0.001 1.22 (0.54-2.78) 0.532 0.78 (0.47-1.29) 0.210 
Genetic - - 0.70 (0.23-2.09) 0.401 0.99 (0.58-1.68) 0.954 
Abdominal wall - - 0.89 (0.20-3.85) 0.838 1.07 (0.41-2.75) 0.849 
Ear, face & neck - - 0.53 (0.05-7.01) 0.391 1.03 (0.26-4.01) 0.957 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy  
¥Reference category = non-smokers during early pregnancy, ۆ adjusted for maternal age at conception, Townsend score, maternal hypertension, 
diabetes and epilepsy      MCAs= Major Congenital Anomalies, AOR = Adjusted Odds Ratio, CI = confidence interval 
$ e.g. Asplenia, conjoined twins etc.
157 
 
6.3.4.3 Exposure window changed to 2nd/3rd trimester 
When NRT exposure in the 2nd/3rd trimester was assessed the absolute risks of 
MCAs in the NRT group were lower than the risks in early pregnancy 
(235/10,000 live births compared to 370/10,000 live births) and also the risk in 
all live births (279/10,000 live births). However, the association between NRT 
exposure, smoking during early pregnancy and MCAs remained unchanged with 
no significant association between NRT exposure and smoking compared to non-
smokers. Table 6-11 presents the absolute risks of MCAs by each exposure 
group in 2nd/3rd trimester and Table 6-12  presents adjusted odds ratio for NRT 
exposure and smoking in 2nd/3rd trimester. 
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Table 6-11 - Absolute risks of major congenital anomalies by NRT exposure and maternal smoking during 2nd/3rd trimester 
 All children NRT exposed group* Smokers** Non-smokers*** Unknown 
 N=230,648  n= 1,827 n= 37,250 n=112,419 n= 79,152 
 n ۆ  n/10,000 n n/10,000 n n/10,000 n n/10,000 n n/10,000 
All MCAs combined 6,422 278 43 235 1,024 275 3,070 273 2,285 289 
Heart 2,021 87 15 94 327 88 999 87 680 86 
Limb 1,243 54 11 69 183 49 623 55 426 54 
Genital system 1,077 46 12 75 158 43 507 44 400 50 
Urinary system 622 27 6 38 89 24 304 27 223 28 
Chromosomal 438 19 3 19 53 14 216 19 166 21 
Musculoskeletal 416 18 5 31 64 17 196 17 151 19 
Oro-facial cleft 345 15 2 13 57 15 158 14 131 17 
Digestive system 347 15 5 31 44 12 174 15 124 16 
Nervous system 359 15 3 19 58 16 170 15 128 16 
Other malformations$ 316 14 2 13 45 12 150 13 119 15 
Eye 256 11 1 6 32 9 120 11 103 13 
Respiratory system 188 8 10 63 32 9 89 8 57 7 
Genetic 176 8 - - 21 6 82 7 73 9 
Abdominal wall 61 3 - - 20 5 17 1 24 3 
Ear, face & neck 41 2 - - 8 2 15 2 18 2 
MCA = Major Congenital Anomalies, NRT = nicotine replacement therapy 
*NRT=nicotine replacement therapy prescription in late pregnancy, **smoking in pregnancy, *** no smoking in pregnancy 
ۆ each case may have more than one system anomaly, therefore total of all system-specific anomalies may vary 
$ e.g. Asplenia, conjoined twins etc.
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Table 6-12 - Adjusted odds ratio for major congenital anomalies by maternal NRT and smoking exposure during 2nd/3rd 
trimester 
 NRT exposed group*¥ Smokers**¥ Unknown¥ 
 n= 1,827 n= 37,250 n= 79,152 
 AORۆ (99% CI) p-value AORۆ (99% CI) p-value AORۆ (99% CI) p-value 
All MCAs combined 0.85 (0.57-1.26) 0.285 1.00 (0.91-1.10) 0.936 1.06 (0.99-1.14) 0.041 
Heart 1.08 (0.55-2.13) 0.757 1.02 (0.86-1.21) 0.787 0.99 (0.87-1.13) 0.861 
Limb 1.31 (0.59-2.88) 0.380 0.94 (0.75-1.17) 0.487 0.99 (0.84-1.16) 0.847 
Genital system 1.66 (0.78-3.55) 0.082 0.82 (0.72-1.18) 0.411 1.14 (0.96-1.36) 0.047 
Urinary system 1.43 (0.49-4.16) 0.385 0.92 (0.67-1.27) 0.511 1.06 (0.84-1.33) 0.523 
Chromosomal 1.02 (0.23-4.65) 0.961 0.85 (0.56-1.28) 0.313 1.09 (0.83-1.41) 0.424 
Musculoskeletal 1.89 (0.58-6.16) 0.166 1.03 (0.70-1.52) 0.826 1.13 (0.85-1.49) 0.268 
Oro-facial cleft 0.86 (0.14-5.37) 0.828 1.05 (0.69-1.59) 0.748 1.20 (0.88-1.64) 0.123 
Digestive system 2.01 (0.62-6.49) 0.125 0.76 (0.49-1.19) 0.118 1.02 (0.75-1.38) 0.873 
Nervous system 1.17 (0.26-5.24) 0.792 0.98 (0.65-1.47) 0.904 1.13 (0.83-1.53) 0.314 
Other malformations$ 0.96 (0.15-6.02) 0.952 0.93 (0.59-1.44) 0.654 1.14(0.83-1.56) 0.296 
Eye 0.56 (0.04-7.47) 0.567 0.77 (0.45-1.30) 0.197 1.23 (0.87-1.75) 0.121 
Respiratory system 7.61 (2.93-19.74) <0.001 1.07 (0.62-1.86) 0.745 0.93 (0.60-1.44) 0.683 
Genetic - - 0.85 (0.44-1.66) 0.532 1.26 (0.83-1.92) 0.150 
Abdominal wall - - 3.62 (1.54-8.47) <0.001 2.04 (0.89-4.61) 0.025 
Ear, face & neck - - 1.52 (0.45-5.16) 0.376 1.60 (0.58-4.43) 0.230 
*NRT=nicotine replacement therapy prescription in late pregnancy, **smoking in pregnancy  
¥Reference category = non-smokers during early pregnancy, ۆ adjusted for maternal age at conception, Townsend score, maternal hypertension, 
diabetes and epilepsy      MCAs= Major Congenital Anomalies, AOR = Adjusted Odds Ratio, CI = confidence interval 
$ e.g. Asplenia, conjoined twins etc.
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6.4 DISCUSSION  
6.4.1 Principal findings 
This study found that NRT exposure during early pregnancy was not associated 
with an increased risk of overall and system-specific MCAs in the offspring 
compared with non-smokers and smokers except for an increased risk of 
respiratory anomalies; however this finding was based on only 10 cases exposed 
to NRT. These findings remained unaltered when the population was restricted to 
only singleton live-borns and to women with a gestational smoking status 
recording in their primary care data. No increased risks of MCAs were found with 
2nd/3rd trimester NRT exposure.  
 
6.4.2 Strengths and limitations 
This is the largest study to date to investigate the association between NRT 
prescribing in pregnant women and the presence of MCAs in their offspring. 
Because the study was based on routinely collected population-based data, the 
ascertainment of congenital anomaly cases was independent of the exposure 
variable minimising the potential for selection bias in the study. 
Although in the UK congenital anomalies are diagnosed in secondary care, major 
GLDJQRVHVVKRXOGEHFRPPXQLFDWHGWRWKHSDWLHQWV¶JHQHUDOSUDFWLWLRQHUV
resulting in a primary care record for MCAs. The prevalence of MCAs in THIN has 
been shown to be highly comparable to EUROCAT data157. Furthermore, MCA 
diagnosis using clinical coding in electronic primary care data has also been 
validated against doctor-provided written records reported directly from the 
general practice.158   
The study was unable to assess MCAs in pregnancies that ended in stillbirth as 
congenital anomalies are not comprehensively detected and are poorly recorded 
for stillborn children. Nevertheless, this exclusion of stillborn children is unlikely 
to cause substantial underestimation of the cases of MCAs or bias the 
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associations under study because the prevalence of stillbirth in the UK is only 
0.6%254 out of which 8-14% can be attributed to MCAs.255,256 The study also did 
not include any miscarriages as most of the miscarriages take place early in 
pregnancy 257 when women may not know that they are pregnant and therefore 
it is not possible to ascertain MCAs in these.    
3UHYLRXVVWXGLHVKDYHXVHGZRPHQ¶VVHOI-reports to define NRT exposure which 
is subject to reporting errors and bias.100,114 In contrast, the measurement of 
NRT exposure in this study was based on recorded GP prescribing. As discussed 
earlier, in the UK women can access NRT in settings other than the GP practice, 
which means that some women in the smokers /non-smokers category may 
have received NRT from pharmacies or SSSPs, not documented in the GP 
records.  This may bias the estimates towards null. However, as discussed in 
Section 5.4, OTC purchasing of NRT is assumed to be infrequent and GP data 
include SSSP prescribing as well, therefore any misclassification in the exposure 
will be minimal and non-differential.   
Measuring actual drug consumption in any large population-based study is 
difficult and is a limitation in previous studies.114 Similarly, in primary care data 
it is not possible to establish if the women actually used the NRT that was 
prescribed. However, women are generally more motivated to quit during 
pregnancy258 and NRT is only prescribed after a discussion on potential benefits 
and harms and if the woman agrees to use it.79 Although data from RCTs show 
low compliance to NRT especially during pregnancy100,106 most of these report a 
median duration of at least two weeks for NRT use.107-109 The average duration 
of prescribed NRT was two weeks on average as discussed in Section 5.3.2, 
therefore it is assumed that women did comply with the NRT prescription. Also, 
the exposure time of two weeks is fairly short and if there is a higher risk of 
MCAs with longer NRT exposure this study may not have been able to capture it.   
162 
 
Similarly, ascertaining accurate smoking status is difficult in studies, especially 
in pregnant women as there is a high potential for misreporting due to the social 
stigma attached to smoking in pregnancy. All the previous studies investigating 
the association between maternal smoking and MCAs have relied on self-
reported smoking status through interviews or surveys, as biochemical validation 
is practically difficult and expensive in population-based studies.28  Similarly, in 
primary care data it is not possible to be completely certain about the accuracy 
RIWKHVPRNLQJVWDWXVUHFRUGVLQZRPHQ¶VHOHFWURQLFQRWHVDVHQWULHVDUHQRW
biochemically validated and are also based on self-reports of women. In this 
study pre-cRQFHSWLRQUHFRUGVZHUHDOVRLQFOXGHGWRDVFHUWDLQZRPHQ¶VVPRNLQJ
status during early pregnancy which may result in misclassification of some non-
smokers as smokers and bias the effect estimates towards null. However, a 
substantial misclassification is unlikely as approximately 35-50% of pregnancies 
in the UK are unplanned,31, 32  which means that only some women are likely to 
make positive behaviour changes such as quitting smoking before attempting to 
conceive. To address this issue the risks of MCAs were recalculated using only 
gestational smoking records to define smokers and non-smokers and the 
findings remained unchanged. 
Congenital anomaly is a rare condition and from previous work it is known that 
NRT prescribing among pregnant women is also rare.252  Therefore, only 1,594 
children had mothers with NRT prescriptions in early pregnancy which although 
did not provide adequate power (post-hoc power: 60%) but was still about 5 
times bigger than the previous study.114 The number of NRT exposed cases of 
MCA was also 6 times higher than the Danish study (58 vs 11 cases). 
Nevertheless, much larger numbers are needed to assess the association 
between NRT exposure and specific anomaly groups.  
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6.4.3 Interpretation and conclusion in light of the current literature 
In this study the odds of major congenital anomalies in offspring of women 
prescribed NRT was 34% higher compared to non-smokers, although this finding 
was not statistically significant. Similarly, the absolute risks of system-specific 
anomalies were also generally higher than in the overall population and 
smokers, although these differences were small. A potential explanation for this 
finding may be that women who were prescribed NRT during pregnancy may be 
heavier smokers for some part of their pregnancy or immediately before their 
pregnancy and found it difficult to quit without pharmacotherapy 259,260 leading 
to confounding by indication. Although data on the exact time of NRT 
prescription in pregnancy was available, there is still inadequate information in 
the data regarding the smoking intensity of women before getting an NRT 
prescription. Therefore, it is difficult to completely separate the effects of 
smoking for some part of pregnancy from the effects of NRT. Additionally, 
despite adjustments in the analysis for sociodemographic factors and maternal 
morbidities, women prescribed NRT may have differed in unrecorded ways. 
Thus, unmeasured confounding factors may have contributed to the higher OR 
point estimate for NRT. 
The only observational study on NRT and congenital anomalies, using the DNBC, 
showed that the women who used NRT in the first 12 weeks of pregnancy, but 
did not smoke, were more likely to have infants with congenital anomalies (OR 
1.61, 95% CI 1.01-2.58) compared to non-smokers however when the analysis 
was only restricted to MCAs no association was found (OR 1.13, 95% CI 0.62-
2.07).114  The exposure time in the DNBC study was very similar to this study 
(i.e. early pregnancy) and despite the different exposure definition (self-reported 
NRT use in the DNBC study and GP prescribed NRT in this study) both the 
studies did not find any significantly increased risk of major congenital 
anomalies in relation to NRT, which is reassuring. In comparison, the SNAP trial 
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assessed NRT use at a later stage of pregnancy and reported a 30% lower 
likelihood of congenital anomalies in the NRT group compared to placebo group; 
however the results were not statistically significant and based on a very small 
number of events (9 events in NRT group compared to 13 events in placebo 
group).100 When the exposure time in this study was changed to 2nd/3rd trimester 
NRT exposure the association between NRT and major CAs was did not become 
statistically significant, which mirrors the findings of the SNAP trial.  
For mothers who smoked during early pregnancy this study found no association 
with congenital anomalies in their infants. This is very similar to the results from 
a large meta-analysis of  172 observational studies on maternal smoking in 
pregnancy with a total of 173,687 malformation cases and 11,674,332 controls,  
which found the OR for all congenital anomalies to be 1.01 (95% CI 0.96-
1.07).28 However, the magnitude of effect for system-specific anomaly groups 
were slightly different e.g. the systematic review found a significantly increased 
risk of heart defects associated with maternal smoking (OR 1.09, 95% CI 1.02-
1.17).28 In comparison, this study found an increase of 2% in the risk of heart 
defects associated with maternal smoking (OR 1.02, 99% CI 0.86-1.21), which 
was not statistically significant. In line with the findings of this chapter, the 
Baltimore-Washington Infant Study also did not find a statistically significant 
association between maternal smoking and congenital heart defects (OR 1.07, 
95% CI 0.80-1.45).225 The meta-analysis also found a higher risk of 
musculoskeletal defects, orofacial clefts, limb defects, eye defects and 
gastrointestinal defects28 contrary to the findings reported here. A potential 
explanation for the difference in the estimates could be the very large sample 
size in the meta-analysis compared to this study and the use of 99% confidence 
intervals compared to the standard 95% CIs presented in the meta-analysis. A 
recent study on Greece based on 167 children with congenital heart defects 
found a three-fold increase in the risk of congenital heart defects associated with 
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maternal smoking227 which is higher compared to the findings reported in this 
chapter and other available literature. This study, however, collected smoking 
exposure in the first trimester retrospectively after the delivery which increases 
the potential for recall bias. Additionally, no adjustments were made for other 
maternal co-morbidities (e.g. epilepsy), and socioeconomic status which may be 
important confounders.238,246,261  The risk of nervous system anomalies was not 
found to be higher with maternal smoking (OR 0.98, 95% CI 0.65-1.47). 
Correspondingly, the OR for neural tube defects, which is the most common 
nervous system anomaly,  in  the NBDPS study, a national study from the US, 
was found to be 0.9 (95% CI 0.8-1.11).262 
The limited evidence of maternal exposure to NRT during pregnancy and the risk 
of congenital anomalies in the offspring has not shown any significant 
associations between these factors. This study with much larger numbers than 
any other previous study did not find a protective or harmful effect of NRT 
during pregnancy. Therefore, it may be likely that there is no true association 
between NRT exposure during pregnancy and congenital anomalies in the 
offspring. However, it is difficult to be completely certain in the absence of 
adequate statistical power, for which an even larger study is required. 
Furthermore, other birth outcomes also need to be assessed in relation to NRT 
and smoking during pregnancy before making conclusions about the overall 
safety of the drug during pregnancy.  
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7 NICOTINE REPLACEMENT THERAPY, MATERNAL 
SMOKING IN PREGNANCY AND OTHER BIRTH 
OUTCOMES 
7.1 INTRODUCTION 
The previous chapter investigated and described the association between 
exposure to NRT and maternal smoking as recorded in primary care data and 
congenital anomalies. This chapter focuses on examining the relationship 
between NRT exposure, maternal smoking and other birth outcomes to 
comprehensively assess the safety of NRT in pregnancy.  
Maternal smoking during pregnancy has been associated with several adverse 
birth outcomes including stillbirth, low birth weight and other birth outcomes as 
discussed in Section 1.1.1. Approximately 4-7% of stillbirths in developed 
countries can be attributed to maternal smoking.29 A population-based study 
from Australia with a total sample of 191,941 births reported the risk of stillbirth 
to be twice as high in smokers compared to non-smokers after 34 weeks of 
gestation. 263 Similar results were reported by a Danish study assessing the risk 
of stillbirth in 25,012 singleton children of pregnant women between September 
1989 and August 1996.264  In addition, a meta-analysis of four studies from 
Australia, Sweden, Canada and the USA found maternal smoking to increase the 
risk of stillbirth by 36%.29 
Maternal smoking has also been linked to low birth weight in infants and has 
been reported as one of the most important preventable causes of low birth 
weight.265 A Dutch study from the early 1990s including approximately 800 
pregnant women reported a 19g reduction in birth weight for each cigarette 
smoked in the day while pregnant.266   As discussed in Section 1.1.1.2 recent 
data from the developed countries reports a reduction of 165g in birth weight 
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associated with maternal smoking.19 This was even greater for heavy smokers 
where the birth weight reduced by 226g compared to non-smokers.20  
Whilst there is clear evidence of the association of smoking with outcomes like 
stillbirth and low birth weight the understanding of the relationship between 
maternal smoking and the mode of delivery is vague.  There are very few 
studies examining this relationship. A recent study conducted in Germany using 
a perinatal database including 170,254 singleton pregnancies found no increased 
risk of caesarean section associated with maternal smoking.31 Similar results 
were found in smaller hospital-based studies from Spain and Hong Kong with no 
statistically significant association between maternal smoking and caesarean 
section.267,268  A cross-sectional study from the UK using 15,288 births from the 
Millenium Cohort Data also did not find any effect of smoking on whether a 
woman had medical intervention at birth (OR 1.003, 95% CI 0.88-1.44) or 
caesarean section (OR 1.15,95% CI 0.95-1.39).269 However, a study conducted 
in a maternity unit at St. Marys hospital, Portsmouth, UK on 400 smoking 
mothers and 400 non-smoking mothers showed that the risk of caesarean 
section was twice as high in smokers compared to non-smokers.270 Similarly, a 
recent study conducted in Israel, including approximately 6000 pregnancies, 
reported the risk of any operative or instrumental intervention to be higher in 
smokers  compared to non-smokers OR 1.24 (95% CI 1.01±1.52).32  
The studies examining the association between NRT and these birth outcomes 
are even more limited. To date, there is only one observational study that has 
assessed the association between maternal NRT use and stillbirth.113 Other 
evidence comes from RCTs of NRT patches and gum with inadequate power to 
assess safety outcomes.100,107,109 Data from the DNBC suggest no increased risk 
of stillbirth associated with NRT use in the first 27 weeks of pregnancy (HR = 
0.57, 95%CI 0.28-1.16) compared to those who did not use NRT and did not 
smoke). In comparison, women who both smoked and used NRT had an HR of 
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0.83 (95%CI 0.34-2.00) compared with non-smoking women who did not use 
NRT. 113 A meta-analysis of three RCTs assessing stillbirth as a secondary 
outcome also reported similar findings with no increased risk of stillbirth 
associated with NRT use compared to placebo (pooled OR 1.98, 95% CI 0.55-
7.07).101 Table 7-1 summarises the studies assessing NRT and birth outcomes 
including stillbirth, birth weight and mode of delivery. 
The few studies assessing the association between NRT and birth weight present 
mixed evidence. Data from the observational studies report either no association 
between NRT and birth weight112 or show an increased risk of low birth weight 
associated with NRT use.111 In comparison, data from the trials report either no 
significant effect of NRT on iQIDQW¶VELUWKZHLJKW100,107,108 or report higher birth 
weight in babies born to women randomised to NRT compared to the placebo 
group (mean difference 337g, (p<0.01)109 (Table 7-1).  
The association between NRT and caesarean section has only been investigated 
in the SNAP trial which found a 45% increased risk of caesarean section 
associated with NRT use compared to placebo (Table 7-1). 
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Table 7-1 - Summary of studies assessing the association between NRT use and birth outcomes 
First 
author, 
year and 
location 
Study methodology Sample size 
(Inclusion/Exclusi
on) 
Exposure Assessment Outcome 
Assessment 
Results for NRT safety 
NRT and stillbirth 
Strandberg
-Larsen 
(2008), 
Denmark 
113 
Cohort study using 
Danish National Birth 
Cohort 
87,032 pregnancies 
between 1996-2002 
NRT self-reported usage, 
total number of weeks with 
NRT use during the first 27 
weeks of gestation, NRT 
type used 
Stillbirth, defined 
as any foetus that 
did not breathe or 
show any other 
signs of life at birth 
after a minimum of 
20 weeks of 
gestation, derived 
from The Civil 
Registration 
System and Danish 
Medical Birth 
Registry 
Women who used NRT during 
pregnancy had a HR of 0.57 (95%CI 
0.28-1.16) for still birth compared to 
those who did not use NRT. Women 
who both smoked and used NRT had a 
HR of 0.83 (95%CI 0.34-2.00) 
compared with non-smoking women 
who did not use NRT 
Coleman 
(2012), UK 
100 
Large, double-blinded, 
placebo-controlled 
multicentre RCT 
1050 participants 
between 16 to 50 
years with 
pregnancies of 12-
24 weeks of 
gestation smoking 
five or more 
cigarettes per day 
 
4 weeks supply of Standard 
nicotine patch (15mg/16 
hrs)  versus  visually 
identical placebo, started on 
the quit date 
Secondary 
outcome: Adverse 
pregnancy and 
birth outcomes 
including stillbirth 
5 cases in NRT group and 2 cases in 
the placebo group. Stillbirth ± OR 
2.59 (95% CI 0.50-13.4) 
 
Oncken 
(2008), 
Connecticu
t and 
Massachus
etts109 
Prospective, 
randomised, double-
blind placebo-
controlled clinical trial. 
100 women 
randomised to 
nicotine gum and 94 
to placebo 
Individualised behavioural 
counselling and 6 week 
treatment with 2mg nicotine 
gum versus placebo 
Stillbirth as a 
secondary outcome 
 
2 cases in the NRT group and 0 cases 
in the placebo group. Stillbirth ± OR  
4.55 (0.22- 93.63) 
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Pollack 
(2007), 
North 
Carolina, 
USA107 
An open-labelled non-
placebo, randomised 
trial  
Cognitive 
Behavioural Therapy 
(CBT)-only (n=59) 
versus CBT+NRT 
(n=122) in pregnant 
women between 13 
and 25 weeks of 
gestation.  
&RQWUROUHFHLYHGD³4XLW
NLW´ZKLFKFRQWDLQHGD
booklet, water bottle, 
straws, candy, 
exercise band, and stress 
management tape), as well 
as 3 counselling sessions 
from a 
³VXSSRUWVSHFLDOLVW´EDVHG
on motivational 
interviewing, trans 
theoretical model and social 
cognitive theory. 
Intervention: as above plus 
an option of NRT by patch, 
gum or lozenge. Participants 
could change mode of 
administration if they 
wished. 
 
Stillbirth as a 
secondary outcome 
 
1 cases in the CBT+NRT group and 1 
case in the only CBT group.  OR 0.49 
(0.03- 7.66) 
NRT and low birth weight 
Coleman 
(2012), UK 
100 
Large, double-blinded, 
placebo-controlled 
multicentre RCT 
1050 participants 
between 16 to 50 
years with 
pregnancies of 12-
24 weeks of 
gestation smoking 
five or more 
cigarettes per day 
 
4 weeks supply of Standard 
nicotine patch (15mg/16 
hrs)  versus  visually 
identical placebo, started on 
the quit date 
Secondary 
outcome: Adverse 
pregnancy and 
birth outcomes 
including birth 
weight 
Low birth weight ± OR 1.38 (95% CI 
0.90-2.09), mean difference in birth 
weight=-0.05 (95% CI -0.17, 0.08). 
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Lassen 
(2010), 
Denmark11
2 
Cohort study using 
Danish National Birth 
Cohort, a nationwide 
study of pregnant 
women and their 
offspring including 
101,042 pregnancies 
between 1996 and 
2002 
72,761 pregnancies 
between 1996 and 
2002 
NRT self-reported usage, 
total number of weeks with 
NRT use during the first 27 
weeks of gestation, NRT 
type used 
Offspring Birth 
weight in mothers 
using NRT 
Total NRT use not significantly 
associated with changes in birth 
weight (b=0.25g per week of NRT use 
(95%CI -2.31, 2.81)). Simultaneous 
use of >1 product associated with a 
statistically insignificant decrease in 
birth weight (b=-10.73g per week of 
NRT use (95% CI -26.51,5.05)) 
Gaither 
(2009), 
North 
Carolina, 
USA 111 
Cross-sectional study 
using data from 2004 
Phase V Pregnancy 
Risk Assessment 
Monitoring System  
6,041 women 
between the ages of 
18-45 years out of 
which 5,716 
included in the final 
analysis 
Smoking,  
NRT prescription 
Versus 
Non-smoking women during 
pregnancy 
Low birth weight 
defined as <2500g 
at birth) 
After the adjustment for age, marital 
status, education and race/ethnicity 
women recommended NRT had twice 
the risk of low birth weight compared 
to non-smokers (OR=1.95, 95%CI 
1.10-3.46) 
Oncken 
(2008), 
Connecticu
t and 
Massachus
etts109 
Prospective, 
randomised, double-
blind placebo-
controlled clinical trial. 
100 women 
randomised to 
nicotine gum and 94 
to placebo 
Individualised behavioural 
counselling and 6 week 
treatment with 2mg nicotine 
gum versus placebo 
Offspring birth 
weight 
 
Mean difference in the birth weight 
between offspring of mothers using 
NRT versus mothers on placebo=337g 
(p<0.001)   
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Pollack 
(2007), 
North 
Carolina, 
USA107 
An open-labelled non-
placebo, randomised 
trial  
Cognitive 
Behavioural Therapy 
(CBT)-only (n=59) 
versus CBT+NRT 
(n=122) in pregnant 
women between 13 
and 25 weeks of 
gestation.  
&RQWUROUHFHLYHGD³4XLW
NLW´ZKLFKFRQWDLQHGD
booklet, water bottle, 
straws, candy, 
exercise band, and stress 
management tape), as well 
as 3 counselling sessions 
from a 
³VXSSRUWVSHFLDOLVW´EDVHG
on motivational 
interviewing, trans 
theoretical model and social 
cognitive theory. 
Intervention: as above plus 
an option of NRT by patch, 
gum or lozenge. Participants 
could change mode of 
administration if they 
wished. 
Birth weight 
 
The mean difference between the 
CBT+NRT and CBT only arm in the 
birth weight = -71g (p=0.51) 
 
Wisborg 
(2000), 
Denmark 
108 
Double-blinded, 
placebo-controlled 
RCT 
Pregnant women 
who smoked ten or 
more cigarettes 
after the first 
trimester (250) were 
randomly assigned 
to receive nicotine 
patches (124) or 
placebo patches 
(126). 
 
 
 
 
Women randomized to 
nicotine were 
treated with 15-mg patches 
(16 hours/day) for 8 weeks, 
and 
10-mg patches (16 
hours/day) for 3 weeks. 
Birth weight 
 
Mean difference between NRT and 
placebo group (186 g, 95% CI 35-336 
g. RR for low birth weight with NRT 
use during pregnancy =0.40, (95% CI 
0.10-1.10) 
 
NRT and mode of delivery 
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Coleman 
(2012), UK 
100 
Large, double-blinded, 
placebo-controlled 
multicentre RCT 
1050 participants 
between 16 to 50 
years with 
pregnancies of 12-
24 weeks of 
gestation smoking 
five or more 
cigarettes per day 
 
4 weeks supply of Standard 
nicotine patch (15mg/16 
hrs)  versus  visually 
identical placebo, started on 
the quit date 
Secondary 
outcome: Adverse 
pregnancy and 
birth outcomes 
including mode of 
delivery 
Caesarean section delivery ± OR 1.45 
(95% CI 1.05-2.01) 
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Given the dearth of information on the safety of NRT use during pregnancy and 
the inconclusive evidence arising from the limited literature available, this 
chapter focuses on examining the associations between NRT and smoking 
exposure during pregnancy as recorded in primary care and adverse birth 
outcomes. The specific objectives for this chapter are: 
1. To examine the risk of stillbirth and fetal death (stillbirth and 
miscarriage) associated with maternal NRT and smoking exposure during 
pregnancy as described in primary care data 
2. To assess the association between maternal NRT and smoking exposure 
during pregnancy, as recorded in primary care data, with birth weight 
3. To assess the association between maternal NRT and smoking exposure 
during pregnancy as described in primary care data and mode of 
delivery 
 
7.2 METHODS 
7.2.1 Study population 
The study population used for assessing stillbirth and mode of delivery was the 
same as described in Section 5.2.1 i.e. all pregnancies between January 2001 
and September 2009 in women of childbearing age (15-49 years) which resulted 
in either a live birth or a stillbirth.  
For low birth weight all live born children delivered between January 2001 and 
December 2009 with linked mother records and a recording for birth weight in 
their primary care records were included in the analysis. Stillborn children only 
constituted 0.07% of the total population and were excluded from this analysis 
as there may be higher risks of fetal growth restriction in stillborns compared to 
liveborns.  
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7.2.2 Exposure 
Two different time windows were used to classify the study population into one 
of the exposure categories: NRT group, smoker, non-smoker and unknown. 
Firstly, early pregnancy NRT and smoking exposure (defined as exposure 
between four weeks before conception until the end of the first trimester), as 
recorded in primary care data, was assessed as described in Section 6.2.2. 
Additionally, the exposure window was expanded to the whole course of 
pregnancy until delivery to assess the effects of NRT or smoking exposure any 
time during pregnancy on stillbirth. This exposure window was then also used for 
assessing the risk of low birth weight and the mode of delivery as fetal growth 
takes place throughout pregnancy. 
 
 
7.2.3 Outcomes 
7.2.3.1 Stillbirth 
Stillbirth was defined as a baby born with no signs of life at or after 28 weeks of 
gestation, in accordance with the WHO definition.271 Information on stillbirth was 
extracted from the birth outcome variable pre-defined in the mother-child linked 
data, which has been described in Section 2.5.  
 
A variable combining both stillbirth and miscarriage was created, called fetal 
death to assess the effect of NRT and smoking exposure on overall fetal death. 
It should however be noted that the information on miscarriages in these data is 
not complete which may have implications on the results. 
 
7.2.3.2 Birth weight 
Firstly, birth weight was also used as a continuous variable to examine the 
change in birth weight by each category of exposure. Then, low birth weight was 
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defined as a live born baby with a birth weight of  less than 2500g (2.5kg) 
according to the WHO definition of low birth weight.11  
 
7.2.3.3 Mode of delivery 
Mode of delivery was also pre-defined in the mother-child linked file and 
categorised as normal delivery, assisted delivery and caesarean section. All 
pregnancies where there was no record of caesarean delivery or an assisted 
delivery were categorised as normal deliveries.  
  
7.2.4 Statistical analysis 
7.2.4.1 Stillbirth 
The absolute risk of stillbirth was calculated by dividing the total number of 
stillbirths by the number of stillbirths and live births combined. Logistic 
regression was used to compute ORs and corresponding 99% CIs for stillbirth for 
the NRT group and smokers, using non-smokers as the reference group.  
Maternal age, Townsend quintile, maternal diabetes, hypertension, asthma, pre-
conception body mass index and mental illnesses were considered as potential 
confounders based on the previous literature.195,199,211,242-244,272-274 The covariates 
which had a significant statistical association with the exposure and the 
outcomes in chi-squared tests were included in the final model. The potential 
clustering of pregnancies among mothers was accounted for using the clustered 
sandwich estimator180,181 The reference group was then changed to smokers and 
the ORs were re-calculated. This analysis was then repeated using the entire 
pregnancy until the outcome as the exposure time for NRT and smoking.  
 
To estimate the association between NRT and smoking exposure during 
pregnancy with fetal death (defined here as stillbirth and miscarriages) the risk 
of fetal death was calculated for NRT and smoking exposure during the entire 
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pregnancy time until the outcome, using the analysis techniques described 
above.  
 
7.2.4.2 Birth weight 
The association between NRT exposure maternal smoking during pregnancy and 
birth weight was analysed using a multiple linear regression model, treating 
birth weight as a continuous outcome. Only complete case analysis was 
conducted i.e. only babies with a recording of birth weight were included in this 
analysis. Potential confounding factors (described above) and clustering were 
adjusted for in the analysis. The regression co-HIILFLHQWǃUepresents the 
average change in birth weight in grams associated with NRT group and smoking 
in relation to non-smokers.  The risk of low birth weight for the NRT group and 
smokers was calculated in a similar fashion using univariable and multivariable 
logistic regression models as described above.   
 
7.2.4.3 Mode of delivery 
A multinomial logistic regression model (for categorical study outcomes) was 
used to obtain relative risk ratios (RRR) for assisted delivery and caesarean 
section relative to normal delivery in the NRT group, smokers and unknown 
categories compared to non-smokers. This model extends logistic regression by 
estimating the effect of one or more exposure variables on the probability that 
the outcome is in a particular category.275 Robust CIs were calculated and 
appropriate adjustments in the RRRs for potential confounders were made in the 
same way as described above.   
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7.2.5 Sensitivity analysis 
7.2.5.1 Reclassifying smokers and non-smokers based on gestational smoking 
status recording 
Similar to the previous chapter, the definition of smokers was restricted to only 
mothers who had a gestational smoking record during pregnancy and the non-
smokers to mothers who had a gestational record in their primary care data 
indicating them to be non-smokers. This was done for both the early pregnancy 
exposure and exposure throughout pregnancy. The absolute and relative risks of 
stillbirth, low birth weight and different modes of delivery were re-calculated 
using this definition.  
 
7.2.5.2 Risk of low birth weight stratified by pre-term birth 
Since birth weight is directly related to gestational age276 the risk of low birth 
weight was further stratified by whether the baby was born preterm or not. 
Preterm birth was defined as babies born alive before 37 weeks of pregnancy in 
line with the WHO definition 277 and deliveries occurring at or after 37 weeks of 
gestation were classified as term deliveries for purposes of this analysis. 
Unadjusted and adjusted ORs and corresponding CIs were calculated separately 
for preterm and term deliveries.  
 
7.2.6 Sample size calculations 
The prevalence of stillbirth in the UK is estimated to be approximately 5/1000 
live and stillbirths.159 Based on the known prescribing prevalence of NRT and 
maternal smoking during pregnancy from previous chapters, a sample size of 
96,641 children with mothers prescribed NRT was needed to detect an OR of 
1.50 with 80% power at 1% level of significance. For maternal smoking, a 
sample size of 12,903 children with mothers who smoked during pregnancy was 
needed to detect an OR of 1.50, with 80% power at 1% level of significance.  
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Considering the standard deviation of birth weight in general population to be 
466g,278 a sample size of 7,646 babies will have 80% power to detect a mean 
difference of 150g with a two-sided level of significance of 5%. The prevalence 
of low birth weight in the UK in 2009 was approximately 7%.279 In light of this, 
and the smoking and NRT prescribing prevalence from the previous chapter,   a 
sample size of 43,029 children with mothers prescribed NRT was needed to 
detect an OR of 1.50 with 80% power at 1% level of significance. For smoking 
exposure a sample of 5,907 children with maternal smoking exposure was 
needed to detect an OR of 1.50 with 80% power at 1% level of significance.  
 
 
7.3 RESULTS  
7.3.1 Stillbirth 
7.3.1.1 Baseline characteristics 
The study population included 255,441 pregnancies delivered between 2001 and 
2009 out of which 1,044 ended in stillbirths, giving a prevalence of 4/1,000 live 
and stillbirths. Pregnancies that were conceived at later ages (>35 years) 
resulted in a higher prevalence of stillbirth. The prevalence of stillbirths was also 
higher in pregnant women with diabetes and mental illness (3.5% and 11.9% 
respectively). The distribution of socioeconomic status, pre-conception BMI, and 
the prevalence of chronic illnesses like asthma and hypertension were 
comparable in women with stillbirth and those with live births. 
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Table 7-2 - Baseline characteristics for all pregnancies, by live birth and 
stillbirth 
 All pregnancies Live births Stillbirths 
N=255,441 N=254,397 N=1,044 
n % n % n % 
Age at conception       
15-19 years 14,141 5.5% 14,066 5.5% 75 7.2% 
20-24 years 40,879 16.0% 40,703 16.0% 176 16.9% 
25-29 years 65,029 25.5% 64,796 25.5% 233 22.3% 
30-34 years 79,959 31.3% 79,683 31.3% 276 26.4% 
35-39 years 45,765 17.9% 45,543 17.9% 222 21.3% 
40-44 years 9,179 3.6% 9,122 3.6% 57 5.5% 
45-49 years 489 0.2% 484 0.2% 5 0.5% 
Townsend score in 
quintiles 
      
Quintile 1 (least deprived) 57,859 22.7% 57,658 22.7% 201 19.3% 
Quintile 2 47,841 18.7% 47,664 18.7% 177 17.0% 
Quintile 3 49,670 19.4% 49,465 19.4% 205 19.6% 
Quintile 4 47,292 18.5% 47,086 18.5% 206 19.7% 
Quintile 5 (most deprived) 36,103 14.1% 35,902 14.1% 201 19.3% 
Missing  16,676 6.5% 16,622 6.5% 54 5.2% 
Pre-conception Body 
Mass Index (kg/m2) 
      
Normal(18.5-24.9) 80,016 31.3% 79,737 31.3% 279 26.7% 
Underweight(<18.5) 5,856 2.3% 5,825 2.3% 31 3.0% 
Overweight(25-29.9) 38,945 15.2% 38,785 15.2% 160 15.3% 
Obese(>=30) 26,741 10.5% 26,595 10.5% 146 14.0% 
Missing 103,883 40.7% 103,455 40.7% 428 41.0% 
Asthma 21,884 8.6% 21,802 8.6% 82 7.9% 
Hypertension 6,885 2.7% 6,848 2.7% 37 3.5% 
Diabetes 5,971 2.3% 5,930 2.3% 41 3.9% 
Mental illness 24,178 9.5% 24,054 9.5% 124 11.9% 
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7.3.1.2 Association between NRT and smoking exposure in early pregnancy and 
stillbirth 
Table 7-3 presents the odds of stillbirth in relation to NRT exposure and 
maternal smoking during early pregnancy. The prevalence of stillbirth in the 
study population was found to be 4/1,000 live and stillbirths. The absolute risk 
of stillbirth was 4/1,000 live and stillbirths amongst the NRT group and 5/1000 
live and stillbirths among smokers.  
In the unadjusted analysis there was no statistically significant increased risk of 
stillbirth associated with NRT exposure during early pregnancy. However, women 
who smoked during early pregnancy were 35% more likely to have stillbirths 
compared to non-smokers (OR 1.35, 99% CI 1.08-1.68). The association 
between NRT exposure in early pregnancy and stillbirth did not reach statistical 
significance when adjusted for the potential confounders (OR 1.19, 99% CI 
0.47-3.01). The association between maternal smoking and stillbirth was, 
however, still significant after adjusting for maternal age at conception, 
Townsend quintile, pre-conception BMI, diabetes and mental illness, with a 27% 
increase in the risk of stillbirth associated with maternal smoking during early 
pregnancy (OR 1.27, 99% CI 1.01-1.60).  
When the reference group was changed to smokers, no increased risk of 
stillbirth was found for NRT exposure in comparison to smoking (OR 0.94, 99% 
CI 0.36-2.38).   
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Table 7-3 ± Risk of stillbirth by NRT and smoking exposure only during early pregnancy 
 Total population  
N=255,441  
Stillbirths 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI)Á 
p-value 
Non-smoker*** 125,261 450 (0.4%) 1  1  
NRT-exposed group * 1,759 8 (0.4%) 1.26 (0.50-3.18) 0.508 1.19 (0.47-3.01) 0.622 
Smoker** 41,603 201 (0.5%) 1.35 (1.08-1.68) <0.001 1.27 (1.01-1.60) 0.007 
Unknown 86,818 385 (0.4%) 1.23 (1.03-1.48) 0.002 1.20 (1.00-1.45) 0.010 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy , ***non-smokers during early pregnancy 
ÁDGMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHGLDEHWHVPHQWDOLOOQHVVDQG%RG\0DVV,QGH[PXOWLSOHELUWKV 
OR=Odds ratio, CI= confidence interval
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7.3.1.3 Association between NRT, smoking exposure during the entire 
pregnancy and stillbirth 
When the exposure time was expanded to include any NRT prescribing or 
smoking until delivery the absolute risks were similar.  
No increased risk of stillbirth was found to be associated with NRT exposure 
(adjusted OR 1.67, 99% CI 0.94-2.99) (Table 7-4). Maternal smoking any time 
during pregnancy was also not found to be associated with an increased risk of 
stillbirth (OR 1.19, 99% CI 0.95-1.52).  
When the reference group was changed to smokers, no increased risk of 
stillbirth was found in the NRT group in comparison to smoking (OR 1.39, 99% 
CI 0.76-2.53).   
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Table 7-4 ± Risk of stillbirth by NRT and smoking exposure throughout pregnancy  
 Total population  
N=255,441  
Stillbirths 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI) Á 
p-value 
Non-smoker*** 123,356 447 (0.4%) 1    
NRT-exposed group * 3,254 21 (0.6%) 1.79 (1.00-3.18) 0.010 1.67 (0.94-2.99) 0.022 
Smoker** 42,089 193 (0.5%) 1.26 (1.00-1.58) 0.001 1.19 (0.95-1.52) 0.046 
Unknown 86,742 383 (0.4%) 1.22 (1.01-1.45) 0.002 1.18 (0.98-1.43) 0.018 
*NRT=nicotine replacement therapy prescription any time during pregnancy, **smoking any time during pregnancy, ***non-smokers 
GXULQJSUHJQDQF\ÁDGMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHGLDEHWHVPHQWDOLOOQHVVDQG%RG\0DVV,QGH[PXOWLSOHELUWKV 
OR=Odds ratio, CI= confidence interval
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7.3.1.4 Association between NRT, smoking exposure and fetal death 
 
Table 7-5 presents the unadjusted and adjusted odds ratios for fetal death in 
relation to NRT and maternal smoking exposure during pregnancy. The 
prevalence of stillbirth and miscarriages together was the highest among current 
smokers (20.8%) and the lowest in the NRT group (9.4%).  
NRT exposure during pregnancy was found to have a protective effect on fetal 
death such that it reduced the risk of fetal death by half (OR 0.44, 99% CI 0.38-
0.51) in comparison to non-smokers. Smoking was found to increase the risk of 
fetal death by 16% (OR 1.16, 99% CI 1.11-1.21) when compared to the risk in 
non-smokers.  
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Table 7-5 ± Risk of fetal death by NRT and smoking exposure throughout pregnancy 
 Total population  
N=311,802  
Fetal death 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted ORÁ  
(99%CI) 
p-value 
Non-smoker*** 150,175 25,962 (17.3%) 1  1  
NRT group * 5,234 491 (9.4%) 0.50 (0.44-0.56) <0.001 0.44 (0.38-0.50) <0.001 
Smoker** 50,643 10,560 (20.8%) 1.26 (1.22-1.30) <0.001 1.16 (1.11-1.21) <0.001 
Unknown 105,750 20,392 (19.3%) 1.14 (1.11-1.17) <0.001 0.95 (0.74-1.21) 0.571 
*NRT=nicotine replacement therapy prescription any time during pregnancy, **smoking any time during pregnancy, ***non-smokers 
GXULQJSUHJQDQF\ÁDGMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHGLDEHWHVPHQWDOLOOQHVVDQG%RG\0DVV,QGH[PXOWLSOHELUWKV 
OR=Odds ratio, CI= confidence interval
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7.3.1.5 Sensitivity analysis 
The results from the sensitivity analysis were very similar to the main results 
showing no statistically significant increased risk of stillbirth in the NRT group in 
both early pregnancy (OR 1.44, 99% CI 0.54-3.82) and throughout pregnancy 
(OR 1.95, 99% CI 1.00-3.63). Similarly, the risk of stillbirth increased by 78% in 
mothers who smoked in early pregnancy (OR 1.78, 99% CI 1.04-3.02). This 
effect decreased when exposure throughout pregnancy was assessed (OR 1.47, 
99% CI 0.96-2.25).  
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Table 7-6 ± Risk of stillbirth by NRT and smoking exposure only during early pregnancy, using only gestational smoking 
records 
 Total population  
N=255,441  
Stillbirths 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI)Á 
p-value 
Non-smoker*** 20,068 59 (0.3%) 1  1  
NRT-exposed group * 1,759 8 (0.4%) 1.55 (0.59-4.09) 0.246 1.44 (0.54-3.82) 0.336 
Smoker** 7,381 41 (0.6%) 1.89 (1.13-3.20) 0.002 1.78 (1.04-3.02) 0.005 
Unknown 226,233 936 (0.4%) 1.41 (0.99-1.99) 0.011 1.37 (0.96-1.93) 0.020 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy , ***non-smokers during early pregnancy 
ÁDGMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHGLDEHWHVPHQWDOLOOQHVVDQG%RG\0DVV,QGH[PXOWLSOHELUWKV 
OR=Odds ratio, CI= confidence interval
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Table 7-7 ± Risk of stillbirth by NRT and smoking exposure throughout pregnancy, using only gestational smoking records 
 Total population  
N=255,441  
Stillbirths 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI) Á 
p-value 
Non-smoker*** 32,203 101 (0.3%) 1  1  
NRT-exposed group * 3,254 21 (0.6%) 1.79 (1.00-3.18) 0.010 1.95 (1.00-3.63) 0.006 
Smoker** 12,126 60 (0.5%) 1.32 (1.06-1.66) 0.001 1.47 (0.96-2.25) 0.019 
Unknown 207,757 862 (0.4%) 1.22 (1.01-1.45) 0.002 1.31 (1.00-1.72) 0.018 
*NRT=nicotine replacement therapy prescription any time during pregnancy, **smoking any time during pregnancy , ***non-smokers 
GXULQJSUHJQDQF\ÁDGMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHGLDEHWHVPHQWDOLOOQHVVDQG%RG\0DVV,QGH[PXOWLSOHELUWKV 
OR=Odds ratio, CI= confidence interval
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7.3.2 Low birth weight 
7.3.2.1 Baseline characteristics 
A total of 96,782 children with linked maternal records had their birth weight 
recorded in THIN out of a total population of 232,242 live born children. The 
distribution of maternal characteristics in children with a recording of birth 
weight and without a recording of birth weight was highly comparable however 
the proportion of missing maternal BMI data was lower in children with who had 
a recording of birth weight compared to those without a recording of birth 
weight (35.4% compared with 44.0%)  (Table 7-8). 
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Table 7-8 - Recording of birth weight and maternal characteristics 
 All births (N=232,242) Birth weight recorded (96,872) No birth weight recorded (135,370) 
N % n % n % 
Age at conception 
      
15-19 years 12,037 5.2% 4,900 5.1% 7,137 5.3% 
20-24 years 36,003 15.5% 15,031 15.5% 20,972 15.5% 
25-29 years 59,203 25.5% 24,722 25.5% 34,481 25.5% 
30-34 years 73,844 31.8% 30,791 31.8% 43,053 31.8% 
35-39 years 42,477 18.3% 17,917 18.5% 24,560 18.1% 
40-44 years 8,341 3.6% 3,376 3.5% 4,965 3.7% 
45-49 years  337 0.1% 135 0.1% 202 0.1% 
Townsend score in quintiles 
      
Quintile 1  (most affluent) 53,916 23.2% 22,061 22.8% 31,855 23.5% 
Quintile 2 43,850 18.9% 17,839 18.4% 26,011 19.2% 
Quintile 3 45,280 19.5% 19,390 20.0% 25,890 19.1% 
Quintile 4 42,696 18.4% 18,109 18.7% 24,587 18.2% 
Quintile 5 (most deprived) 31,884 13.7% 13,053 13.5% 18,831 13.9% 
Missing  14,616 6.3% 6,420 6.6% 8,196 6.1% 
Pre-conception Body Mass Index 
      
Normal(18.5-24.9) 73,002 31.4% 32,813 33.9% 40,189 29.7% 
Underweight(<18.5) 5,225 2.2% 2,317 2.4% 2,908 2.1% 
Overweight(25-29.9) 35,625 15.3% 16,254 16.8% 19,371 14.3% 
Obese(>=30) 24,594 10.6% 11,233 11.6% 13,361 9.9% 
Missing 93,796 40.4% 34,255 35.4% 59,541 44.0% 
Asthma 19,932 8.6% 9,002 9.3% 10,930 8.1% 
Hypertension 6,392 2.8% 2,910 3.0% 3,482 2.6% 
Diabetes 5,490 2.4% 2,400 2.5% 3,090 2.3% 
Mental illness  22,154 9.5% 10,131 10.5% 12,023 8.9% 
Multiple births 8,373 3.6% 3,361 3.5% 5,012 3.7% 
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In the 96,782 children with a recording of birth weight, the mean birth weight 
was 3.41kgs (sd 0.59) and the mean gestational age was 40 weeks (sd 2.11). 
Figure 7-1 presents a histogram of the birth weight (in kilograms) of the 96,782 
children with a recording of birth weight. Birth weight was normally distributed 
with no skewing towards high or low birth weight. Table 7-9 presents the 
maternal characteristics of children with normal and low birth weight.
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Figure 7-1 - Histogram of birth weight in the study population 
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Table 7-9 - Baseline characteristics by birth weight 
 All live births (N=96,872) Normal birth weight (N=90,670) Low birth weight (N= 6,202) 
N % n % n % 
Age at conception 
      
15-19 years 4,900 5.1% 4,549 5.0% 351 5.7% 
20-24 years 15,031 15.5% 14,007 15.4% 1,024 16.5% 
25-29 years 24,722 25.5% 23,231 25.6% 1,491 24.0% 
30-34 years 30,791 31.8% 28,950 31.9% 1,841 29.7% 
35-39 years 17,917 18.5% 16,695 18.4% 1,222 19.7% 
40-44 years 3,376 3.5% 3,124 3.4% 252 4.1% 
45-49 years  135 0.1% 114 0.1% 21 0.3% 
Townsend score in quintiles 
      
Quintile 1  (least deprived) 22,061 22.8% 20,862 23.0% 1,199 19.4% 
Quintile 2 17,839 18.4% 16,791 18.5% 1,048 16.9% 
Quintile 3 19,390 20.0% 18,201 20.1% 1,189 19.2% 
Quintile 4 18,109 18.7% 16,811 18.5% 1,298 20.9% 
Quintile 5 (most deprived) 13,053 13.5% 12,006 13.2% 1,047 16.9% 
Missing  6,420 6.6% 5,999 6.6% 421 6.8% 
Pre-conception Body Mass Index (kg/m2) 
      
Normal(18.5-24.9) 32,813 33.9% 30,667 33.8% 2,146 34.6% 
Underweight(<18.5) 2,317 2.4% 2,008 2.2% 309 5.0% 
Overweight(25-29.9) 16,254 16.8% 15,310 16.9% 944 15.2% 
Obese(>=30) 11,233 11.6% 10,644 11.7% 589 9.5% 
Missing 34,255 35.4% 32,041 35.3% 2,214 35.7% 
Asthma 9,002 9.3% 8,298 9.2% 704 11.4% 
Hypertension 2,910 3.0% 2,501 2.8% 409 6.6% 
Diabetes 2,400 2.5% 2,207 2.4% 193 3.1% 
Mental illness  10,131 10.5% 9,354 10.3% 777 12.5% 
Multiple births 3,361 3.50% 1,823 2.0% 1,538 24.8% 
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7.3.2.2 Association between maternal NRT and smoking exposure during 
pregnancy and birth weight 
 
Table 7-10 describes the change in mean birth weight for the NRT group and 
smokers compared to non-smokers. NRT exposure during pregnancy was 
associated with a statistically significant decrease in birth weight of 176g 
compared to non-VPRNHUVǃ -176g, 99% CI -221g, -131g). In comparison, 
smoking during pregnancy was associated with a statistically significant decrease 
in birth weight of 120g compared to non-VPRNHUVǃ -123g, 99% CI -136g,-
109g).  
 
When the baseline was changed to smokers, the NRT group was found to have 
VOLJKWO\UHGXFHGELUWKZHLJKWFRPSDUHGWRVPRNHUVǃ-5g, 99% CI -9g, -0.7g).
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Table 7-10 - The association between NRT and smoking exposure during pregnancy and mean birth weight 
 Unadjusted change in mean birth weight (g) Adjusted change in mean birth weight(g) 
 ǃ&, p-value ǃ&, p-value 
NRT group * -211 (-258, -164) <0.001 -176 (-221,-131) <0.001 
Smoker** -143 (-157, -129) <0.001 -123 (-136,-109) <0.001 
Unknown -30 (-41,-19) <0.001 -28 (-39,-17) <0.001 
Non-smokers during early pregnancy considered as baseline 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy  
Á$GMXVWHGIRUPDWHUQDODJHDWFRQFHSWLRQ7RZQVHQGVFRUHPDWHUQDOK\SHUWHQVLRQGLDEHWHVDVWKPDPHQWDOLOOQHVV%RG\0DVVIndex 
CI = confidence interval, OR = Odds ratio  
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7.3.2.3 Association between NRT exposure, smoking and low birth weight 
Table 7-11 presents the prevalence of low birth weight by NRT and smoking 
exposure in mothers and the corresponding unadjusted and adjusted odds ratios 
(99% CI). The prevalence of low birth weight was the highest in the NRT group 
followed by smokers (11.0% and 9.0% respectively). Compared to non-
smokers, children born to women in the NRT group were over twice as likely and 
children born to smokers were 64% more likely to have low birth weight. When 
adjusted for potential confounders, the risk of low birth weight in the NRT group 
was 93% higher compared to non-smokers (OR 1.93, 99% CI 1.48-2.53). 
Similarly, the risk of low birth weight in smokers was 69% higher (OR 1.69, 99% 
CI 1.53-1.86) compared to non-smoking mothers. When the reference group 
was changed to smokers, there was no increased risk of low birth weight in the 
NRT group compared to smokers (OR 1.24, 99% CI 0.97-1.59) (p=0.023).    
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Table 7-11 ± Risk of low birth weight by NRT and smoking exposure during pregnancy 
 Total population  
N=96,872  
Low birth weight 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI) Á 
p-value 
Non-smoker*** 49,452 2,796 (5.6%) 1  1  
NRT group * 1,223 135 (11.0%) 2.07 (1.63-2.63) <0.001 1.93 (1.48-2.53) <0.001 
Smoker** 16,135 1,445 (9.0%) 1.64 (1.50-1.79) <0.001 1.69 (1.53-1.86) <0.001 
Unknown 30,062 1,826 (6.1%) 1.08 (0.99-1.16) 0.014 1.09 (0.99-1.18) 0.015 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, ***non-smokers during pregnancy  
Á Adjusted for maternal age, Townsend score, maternal hypertension, diabetes, asthma, mental illness, Body Mass Index 
CI = confidence interval, OR = Odds ratio 
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7.3.2.4 Sensitivity analysis 
7.3.2.4.1 Maternal NRT and smoking during pregnancy and birth weight, using 
only gestational smoking records 
Table 7-12 describes the change in mean birth weight for NRT group and 
smokers compared to non-smokers, using only gestational smoking records. NRT 
exposure during pregnancy was still associated with a statistically significant 
decrease in birth weight of 168g compared to non-VPRNHUVǃ -168g, 99% CI 
-214g, -122g). In comparison, smoking during pregnancy was associated with a 
statistically significant decrease in birth weight of 139g compared to non-
smRNHUVǃ -139g, 99% CI -165g,-113g).  
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Table 7-12 - The association between NRT and smoking exposure during pregnancy and mean birth weight, using only 
gestational smoking records 
 Unadjusted change in mean birth weight (g) Adjusted change in mean birth weight(g) 
 ǃ&, p-value ǃ&, p-value 
NRT group * -207 (-255, -158) <0.001 -168 (-214,-122) <0.001 
Smoker** -168 (-194, -141) <0.001 -139 (-165,-113) <0.001 
Unknown -26 (-41,-12) <0.001 -22 (-35,-8) <0.001 
Non-smokers during early pregnancy considered as baseline 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy  
Á$GMXVWHGIRUPDWHUQDODJHDWFRQFHSWLRQ7RZQVHQGVFRUHPDWHUQDOhypertension, diabetes, asthma, mental illness, Body Mass Index 
CI = confidence interval, OR = Odds ratio  
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7.3.2.4.2 Reclassifying smokers and non-smokers based on gestational smoking 
status recording 
Table 7-13 presents the prevalence of low birth weight by NRT and smoking 
exposure in mothers and the corresponding unadjusted and adjusted ORs (99% 
CI) using only gestational smoking status records. The prevalence of low birth 
weight across the exposure groups was very similar to the main analysis (11.0% 
in the NRT group and 9.4% in smokers). After adjusting for potential 
confounders children born to women in the NRT group were 88% more likely 
(OR 1.88, 99% CI 1.42-2.49) and children born to smokers were 73% more 
likely (OR 1.73, 99% CI 1.45-2.06) to be of low birth weight compared to 
children born to non-smokers during pregnancy.  
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Table 7-13 - Unadjusted and adjusted Odds ratio for low birth weight by NRT and smoking exposure, using only definitive 
smokers and non-smokers 
 Total population  
N=96,872  
Low birth weight 
n (%) 
Unadjusted OR  
(99% CI)  
p-value  Adjusted OR  
(99%CI) Á 
p-value 
Non-smoker*** 13,088 740 (5.6%) 1  1  
NRT-exposed group * 1,223 135 (11.0%) 2.07 (1.48-2.03) <0.001 1.88 (1.42-2.49) <0.001 
Smoker** 4,622 435 (9.4%) 1.73 (1.60-2.67) <0.001 1.73 (1.45-2.06) <0.001 
Unknown 77,939 4,892 (6.3%) 1.12 (1.00-1.24) 0.006 1.13 (0.99-1.24) 0.012 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, ***non-smokers during early pregnancy  
Á Adjusted for maternal age, Townsend score, maternal hypertension, diabetes, asthma, mental illness, Body Mass Index 
CI = confidence interval, OR = Odds ratio 
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7.3.2.4.3 Risk of low birth weight stratified by pre-term birth 
Table 7-14 shows the risk of low birth weight by NRT and smoking exposure 
stratified by preterm birth. Both maternal NRT and smoking exposure during 
pregnancy were found to be associated with low birth weight in babies in both 
preterm and term births. However, the risk of low birth weight was slightly 
higher in term births. 
When direct comparisons were made with smokers in both term and pre-term 
birth, NRT was not found to have any statistically significant increased risk (OR 
1.31, 99% CI 0.79-2.20 for pre-term birth and OR 0.99, 99% CI 0.68-1.46 for 
term births).  
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Table 7-14 - Unadjusted and adjusted odds ratio for low birth weight by NRT and smoking exposure, stratified by preterm 
birth 
 Unadjusted OR (99% CI)  p-value  Adjusted OR (95% CIÁ p-value 
Term birth 
Non-smoker*** 1  1  
NRT group * 2.18 (1.54-3.10) <0.001 1.82 (1.25-2.66) <0.001 
Smoker** 1.96 (1.73-2.22) <0.001 1.83 (1.59-2.09) <0.001 
Unknown 1.14 (1.00-1.27) 0.006 1.09 (0.97-1.24) 0.053 
Pre-term birth 
Non-smoker*** 1  1  
NRT group * 1.77 (1.10-2.85) 0.002 2.00 (1.21-3.31) <0.001 
Smoker** 1.28 (1.09-1.51) <0.001 1.52 (1.27-1.82) <0.001 
Unknown 1.00 (0.87-1.15) 0.972 1.06 (0.91-1.23) 0.354 
*NRT=nicotine replacement therapy prescription in early pregnancy, **smoking in early pregnancy, ***non-smokers during early pregnancy 
 Á$GMXVWHGIRUPDWHUQDODJH7RZQVHQGVFRUHPDWHUQDOK\SHUWHQVLRQGLDEHWHVDVWKPDPHQWDOLOOQHVV%RG\0DVV,QGH[ 
CI = confidence interval, OR = Odds ratio 
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7.3.3 Mode of delivery 
A total of 255,441 pregnancies among a cohort of 201,465 mothers were 
identified. Approximately three-quarters of all pregnancies (76.5%) were 
delivered through normal vaginal delivery, 6.2% through assisted delivery and 
17.3% through caesarean section. Compared to the normal and assisted 
deliveries, women with caesarean sections were older and more obese and had a 
higher prevalence of hypertension, diabetes and mental illness. Table 7-15 
presents the baseline characteristics of women in all three outcome groups.  
Asthma and mental illness were found to be most common in current smokers 
and the NRT group. In addition, approximately 50% mothers in smokers group 
and NRT group were more deprived (Townsend quintile 4 and 5). Table 7-16 
presents maternal characteristics by NRT exposure and smoking among the 
study population. Women prescribed NRT and smokers were more likely to be 
from younger and more deprived groups. Additionally, the prevalence of asthma 
and mental illness was the highest among pregnant women who smoked during 
pregnancy or were prescribed NRT during pregnancy.  
The prevalence of assisted delivery was found to be the highest in non-smokers 
KRZHYHULWZDVQ¶WYHU\GLIIHUHQWLQRWKHUH[SRVXUHJURXSVLQ157
group and 5.7% in smokers and unknown group). Similarly, the prevalence of 
caesarean section was also found to be the highest in non-smokers (18.3%). 
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Table 7-15 - Baseline characteristics for all modes of delivery 
Baseline characteristics 
All Normal delivery Assisted delivery Caesarean delivery 
N=255,441 n=195,523 n=15,835 n=44,083 
n % n  % n % n % 
Age at conception          
15-19 years 14,141 5.5% 11,776 6.0% 974 6.2% 1,391 3.2% 
20-24 years 40,879 16.0% 33,271 17.0% 2,452 15.5% 5,156 11.7% 
25-29 years 65,029 25.5% 50,717 25.9% 4,271 27.0% 10,041 22.8% 
30-34 years 79,959 31.3% 59,892 30.6% 5,187 32.8% 14,880 33.8% 
35-39 years 45,765 17.9% 33,182 17.0% 2,494 15.7% 10,089 22.9% 
40-44 years 9,179 3.6% 6,374 3.3% 429 2.7% 2,376 5.4% 
45-49 years 489 0.2% 311 0.2% 28 0.2% 150 0.3% 
Townsend score in quintiles         
Quintile 1 (least deprived) 57,859 22.7% 43,195 22.1% 4,028 25.4% 10,636 24.1% 
Quintile 2 47,841 18.7% 35,996 18.4% 3,274 20.7% 8,571 19.4% 
Quintile 3 49,670 19.4% 37,889 19.4% 3,147 19.9% 8,634 19.6% 
Quintile 4 47,292 18.5% 36,933 18.9% 2,601 16.4% 7,758 17.6% 
Quintile 5 (most deprived) 36,103 14.1% 28,657 14.7% 1,785 11.3% 5,661 12.8% 
Missing 16,676 6.5% 12,853 6.6% 1,000 6.3% 2,823 6.4% 
Pre-pregnancy Body Mass Index (kg/m2)         
Normal(18.5-24.9) 80,016 22.7% 62,131 31.8% 5,724 36.1% 12,161 27.6% 
Underweight(<18.5) 5,856 18.7% 4,737 2.4% 391 2.5% 728 1.7% 
Overweight(25-29.9) 38,945 19.4% 28,914 14.8% 2,385 15.1% 7,646 17.3% 
Obese(>=30) 26,741 18.5% 18,732 9.6% 1,222 7.7% 6,787 15.4% 
Missing 103,883 14.1% 81,009 41.4% 6,113 38.6% 16,761 38.0% 
Asthma 21,884 22.7% 16,358 8.4% 1,414 8.9% 4,112 9.3% 
Hypertension 6,885 18.7% 4,385 2.2% 422 2.7% 2,078 4.7% 
Diabetes 5,971 19.4% 3,588 1.8% 356 2.2% 2,027 4.6% 
Mental illness 24,178 18.5% 18,338 9.4% 1,385 8.7% 4,455 10.1% 
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Table 7-16 - Baseline characteristics by NRT and smoking exposure during pregnancy 
 
 
 
All pregnancies NRT group* Smokers** Non-smokers*** Unknown 
N=255,441 n=3,254 n=42,089 n=123,356 n=86,742 
n % n % n % n % n % 
Age at conception  
          15-19 years 14,141 5.5% 306 9.4% 4,649 11.0% 4,558 3.7% 4,628 5.3% 
20-24 years 40,879 16.0% 791 24.3% 11,421 27.1% 16,387 13.3% 12,280 14.2% 
25-29 years 65,029 25.5% 847 26.0% 11,282 26.8% 32,383 26.3% 20,517 23.7% 
30-34 years 79,959 31.3% 773 23.8% 8,980 21.3% 41,389 33.6% 28,817 33.2% 
35-39 years 45,765 17.9% 447 13.7% 4,767 11.3% 23,692 19.2% 16,859 19.4% 
40-44 years 9,179 3.6% 83 2.6% 944 2.2% 4,717 3.8% 3,435 4.0% 
45-49 years 489 0.2% 7 0.2% 46 0.1% 230 0.2% 206 0.2% 
Townsend score in quintiles           
Quintile 1 ± least deprived 57,859 22.7% 334 10.3% 5,141 12.2% 30,828 25.0% 21,556 24.9% 
Quintile 2 47,841 18.7% 381 11.7% 5,886 14.0% 24,779 20.1% 16,795 19.4% 
Quintile 3 49,670 19.4% 620 19.1% 8,258 19.6% 24,084 19.5% 16,708 19.3% 
Quintile 4 47,292 18.5% 884 27.2% 10,478 24.9% 20,636 16.7% 15,294 17.6% 
Quintile 5 - most deprived 36,103 14.1% 804 24.7% 9,624 22.9% 14,068 11.4% 11,607 13.4% 
Missing 16,676 6.5% 231 7.1% 2,702 6.4% 8,961 7.3% 4,782 5.5% 
Pre-conception Body Mass Index 
(kg/m2)           
Normal(18.0-24.9) 80,016 22.7% 1,017 31.3% 14,127 33.6% 48,171 39.1% 16,701 19.3% 
Underweight(<18.0) 5,856 18.7% 101 3.1% 1,491 3.5% 2,984 2.4% 1,280 1.5% 
Overweight(25-29.9) 38,945 19.4% 515 15.8% 6,860 16.3% 23,060 18.7% 8,510 9.8% 
Obese(>=30) 26,741 18.5% 405 12.4% 5,104 12.1% 15,375 12.5% 5,857 6.8% 
Missing 103,883 14.1% 1,216 37.4% 14,507 34.5% 33,766 27.4% 54,394 62.7% 
Asthma 21,884 22.7% 404 12.4% 4,868 11.5% 12,416 10.1% 4,196 4.9% 
Hypertension 6,885 18.7% 70 2.3% 882 2.1% 3,965 3.2% 1,968 2.3% 
Diabetes  5,971 19.4% 70 2.6% 865 2.0% 3,548 2.9% 1,488 1.7% 
Mental illness 24,178 18.5% 625 19.0% 6,549 15.5% 9,604 7.8% 7,400 8.5% 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, *** No smoking in  pregnancy, 
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Table 7-17 - Breakdown of mode of deliveries by NRT and smoking exposure 
Mode of delivery 
Total NRT group* Smokers** Non-smokers*** Unknown 
N=255,441 n=3,254 n=42,089 n=123,356 n=86,742 
Normal 195,523 (76.5%) 2,551 (78.4%) 33,019 (78.5%) 92,452 (75%) 67,501 (77.8%) 
Assisted 15,835 (6.2%) 159 (4.9%) 2,415 (5.7%) 8,355 (6.8%) 4,909 (5.7%) 
C-section 44,083 (17.3%) 544 (16.7%) 6,658 (15.8%)  22,549 (18.3%)  14,332 (16.5%) 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, *** No smoking in pregnancy
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Table 7-18 presents the unadjusted and adjusted RRRs for each mode of 
delivery for NRT and smoking exposure during pregnancy compared to non-
smokers. In the unadjusted analysis pregnant women who were prescribed NRT 
during pregnancy had a 31% reduced risk of assisted delivery (RRR 0.69, 99% 
CI 0.55-0.85) and 13% reduced risk of caesarean sections (RRR 0.87, 99% CI 
0.77-0.99) compared to non-smokers. Smokers had consistently decreased risks 
of both assisted delivery and caesarean section compared with women from the 
referent group (non-smokers). After adjusting for maternal characteristics, NRT 
exposure during pregnancy was still significantly associated with a 25% 
reduction in the risk of assisted delivery however the association between NRT 
exposure and caesarean section was not statistically significant (p=0.566). 
  
When the reference category was changed to current smokers, the relative risk 
of assisted delivery in the NRT group decreased by 12%, however this was not 
statistically significant. Similarly, the relative risk of caesarean section in the 
NRT group compared to smokers was 1.01 (99% CI 0.89-1.16) which indicated 
no statistically significant association. 
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Table 7-18 - Unadjusted and adjusted relative risk ratios of each mode of delivery relative to normal delivery by NRT and 
smoking exposure during pregnancy compared to non-smokers 
 Unadjusted Adjusted Á 
 Assisted Delivery C-section Assisted delivery C-section 
 RRR (99% CI) p-
value 
RRR (99% CI) p-
value 
RRR(99% CI) p-
value 
RRR(99% CI) p-value  
Non-smoker*** 1  1  1  1  
NRT group * 0.69 (0.55-0.85) <0.001 0.87 (0.77-0.99) 0.005 0.75 (0.60-0.93) <0.001 0.97 (0.85-1.10) 0.566 
Smoker** 0.80 (0.75-0.86) <0.001 0.83 (0.80-0.86) <0.001 0.85 (0.80-0.91) <0.001 0.96 (0.92-1.00) 0.004 
Unknown 0.80 (0.77-0.84) <0.001 0.87 (0.84-0.90) <0.001 0.84 (0.80-0.88) <0.001 0.92 (0.89-0.95) <0.001 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, *** No VPRNLQJLQSUHJQDQF\ÁDGMXVWHGIRU
maternal age, Townsend score, diabetes, asthma, hypertension, mental illness, RRR= Relative Risk Ratio, CI=Confidence Interval 
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Table 7-19 - Unadjusted and adjusted relative risk ratios of each mode of delivery relative to normal delivery in non-
smokers and the NRT group compared to smokers 
 Unadjusted Adjusted Á 
 Assisted Delivery C-section Assisted delivery C-section 
 RRR (95% CI) p-
value 
RRR (95% CI) p-
value 
RRR(95% CI) p-
value 
RRR(95% CI) p-
value  
Non-smoker*** 1.24 (1.16-1.32) <0.001 1.21 (1.16-1.26) <0.001 1.18 (1.10-1.26) <0.001 1.05 (1.00-1.09) 0.007 
NRT group * 0.85 (0.68-1.06) 0.060 1.06 (0.93-1.20) 0.491 0.88 (0.70-1.08) 0.118 1.01 (0.89-1.16) 0.733 
Smoker** 1  1  1  1  
Unknown 1.00 (0.93-1.06) 0.864 1.05 (1.00-1.10) 0.002 0.99 (0.92-1.05) 0.599 0.96 (0.92-1.00) 0.016 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, *** No smoking in pregnancyÁDGMXVWHGIRU
maternal age, Townsend score, diabetes, asthma, hypertension, mental illness 
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7.3.3.1 Sensitivity analysis 
When smokers and non-smokers were reclassified based on the presence of 
gestational smoking status records, the proportion of total smokers reduced to 
4.8% and non-smokers to 12.6%. However, the distribution of normal, assisted 
and caesarean deliveries remained similar to the main analysis. 
In the unadjusted analysis women in the NRT group had a 31% reduced risk of 
assisted delivery (RRR 0.69, 99% CI 0.55-0.85) and a 13% reduced risk of 
caesarean sections (RRR 0.87, 99% CI 0.77-0.99) compared to non-smokers. 
Smokers had consistently decreased risks of both assisted delivery and 
caesarean section compared with women from the referent group (non-
smokers). After adjusting for maternal characteristics, NRT exposure during 
pregnancy was significantly associated with a 32% reduction in the risk of 
assisted delivery, however the association between NRT exposure and caesarean 
section was not statistically significant anymore (p=0.120). 
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Table 7-20 - Unadjusted and adjusted relative risk ratios of each mode of delivery relative to normal delivery by NRT and 
smoking exposure during pregnancy compared to non-smokers, using definitive smokers and non-smokers 
 Unadjusted Adjusted Á 
 Assisted Delivery C-section Assisted delivery C-section 
 RRR (99% CI) p-
value 
RRR (99% CI) p-
value 
RRR(99% CI) p-
value 
RRR(99% CI) p-value  
Non-smoker*** 1  1  1  1  
NRT group * 0.63 (0.51-0.79) <0.001 0.84 (0.74-0.96) 0.005 0.68 (0.54-0.85) <0.001 0.92 (0.81-1.05) 0.120 
Smoker** 0.71 (0.64-0.80) <0.001 0.76 (0.70-0.82) <0.001 0.76 (0.68-0.86) <0.001 0.88 (0.81-0.95) <0.001 
Unknown 0.81 (0.76-0.86) <0.001 0.88 (0.85-0.92) <0.001 0.82 (0.77-0.87) <0.001 0.91 (0.87-0.95) <0.001 
*NRT=nicotine replacement therapy prescription in pregnancy, **smoking in pregnancy, *** No smoking in pregnancy, ÁDGMXVWHGIRU
maternal age, Townsend score, diabetes, asthma, hypertension, mental illness, RRR= relative risk ratio, CI=confidence interval 
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7.4 DISCUSSION  
7.4.1 Principal findings 
This study, using a large population based dataset, found no significant 
association between NRT exposure during the first trimester, and any time 
during pregnancy, and stillbirth. However, maternal smoking during early 
pregnancy was found to increase the risk of stillbirth by 27%. In contrast, 
maternal smoking any time during pregnancy did not significantly increase the 
risk of stillbirth. Compared to non-smokers, the risk of low birth weight babies 
was 93% higher in the NRT group and 69% higher in smokers. The mean birth 
weight in babies in the NRT group was 176g lower than those of non-smoker, 
and the mean birth weight in the smokers group was 123g lower than those of 
non-smokers. However, there was no statistically significant difference between 
the risk of low birth weight in the NRT group and smokers. The study did not 
find a significantly increased risk of assisted delivery or caesarean section in the 
NRT group compared to smokers and no significant risk of caesarean section in 
current smokers compared to non-smokers. However, it found that the risk of 
assisted delivery decreased by 25% in the NRT group and 15% in smokers 
compared to non-smokers.  
 
7.4.2 Strengths and limitations 
This is the first population-based report to assess the effects of NRT on adverse 
birth outcomes in the UK and the largest international study conducted thus far. 
Furthermore, since these data are prospectively recorded the potential for recall 
bias is greatly minimised. The measurement of drug exposure in the study was 
based on GP prescribing records rather than self-reports, reducing the potential 
for recall bias. However, the exposure measurement may still be subject to 
misclassification, which has been discussed in detail in Section 6.4.2.  
215 
 
Due to the paucity of smoking records during pregnancy, it was not possible to 
accurately ascertain smoking status at each stage of pregnancy. Therefore if 
there was any medical record indicating smoking during pregnancy women were 
assumed to be smoking during that pregnancy. Some of these women may have 
quit during the course of pregnancy but given the fluctuations of smoking status 
in pregnancy and the risk of relapse, 183  these women were still categorised as 
smokers. Therefore, the risk of adverse birth outcomes in relation to maternal 
smoking during pregnancy may be slightly underestimated. However, the 
potential for misclassification between the exposure groups cannot be 
completely eliminated from the previous Danish studies as well because smoking 
status was self-reported between 12-16 weeks of gestation and was then 
assumed to be constant until the end of pregnancy. In contrast, the findings 
reported here are based on the effects of NRT and smoking during the entire 
pregnancy in addition to early pregnancy as recorded in primary care data. 
However, for some women there was only a smoking record in the first trimester 
and therefore the effect estimates may not differ greatly between the two 
exposure windows. Furthermore, data on intensity of smoking was not complete 
which limited the ability of the study to examine any dose response effects of 
maternal smoking on adverse birth outcomes.  
Whilst there may be confounding-by-LQGLFDWLRQE\ZRPHQ¶VVPRNLQJLQWHQVLW\LQ
that women who were prescribed NRT may be heavier smokers to start with, 
pregnant women getting NRT prescriptions could also be the women modifying 
their potentially harmful exposures for the better health of the baby. These could 
include smoking, alcohol use, dietary habits or other unmeasured factors.  
Although the ORs have been adjusted for a number of potential confounders, 
other unmeasured factors like labour and delivery complications, and household 
smoking were not adjusted for as enough information was not available in the 
data. Furthermore, the duration of NRT prescription in these data was relatively 
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short i.e. two weeks so if there is truly a beneficial or harmful effect of NRT this 
may be slightly underestimated.  
Stillborn babies are usually not registered in primary care. Therefore, the 
ascertainment of stillbirth in this study is based on the documentation of such 
events in maternal primary care records. Approximately 97% of deliveries in 
England and Wales in 2011 took place in the NHS hospitals, maternity units and 
maternity wings280 and all the delivery information recorded in the inpatient data 
should, but may not always, be transferred onto the primary care records. 
Therefore, this study may have missed cases of stillbirth. Nevertheless, the 
prevalence of stillbirth in this study was 4/1,000 live and stillbirths, which is 
comparable to the national prevalence of 5.2/1,000 births in the UK in 2009.159 
A study assessing the completeness of maternity data in UK primary and 
secondary care between 1998 and 2009 in one general practice found that birth 
weight and mode of delivery were recorded in only about 14% of 1,212 
pregnancies with a linked child record in the primary care data (THIN) compared 
to 61% of the 3,255 pregnancies in secondary care data (Hospital Episodes 
Statistics (HES)).281 The study discussed in this chapter however has data from 
approximately 500 practices from across the UK and had birth weight recorded 
for 42% of the babies with linked maternal records in THIN. Nevertheless, using 
a population of cases with a recording of birth weight, the prevalence of low 
birth weight was found to be 6.4% which is highly comparable to the national 
average of about 7%. 279,282 Furthermore, birth weight when plotted graphically 
was found to be normally distributed indicating that the selected population was 
broadly representative of the overall population and the presence of birth weight 
record did not differ by low or high birth weight. Additionally, the maternal 
characteristics in children with a recording of birth weight were highly 
comparable to the maternal characteristics in children without a recording of 
birth weight in primary care again indicating that this selected sample was 
217 
 
representative of the overall population and therefore any selection bias is 
unlikely to be present.  
The prevalence of caesarean sections and assisted deliveries in this study  was 
found to be much lower than the national prevalence of approximately 25% and 
12% respectively in 2009.283,284 All the pregnancies where no caesarean section 
or assisted delivery was recorded were assumed to be delivered through normal 
vaginal delivery, over-estimating the proportion of normal deliveries. This in turn 
may result in non-differential misclassification of the outcome and consequently 
bias the effect estimate towards null.  
 
7.4.3 Comparison with current literature 
7.4.3.1 NRT and stillbirth 
NRT exposure during early pregnancy or any time during the entire pregnancy 
was not found to be associated with an increased risk of stillbirth. The study 
including 87,032 pregnancies from the DNBC, with information on smoking and 
NRT use in the first trimester, found that for women who used NRT there was no 
statistically significant increase in the risk of stillbirth (HR 0.57, 95% CI 0.28-
1.16) compared to non-smokers.113  The non-smoker group in their study 
included ex-smokers who quit before conception but may be using NRT in 
pregnancy to avoid a smoking relapse. This may have resulted in 
misclassification of their exposure variable and under-estimate the effects of 
NRT use in pregnancy.  Despite the differences in the exposure window and 
definition of stillbirth, the Danish study found very similar results to the ones 
presented in this chapter. The association between NRT exposure and stillbirth 
did not reach statistical significance, which is in line with the SNAP trial results100 
and the pooled estimates from the meta-analysis101 again suggesting that the 
use of NRT does not significantly increase the risk of stillbirth.   
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The study found that smoking during early pregnancy increases the risk of 
stillbirth, which is consistent with the current literature. The study using DNBC 
found the risk of stillbirth to be 46% higher in smokers (HR 1.46, 95% CI 1.17-
1.82) compared to non-smokers using smoking information from the first 
trimester.113 Similarly, another Danish study based on a cohort of 25,102 live 
born singleton children collected smoking data before 30 weeks of gestation and 
found the risk of stillbirth to be twice as high compared to non-smokers.264  .   
These differences could be attributed to the use of slightly different definitions of 
stillbirth, ascertainment of smoking status, which was mostly self-reported in 
these studies and also the use of different populations with slightly different 
prevalence of maternal smoking and stillbirth. In addition, the choice of 
confounders in each of the previous studies and their definitions and data quality 
may also contribute to the slight difference in the effect estimates of these 
studies. 
Other studies which assessed smoking at the end of pregnancy or where the 
exact time of smoking assessment was not specified found the risk of stillbirth in 
smokers to be 34%285  to over two fold  29,264,273,286,287 higher compared to non-
smokers. In contrast, when the exposure window was expanded to the whole of 
pregnancy in this study, smoking was not found to be associated with an 
increase in stillbirth. A population-based cohort study from Sweden reported a 
significant interaction between gestational age and the effects of smoking; As 
pregnancy advanced, the risk of stillbirth associated with smoking decreased.288 
This may partly explain the lack of statistically significant association between 
smoking and stillbirth considering the complete duration of pregnancy.  
Smoking reduces fetal oxygenation through increased blood levels of 
carboxyhaemoglobin and impairment of oxygen unloading.264  This along with 
prostacyclin synthesis increases vascular resistance and decreases fetal blood 
flow. Nicotine in tobacco smoke is also postulated to cause vasoconstriction.264 
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All these effects collectively result in fetal growth restriction and placental 
complications, which are the most important causes of still birth.288,289  Thus, 
this association seems to be biologically plausible. However, from the findings of 
this study and the previous study it does not seem likely that nicotine alone can 
result in stillbirth. The study also highlights that the effects of smoking may be 
more harmful to the immature foetus and placenta.  
Although no significant associations were found between NRT and smoking 
exposure during pregnancy and fetal death, maternal smoking is an important 
risk factor for miscarriage which may contribute to these fetal deaths. A recent 
meta-analysis of 98 observational studies concluded that any active smoking 
during pregnancy was associated with an increased risk of miscarriage (RR 1.23, 
95% CI 1.16-1.30).30 Although the prevalence of smoking may be higher in 
women having miscarriages, the extent to which details of a miscarriage event is 
documented in primary care is currently not known. However, many women may 
not know that they are pregnant at the time of the miscarriage and therefore the 
recording and ascertainment of such events in the data is not expected to be 
complete. The reported prevalence of miscarriage in studies is 20%.290,291 
However, only 13% of pregnancies were recorded to end in miscarriage in the 
primary care data. This may explain the lack of statistically significant 
associations between smoking and fetal death found in the study.  
 
7.4.3.2 NRT and birth weight 
NRT exposure during pregnancy was found to be associated with a reduction in 
birth weight compared to not smoking with a 74% increased risk of low birth 
weight in babies of mothers prescribed NRT compared to non-smokers. A study 
using the PRAMS data to assess the association between NRT use and adverse 
birth outcomes in approximately 6,000 women in the USA found the risk of 
having a low birth weight baby in NRT users to be about two fold compared to 
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non-smokers, 111 which is very similar to the findings of this study.  Contrary to 
the findings reported in this chapter, a study using the DNBC found no 
significant association between the duration of NRT use, type of NRT product 
used and offspring birth weight.112 However, the Danish study primarily assessed 
NRT use within the first 27 weeks of pregnancy which limits the validity of the 
findings as fetal weight gain essentially takes place in the second and third 
trimester and the effects of smoking on fetal growth are more pronounced in the 
late stages of pregnancy.292,293 Results from the trials report inconclusive 
evidence regarding the use of NRT during pregnancy and birth weight with some 
trials reporting no association between NRT use and birth weight100,107 and some 
reporting higher birth weights in the NRT groups compared to placebo 
groups.108,109 However, the interpretation of these findings from the trials is 
complicated by their inadequate power to assess safety outcomes and is highly 
dependent on compliance and adherence to treatments in both arms.   
The study reiterates that smoking during pregnancy has a negative effect on 
fetal growth such that the risk of low birth weight was 63% higher in smokers 
compared to non-smokers and babies of smokers weighed 120g less than babies 
of non-smokers. This is consistent with previous studies which also found a 
decrease in birth weight of approximately 160g in babies of smokers compared 
to non-smokers.19,20   
The risk of low birth weight associated with NRT and smoking were not found to 
be very different in the pre-term and term babies. This implies that the risk of 
low birth weight associated with NRT and smoking exposure holds regardless of 
gestational age. There are several proposed mechanisms by which smoking and 
NRT may affect birth weight. Nicotine is water soluble and consequently can 
pass through the placenta into the developing fetal circulation that is unable to 
metabolise nicotine in the same way as a fully developed adult system. 
Therefore, the concentration of nicotine builds up over pregnancy in the 
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placental tissues and amniotic fluids.294 Nicotine concentrations are reported to 
be 15% higher in the fetal circulation and 88% higher in the amniotic fluids than 
in the maternal circulation in smokers.295 Therefore, although NRT may deliver 
lower concentrations of nicotine in the blood than smoking the concentrations in 
fetal circulation will still be higher than the maternal circulation. This may result 
in poor oxygen and nutrient delivery to the fetus resulting in poor organ 
development and low birth weight.294 A case-control study using magnetic 
resonance imaging (MRI) to assess organ growth and overall fetal growth in 26 
pregnant women found lower brain volumes, kidney volumes, impaired lung 
growth and total fetal volumes in smoking mothers compared to non-smoking 
mothers, indicating poor organ development.294 Another study based on 7,098 
pregnant women in Rotterdam, the Netherlands found an association between 
maternal smoking and reduced fetal head circumference, abdominal 
circumference and femur length.296 An alternative proposed mechanism could be 
the suppression of appetite in mothers again leading to poor nutrient intake and 
inadequate nutrient delivery to the foetus. Lastly, the structure of nicotine is 
very similar to acetylcholine, which is one of the main enzymes in the nervous 
system and also regulates cell growth in the developing fetus.112,297  Hence, it 
may alter cell growth signalling in the fetus leading to impaired growth and low 
birth weight. 274   Carbon monoxide in cigarettes may worsen this by causing 
fetal hypoxia.294  
This study found no added benefit of using NRT over smoking in relation to birth 
weight and the risk of low birth weight was slightly higher in the nicotine group 
in comparison to smokers. This association may be confounded by how nicotine-
dependent these women in the NRT group were and how intensely they smoked 
before NRT prescription, which has been discussed in detail in Section 6.4.2. 
Also, detailed information on NRT use and compliance was not available and it 
may be possible that women used NRT and smoked as well, or had periods of 
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relapses between NRT. These possibilities cannot be completely ruled out. 
Lastly, there may also be some residual confounding through weight loss during 
pregnancy as maternal weight changes during pregnancy are directly related to 
infant birth weight 298and NRT is known to suppress appetite299  which may 
reduce maternal weight or other unmeasured factors, information for which was 
not available in the current data.  
 
7.4.3.3 NRT and mode of delivery 
The SNAP trial found a 45% increase in the risk of caesarean section deliveries 
with NRT use compared to placebo, however adherence to the therapy was low 
in both NRT and placebo group and the rate of abstinence from the quit date 
until delivery was less than 10%.100 Furthermore, the study was adequately 
powered to assess abstinence but not the safety of NRT therefore this finding 
may be solely due to chance as the authors have discussed. In contrast, this 
study found no increased risk of caesarean section in the NRT group compared 
to current smokers or non-smokers. Nicotine is postulated to affect the maternal 
circulation of the placenta which can cause a consequent impairment of oxygen 
transfer to the fetus leading to an increased need for operative interventions for 
delivery such as caesarean section or assisted delivery. 32 However, the 
cardiovascular effects of NRT on both the mother and the fetus are very small 
300,301, which is reflected in the study findings. Furthermore, a hospital-based 
case-control study from France, based on approximately 600 women, aimed to 
examine the risk factors for caesarean section found similar results with no 
significant associations between maternal smoking and caesarean section. 302 
The only study to examine the association between smoking and assisted 
delivery 269 was based on the longitudinal Millennium Cohort from the UK and 
found no association between maternal smoking during pregnancy and the risk 
of assisted deliveries (OR 1.003, 95% CI 0.88-1.14). However, the findings from 
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this chapter paradoxically report a small protective effect of NRT and smoking 
exposure on assisted deliveries such that the risk of caesarean section reduced 
by 28% in NRT group and 15% in smokers compared to non-smokers. There 
may be several explanations for this finding; it may be simply due to the 
misclassification of some assisted deliveries as normal deliveries in current 
smokers, due to unmeasured confounding, or smoking may truly reduce the risk 
of assisted deliveries just like its incongruous protective effect on pre-eclampsia. 
10,303. Nevertheless the absolute risk of assisted deliveries in NRT group, smokers 
and non-smokers was not very different (4.8%, 5.7% and 6.8% respectively) 
making this difference in the risk less clinically relevant.   
  
7.5 CHAPTER CONCLUSIONS 
This chapter as a whole aimed to assess different birth outcomes in relation to 
NRT and maternal smoking during pregnancy and found no increased risk of 
stillbirth in the NRT group compared to non-smokers, which is encouraging. In 
contrast, maternal smoking during pregnancy was found to increase the risk of 
stillbirth. Women who were prescribed NRT or smoked during pregnancy had 
higher risks of having a low birth weight baby compared to non-smokers. Lastly, 
the risk of caesarean sections in the NRT group and smokers was found to be 
similar to non-smokers however the risk of assisted deliveries was lower in 
comparison to non-smokers. Based on these findings it can be said that NRT 
exposure during pregnancy has no increased risks of stillbirth, low birth weight 
and caesarean section in comparison to maternal smoking. Nevertheless, these 
findings represent NRT exposure as recorded in general practice data only and 
therefore need to be interpreted with caution due to the limitations discussed 
above. Other immediate and long-term neonatal and paediatric outcomes need 
to be examined carefully before NRT can be considered to be completely safe 
during pregnancy. 
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8 OVERALL CONCLUSIONS, IMPLICATIONS AND 
FUTURE DIRECTIONS FOR RESEARCH 
The overall aims of this thesis were to assess the potential usefulness of primary 
care data to inform assessment of smoking behaviours in pregnant women at a 
population level and to investigate the prescribing and safety of NRT among 
pregnant women. This concluding chapter summarises key findings from the 
research presented in this thesis, highlights clinical and public health 
implications and makes recommendations for future public health practice and 
research areas in relation to maternal smoking ascertainment (Section 8.1) and 
NRT prescribing and safety (Section 8.2).  
 
8.1 QUALITY OF MATERNAL SMOKING STATUS DATA DURING 
PREGNANCY IN PRIMARY CARE 
8.1.1 Summary of main findings 
+DYLQJVPRNLQJVWDWXVUHFRUGHGLQDSUHJQDQWZRPHQ¶VPHGLFDOUHFRUGVLVQRW
only useful for clinical management, but can also increase the potential utility of 
primary care data in informing national smoking estimates for pregnant women 
in a cost-effective and timely manner. The studies in this thesis have highlighted 
several features of the recording of smoking status during pregnancy in primary 
care data which must be taken into account when using these data to study the 
trends in the epidemiology of smoking or the provision of smoking cessation 
treatments. It showed that the recording of smoking status during pregnancy is 
incomplete and only present in less than 30% of the pregnant population under 
study. Therefore currently, certain informed assumptions need to be made to 
enhance the utility of these data for assessing smoking and smoking cessation 
treatment among pregnant women at a population level.  Two such assumptions 
based on the QOF rules were tested in this thesis i.e. including smoking records 
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from 27 months before conception and smoking records ever before delivery to 
determine the smoking status for pregnancies where there was no gestational 
smoking record available. Smoking estimates using the 27 months assumption 
were generally found to have better comparability to other available data 
sources and therefore smoking records from 27 months before conception were 
considered to determine smoking status during pregnancy where gestational 
smoking status was missing. At an individual level, however, women do not have 
enough records of smoking status during pregnancy to assess changes in their 
smoking status throughout pregnancy. 
  
8.1.2 Implications for further research 
Data from this thesis suggest that the completeness of smoking status recording 
during pregnancy in primary care data is improving over the years with about 
40% women with smoking status recorded during pregnancy in 2009.  Further 
research demonstrating this trend in future years may strengthen the utility of 
THIN for research on smoking in relation to pregnancy. 
  
8.1.2.1 Statistical methods for missing data 
In this thesis simple imputations were made for missing smoking data using 
assumptions based on QOF recording rules to provide an appropriate population 
of smokers for analysis. An alternative approach could be to use multiple 
imputation techniques to statistically impute smoking status during pregnancy, 
for which first the patterns of missing data will need be to be assessed (e.g. 
missing at random, missing not at random, missing by age, sex, disease or any 
other factors). Data on smoking could be imputed based on multinomial 
regression techniques.304 Finally the results from these multiple imputation 
techniques can be compared from the results in this thesis to assess the validity 
of both approaches. This could be done by reviewing the records of a random 
group of pregnant women from general practices or surveying pregnant women 
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and comparing the self-reported smoking prevalence in this subgroup to the 
prevalence using recorded and imputed smoking status to investigate the 
potential validity of primary care data to predict smoking status during 
pregnancy. However, data anonymity in THIN may make this difficult and may 
also require substantial manpower, training and resources. An alternative 
approach could be to use the Additional Information Services (AIS) offered by 
THIN to provide more information to researchers which includes anonymised 
patient or GP questionnaires, copies of patient-related correspondence, 
laboratory tests etc.163 This service can be used to collect self-reported smoking 
information from pregnant women to calculate smoking prevalence and validate 
the approaches discussed above. However, this may involve payments which 
may not always be available in projects.  
 
8.1.2.2 Use of free text data 
GPs may sometimes record more details on smoking status as free text data, 
which were not available for use for the purposes of this research. Free-text 
information from primary care records has been previously used to estimate 
death rates305 and the incidence of rheumatoid arthritis306 previously. However, 
no studies have assessed the utility of these data to improve estimates of 
smoking prevalence in pregnancy or wider general population. Nevertheless, 
researchers in the Division of Epidemiology and Public Health, University of 
Nottingham are currently analysing free text records in detail and have found 
that a lot of smoking information is recorded in the free text in primary care 
data (Vishal Basra, personal communication, 3rd February 2014). Such free text 
data are available to researchers, subject to relevant payments, and may 
provide more in-depth data on smoking status and fluctuations occurring during 
pregnancy and add to the partially incomplete coded information on smoking 
status during pregnancy.  
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8.1.2.3 Mixed methods research 
This thesis investigated maternal characteristics related to the completeness of 
maternal smoking status recording in pregnancy. GP characteristics such as 
gender, training, smoking status may influence the recording of smoking status 
in the general population.307,308  Similarly, certain practice characteristics (e.g. 
location, catchment area and staffing etc.) may also influence the recording and 
provision of smoking cessation advice.309  However, more research is needed on 
the influence of these factors on the recording of smoking status and provision 
and recording of smoking cessation advice in pregnant women. Therefore mixed-
methods research using both qualitative and quantitative studies on the patient, 
caregiver and practice attributes may provide some valuable insights into how 
smoking status is recorded during pregnancy.  
 
8.1.2.4 Using other primary care data to answer similar questions 
There are other larger primary care datasets available for research purposes in 
the UK such as QRESEARCH and the Clinical Practice Research Database (CPRD) 
formerly known as the GPRD, which is also linked to the maternity data from 
Hospital Episode Statistics (HES), and the Office for National Statistics (ONS) 
data. The CPRD currently has over 650 practices and data on over 5 million 
patients310 and QRESEARCH contains data from over 600 practices.144 The 
methods used here to define smoking status and investigate the quality of data 
can be applied to these other datasets when assessing the trends in maternal 
smoking prevalence and these larger datasets can be used for external 
validation of the associations between NRT and birth outcomes in future once 
pregnancy cohort is established in these data. 
 
8.1.2.5 Potential linkage with midwives notes 
Midwives are the main point of contact for women during pregnancy and are also 
responsible along with other health care team members for assessing and 
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documenting the smoking status of pregnant women. A recent study assessing 
the consistency and completeness of maternity hand-held notes in the UK 
analysed 63 different sets of hand-held notes currently in use in the UK and 
found that smoking related questions were part of all these notes.184 Therefore, 
smoking status recording in the hand-held midwives notes may be more 
complete than primary care data. However, currently there is no research 
LQYHVWLJDWLQJKRZFRPSOHWHWKLVLQIRUPDWLRQLVLQWKHPLGZLYHV¶QRWHV$OVRVLQFH
there is no centralised recording and documenting system for midwives this 
information is not at hand after delivery. Therefore, electronic linkages between 
midwives notes and primary care data, or electronic imaging or transmission of 
midwives notes into the GP data, may be very useful not only to assess smoking 
and smoking cessation treatments during pregnancy but to also provide a 
detailed description of other events occurring during pregnancy to supplement 
and augment the information already present in primary care data. The 
Maternity Data Set by the Health and Social Care Information Centre311 could be 
used as a template for this to extract maternity data, which could then be linked 
to primary care data. 
 
8.1.3 Implications for clinical practice and policy 
Given the detrimental effects of maternal smoking during pregnancy, more 
accurate and up-to-date recording of smoking status in the pregnant population 
is vital in planning and delivering health services and other interventions to 
promote smoking cessation.  The antenatal care model in the UK is midwife-led 
where midwives are responsible for care of women during pregnancy. However, 
current guidelines recommend that monitoring of smoking status during 
pregnancy should be a shared responsibility between all healthcare professionals 
involved in the care of pregnant women, including the GPs and midwives.74,79,165 
The Royal College of Midwives recommends that during pregnancy midwives 
VKRXOGKDYHIXOOFRQILGHQWLDODFFHVVWRDZRPDQ¶VZULWWHQDQGHOHFWURQLFUHFRUGV
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and GPs should ensure that all significant and relevant information is copied into 
womeQ¶VKDQG-held maternity records.166 Similarly, relevant information 
collected by midwives during pregnancy should also be communicated to the 
GPs and fed back into the electronic primary care records. Therefore, 
appropriate methods should be introduced to improve communication and 
documentation of such information between the midwives and GPs during 
pregnancy. One such method could be the use of electronic tools, such as digital 
pens, to complete hand-held maternity records which may then also transmit 
data to other central sources such as primary care. This will enable continuity of 
care and better communication between the GPs and midwives without requiring 
any extra time and effort.  
Electronic patient-reported outcomes (e-PROs) is a fairly new concept in e-
Health research where patients can report their health outcomes electronically. 
312 ePROs are commonly used in clinical trials where patients can report the 
intensity, frequency, duration of symptoms (e.g. the Pulmonary Artery 
Hypertension ± Symptoms and Impact (PAHSYMPACT) which measures the 
symptoms and impact of pulmonary artery hypertension using an electronic 
device), physiological measures (peak expiratory flow using a peak flow meter 
device which can transmit information directly to a central database).313 Several 
modes of data collection can be used for this such as digital pens, smart phones, 
tablets, mobile applications and web-based responses etc.313  ePROs are now 
being integrated into clinical care especially for cancer patients and the 
compliance to such tools has been reported to be good.314 This concept could 
also be integrated in primary care data to obtain a detailed snapshot of several 
outcomes including smoking behaviour during pregnancy by giving women more 
control of their data and allowing them to enter their information themselves. 
This is in the early stages of development in the UK312 but may be a useful tool 
in future to monitor patterns and trends of maternal smoking during pregnancy.  
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Based on the results from this work, it can be observed that the recording of 
smoking status improved in conditions which were included in the QOF such as 
diabetes, asthma, hypertension etc. This raises an important issue of whether 
pregnancy should be included as a condition in the QOF to record smoking 
status, given the current gaps in the recording of smoking status in pregnant 
women in primary care. Although some women may go to a midwife directly, 
according to the National Perinatal Epidemiology Unit 77% of women see their 
GP first for pregnancy care.167 This may be an opportune time for the GPs to 
DVVHVVDQGGRFXPHQWZRPHQ¶VVPRNLQJVWDWXVDQGSURYLGHEULHIDGYLFHDQG
guidance on the resources available to quit. Therefore, including smoking status 
and cessation advice in pregnancy as a QOF recording target and linking 
payments to it may not only increase this recording in primary care data but also 
make the GPs more vigilant of monitoring smoking during pregnancy and 
providing referrals to interventions and services that are proven to work, 
thereby decreasing the overall smoking prevalence a little, if not substantially.  
 
8.2 PRESCRIBING AND SAFETY OF NRT IN PREGNANCY 
8.2.1 Summary of main findings 
Trends in NRT prescribing, its use and safety were the gaps in the current 
literature highlighted by the WHO in the recent recommendations for the 
prevention and management of tobacco use in pregnancy.73 Three studies in this 
thesis focused on these highlighted areas and assessed the prescribing of NRT in 
and around pregnancy across the UK and safety outcomes: major congenital 
anomalies, stillbirth, birth weight and mode of delivery.    
 
The prescribing of NRT in and around pregnancy has increased substantially 
following its availability as an NHS prescription; however, the annual prescribing 
prevalence plateaued after the relaxation of licensing arrangements in 2005. 
Nevertheless, overall prescribing in the post-relaxation period was found to be 
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about twice as high compared to prescribing in the pre-relaxation period. The 
prescribing prevalence of NRT during pregnancy was almost double that of the 
prescribing prevalence in the nine months immediately before and after 
pregnancy; however, most women only had a record of single NRT prescription 
during pregnancy, lasting two weeks on average. Prescribing of NRT was also 
found to increase with greater socio-economic deprivation and the presence of 
comorbidities like asthma and mental illness.  
 
No increased risk of congenital anomalies was found in the NRT group compared 
to smokers or non-smokers except for respiratory anomalies however this 
estimate was based on only 10 exposed cases. The risk of stillbirth in the NRT 
group was similar to non-smokers, which is encouraging. In contrast, maternal 
smoking during pregnancy was found to increase the risk of stillbirth. Contrarily, 
women who were prescribed NRT or who smoked during pregnancy had higher 
risks of having a low birth weight baby compared to non-smokers. Lastly, the 
risk of caesarean sections in the NRT group and current smokers was found to 
be similar to non-smokers, however the risk of assisted deliveries was lower in 
comparison to non-smokers.  
 
8.2.2 Implications for further research 
8.2.2.1 Potential data linkages 
Currently primary care data such as THIN are one of the best available resources 
in the UK to examine population-level trends and patterns of NRT prescribing 
during pregnancy. Data from the NHS-SSS may only represent a subgroup of 
very motivated pregnant women. However, access to these data may provide 
useful information not only on the patterns and success of NRT use but also on 
other cessation interventions. A potential-linkage system between primary care 
and the NHS-SSS data may be useful in describing NRT use during pregnancy 
throughout the UK. Moreover, it will also give a more detailed account of quit 
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attempts made by women both during and outside pregnancy and the outcome 
of those quit attempts. However, no such links exist presently. NRT data can 
also be obtained from other data sources like OTC sales data which are available 
commercially (e.g. Electronic Point of Sales scanner data140) and the ePACT data 
which monitor electronic drug prescribing. However, currently these data do not 
have any specific information on sales and dispensing to pregnant women. 
Women get free prescriptions during pregnancy as discussed earlier in the thesis 
and therefore if pregnant women are flagged up in these sales and prescribing 
data, then these data may be able to supplement the estimates from primary 
care data and give a more comprehensive picture of NRT prescribing and use 
during pregnancy in the UK.  
Information on birth weight and mode of delivery in this work was missing for a 
substantial number of pregnancies. As indicated earlier, this information is 
expected to be more complete in secondary care data. Therefore, potential 
linkages between primary and secondary data may present more accurate 
estimates and reduce the proportion of missing data substantially. The CPRD 
primary care data have now been linked to HES and HES maternity, and HES 
linkages with THIN data have now been completed for approximately 70 
practices with more practices being added with every release.  This will not only 
improve the information on these selected outcomes but will also provide 
information on a number of labour and delivery events and complications which 
may be important when assessing the impact of drugs or smoking in future. The 
completeness and quality of the exposure data (smoking and NRT) can also be 
improved by potential linkages suggested above. 
 
8.2.2.2 Qualitative research 
Apart from these objective measures of NRT prescribing it is also important to 
combine subjective measures (such as self-reported use of NRT and outcomes of 
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quit attempts). 7KHRQO\TXDOLWDWLYHVWXG\DVVHVVLQJZRPHQ¶VSHUVSHFWLYHVRQ
barriers and facilitators of smoking cessation using NRT was conducted on a 
small selected sample of pregnant smokers in Australia.118 Therefore, qualitative 
studies using focus groups of pregnant smokers may therefore help explore the 
barriers and facilitators that pregnant women experience in using NRT. This may 
DOVRSURYLGHPRUHLQIRUPDWLRQRQZRPHQ¶VFKRLFHVRI157IRUPVDVHDFKIorm 
has a slightly different dose of NRT and mechanism of action which may have 
implications for the safety of the drug. It will also be instrumental in exploring 
the socio-demographic characteristics of women in relation to NRT prescribing in 
more detail which will help policy makers and public health professionals in 
tailoring these services and targeting special groups to encourage smoking 
cessation.   
 
8.2.2.3 Larger studies 
Although this was one of the biggest studies to determine the association 
between NRT, maternal smoking and congenital anomaly a bigger sample size is 
required to provide more power to the analysis and generate more precise risk 
estimates associated with smoking and NRT use. Therefore, a study using more 
recent primary care data, with more practices, more pregnancies and longer 
follow-up time, using similar methods is warranted. This will improve the 
precision of the estimates. However, considering the prevalence of congenital 
anomalies, the statistical power of epidemiological studies may always be limited 
in assessing the risks for system-specific anomaly groups especially the more 
rare ones.  
 
8.2.2.4 Other outcomes 
In addition to the outcomes assessed in this thesis other immediate and long-
term neonatal and paediatric outcomes such as neonatal intensive care 
admissions, neonatal deaths, respiratory infections in early life etc., need to be 
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examined carefully before NRT can be deemed to be completely safe during 
pregnancy. The only available estimates for the association between nicotine 
replacement therapy and neonatal outcomes comes from trials 100and currently 
the evidence is inconclusive. A meta-analysis of three trials of NRT in pregnancy 
found a pooled OR of 0.94 (95% CI 0.64-1.88) for neonatal intensive care 
admissions and 0.28 (95% CI 0.06-1.41) for neonatal death.101 
 
8.2.3 Implications for clinical practice and policy 
Considering that NRT use in the general population for smoking cessation is 
recommended for at least eight to twelve weeks, two weeks of NRT may not be 
truly helpful for women to quit smoking. The findings also indicated that only 1% 
of women of reproductive age who smoke are prescribed NRT before they get 
pregnant, indicating a missed opportunity to assist many young women in 
quitting smoking. Whilst interactions between health professionals and women 
during pregnancy should be used to discuss and offer interventions to promote 
smoking cessation, greater potential benefit would be derived from starting 
before pregnancy which should be a focus for women and health care providers.  
Currently, NRT use is recommended by the national guidelines for smoking 
cessation aid during pregnancy, where pregnant women cannot quit without 
NRT.79  However, NRT should not be considered as a panacea for smoking 
cessation during pregnancy and smoking cessation without pharmacotherapy 
should be encouraged to help pregnant women quit. Health care professionals 
need to encourage women to quit before pregnancy to reduce the risks 
associated with any kind of nicotine exposure to the foetus. Also given, the 
HIIHFWLYHQHVVRI157RXWVLGHSUHJQDQF\LW¶VXVHGXULQJSRVWSDUWXPSHULRGFDQEH
encouraged more to prevent postpartum relapse in women who quit during 
pregnancy. 
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10.5 MEDICAL READ CODES FOR 
SMOKING 
Medcode Description 
137L.00 Current non-smoker 
1371.11 Non-smoker 
63C5.00 Maternal tobacco abuse 
137a.00 Pipe tobacco consumption 
137..00 Tobacco consumption 
137X.00 Cigarette consumption 
6893.00 Tobacco usage screen 
68T..00 Tobacco usage screen 
137Y.00 Cigar consumption 
137Z.00 Tobacco consumption NOS 
ZV4K000 [V]Tobacco use 
745H000 Nicotine replacement therapy using 
nicotine patches 
8H7i.00 Referral to smoking cessation advisor 
6791.00 Health ed. - smoking 
E251.00 Tobacco dependence 
137Q.00 Smoking started 
137H.00 Pipe smoker 
137M.00 Rolls own cigarettes 
1372.11 Occasional smoker 
137h.00 Minutes from waking to first tobacco 
consumption 
137c.00 Thinking about stopping smoking 
E251200 Tobacco dependence, episodic 
137d.00 Not interested in stopping smoking 
E251z00 Tobacco dependence NOS 
745H100 Nicotine replacement therapy using 
nicotine gum 
1374.00 Moderate smoker - 10-19 cigs/d 
8HTK.00 Referral to stop-smoking clinic 
9OO7.00 Stop smoking monitor verb.inv. 
137f.00 Reason for restarting smoking 
ZRBm211 FTND - Fagerstrom test for nicotine 
dependence 
8I39.00 Nicotine replacement therapy refused 
137b.00 Ready to stop smoking 
137e.00 Smoking restarted 
745Hy00 Other specified smoking cessation 
therapy 
8CAg.00 Smoking cessation advice provided by 
community pharmacist 
1373.00 Light smoker - 1-9 cigs/day 
13p5.00 Smoking cessation programme start 
date 
38DH.00 Fagerstr test for nicotine dep 
E251000 Tobacco dependence, unspecified 
8B3Y.00 Over the counter nicotine replacement 
therapy 
745H200 Nicotine replacement therapy using 
nicotine inhalator 
137J.00 Cigar smoker 
67A3.00 Pregnancy smoking advice 
137R.00 Current smoker 
ZV6D800 [V]Tobacco abuse counselling 
8BP3.00 Nicotine replacement therapy provided 
by community pharmacis 
E251100 Tobacco dependence, continuous 
8B3f.00 Nicotine replacement therapy provided 
free 
8B2B.00 Nicotine replacement therapy 
8I2I.00 Nicotine replacement therapy 
contraindicated 
13p0.00 Negotiated date for cessation of smoking 
ZRaM.11 MFS - Motives for smoking scale 
8HkQ.00 Referral to NHS stop smoking service 
ZRao.11 OFS - Occasions for smoking scale 
67H6.00 Brief intervention for smoking cessation 
)ZRao.00 Occasions for smoking scale 
8CAL.00 Smoking cessation advice 
137..11 Smoker - amount smoked 
137P.11 Smoker 
ZRBm200 Fagerstrom test for nicotine dependence 
137V.00 Smoking reduced 
137C.00 Keeps trying to stop smoking 
13p5000 Practice based smoking cessation 
programme start date 
ZRh4.00 Reasons for smoking scale 
1372.00 Trivial smoker - < 1 cig/day 
8IAj.00 Smoking cessation advice declined 
745H300 Nicotine replacement therapy using 
nicotine lozenges 
137m.00 Failed attempt to stop smoking 
1376.00 Very heavy smoker - 40+cigs/d 
137Q.11 Smoking restarted 
137P.00 Cigarette smoker 
ZRaM.00 Motives for smoking scale 
ZG23300 Advice on smoking 
9OO8.00 Stop smoking monitor phone inv 
ZRh4.11 RFS - Reasons for smoking scale 
137G.00 Trying to give up smoking 
67H1.00 Lifestyle advice regarding smoking 
745H400 Smoking cessation drug therapy 
1375.00 Heavy smoker - 20-39 cigs/day 
ZRao.00 Occasions for smoking scale 
E251300 Tobacco dependence in remission 
1378.00 Ex-light smoker (1-9/day) 
137A.00 Ex-heavy smoker (20-39/day) 
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137S.00 Ex smoker 
137l.00 Ex roll-up cigarette smoker 
137j.00 Ex-cigarette smoker 
1379.00 Ex-moderate smoker (10-19/day) 
137N.00 Ex pipe smoker 
137B.00 Ex-very heavy smoker (40+/day) 
137K.00 Stopped smoking 
1377.00 Ex-trivial smoker (<1/day) 
137T.00 Date ceased smoking 
137F.00 Ex-smoker - amount unknown 
137K000 Recently stopped smoking 
137O.00 Ex cigar smoker 
1371.00 Never smoked tobacco 
13p4.00 Smoking free weeks 
9N4M.00 DNA - Did not attend smoking cessation 
clinic 
9OO5.00 Stop smoking monitor 2nd lettr 
13p2.00 Smoking status between 4 and 52 weeks 
9OO3.00 Stop smoking monitor default 
9OOA.00 Stop smoking monitor.chck done 
9OO..12 Stop smoking monitoring admin. 
E023.00 Nicotine withdrawal 
ZV11600 [V]Personal history of tobacco abuse 
13p6.00 Carbon monoxide reading at 4 weeks 
9OOZ.00 Stop smoking monitor admin.NOS 
13p..00 Smoking cessation milestones 
137g.00 Cigarette pack-years 
9OO..11 Stop smoking clinic admin. 
9OO1.00 Attends stop smoking monitor. 
13p3.00 Smoking status at 52 weeks 
9N2k.00 Seen by smoking cessation advisor 
9OO6.00 Stop smoking monitor 3rd lettr 
9OO2.00 Refuses stop smoking monitor 
9OO..00 Anti-smoking monitoring admin. 
4I90.00 Expired carbon monoxide concentration 
8HBM.00 Stop smoking face to face follow-up 
745H.00 Smoking cessation therapy 
745Hz00 Smoking cessation therapy NOS 
137D.00 Admitted tobacco cons untrue ? 
13p1.00 Smoking status at 4 weeks 
9OO4.00 Stop smoking monitor 1st lettr 
137E.00 Tobacco consumption unknown 
9OO9.00 Stop smoking monitoring delete 
 
10.6 MULTILEX DRUG CODES FOR 
SMOKING CESSATION 
MEDICATIONS 
Drugcode Generic name 
92309998 BUPROPION mr tab 150mg 
92311998 BUPROPION mr tab 150mg 
93447992 NICONIL 
96930992 NICONIL PATCH 15 MG 
96924992 NICONIL PATCH 30 MG 
83326998 NICOTINE BITARTRATE sf loz 1mg 
82527998 NICOTINE BITARTRATE sf loz 1mg 
87922998 NICOTINE BITARTRATE sf loz 2mg 
82526998 NICOTINE BITARTRATE sf loz 2mg 
82603998 NICOTINE BITARTRATE sublingual tab 
2mg 
82604998 NICOTINE BITARTRATE sublingual tab 
2mg 
96845992 NICOTINE TRANSDERMAL PATCH 20CM 
96844992 NICOTINE TRANSDERMAL PATCH 30CM 
82473998 NICOTINE chewing gum 2mg 
82506998 NICOTINE chewing gum 2mg 
89112998 NICOTINE chewing gum 2mg 
82502998 NICOTINE chewing gum 2mg 
82475998 NICOTINE chewing gum 2mg 
95727998 NICOTINE chewing gum 2mg 
82504998 NICOTINE chewing gum 2mg 
98904998 NICOTINE chewing gum 2mg 
82476998 NICOTINE chewing gum 2mg 
82503998 NICOTINE chewing gum 2mg 
91248998 NICOTINE chewing gum 2mg 
82505998 NICOTINE chewing gum 2mg 
82474998 NICOTINE chewing gum 2mg 
82498998 NICOTINE chewing gum 4mg 
82472998 NICOTINE chewing gum 4mg 
82469998 NICOTINE chewing gum 4mg 
82499998 NICOTINE chewing gum 4mg 
82497998 NICOTINE chewing gum 4mg 
95727997 NICOTINE chewing gum 4mg 
91248997 NICOTINE chewing gum 4mg 
82496998 NICOTINE chewing gum 4mg 
98904997 NICOTINE chewing gum 4mg 
82470998 NICOTINE chewing gum 4mg 
82471998 NICOTINE chewing gum 4mg 
89110998 NICOTINE chewing gum 4mg 
82501998 NICOTINE chewing gum 4mg 
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88291998 NICOTINE inh cartridge 10mg 
88288998 NICOTINE inh cartridge 10mg 
89863998 NICOTINE loz 0.35mg 
92840997 NICOTINE loz 0.35mg 
92840998 NICOTINE mint flav chew gum 2mg 
92841998 NICOTINE mint flav chew gum 2mg 
95727996 NICOTINE mint flav chew gum 4mg 
98904996 NICOTINE mint flav chew gum 4mg 
82490998 NICOTINE nasal spray 10mg/ml 
92657998 NICOTINE nasal spray 10mg/ml 
92836998 NICOTINE nasal spray 10mg/ml 
83272998 NICOTINE patch 10mg 
97739997 NICOTINE patch 10mg 
82494998 NICOTINE patch 10mg 
97763997 NICOTINE patch 10mg 
98581997 NICOTINE patch 11mg/24 hr 
92892997 NICOTINE patch 11mg/24 hr 
97673997 NICOTINE patch 14mg 
82510998 NICOTINE patch 14mg 
82771998 NICOTINE patch 14mg 
88005997 NICOTINE patch 14mg 
82509998 NICOTINE patch 14mg 
97737997 NICOTINE patch 14mg 
97740997 NICOTINE patch 14mg 
84468998 NICOTINE patch 14mg 
97763996 NICOTINE patch 15mg 
83271998 NICOTINE patch 15mg 
82492998 NICOTINE patch 15mg 
97739996 NICOTINE patch 15mg 
82770998 NICOTINE patch 21mg 
97737996 NICOTINE patch 21mg 
84466998 NICOTINE patch 21mg 
88005996 NICOTINE patch 21mg 
82508998 NICOTINE patch 21mg 
82507998 NICOTINE patch 21mg 
97673996 NICOTINE patch 21mg 
97740996 NICOTINE patch 21mg 
98581998 NICOTINE patch 22mg/24 hr 
92892998 NICOTINE patch 22mg/24 hr 
83270998 NICOTINE patch 25mg 
83273998 NICOTINE patch 25mg 
97763998 NICOTINE patch 5mg 
97739998 NICOTINE patch 5mg 
82495998 NICOTINE patch 5mg 
82723998 NICOTINE patch 7mg 
97673998 NICOTINE patch 7mg 
97740998 NICOTINE patch 7mg 
82511998 NICOTINE patch 7mg 
84469998 NICOTINE patch 7mg 
97737998 NICOTINE patch 7mg 
82512998 NICOTINE patch 7mg 
88005998 NICOTINE patch 7mg 
82429998 NICOTINE patch+gum 15mg + 2mg 
82428998 NICOTINE patch+gum 15mg + 2mg 
84442998 NICOTINE sf loz 1.5mg 
84443998 NICOTINE sf loz 1.5mg 
81928998 NICOTINE sf loz 1.5mg 
82707998 NICOTINE sf loz 1.5mg 
91248996 NICOTINE sf loz 1mg 
98430998 NICOTINE sf loz 1mg 
91162998 NICOTINE sf loz 2mg 
92889990 NICOTINE sf loz 2mg 
87920998 NICOTINE sf loz 2mg 
91384998 NICOTINE sf loz 2mg 
83301998 NICOTINE sf loz 4mg 
82706998 NICOTINE sf loz 4mg 
87919998 NICOTINE sf loz 4mg 
92888990 NICOTINE sf loz 4mg 
98082998 NICOTINE sf loz 4mg 
91848998 NICOTINE sf loz 4mg 
92840996 NICOTINE sublingual tab 2mg 
82500998 NICOTINE sublingual tab 2mg 
92841997 NICOTINE sublingual tab 2mg 
85397998 VARENICLINE tabs 1mg 
85400998 VARENICLINE tabs 1mg 
85401998 VARENICLINE tabs 500 micrograms 
85398998 VARENICLINE tabs 500 micrograms 
85403998 VARENICLINE tabs 500micrograms + 
1mg 
85399998 VARENICLINE tabs 500micrograms + 
1mg 
 
 
10.7 AHD CODES FOR SMOKING 
Ahd code Description  
1003040000 Smoking  
1064100000 Advice given  
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10.8 CODE LISTS FOR 
COMORBIDITIES  
10.8.1 Medical READ codes for 
Diabetes Mellitus 
Medcode Description 
C101000 Diabetes mellitus, juvenile type, with 
ketoacidosis 
C108311 Type I diabetes mellitus with multiple 
complications 
C108600 Insulin dependent diabetes mellitus 
with gangrene 
C10E311 Type I diabetes mellitus with multiple 
complications 
C108112 Type 1 diabetes mellitus with 
ophthalmic complications 
C108300 Insulin dependent diabetes mellitus 
with multiple complicatn 
C108F11 Type I diabetes mellitus with diabetic 
cataract 
C108E00 Insulin dependent diabetes mellitus 
with hypoglycaemic coma 
C108012 Type 1 diabetes mellitus with renal 
complications 
C10EJ11 Type I diabetes mellitus with 
neuropathic arthropathy 
C108912 Type 1 diabetes mellitus maturity onset 
C10E800 Type 1 diabetes mellitus - poor control 
C10EM00 Type 1 diabetes mellitus with 
ketoacidosis 
C10E700 Type 1 diabetes mellitus with 
retinopathy 
C108D00 Insulin dependent diabetes mellitus 
with nephropathy 
C10EH00 Type 1 diabetes mellitus with 
arthropathy 
C10EA00 Type 1 diabetes mellitus without 
complication 
C107000 Diabetes mellitus, juvenile +peripheral 
circulatory disorder 
C101y00 Other specified diabetes mellitus with 
ketoacidosis 
C100011 Insulin dependent diabetes mellitus 
C108.00 Insulin dependent diabetes mellitus 
C108F12 Type 1 diabetes mellitus with diabetic 
cataract 
C10EA12 Insulin-dependent diabetes without 
complication 
C10EB11 Type I diabetes mellitus with 
mononeuropathy 
C10EP11 Type I diabetes mellitus with exudative 
maculopathy 
C108512 Type 1 diabetes mellitus with ulcer 
C108D12 Type 1 diabetes mellitus with 
nephropathy 
C101.00 Diabetes mellitus with ketoacidosis 
C108C12 Type 1 diabetes mellitus with 
polyneuropathy 
C102.00 Diabetes mellitus with hyperosmolar 
coma 
C10C.00 Diabetes mellitus autosomal dominant 
C10E712 Insulin dependent diabetes mellitus 
with retinopathy 
C10E612 Insulin dependent diabetes mellitus 
with gangrene 
C108100 Insulin-dependent diabetes mellitus 
with ophthalmic comps 
C108312 Type 1 diabetes mellitus with multiple 
complications 
C108411 Unstable type I diabetes mellitus 
C108.13 Type I diabetes mellitus 
C10ED11 Type I diabetes mellitus with 
nephropathy 
C108111 Type I diabetes mellitus with 
ophthalmic complications 
C108712 Type 1 diabetes mellitus with 
retinopathy 
C108F00 Insulin dependent diabetes mellitus 
with diabetic cataract 
C108H12 Type 1 diabetes mellitus with 
arthropathy 
C108A11 Type I diabetes mellitus without 
complication 
C108000 Insulin-dependent diabetes mellitus 
with renal complications 
C108B00 Insulin dependent diabetes mellitus 
with mononeuropathy 
C108C00 Insulin dependent diabetes mellitus 
with polyneuropathy 
C108C11 Type I diabetes mellitus with 
polyneuropathy 
K081.00 Nephrogenic diabetes insipidus 
C10E211 Type I diabetes mellitus with 
neurological complications 
C10EP00 Type 1 diabetes mellitus with exudative 
maculopathy 
C10EK11 Type I diabetes mellitus with persistent 
proteinuria 
C10EC00 Type 1 diabetes mellitus with 
polyneuropathy 
C10E412 Unstable insulin dependent diabetes 
mellitus 
C10EN11 Type I diabetes mellitus with 
ketoacidotic coma 
C10EB12 Insulin dependent diabetes mellitus 
with mononeuropathy 
C10E212 Insulin-dependent diabetes mellitus 
with neurological comps 
C108812 Type 1 diabetes mellitus - poor control 
C108G11 Type I diabetes mellitus with peripheral 
angiopathy 
C10EE00 Type 1 diabetes mellitus with 
hypoglycaemic coma 
C108J12 Type 1 diabetes mellitus with 
neuropathic arthropathy 
C10E511 Type I diabetes mellitus with ulcer 
C10E.12 Insulin dependent diabetes mellitus 
C108500 Insulin dependent diabetes mellitus 
with ulcer 
C108E12 Type 1 diabetes mellitus with 
hypoglycaemic coma 
C108212 Type 1 diabetes mellitus with 
neurological complications 
C10EC12 Insulin dependent diabetes mellitus 
with polyneuropathy 
C108911 Type I diabetes mellitus maturity onset 
C108B12 Type 1 diabetes mellitus with 
mononeuropathy 
C108E11 Type I diabetes mellitus with 
hypoglycaemic coma 
C10E300 Type 1 diabetes mellitus with multiple 
complications 
C10E600 Type 1 diabetes mellitus with gangrene 
C108700 Insulin dependent diabetes mellitus 
with retinopathy 
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C10z000 Diabetes mellitus, juvenile type, + 
unspecified complication 
C108800 Insulin dependent diabetes mellitus - 
poor control 
C10E200 Type 1 diabetes mellitus with 
neurological complications 
C10E112 Insulin-dependent diabetes mellitus 
with ophthalmic comps 
C108900 Insulin dependent diabetes maturity 
onset 
C10E011 Type I diabetes mellitus with renal 
complications 
ZRbH.00 Perceived control of insulin-dependent 
diabetes 
C10EH12 Insulin dependent diabetes mellitus 
with arthropathy 
C10E400 Unstable type 1 diabetes mellitus 
C10E.11 Type I diabetes mellitus 
C10E611 Type I diabetes mellitus with gangrene 
ZC2C900 Dietary advice for type I diabetes 
C108200 Insulin-dependent diabetes mellitus 
with neurological comps 
C10E812 Insulin dependent diabetes mellitus - 
poor control 
C108D11 Type I diabetes mellitus with 
nephropathy 
C10EK00 Type 1 diabetes mellitus with persistent 
proteinuria 
C108H00 Insulin dependent diabetes mellitus 
with arthropathy 
C108811 Type I diabetes mellitus - poor control 
C10EQ00 Type 1 diabetes mellitus with 
gastroparesis 
C10E111 Type I diabetes mellitus with 
ophthalmic complications 
C10EL00 Type 1 diabetes mellitus with persistent 
microalbuminuria 
C10EE12 Insulin dependent diabetes mellitus 
with hypoglycaemic coma 
C108211 Type I diabetes mellitus with 
neurological complications 
C108.11 IDDM-Insulin dependent diabetes 
mellitus 
C10E100 Type 1 diabetes mellitus with 
ophthalmic complications 
C108A12 Type 1 diabetes mellitus without 
complication 
C10E012 Insulin-dependent diabetes mellitus 
with renal complications 
C106000 Diabetes mellitus, juvenile, + 
neurological manifestation 
C10FS00 Maternally inherited diabetes mellitus 
C10E911 Type I diabetes mellitus maturity onset 
C108711 Type I diabetes mellitus with 
retinopathy 
C108J11 Type I diabetes mellitus with 
neuropathic arthropathy 
C108511 Type I diabetes mellitus with ulcer 
C101100 Diabetes mellitus, adult onset, with 
ketoacidosis 
C10EA11 Type I diabetes mellitus without 
complication 
C10E811 Type I diabetes mellitus - poor control 
C108011 Type I diabetes mellitus with renal 
complications 
C10E912 Insulin dependent diabetes maturity 
onset 
C10E000 Type 1 diabetes mellitus with renal 
complications 
C10EF11 Type I diabetes mellitus with diabetic 
cataract 
C10EE11 Type I diabetes mellitus with 
hypoglycaemic coma 
C108G12 Type 1 diabetes mellitus with peripheral 
angiopathy 
C10EF12 Insulin dependent diabetes mellitus 
with diabetic cataract 
C10ED00 Type 1 diabetes mellitus with 
nephropathy 
C10EL11 Type I diabetes mellitus with persistent 
microalbuminuria 
C10EC11 Type I diabetes mellitus with 
polyneuropathy 
C104000 Diabetes mellitus, juvenile type, with 
renal manifestation 
C10ED12 Insulin dependent diabetes mellitus 
with nephropathy 
C10E411 Unstable type I diabetes mellitus 
C108611 Type I diabetes mellitus with gangrene 
C10E711 Type I diabetes mellitus with 
retinopathy 
C10EB00 Type 1 diabetes mellitus with 
mononeuropathy 
C10EH11 Type I diabetes mellitus with 
arthropathy 
C10EG11 Type I diabetes mellitus with peripheral 
angiopathy 
C10G000 Secondary pancreatic diabetes mellitus 
without complication 
66An.00 Diabetes type 1 review 
C10E312 Insulin dependent diabetes mellitus 
with multiple complicat 
C10EF00 Type 1 diabetes mellitus with diabetic 
cataract 
C108.12 Type 1 diabetes mellitus 
C10G.00 Secondary pancreatic diabetes mellitus 
C10EJ00 Type 1 diabetes mellitus with 
neuropathic arthropathy 
C10E512 Insulin dependent diabetes mellitus 
with ulcer 
C108H11 Type I diabetes mellitus with 
arthropathy 
C108400 Unstable insulin dependent diabetes 
mellitus 
C10EM11 Type I diabetes mellitus with 
ketoacidosis 
C10EN00 Type 1 diabetes mellitus with 
ketoacidotic coma 
C10E.00 Type 1 diabetes mellitus 
C105000 Diabetes mellitus, juvenile type, + 
ophthalmic manifestation 
C101z00 Diabetes mellitus NOS with ketoacidosis 
C10y000 Diabetes mellitus, juvenile, + other 
specified manifestation 
C10EG00 Type 1 diabetes mellitus with peripheral 
angiopathy 
C10E900 Type 1 diabetes mellitus maturity onset 
C108412 Unstable type 1 diabetes mellitus 
C108B11 Type I diabetes mellitus with 
mononeuropathy 
ZC2C911 Diet advice for insulin-dependent 
diabetes 
C108A00 Insulin-dependent diabetes without 
complication 
C10E500 Type 1 diabetes mellitus with ulcer 
C108612 Type 1 diabetes mellitus with gangrene 
C102000 Diabetes mellitus, juvenile type, with 
hyperosmolar coma 
C109700 Non-insulin dependent diabetes mellitus 
- poor control 
C109300 Non-insulin-dependent diabetes mellitus 
with multiple comps 
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C10FF11 Type II diabetes mellitus with 
peripheral angiopathy 
C104100 Diabetes mellitus, adult onset, with 
renal manifestation 
C109E11 Type II diabetes mellitus with diabetic 
cataract 
C109111 Type II diabetes mellitus with 
ophthalmic complications 
C109411 Type II diabetes mellitus with ulcer 
C109E12 Type 2 diabetes mellitus with diabetic 
cataract 
C10ER00 Latent autoimmune diabetes mellitus in 
adult 
C10F111 Type II diabetes mellitus with 
ophthalmic complications 
C109312 Type 2 diabetes mellitus with multiple 
complications 
C10F611 Type II diabetes mellitus with 
retinopathy 
C10F211 Type II diabetes mellitus with 
neurological complications 
C10FP00 Type 2 diabetes mellitus with 
ketoacidotic coma 
C109H11 Type II diabetes mellitus with 
neuropathic arthropathy 
C109C11 Type II diabetes mellitus with 
nephropathy 
C109900 Non-insulin-dependent diabetes mellitus 
without complication 
ZC2CA11 Dietary advice non-insulin-dependent 
diabetes 
C105100 Diabetes mellitus, adult onset, + 
ophthalmic manifestation 
C109C00 Non-insulin dependent diabetes mellitus 
with nephropathy 
C10F600 Type 2 diabetes mellitus with 
retinopathy 
C109A11 Type II diabetes mellitus with 
mononeuropathy 
C10F011 Type II diabetes mellitus with renal 
complications 
C100112 Non-insulin dependent diabetes mellitus 
C109200 Non-insulin-dependent diabetes mellitus 
with neuro comps 
C10FQ00 Type 2 diabetes mellitus with exudative 
maculopathy 
C10F400 Type 2 diabetes mellitus with ulcer 
C10FL11 Type II diabetes mellitus with persistent 
proteinuria 
C109712 Type 2 diabetes mellitus - poor control 
C109B00 Non-insulin dependent diabetes mellitus 
with polyneuropathy 
C10FE11 Type II diabetes mellitus with diabetic 
cataract 
C109100 Non-insulin-dependent diabetes mellitus 
with ophthalm comps 
C109112 Type 2 diabetes mellitus with 
ophthalmic complications 
C10F100 Type 2 diabetes mellitus with 
ophthalmic complications 
C10FG00 Type 2 diabetes mellitus with 
arthropathy 
C100111 Maturity onset diabetes 
C10FM11 Type II diabetes mellitus with persistent 
microalbuminuria 
C10FR00 Type 2 diabetes mellitus with 
gastroparesis 
C109212 Type 2 diabetes mellitus with 
neurological complications 
C109612 Type 2 diabetes mellitus with 
retinopathy 
C10F511 Type II diabetes mellitus with gangrene 
C109G12 Type 2 diabetes mellitus with 
arthropathy 
C107200 Diabetes mellitus, adult with gangrene 
C109400 Non-insulin dependent diabetes mellitus 
with ulcer 
C109F12 Type 2 diabetes mellitus with peripheral 
angiopathy 
C10C.11 Maturity onset diabetes in youth 
C109J00 Insulin treated Type 2 diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent 
diabetes mellitus 
C109E00 Non-insulin depend diabetes mellitus 
with diabetic cataract 
C109511 Type II diabetes mellitus with gangrene 
C10FK00 Hyperosmolar non-ketotic state in type 
2 diabetes mellitus 
C10FF00 Type 2 diabetes mellitus with peripheral 
angiopathy 
C109.13 Type II diabetes mellitus 
C109600 Non-insulin-dependent diabetes mellitus 
with retinopathy 
C109G00 Non-insulin dependent diabetes mellitus 
with arthropathy 
C109012 Type 2 diabetes mellitus with renal 
complications 
C10F911 Type II diabetes mellitus without 
complication 
C107100 Diabetes mellitus, adult, + peripheral 
circulatory disorder 
C109D00 Non-insulin dependent diabetes mellitus 
with hypoglyca coma 
C109000 Non-insulin-dependent diabetes mellitus 
with renal comps 
C10F500 Type 2 diabetes mellitus with gangrene 
66Ao.00 Diabetes type 2 review 
C109D12 Type 2 diabetes mellitus with 
hypoglycaemic coma 
C109412 Type 2 diabetes mellitus with ulcer 
C10FQ11 Type II diabetes mellitus with exudative 
maculopathy 
C10FG11 Type II diabetes mellitus with 
arthropathy 
C10F900 Type 2 diabetes mellitus without 
complication 
C109.12 Type 2 diabetes mellitus 
C109.00 Non-insulin dependent diabetes mellitus 
C10FN00 Type 2 diabetes mellitus with 
ketoacidosis 
C10FH00 Type 2 diabetes mellitus with 
neuropathic arthropathy 
C109G11 Type II diabetes mellitus with 
arthropathy 
C109500 Non-insulin dependent diabetes mellitus 
with gangrene 
C10FC00 Type 2 diabetes mellitus with 
nephropathy 
C10F.11 Type II diabetes mellitus 
C10F711 Type II diabetes mellitus - poor control 
C10F300 Type 2 diabetes mellitus with multiple 
complications 
C10FE00 Type 2 diabetes mellitus with diabetic 
cataract 
C10F311 Type II diabetes mellitus with multiple 
complications 
C106100 Diabetes mellitus, adult onset, + 
neurological manifestation 
C10D.11 Maturity onset diabetes in youth type 2 
C10z100 Diabetes mellitus, adult onset, + 
unspecified complication 
C109J11 Insulin treated non-insulin dependent 
diabetes mellitus 
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C109J12 Insulin treated Type II diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal 
complications 
ZC2CA00 Dietary advice for type II diabetes 
C10y100 Diabetes mellitus, adult, + other 
specified manifestation 
C109211 Type II diabetes mellitus with 
neurological complications 
C109C12 Type 2 diabetes mellitus with 
nephropathy 
C10FM00 Type 2 diabetes mellitus with persistent 
microalbuminuria 
C109F11 Type II diabetes mellitus with 
peripheral angiopathy 
C109912 Type 2 diabetes mellitus without 
complication 
C10C.12 Maturity onset diabetes in youth type 1 
C10D.00 Diabetes mellitus autosomal dominant 
type 2 
C109512 Type 2 diabetes mellitus with gangrene 
C109A00 Non-insulin dependent diabetes mellitus 
with mononeuropathy 
C109611 Type II diabetes mellitus with 
retinopathy 
C10FN11 Type II diabetes mellitus with 
ketoacidosis 
C109B12 Type 2 diabetes mellitus with 
polyneuropathy 
C109H12 Type 2 diabetes mellitus with 
neuropathic arthropathy 
C10FH11 Type II diabetes mellitus with 
neuropathic arthropathy 
C109911 Type II diabetes mellitus without 
complication 
C10FD11 Type II diabetes mellitus with 
hypoglycaemic coma 
C10FA11 Type II diabetes mellitus with 
mononeuropathy 
C10F411 Type II diabetes mellitus with ulcer 
C109711 Type II diabetes mellitus - poor control 
C109B11 Type II diabetes mellitus with 
polyneuropathy 
C109K00 Hyperosmolar non-ketotic state in type 
2 diabetes mellitus 
C10FB11 Type II diabetes mellitus with 
polyneuropathy 
C10F200 Type 2 diabetes mellitus with 
neurological complications 
C109D11 Type II diabetes mellitus with 
hypoglycaemic coma 
C10F.00 Type 2 diabetes mellitus 
C109311 Type II diabetes mellitus with multiple 
complications 
C10FJ00 Insulin treated Type 2 diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent 
proteinuria 
C109A12 Type 2 diabetes mellitus with 
mononeuropathy 
C10FD00 Type 2 diabetes mellitus with 
hypoglycaemic coma 
C10FB00 Type 2 diabetes mellitus with 
polyneuropathy 
C109011 Type II diabetes mellitus with renal 
complications 
C10FA00 Type 2 diabetes mellitus with 
mononeuropathy 
C10FC11 Type II diabetes mellitus with 
nephropathy 
C10FJ11 Insulin treated Type II diabetes mellitus 
ZC2C800 Dietary advice for diabetes mellitus 
C10F700 Type 2 diabetes mellitus - poor control 
C10FP11 Type II diabetes mellitus with 
ketoacidotic coma 
C106.13 Diabetes mellitus with polyneuropathy 
C10N000 Secondary diabetes mellitus without 
complication 
C100.00 Diabetes mellitus with no mention of 
complication 
C107z00 Diabetes mellitus NOS with peripheral 
circulatory disorder 
C10zz00 Diabetes mellitus NOS with unspecified 
complication 
2G5C.00 Foot abnormality - diabetes related 
66AJ100 Brittle diabetes 
8I84.00 Did not complete XPERT diabetes 
structured education program 
L180100 Diabetes mellitus during pregnancy - 
baby delivered 
9OLL.00 XPERT diabetes structured education 
programme completed 
66AQ.00 Diabetes: shared care programme 
C350011 Bronzed diabetes 
C10N100 Cystic fibrosis related diabetes mellitus 
9NM0.00 Attending diabetes clinic 
C103000 Diabetes mellitus, juvenile type, with 
ketoacidotic coma 
2G51100 Foot abnormality - non-diabetes 
2G5D.00 Foot abnormality - non-diabetes 
9OLZ.00 Diabetes monitoring admin.NOS 
L180200 Diabetes mellitus in puerperium - baby 
delivered 
8CR2.00 Diabetes clinical management plan 
C105y00 Other specified diabetes mellitus with 
ophthalmic complicatn 
9NiD.00 Did not attend DESMOND diabetes 
structured education program 
9h41.00 Excepted from diabetes qual indicators: 
Patient unsuitable 
679L.00 Health education - diabetes 
8I82.00 Did not complete DAFNE diabetes 
structured education program 
918T.00 Diabetes key contact 
2126300 Diabetes resolved 
C104y00 Other specified diabetes mellitus with 
renal complications 
9OL1.00 Attends diabetes monitoring 
9OL2.00 Refuses diabetes monitoring 
8H4e.00 Referral to diabetes special interest 
general practitioner 
9N0n.00 Seen in community diabetes specialist 
clinic 
8Hj5.00 Referral to XPERT diabetes structured 
education programme 
8H7f.00 Referral to diabetes nurse 
8Hj0.00 Referral to diabetes structured 
education programme 
9OL7.00 Diabetes monitor.verbal invite 
ZRBa.00 Education score - diabetes 
66AP.00 Diabetes: practice programme 
9OLB.00 Attended diabetes structured education 
programme 
9OLF.00 Diabetes structured education 
programme completed 
9OL3.00 Diabetes monitoring default 
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9OL9.00 Diabetes monitoring deleted 
8HTe.00 Referral to diabetes preconception 
counselling clinic 
ZL62500 Referral to diabetes nurse 
8Hj3.00 Referral to DAFNE diabetes structured 
education programme 
8I83.00 Did not complete DESMOND diabetes 
structured educat program 
C100100 Diabetes mellitus, adult onset, no 
mention of complication 
C107.00 Diabetes mellitus with peripheral 
circulatory disorder 
8I81.00 Did not complete diabetes structured 
education programme 
8Hj1.00 Family/carer referral to diabetes 
structured education prog 
C100000 Diabetes mellitus, juvenile type, no 
mention of complication 
66AU.00 Diabetes care by hospital only 
L180000 Diabetes mellitus - unspec whether in 
pregnancy/puerperium 
9M00.00 Informed consent for diabetes national 
audit 
9NiE.00 Did not attend XPERT diabetes 
structured education programme 
C106.00 Diabetes mellitus with neurological 
manifestation 
C104.00 Diabetes mellitus with renal 
manifestation 
C103z00 Diabetes mellitus NOS with ketoacidotic 
coma 
9OL..00 Diabetes monitoring admin. 
C105.00 Diabetes mellitus with ophthalmic 
manifestation 
Cyu2.00 [X]Diabetes mellitus 
9OLC.00 Family/carer attended diabetes 
structured education prog 
L180.00 Diabetes mellitus during 
pregnancy/childbirth/puerperium 
212H.00 Diabetes resolved 
C135.00 Diabetes insipidus 
C106z00 Diabetes mellitus NOS with neurological 
manifestation 
C106.12 Diabetes mellitus with neuropathy 
C107.12 Diabetes with gangrene 
9OLG.00 Attended XPERT diabetes structured 
education programme 
9OLH.00 Attended DAFNE diabetes structured 
education programme 
3881.00 Education score - diabetes 
66A8.00 Has seen dietician - diabetes 
9OL4.00 Diabetes monitoring 1st letter 
Kyu0300 [X]Glomerular disorders in diabetes 
mellitus 
C103y00 Other specified diabetes mellitus with 
coma 
9Nl4.00 Seen by general practitioner special 
interest in diabetes 
C10yz00 Diabetes mellitus NOS with other 
specified manifestation 
C10z.00 Diabetes mellitus with unspecified 
complication 
C103100 Diabetes mellitus, adult onset, with 
ketoacidotic coma 
9OLM.00 Diabetes structured education 
programme declined 
C108z00 Unspecified diabetes mellitus with 
multiple complications 
8Hg4.00 Discharged from care of diabetes 
specialist nurse 
8Hl4.00 Referral to community diabetes 
specialist nurse 
C104z00 Diabetes mellitis with nephropathy NOS 
9OL5.00 Diabetes monitoring 2nd letter 
F372.00 Polyneuropathy in diabetes 
Cyu2300 [X]Unspecified diabetes mellitus with 
renal complications 
3882.00 Diabetes well being questionnaire 
C10y.00 Diabetes mellitus with other specified 
manifestation 
C10..00 Diabetes mellitus 
7276.00 Pan retinal photocoagulation for 
diabetes 
9OLJ.00 DAFNE diabetes structured education 
programme completed 
ZRB6.00 Diabetes wellbeing questionnaire 
C106y00 Other specified diabetes mellitus with 
neurological comps 
C10M000 Lipoatrophic diabetes mellitus without 
complication 
3883.00 Diabetes treatment satisfaction 
questionnaire 
8CS0.00 Diabetes care plan agreed 
C103.00 Diabetes mellitus with ketoacidotic 
coma 
C108y00 Other specified diabetes mellitus with 
multiple comps 
2BBF.00 Retinal abnormality - diabetes related 
C314.11 Renal diabetes 
9OL6.00 Diabetes monitoring 3rd letter 
66AJ.11 Unstable diabetes 
9OL8.00 Diabetes monitor.phone invite 
C10yy00 Other specified diabetes mellitus with 
other spec comps 
ZRB4.00 Diabetes clinic satisfaction 
questionnaire 
F171100 Autonomic neuropathy due to diabetes 
ZRB5.11 DTSQ - Diabetes treatment satisfaction 
questionnaire 
8B3l.00 Diabetes medication review 
9OLA.11 Diabetes monitored 
9NN9.00 Under care of diabetes specialist nurse 
9NiA.00 Did not attend diabetes structured 
education programme 
C135.12 Diabetes insipidus - pituitary 
R102.11 [D]Prediabetes 
K01x100 Nephrotic syndrome in diabetes mellitus 
C102z00 Diabetes mellitus NOS with 
hyperosmolar coma 
66AX.00 Diabetes: shared care in pregnancy - 
diabetol and obstet 
9h4..00 Exception reporting: diabetes quality 
indicators 
L180400 Diabetes mellitus in pueperium - baby 
previously delivered 
ZRB5.00 Diabetes treatment satisfaction 
questionnaire 
8Hj4.00 Referral to DESMOND diabetes 
structured education programme 
9OLA.00 Diabetes monitor. check done 
ZV65312 [V]Dietary counselling in diabetes 
mellitus 
ZRB6.11 DWBQ - Diabetes wellbeing 
questionnaire 
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679R.00 Patient offered diabetes structured 
education programme 
9OLK.00 DESMOND diabetes structured 
education programme completed 
C10N.00 Secondary diabetes mellitus 
8BL2.00 Patient on maximal tolerated therapy 
for diabetes 
Cyu2000 [X]Other specified diabetes mellitus 
C10zy00 Other specified diabetes mellitus with 
unspecified comps 
C105z00 Diabetes mellitus NOS with ophthalmic 
manifestation 
C100z00 Diabetes mellitus NOS with no mention 
of complication 
C107y00 Other specified diabetes mellitus with 
periph circ comps 
66Af.00 Patient diabetes education review 
C102100 Diabetes mellitus, adult onset, with 
hyperosmolar coma 
C10M.00 Lipoatrophic diabetes mellitus 
66AR.00 Diabetes management plan given 
L180300 Diabetes mellitus during pregnancy - 
baby not yet delivered 
C107.11 Diabetes mellitus with gangrene 
9M10.00 Informed dissent for diabetes national 
audit 
9OL..11 Diabetes clinic administration 
2G51000 Foot abnormality - diabetes related 
66A9.00 Understands diet - diabetes 
L180z00 Diabetes mellitus in 
pregnancy/childbirth/puerperium NOS 
9h42.00 Excepted from diabetes quality 
indicators: Informed dissent 
8CP2.00 Transition of diabetes care options 
discussed 
ZRB4.11 CSQ - Diabetes clinic satisfaction 
questionnaire 
9NiC.00 Did not attend DAFNE diabetes 
structured education programme 
L180800 Diabetes mellitus arising in pregnancy 
L180900 Gestational diabetes mellitus 
Q44B.00 Syndrome of infant of mother with 
gestational diabetes 
ZC2CB00 Dietary advice for gestational diabetes 
L180811 Gestational diabetes mellitus 
14F4.00 H/O: Admission in last year for diabetes 
foot problem 
Lyu2900 [X]Pre-existing diabetes mellitus, 
unspecified 
1434.00 H/O: diabetes mellitus 
L180700 Pre-existing malnutrition-related 
diabetes mellitus 
L180500 Pre-existing diabetes mellitus, insulin-
dependent 
L180X00 Pre-existing diabetes mellitus, 
unspecified 
ZV13F00 [V]Personal history of gestational 
diabetes mellitus 
L180600 Pre-existing diabetes mellitus, non-
insulin-dependent 
C10AX00 Malnutrit-relat diabetes mellitus with 
other spec comps 
Cyu2100 [X]Malnutrit-relat diabetes mellitus with 
other spec comps 
C10A200 Malnutrition-related diabetes mellitus 
with renal complicatn 
C10A300 Malnutrit-related diabetes mellitus wth 
ophthalmic complicat 
C10A100 Malnutrition-related diabetes mellitus 
with ketoacidosis 
C10A000 Malnutrition-related diabetes mellitus 
with coma 
C10A500 Malnutritn-relat diabetes melitus wth 
periph circul complctn 
C10A700 Malnutrition-related diabetes mellitus 
without complications 
C10A.00 Malnutrition-related diabetes mellitus 
Cyu2200 [X]Malnutrit-related diabetes mellitus 
with unspec complics 
C10AW00 Malnutrit-related diabetes mellitus with 
unspec complics 
C10A600 Malnutrition-related diabetes mellitus 
with multiple comps 
C10A400 Malnutrition-related diabetes mellitus 
wth neuro complicatns 
 
10.8.2 Multilex drug codes for 
Diabetes Mellitus 
Drugcode Generic name 
86177998 INSULIN ISOPHANE BOVINE 
CARTRIDGE inj susp 100 units/ml 
90683997 Biphasic isophane insulin product 
92376997 Biphasic isophane insulin product 
86249998 Insulin biphasic lispro disposable pen 
inj susp 25:75; 100 units/ml 3ml 
disposable pen(s) 5 
96047998 INSULIN NEUTRAL HUMAN inj 100 
units/ml 
94322998 Insulin isophane human crb inj 100 
iu/ml 3ml disposable pen(s) 5 
97524998 INSULIN SOLUBLE BOVINE inj 100 
units/ml 
98227998 INSULIN SOLUBLE HUMAN VIAL inj 
soln 100 units/ml 
98228998 INSULIN ISOPHANE HUMAN EMP inj 
100 units/ml 
91295998 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
96053997 ISOPHANE INSULIN 100iu/mL 10m 
86243998 Insulin glargine vial inj soln 100 
units/ml 1 10ml vial(s) 
86237998 Insulin glulisine vial inj soln 100 
units/ml 1 10ml vial(s) 
86303998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 30:70; 
100 units/ml 
92940994 INSULIN 1mL syrg+12mm(29G) ndl 
90012998 Insulin lispro human prb inj 100 
iu/ml 3ml disposable pen(s) 5 
91777994 NovoPenclassic 
97598992 Insulin isophane (nph) 40 i/u  0 
98225998 INSULIN BIPHASIC ISOPHANE 
HUMAN EMP inj 50:50; 100 units/ml 
96283992 Insulin isophane (nph) 100 i/u inj  0 
86269998 INSULIN ISOPHANE HUMAN 
DISPOSABLE PEN inj susp 100 
units/ml 
96292992 Insulin isophane (highly purified) 
100 i/u inj  0 
96076992 Insulin bovine protamine zinc 100 i/u 
inj  0 
90681998 Biphasic isophane insulin product 
86284998 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
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15:85; 100 units/ml 
86254998 Insulin lispro disposable pen inj soln 
100 units/ml 5 3ml disposable 
pen(s) 
91275998 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 10:90; 100 units/ml 
97601992 Insulin zinc semilente susp bp 100 
i/u inj  0 
86308998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 20:80; 
100 units/ml 
97322997 INSULIN SOLUBLE HUMAN PYR inj 
100 units/ml 
96061998 Insulin zinc mixed bovine vial inj 
susp 100 units/ml 10ml vial(s) 1 
89555998 Insulin biphasic aspart human pyr inj 
30:70; 100 units/ml 3ml disposable 
pen(s) 5 
86253998 INSULIN LISPRO VIAL inj soln 100 
units/ml 
91505998 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
86250998 Insulin biphasic lispro cartridge inj 
susp 25:75; 100 units/ml 3ml 
cartridge(s) 5 
94292998 INSULIN SOLUBLE HUMAN EMP inj 
100 units/ml 
91293997 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 20:80; 100 units/ml 
97854998 INSULIN ISOPHANE HUMAN CRB inj 
100 iu/ml 
88973994 Autopen Junior 
94296998 INSULIN ISOPHANE HUMAN EMP inj 
100 units/ml 
96794992 Biphasic isophane insulin product 
86186998 INSULIN BIPHASIC ISOPHANE 
PORCINE CARTRIDGE inj susp 
30:70; 100 units/ml 
86191998 INSULIN ISOPHANE PORCINE VIAL 
inj susp 100 units/ml 
91276998 INSULIN ISOPHANE HUMAN PRB inj 
100 iu/ml 
90681996 Biphasic isophane insulin product 
86266998 INSULIN ISOPHANE HUMAN 
DISPOSABLE PEN inj susp 100 
units/ml 
90817994 BD Ultra Pen 
96291992 ISOPHANE INSULIN 100iu/mL 10m 
84779998 INSULIN DETEMIR DISPOSABLE PEN 
inj soln 100 units/ml 
91292997 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
90697997 Biphasic isophane insulin product 
91294997 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 10:90; 100 units/ml 
92376998 Biphasic isophane insulin product 
96053996 Biphasic isophane insulin product 
86288998 Biphasic isophane insulin product 
96792992 Biphasic isophane insulin product 
86256998 Insulin lispro vial inj soln 100 
units/ml 1 10ml vial(s) 
86189998 ISOPHANE INSULIN 100iu/mL 10m 
86242998 Insulin glargine disposable pen inj 
soln 100 units/ml 5 3ml disposable 
pen(s) 
91292996 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
95162992 NEUTRAL INSULIN 100iu/mL 10mL 
92908998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 20:80; 100 units/ml 
98239994 U100 insulin syringe 0.5ml 
syringe(s) 100 
86260998 INSULIN BIPHASIC ASPART 
CARTRIDGE inj susp 30:70; 100 
units/ml 
86182998 INSULIN SOLUBLE PORCINE 
CARTRIDGE inj soln 100 units/ml 
86193998 Insulin isophane porcine cartridge inj 
susp 100 units/ml 3ml cartridge(s) 5 
86314998 INSULIN SOLUBLE HUMAN 
CARTRIDGE inj soln 100 units/ml 
94319998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 10:90; 100 units/ml 
90689998 Insulin soluble human prb inj 100 
units/ml 5ml vial(s) 1 
88210994 Autopen Special Edition 
97527998 INSULIN ZINC MIXED BOVINE VIAL 
inj susp 100 units/ml 
91274998 INSULIN SOLUBLE HUMAN 
DISPOSABLE PEN inj soln 100 
units/ml 
92906998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 50:50; 100 units/ml 
86274998 Insulin isophane human disposable 
pen inj susp 100 units/ml 5 3ml 
disposable pen(s) 
95168992 Insulin zinc suspension amorphous 
product 
98505998 INSULIN ZINC MIXED BOVINE VIAL 
inj susp 100 units/ml 
99480998 INSULIN ZINC susp MIXED BOVINE 
& PORCINE inj 100 units/ml 
86549998 INSULIN GLULISINE CARTRIDGE inj 
soln 100 units/ml 
87415994 Humapen Ergoburgundy 
88413998 INSULIN SOLUBLE PORCINE VIAL inj 
soln 100 units/ml 
94298998 INSULIN BIPHASIC ISOPHANE 
HUMAN EMP inj 25:75; 100 units/ml 
85591998 INSULIN GLULISINE CARTRIDGE inj 
soln 100 units/ml 
86305998 Biphasic isophane insulin product 
97600992 Insulin bovine protamine zinc 40 i/u 
inj  0 
86080998 INSULIN ISOPHANE HUMAN 
DISPOSABLE PEN inj susp 100 
units/ml 
90684997 Biphasic isophane insulin product 
88995998 INSULIN ISOPHANE PORCINE inj 100 
units/ml 
96052998 Insulin isophane mixed human inj 
100 units/ml 3ml cartridge(s) 5 
86315998 INSULIN SOLUBLE HUMAN 
CARTRIDGE inj soln 100 units/ml 
86313998 INSULIN SOLUBLE HUMAN 
DISPOSABLE PEN inj soln 100 
units/ml 
86185998 Insulin soluble porcine vial inj soln 
100 units/ml 10ml vial(s) 1 
86298998 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
30:70; 100 units/ml 
96045998 Isophane insulin inj 100 iu/ml 10ml 
vial(s) 1 
88974994 Autopen Junior 
90169998 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
30:70; 100 units/ml 
94299998 INSULIN BIPHASIC ISOPHANE 
HUMAN EMP inj 50:50; 100 units/ml 
86267998 INSULIN ISOPHANE HUMAN VIAL inj 
susp 100 units/ml 
86282998 Biphasic isophane insulin product 
292 
 
99532998 INSULIN ISOPHANE PORCINE VIAL 
inj susp 100 units/ml 
86169998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 50:50; 
100 units/ml 
94297998 INSULIN BIPHASIC ISOPHANE 
HUMAN EMP inj 15:85; 100 units/ml 
91273998 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 40:60; 100 units/ml 
96281992 Insulin soluble 320 i/u inj  0 
96284992 Isophane insulin product 
86310998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 10:90; 
100 units/ml 
98817998 INSULIN ZINC susp CRYSTALLINE 
HUMAN PRB - INTERMEDIATE 
ACTING inj 100 units/ml 
88211994 Autopen Special Edition 
99356998 INSULIN SOLUBLE BOVINE inj 100 
units/ml 
91293998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 20:80; 100 units/ml 
86214998 Insulin glulisine disposable pen inj 
soln 100 units/ml 5 3ml disposable 
pen(s) 
90690998 Insulin soluble human emp inj 100 
units/ml 10ml vial(s) 1 
98238994 U100 pre-set insulin syringe 1ml 
sp.36 [2a] 1 syringe(s) 
94477992 NEUTRAL INSULIN 100iu/mL 10mL 
97322998 INSULIN SOLUBLE HUMAN PYR inj 
100 units/ml 
86252998 INSULIN LISPRO CARTRIDGE inj soln 
100 units/ml 
86179998 Insulin isophane bovine cartridge inj 
susp 100 units/ml 3ml cartridge(s) 5 
97244992 INSULIN/DEPOT 
86278998 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
25:75; 100 units/ml 
90697996 Biphasic isophane insulin product 
99359998 INSULIN ISOPHANE BOVINE inj 100 
units/ml 
91758998 Insulin glargine inj 100 iu/ml 3ml 
cartridge(s) 5 
86271998 INSULIN ISOPHANE HUMAN VIAL inj 
susp 100 units/ml 
96561992 INSULIN SYRINGE 
99976992 Insulin soluble 100 i/u inj  0 
86176998 Insulin soluble bovine vial inj soln 
100 units/ml 10ml vial(s) 1 
86264998 Insulin aspart cartridge inj soln 100 
units/ml 5 3ml cartridge(s) 
96290992 Insulin neutral (purified) 100 i/u inj  
0 
86180998 Insulin isophane bovine vial inj susp 
100 units/ml 10ml vial(s) 1 
83405998 INSULIN BIPHASIC LISPRO 
DISPOSABLE PEN inj susp 50:50; 
100 units/ml 
99556998 INSULIN ZINC susp MIXED HUMAN 
PYR inj 100 units/ml 
99048992 Syringe insulin (bs1619/1) 2ml  0 
83403998 INSULIN LISPRO DISPOSABLE PEN 
inj soln 100 units/ml 
89990998 Insulin biphasic lispro human prb inj 
25:75; 100 units/ml 3ml disposable 
pen(s) 5 
86247998 INSULIN BIPHASIC LISPRO 
DISPOSABLE PEN inj susp 25:75; 
100 units/ml 
97268994 U100 insulin syringe 1ml 100 
syringe(s) 
90682998 Biphasic isophane insulin product 
99401998 INSULIN ZINC susp MIXED PORCINE 
inj 100 units/ml 
97323998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
97526998 INSULIN ISOPHANE BOVINE inj 100 
units/ml 
89685994 U100 insulin syringe 0.5ml 
97639992 INSULIN/COMBINATION 
91289998 INSULIN BIPHASIC ISOPHANE 
HUMAN CRB inj 15:85; 100 units/ml 
90015998 INSULIN LISPRO HUMAN PRB inj 100 
iu/ml 
98474990 INSULIN SOLUBLE BOVINE inj 100 
units/ml 
96286992 NEUTRAL INSULIN 100iu/mL 10mL 
86301998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 30:70; 
100 units/ml 
86251998 INSULIN LISPRO DISPOSABLE PEN 
inj soln 100 units/ml 
96050998 Neutral insulin bovine inj 100 iu/ml 
3ml cartridge(s) 5 
86241998 Insulin glargine cartridge inj soln 
100 units/ml 5 3ml cartridge(s) 
96688992 Insulin neutral (human) 100 i/u inj  
0 
86077998 Insulin biphasic lispro disposable pen 
inj susp 50:50; 100 units/ml 3ml 
disposable pen(s) 5 
88297994 One Touch Ultra 
86265998 Insulin aspart vial inj soln 100 
units/ml 1 10ml vial(s) 
96063998 Insulin neutral human inj 100 
units/ml 10ml vial(s) 1 
86175998 Insulin soluble bovine cartridge inj 
soln 100 units/ml 3ml cartridge(s) 5 
90682996 Biphasic isophane insulin product 
89554998 INSULIN BIPHASIC ASPART HUMAN 
PYR inj 30:70; 100 units/ml 
87471998 INSULIN DETEMIR DISPOSABLE PEN 
inj soln 100 units/ml 
93137992 Insulin isophane (human) 100 i/u inj  
0 
90682997 Biphasic isophane insulin product 
97053998 INSULIN ZINC susp MIXED HUMAN 
PRB inj 100 units/ml 
86248998 INSULIN BIPHASIC LISPRO 
CARTRIDGE inj susp 25:75; 100 
units/ml 
86081998 INSULIN ISOPHANE HUMAN VIAL inj 
susp 100 units/ml 
96787992 Soluble neutral insulin product 
91509998 INSULIN ASPART DISPOSABLE PEN 
inj soln 100 units/ml 
86272998 INSULIN GLARGINE CARTRIDGE inj 
soln 100 units/ml 
98198998 INSULIN ASPART CARTRIDGE inj 
soln 100 units/ml 
96294992 Insulin zinc bovine susp 100 i/u inj  
0 
86281998 Biphasic isophane insulin product 
87967998 Biphasic isophane insulin product 
86285998 Biphasic isophane insulin product 
92555998 INSULIN GLARGINE inj 100 iu/ml 
98480998 INSULIN SOLUBLE PORCINE inj 100 
units/ml 
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92909998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 10:90; 100 units/ml 
86316998 INSULIN SOLUBLE HUMAN VIAL inj 
soln 100 units/ml 
94337998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
89888998 Biphasic isophane insulin product 
99553998 INSULIN SOLUBLE HUMAN PRB inj 
100 units/ml 
90168998 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
90697998 Biphasic isophane insulin product 
93713998 Insulin disp 1ml syringe appliance(s) 
1 
91294998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 10:90; 100 units/ml 
94413998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 40:60; 100 units/ml 
97052996 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 30:70; 100 units/ml 
88978998 INSULIN BIPHASIC ISOPHANE 
PORCINE inj 30:70; 100 units/ml 
92323998 INSULIN BIPHASIC LISPRO 
DISPOSABLE PEN inj susp 50:50; 
100 units/ml 
91291997 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 40:60; 100 units/ml 
86044998 INSULIN HUMAN inhalation pwdr 
3mg 
96064992 Insulin zinc suspension amorphous 
product 
96057998 Insulin zinc susp crystalline human 
prb - intermediate acting inj 100 
units/ml 10ml vial(s) 1 
91290996 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 50:50; 100 units/ml 
96289992 Insulin zinc suspension crystalline 
product 
86295998 Biphasic isophane insulin product 
90828994 Novopen 3fun-blue 
98507998 INSULIN SOLUBLE BOVINE inj 100 
units/ml 
97602992 Insulin soluble 40 i/u inj  0 
92649994 Novofine 
97528998 INSULIN PROTAMINE ZINC BOVINE 
VIAL inj susp 100 units/ml 
98895998 INSULIN BIPHASIC LISPRO HUMAN 
PRB inj 25:75; 100 units/ml 
90684998 Biphasic isophane insulin product 
86553998 Insulin glulisine inj soln 100 units/ml 
3ml disposable pen(s) 5 
90685998 Insulin zinc susp mixed human prb 
inj 100 units/ml 10ml vial(s) 1 
97051997 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 50:50; 100 units/ml 
94328998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 20:80; 100 units/ml 
98982998 INSULIN SOLUBLE PORCINE inj 100 
units/ml 
99402998 INSULIN ASPART VIAL inj soln 100 
units/ml 
94948998 Insulin soluble porcine inj 100 
units/ml 3ml cartridge(s) 5 
99144998 INSULIN ZINC susp AMORPHOUS 
PORCINE inj 100 units/ml 
86183998 INSULIN SOLUBLE PORCINE VIAL inj 
soln 100 units/ml 
91275996 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
30:70; 100 units/ml 
95165992 Biphasic isophane insulin product 
86275998 Insulin isophane human cartridge inj 
susp 100 units/ml 5 3ml cartridge(s) 
86240998 INSULIN GLARGINE VIAL inj soln 
100 units/ml 
90688998 Insulin isophane human pyr inj 100 
iu/ml 3ml pre-filled syringe 5 
86255998 Insulin lispro cartridge inj soln 100 
units/ml 5 3ml cartridge(s) 
91292998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
86268998 INSULIN ISOPHANE HUMAN 
CARTRIDGE inj susp 100 units/ml 
86168998 INSULIN ISOPHANE HUMAN 
CARTRIDGE inj susp 100 units/ml 
90508994 Novopen 3demi 
91291998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 40:60; 100 units/ml 
86291998 Biphasic isophane insulin product 
98506998 INSULIN ISOPHANE BOVINE inj 100 
units/ml 
86246998 Insulin detemir cartridge inj soln 100 
units/ml 5 3ml cartridge(s) 
96056998 INSULINISOPHANE BOVINE 
99196998 INSULIN BIPHASIC inj 100 units/ml 
96044992 Insulin bp 100 i/u  0 
94202992 Soluble neutral insulin product 
86317998 Insulin soluble human cartridge inj 
soln 100 units/ml 5 3ml cartridge(s) 
90829994 Novopen 3fun-red 
96049998 INSULIN SOLUBLE PORCINE inj 100 
units/ml 
86261998 Insulin biphasic aspart disposable 
pen inj susp 30:70; 100 units/ml 
3ml disposable pen(s) 5 
86174998 INSULIN SOLUBLE BOVINE 
CARTRIDGE inj soln 100 units/ml 
86215998 INSULIN GLULISINE DISPOSABLE 
PEN inj soln 100 units/ml 
92456994 Novofine 
92907998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 40:60; 100 units/ml 
95150997 TOLAZAMIDE 
99415998 INSULIN BIPHASIC ISOPHANE 
PORCINE VIAL inj susp 30:70; 100 
units/ml 
91933994 NovoPen 
91612998 INSULIN ASPART HUMAN PYR inj 100 
iu/ml 
96295992 Soluble neutral insulin product 
86551998 INSULIN GLULISINE VIAL inj soln 
100 units/ml 
96795992 Isophane insulin product 
93467992 Insulin soluble inj i/u^2  0 
99047992 Syringe pre-set insulin for blind 2ml  
0 
86046998 Insulin human inhalation pwdr 3mg 
90 blisters 
96046998 Insulin zinc lente bovine vial inj susp 
100 units/ml 1 10ml vial(s) 
87008994 Optipen Pro 1 
87967997 Biphasic isophane insulin product 
96059998 Insulin zinc susp amorphous porcine 
inj 100 units/ml 10ml vial(s) 1 
99554998 INSULIN ISOPHANE HUMAN PRB inj 
100 iu/ml 
86270998 INSULIN ISOPHANE HUMAN 
CARTRIDGE inj susp 100 units/ml 
90379998 Insulin aspart human pyr inj 100 
iu/ml 3ml disposable pen(s) 5 
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96058998 Insulin zinc susp crystalline human 
pyr - long acting inj 100 units/ml 
10ml vial(s) 1 
98481997 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
96282992 Biphasic isophane insulin product 
96293992 Insulin zinc semilente susp 80 i/u inj  
0 
86259998 INSULIN BIPHASIC ASPART 
DISPOSABLE PEN inj susp 30:70; 
100 units/ml 
91700998 INSULIN BIPHASIC ISOPHANE 
HUMAN CRB inj 50:50; 100 units/ml 
89990997 Insulin biphasic lispro human prb inj 
50:50; 100 units/ml 3ml disposable 
pen(s) 5 
86318998 Biphasic isophane insulin product 
93714996 Insulin 1 ml syringe appliance(s) 1 
86029998 Insulin biphasic lispro cartridge inj 
susp 50:50; 100 units/ml 3ml 
cartridge(s) 5 
98228997 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
93713997 Insulin 2 ml syringe appliance(s) 1 
98268998 INSULIN ZINC susp CRYSTALLINE 
HUMAN PYR - LONG ACTING inj 100 
units/ml 
86194998 Insulin isophane porcine vial inj susp 
100 units/ml 10ml vial(s) 1 
86188998 Biphasic isophane insulin product 
86306998 Biphasic isophane insulin product 
86286998 INSULIN BIPHASIC ISOPHANE 
HUMAN DISPOSABLE PEN inj susp 
50:50; 100 units/ml 
93713996 Insulin pre-set 1 ml syringe 
appliance(s) 1 
96055998 Insulin isophane porcine inj 100 
units/ml 10ml vial(s) 1 
99977992 Biphasic insulin product 
86028998 INSULIN BIPHASIC LISPRO 
CARTRIDGE inj susp 50:50; 100 
units/ml 
96065998 Human insulin 100u/mL inj cart 
86184998 Insulin soluble porcine cartridge inj 
soln 100 units/ml 3ml cartridge(s) 5 
96287992 ISOPHANE INSULIN 100iu/mL 10m 
95846992 ZINC BOVINE & PORCINE INSULIN 
SUSPENSION 
89684994 U100 insulin syringe 1ml 
84421998 INSULIN GLULISINE DISPOSABLE 
PEN inj soln 100 units/ml 
96054998 Insulin isophane human inj 100 
iu/ml 3ml cartridge(s) 5 
91767994 NovoPenfun 
90698998 Insulin zinc susp mixed bovine & 
porcine inj 100 units/ml 10ml vial(s) 
1 
86047998 Insulin human inhalation pwdr 1mg 
90 blisters 
98525990 INSULIN ZINC MIXED BOVINE VIAL 
inj susp 100 units/ml 
96060998 Insulin zinc susp mixed human pyr 
inj 100 units/ml 10ml vial(s) 1 
98228996 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
96285992 Protamine zinc insulin product 
95158992 NEUTRAL INSULIN 100iu/mL 10mL 
88851998 INSULIN SOLUBLE HUMAN CRB inj 
100 iu/ml 
91701998 INSULIN BIPHASIC ISOPHANE 
HUMAN CRB inj 25:75; 100 units/ml 
96046992 Biphasic isophane insulin product 
86245998 Insulin detemir disposable pen inj 
soln 100 units/ml 5 3ml disposable 
pen(s) 
86262998 Insulin biphasic aspart cartridge inj 
susp 30:70; 100 units/ml 3ml 
cartridge(s) 5 
92932998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 30:70; 100 units/ml 
93714997 Insulin disp 0.5ml syringe 
appliance(s) 1 
86312998 INSULIN SOLUBLE HUMAN VIAL inj 
soln 100 units/ml 
86190998 INSULIN ISOPHANE PORCINE 
CARTRIDGE inj susp 100 units/ml 
86173998 INSULIN SOLUBLE BOVINE VIAL inj 
soln 100 units/ml 
89082994 Novopen Juniorgreen 
96053998 Biphasic isophane insulin product 
90684996 Biphasic isophane insulin product 
88999998 INSULIN SOLUBLE PORCINE inj 100 
units/ml 
99533998 INSULIN BIPHASIC ISOPHANE 
PORCINE inj 50:50; 100 units/ml 
86187998 INSULIN BIPHASIC ISOPHANE 
PORCINE VIAL inj susp 30:70; 100 
units/ml 
86287998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 50:50; 
100 units/ml 
90686998 Insulin isophane human emp inj 100 
units/ml 3ml cartridge(s) 5 
86283998 Biphasic isophane insulin product 
95163992 ISOPHANE INSULIN 100iu/mL 10m 
90691998 Insulin soluble human pyr inj 100 
units/ml 3ml cartridge(s) 5 
88003998 Insulin soluble human crb inj 100 
iu/ml 3ml disposable pen(s) 5 
87416994 Humapen Ergoteal 
94436998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 50:50; 100 units/ml 
99360998 INSULIN ZINC MIXED BOVINE VIAL 
inj susp 100 units/ml 
91160998 Insulin zinc susp mixed porcine inj 
100 units/ml 10ml vial(s) 1 
98226998 INSULIN BIPHASIC ISOPHANE 
HUMAN EMP inj 30:70; 100 units/ml 
86319998 Insulin soluble human vial inj soln 
100 units/ml 1 10ml vial(s) 
90681997 Biphasic isophane insulin product 
83404998 INSULIN BIPHASIC LISPRO 
DISPOSABLE PEN inj susp 25:75; 
100 units/ml 
86078998 INSULIN BIPHASIC ISOPHANE 
HUMAN VIAL inj susp 30:70; 100 
units/ml 
86276998 Insulin isophane human vial inj susp 
100 units/ml 1 5ml vial(s) 
91275997 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 20:80; 100 units/ml 
89081994 Novopen Junioryellow 
96689992 Insulin zinc crystalline susp 100 i/u 
inj  0 
96062998 Insulin biphasic inj 100 units/ml 
10ml vial(s) 1 
97599992 ISOPHANE INSULIN 100iu/mL 10m 
86239998 INSULIN GLARGINE DISPOSABLE 
PEN inj soln 100 units/ml 
90683998 Biphasic isophane insulin product 
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99978992 Insulin isophane (purified) 100 i/u inj  
0 
90830994 Novopen 3classic 
98481998 INSULIN ISOPHANE HUMAN PYR inj 
100 iu/ml 
86280998 INSULIN BIPHASIC ISOPHANE 
HUMAN VIAL inj susp 25:75; 100 
units/ml 
97051998 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 40:60; 100 units/ml 
92376996 Biphasic isophane insulin product 
95164992 INSULIN/BOVINE INSULIN ZINC 
SUSPN/PURE 
96048998 INSULIN NEUTRAL HUMAN inj 100 
units/ml 
96064998 Insulin neutral bovine inj 100 
units/ml 10ml vial(s) 1 
93714998 Insulin 0.5 ml syringe appliance(s) 1 
91290997 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 50:50; 100 units/ml 
86238998 INSULIN GLARGINE CARTRIDGE inj 
soln 100 units/ml 
97525998 INSULIN SOLUBLE BOVINE inj 100 
units/ml 
84422998 INSULIN GLARGINE DISPOSABLE 
PEN inj soln 100 units/ml 
91641994 Humapen 
96548992 Biphasic isophane insulin product 
93139992 Insulin isophane 100 i/u  0 
91273997 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 50:50; 100 units/ml 
97052998 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 10:90; 100 units/ml 
96051998 Insulin protamine zinc bovine vial inj 
susp 100 units/ml 10ml vial(s) 1 
86178998.00 INSULIN ISOPHANE BOVINE VIAL inj 
susp 100 units/ml 
90687998 Insulin isophane human prb inj 100 
iu/ml 5ml vial(s) 1 
98048990 INSULIN ISOPHANE BOVINE inj 100 
units/ml 
87472998 INSULIN DETEMIR CARTRIDGE inj 
soln 100 units/ml 
86294998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 40:60; 
100 units/ml 
86309998 Biphasic isophane insulin product 
97052997 INSULIN BIPHASIC ISOPHANE 
HUMAN PRB inj 20:80; 100 units/ml 
86300998 INSULIN BIPHASIC ISOPHANE 
HUMAN VIAL inj susp 30:70; 100 
units/ml 
86263998 Insulin aspart disposable pen inj soln 
100 units/ml 5 3ml disposable 
pen(s) 
86279998 INSULIN BIPHASIC ISOPHANE 
HUMAN CARTRIDGE inj susp 25:75; 
100 units/ml 
91290998 INSULIN BIPHASIC ISOPHANE 
HUMAN PYR inj 50:50; 100 units/ml 
99557998 INSULIN SOLUBLE HUMAN PYR inj 
100 units/ml 
86236998 Insulin glulisine cartridge inj soln 
100 units/ml 5 3ml cartridge(s) 
86311998 Biphasic isophane insulin product 
86304998 Biphasic isophane insulin product 
87473998 Insulin detemir inj soln 100 iu/ml 
3ml disposable pen(s) 5 
86045998 INSULIN HUMAN inhalation pwdr 
1mg 
97834990.00 GLIPIZIDE tabs 5mg 
97026990 GLICLAZIDE tabs 80mg 
88449997 Glimepiride tabs 1mg 30 tablet(s) 
97146990.00 GLIPIZIDE tabs 5mg 
97537997 GLIBENCLAMIDE tabs 5mg 
93781990 GLICLAZIDE tabs 80mg 
93542990 GLIMEPIRIDE tabs 4mg 
93562990 GLIMEPIRIDE tabs 3mg 
95025990.00 GLICLAZIDE tabs 80mg 
97303998 GLICLAZIDE tabs 80mg 
96280998 GLIQUIDONE 
98643990 GLIBENCLAMIDE tabs 5mg 
91407998 GLICLAZIDE mr tab 30mg 
93372990 GLIMEPIRIDE tabs 2mg 
98418989 GLIBENCLAMIDE tabs 5mg 
95403990 TOLBUTAMIDE tabs 500mg 
99349990 TOLBUTAMIDE tabs 500mg 
83838998 GLIMEPIRIDE tabs 2mg 
99754998 ACETOHEXAMIDE 
98418990 GLIBENCLAMIDE tabs 2.5mg 
93373990 GLIMEPIRIDE tabs 1mg 
96427990 GLICLAZIDE tabs 80mg 
99582989 GLIBENCLAMIDE tabs 2.5mg 
93095990 GLIMEPIRIDE tabs 2mg 
83410998 GLICLAZIDE mr tab 30mg 
97590990 GLICLAZIDE tabs 80mg 
98664990 GLIBENCLAMIDE tabs 5mg 
88447997 GLIMEPIRIDE tabs 1mg 
97202990 GLIPIZIDE tabs 5mg 
88355998 Glimepiride tabs 4mg 30 tablet(s) 
93096990 GLIMEPIRIDE tabs 1mg 
83916998 GLICLAZIDE mr tab 30mg 
88528998 TROGLITAZONE 
97089998 TOLBUTAMIDE tabs 500mg 
99195998 TOLBUTAMIDE tabs 500mg 
83836998 GLIMEPIRIDE tabs 4mg 
95672992 TOLBUTAMIDE 
97057998 GLIBENCLAMIDE tabs 5mg 
97775989 CHLORPROPAMIDE tabs 250mg 
99582990 GLIBENCLAMIDE tabs 5mg 
96495990 GLICLAZIDE tabs 80mg 
95898990 GLICLAZIDE tabs 80mg 
93322990 GLIMEPIRIDE tabs 3mg 
97751990 GLIBENCLAMIDE tabs 2.5mg 
95255992 CHLORPROPAMIDE 
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96687998 CHLORPROPAMIDE tabs 250mg 
95288990 TOLBUTAMIDE tabs 500mg 
99246990 CHLORPROPAMIDE tabs 100mg 
96795990 GLIPIZIDE tabs 5mg 
96893990 GLIPIZIDE tabs 5mg 
93545990 GLIMEPIRIDE tabs 1mg 
96755997 Chlorpropamide tabs 250mg 28 
tablet(s) 
99764998 CHLORPROPAMIDE tabs 100mg 
97537998 GLIBENCLAMIDE tabs 2.5mg 
96615989 CHLORPROPAMIDE tabs 250mg 
97583997 GLIBENCLAMIDE tabs 5mg 
96559990 GLIBENCLAMIDE tabs 2.5mg 
86018998 GLICLAZIDE 
93323990 GLIMEPIRIDE tabs 2mg 
97097998 GLIBENCLAMIDE tabs 2.5mg 
88334998 GLIMEPIRIDE tabs 4mg 
96221990 GLIBENCLAMIDE tabs 2.5mg 
93371990 GLIMEPIRIDE tabs 3mg 
84783998 Tolbutamide oral liq 
93126990 GLIMEPIRIDE tabs 3mg 
93564990 GLIMEPIRIDE tabs 1mg 
97236992 GLIBENCLAMIDE 
99581989 GLIBENCLAMIDE tabs 5mg 
96282997.00 Glipizide tabs 5mg 60 tablet(s) 
88447996 GLIMEPIRIDE tabs 3mg 
99668997 GLIBENCLAMIDE tabs 5mg 
97097997 GLIBENCLAMIDE tabs 5mg 
96281998 GLIPIZIDE tabs 2.5mg 
83887998 Chlorpropamide oral liq 
97552990 GLIBENCLAMIDE tabs 2.5mg 
97166990 GLICLAZIDE tabs 80mg 
94333992 TOLBUTAMIDE I/V 
98643989 GLIBENCLAMIDE tabs 2.5mg 
99247990 CHLORPROPAMIDE tabs 100mg 
93119990 GLIMEPIRIDE tabs 3mg 
95446990 GLICLAZIDE tabs 80mg 
95601990 GLIBENCLAMIDE tabs 5mg 
98188989 CHLORPROPAMIDE tabs 250mg 
97133992 CHLORPROPAMIDE 
85003998 Gliclazide oral liq 
99246989 CHLORPROPAMIDE tabs 250mg 
93901990 GLICLAZIDE tabs 80mg 
93125990 GLIMEPIRIDE tabs 4mg 
88447998 GLIMEPIRIDE tabs 2mg 
97109998 Tolbutamide tabs 500mg 28 tablet(s) 
97889990 GLICLAZIDE tabs 80mg 
97938990 GLICLAZIDE tabs 80mg 
98188990 CHLORPROPAMIDE tabs 100mg 
96220990 GLIBENCLAMIDE tabs 5mg 
99348990 TOLBUTAMIDE tabs 500mg 
99668998 GLIBENCLAMIDE tabs 2.5mg 
97775990 CHLORPROPAMIDE tabs 100mg 
97538990 GLICLAZIDE tabs 80mg 
99764997 CHLORPROPAMIDE tabs 250mg 
93561990 GLIMEPIRIDE tabs 4mg 
93118990 GLIMEPIRIDE tabs 4mg 
93544990 GLIMEPIRIDE tabs 2mg 
93867990 TOLBUTAMIDE tabs 500mg 
93370990 GLIMEPIRIDE tabs 4mg 
93128990 GLIMEPIRIDE tabs 1mg 
99580990 GLIBENCLAMIDE tabs 5mg 
88449998 Glimepiride tabs 2mg 30 tablet(s) 
97717998 GLICLAZIDE tabs 80mg 
99247989 CHLORPROPAMIDE tabs 250mg 
97158990 GLIPIZIDE tabs 5mg 
99347990 TOLBUTAMIDE tabs 500mg 
93121990 GLIMEPIRIDE tabs 1mg 
97127998 Glibenclamide tabs 2.5mg 28 tablet 
blister pack 
96707990 GLICLAZIDE tabs 80mg 
95422990 TOLBUTAMIDE tabs 500mg 
96699990 GLIPIZIDE tabs 5mg 
97127997 Glibenclamide tabs 5mg 28 tablet 
blister pack 
97751989 GLIBENCLAMIDE tabs 5mg 
96615990 CHLORPROPAMIDE tabs 100mg 
85901998 GLIBENCLAMIDE 
97032990 GLICLAZIDE tabs 80mg 
83837998 GLIMEPIRIDE tabs 3mg 
93324990 GLIMEPIRIDE tabs 1mg 
93094990 GLIMEPIRIDE tabs 3mg 
99580989 GLIBENCLAMIDE tabs 2.5mg 
96282998 Glipizide tabs 2.5mg 28 tablet(s) 
99041990 TOLBUTAMIDE tabs 500mg 
99787998 GLIBENCLAMIDE tabs 5mg 
99230998 TOLBUTAMIDE tabs 500mg 
99588998 GLIBORNURIDE 
96283997 Gliclazide mr tab 30mg 112 tablet(s) 
91247998 GLICLAZIDE tabs 80mg 
98133990 GLICLAZIDE tabs 80mg 
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99419998 GLIPIZIDE tabs 5mg 
85265998 Glibenclamide oral liq 
84684998 Rosiglitazone + glimepiride (ipu) 
tabs 8mg + 4mg 
95149998 TOLAZAMIDE 
98053990 TOLBUTAMIDE tabs 500mg 
88135998 GLICLAZIDE tabs 80mg 
98548990 GLIBENCLAMIDE tabs 5mg 
97154990 GLICLAZIDE tabs 80mg 
99145998 GLIBENCLAMIDE tabs 2.5mg 
93127990 GLIMEPIRIDE tabs 2mg 
96755998 Chlorpropamide tabs 100mg 250 
tablet(s) 
84685998 Rosiglitazone + glimepiride (ipu) 
tabs 4mg + 4mg 
99591998 GLIPIZIDE tabs 5mg 
97552989 GLIBENCLAMIDE tabs 5mg 
95148998 TOLBUTAMIDE 
97057997 GLIBENCLAMIDE tabs 2.5mg 
99581990 GLIBENCLAMIDE tabs 2.5mg 
88449996 Glimepiride tabs 3mg 30 tablet(s) 
83949998 GLICLAZIDE mr tab 30mg 
96981998 ACETOHEXAMIDE 
92518997 GLIBENCLAMIDE tabs 5mg 
96283998 Gliclazide tabs 80mg 120 tablet(s) 
99589998 GLIQUIDONE 
98664989 GLIBENCLAMIDE tabs 2.5mg 
83839998 GLIMEPIRIDE tabs 1mg 
93120990 GLIMEPIRIDE tabs 2mg 
97583998 GLIBENCLAMIDE tabs 2.5mg 
95150998 TOLAZAMIDE 
93563990 GLIMEPIRIDE tabs 2mg 
95256992 CHLORPROPAMIDE 
94371992 TOLBUTAMIDE 
93093990 GLIMEPIRIDE tabs 4mg 
95674992 TOLBUTAMIDE 
92518998 GLIBENCLAMIDE tabs 2.5mg 
93543990 GLIMEPIRIDE tabs 3mg 
92831990 GLICLAZIDE mr tab 30mg 
96296990 METFORMIN tabs 500mg 
84009998 VILDAGLIPTIN + METFORMIN tabs 
50mg + 850mg 
85622998 PIOGLITAZONE + METFORMIN tabs 
15mg + 850mg 
99590998 METFORMIN tabs 500mg 
96270989 METFORMIN tabs 850mg 
94248990 METFORMIN tabs 500mg 
84011998 Vildagliptin + metformin tabs 50mg 
+ 850mg tablet(s) 60 
99514989 METFORMIN tabs 850mg 
99514990 METFORMIN tabs 500mg 
92983990 METFORMIN oral soln 500mg/5ml 
97087998 Metformin tabs 500mg 30 tablet(s) 
95600990 METFORMIN tabs 500mg 
99590997 METFORMIN tabs 850mg 
95272992 METFORMIN 
94246990 METFORMIN tabs 850mg 
87180998 ROSIGLITAZONE + METFORMIN tabs 
2mg + 1000mg 
96850990 METFORMIN tabs 500mg 
87773998 Rosiglitazone + metformin tabs 2mg 
+ 500mg 112 tablet(s) 
98494990 METFORMIN tabs 500mg 
91221997 METFORMIN tabs 850mg 
83733998 Metformin mr tab 750mg tablet(s) 
28 
98654989 METFORMIN tabs 500mg 
91221998 METFORMIN tabs 500mg 
99513989 METFORMIN tabs 850mg 
87054998 Metformin mr tab 500mg 56 
tablet(s) 
99149990 METFORMIN tabs 500mg 
96296989 METFORMIN tabs 850mg 
98125989 METFORMIN tabs 850mg 
84008998 VILDAGLIPTIN + METFORMIN tabs 
50mg + 1000mg 
94280992 PHENFORMIN HYDROCHLORIDE S/R 
87536998 Metformin oral susp 100mg/ml mls 
150 
97110990 METFORMIN tabs 500mg 
95381990 METFORMIN tabs 500mg 
87182998 Rosiglitazone + metformin tabs 2mg 
+ 1000mg 56 tablet(s) 
98493989 METFORMIN tabs 500mg 
85406998 Metformin (ipu) tabs 1000mg 
95239990 METFORMIN tabs 850mg 
99149989 METFORMIN tabs 850mg 
87053998 METFORMIN mr tab 500mg 
95228990 METFORMIN tabs 500mg 
97087997 Metformin tabs 850mg 28 tablet(s) 
94978990 METFORMIN oral susp 100mg/ml 
87772998 Metformin + rosiglitazone tabs 
500mg + 2mg 112 tablet(s) 
95880997 METFORMIN tabs 850mg 
93167990 METFORMIN oral soln 500mg/5ml 
87774998 Metformin + rosiglitazone tabs 
500mg + 1mg 112 tablet(s) 
94518990 METFORMIN tabs 850mg 
85673998 METFORMIN oral soln 500mg/5ml 
85554998 Metformin caps 
95298990 METFORMIN tabs 850mg 
87181998 Rosiglitazone + metformin tabs 4mg 
+ 1000mg 56 tablet(s) 
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83732998 METFORMIN mr tab 750mg 
95271992 Metformin hcl 850 mg tab  0 
85624998 Metformin + pioglitazone tabs 
850mg + 15mg 56 tablet(s) 
99513990 METFORMIN tabs 500mg 
94235992 Metformin hcl 500 mg tab  0 
85625998 Pioglitazone + metformin tabs 15mg 
+ 850mg tablet(s) 56 
83401998 Sitagliptin + metformin (ipu) tabs 
50mg + 1000mg 
85555998 Metformin oral liq 
83619998 METFORMIN mr tab 500mg 
87165998 Metformin + rosiglitazone tabs 
1000mg + 4mg 56 tablet(s) 
98654990 METFORMIN tabs 850mg 
95599990 METFORMIN tabs 850mg 
96270990 METFORMIN tabs 500mg 
87770998 ROSIGLITAZONE + METFORMIN tabs 
2mg + 500mg 
87166998 Metformin + rosiglitazone tabs 
1000mg + 2mg 56 tablet(s) 
95380990 METFORMIN tabs 850mg 
87775998 Rosiglitazone + metformin tabs 1mg 
+ 500mg 112 tablet(s) 
98125990 METFORMIN tabs 500mg 
95270992 METFORMIN 
89155998 METFORMIN tabs 500mg 
87882998 METFORMIN tabs 850mg 
95299990 METFORMIN tabs 500mg 
89155997 METFORMIN tabs 850mg 
95880998 METFORMIN tabs 500mg 
97110989 METFORMIN tabs 850mg 
87883998 METFORMIN tabs 500mg 
87771998 ROSIGLITAZONE + METFORMIN tabs 
1mg + 500mg 
94473990 METFORMIN tabs 850mg 
87179998 ROSIGLITAZONE + METFORMIN tabs 
4mg + 1000mg 
85674998 Metformin oral soln 500mg/5ml 150 
mls 
96850989 METFORMIN tabs 850mg 
94519990 METFORMIN tabs 500mg 
98493990 METFORMIN tabs 850mg 
94474990 METFORMIN tabs 500mg 
83402998 Sitagliptin + metformin (ipu) tabs 
50mg + 850mg 
84010998 Vildagliptin + metformin tabs 50mg 
+ 1000mg tablet(s) 60 
96110990 METFORMIN tabs 850mg 
96111990 METFORMIN tabs 500mg 
92238997 PIOGLITAZONE tabs 30mg 
88131997 NATEGLINIDE tabs 120mg 
84338998 VILDAGLIPTIN tabs 50mg 
88132996 Nateglinide tabs 180mg 84 tablet(s) 
90048996 ROSIGLITAZONE tabs 8mg 
88131996 NATEGLINIDE tabs 180mg 
89763996 Rosiglitazone tabs 8mg 28 tablet(s) 
84694998 EXENATIDE inj 5 micrograms 
84696998 Exenatide inj 10micrograms 1 pre-
filled pen 
84693998 EXENATIDE inj 10micrograms 
92237997 Pioglitazone tabs 30mg 28 tablet(s) 
92238998 PIOGLITAZONE tabs 15mg 
89763997 Rosiglitazone tabs 4mg 56 tablet(s) 
98915998 Acarbose tabs 50mg 90 tablet(s) 
92237998 Pioglitazone tabs 15mg 28 tablet(s) 
85267998 REPAGLINIDE tabs 1mg 
85266998 REPAGLINIDE tabs 2mg 
99587998 GLYMIDINE SODIUM 
88132997 Nateglinide tabs 120mg 84 tablet(s) 
88528996 TROGLITAZONE 
90048998 ROSIGLITAZONE tabs 2mg 
90048997 ROSIGLITAZONE tabs 4mg 
88131998 NATEGLINIDE tabs 60mg 
91924997 Repaglinide tabs 1mg 90 tablet(s) 
91924998 Repaglinide tabs 500 micrograms 90 
tablet(s) 
91923997 REPAGLINIDE tabs 1mg 
89763998 ROSIGLITAZONE 
97800994 Dextrostix 
87884998 PIOGLITAZONE tabs 45mg 
84697998 Exenatide inj 5 micrograms 1 pre-
filled pen 
91924996 Repaglinide tabs 2mg 90 tablet(s) 
88528997 TROGLITAZONE 
98475997 ACARBOSE tabs 100mg 
87885998 Pioglitazone tabs 45mg 28 tablet(s) 
84639998 SITAGLIPTIN tabs 100mg 
85268998 REPAGLINIDE tabs 500 micrograms 
88523996 TROGLITAZONE 
98475998 ACARBOSE tabs 50mg 
83830998 Pioglitazone oral liq 
95752990 DEXTROSE 
INTRAVENOUSHUDDERSFIELD R.I. 
91923998 REPAGLINIDE tabs 500 micrograms 
91559998 GLIBORNURIDE 
84341998 Vildagliptin tabs 50mg tablet(s) 56 
95149997 TOLAZAMIDE 
91923996 REPAGLINIDE tabs 2mg 
98333994 Clinitest 
88132998 Nateglinide tabs 60mg 84 tablet(s) 
98915997 Acarbose tabs 100mg 90 tablet(s) 
95130994 Glucotide 
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88523998 TROGLITAZONE 
96262989 GLUCOSE 
99261998 GLUCOSE 
94470992 GLYMIDINE 
84640998 Sitagliptin tabs 100mg 28 tablet(s) 
96406998 Diazoxide tabs 50mg 100 tablet(s) 
87537998 DIAZOXIDE 
85521998 Diazoxide oral liq 
85412998 DIAZOXIDE 
94581998 Glucagon inj 1mg 1mg vial + pre-
filled syringe 1 
96406997 Diazoxide inj 300mg/20ml 5 
ampoule(s) 
99670998 DIAZOXIDE tabs 50mg 
93176990 DIAZOXIDE oral susp 50mg/5ml 
96638992 DIAZOXIDE 
92061998 GLUCAGON inj 1mg 
98896998 GLUCAGON inj 1mg 
94582998 GLUCAGON inj 1mg 
99669998 DIAZOXIDE inj 300mg/20ml 
94581997 Glucagon inj 10mg 1 10mg vial + 
diluent 
87184998 DIAZOXIDE  BCM 
94582997 GLUCAGON inj 10mg 
85496994 U100 SINGLE USE INS SYR+12MM 
NDL30G 
95414992 PHENFORMIN HYDROCHLORIDE S/R 
86862994 Ascensia Autodisc 
90168994 U100single use 
89909994 Advantage II 
93078992 BLOOD GLUCOSE TEST STRIPS 
94064994 Cleanlet 25type A 
97723994 Monolet Extratype A 
90165994 U100single use 
87322994 mhi-500 
88310994 Glucoflex-R 
90411994 Vitrex Gentle 
90435994 U100single use 
98877992 LANCET 
98861992 INSULIN NEEDLES 
98329994 Ketur Test 
96262988 GLUCOSE 
87320994 mhi-500 
90147994 U100single use 
90271994 U100single use 
94192994 Unilet Superlitetype B 
88473994 U100single use 
89346998 GLUCOSE10% + KCL (HRI) 
97281992 DIAGNOSTIC SOLUTION-TABLETS 
OF COPPER 
90430994 U100single use 
96253998 GUAR GUM 
96253997 GUAR GUM 
91577994 Medi-Test Protein 2 
85888994 U100 SINGLE USE INS SYR+8MM 
NDLE30G 1ML 
90434994 U100single use 
97778994 Albym Test 
90282994 Labstix 
99648989 DEXTROSE 
95843990 GLUCOSE10% + KCL (HRI) 
97948996 GLUCOSE 
85557994 MHI-500 3 MONTH CONSUMABLE 
KIT SIZE 7 NOZZLE 
89897994 Unilet GPtype A 
88219994 Medisense Soft-Sense 
85560994 MHI-500 NEEDLE FREE STARTER KIT 
90412994 Vitrex Softtype A 
96686992 BLOOD GLUCOSE REAGENT STRIPS 
1-22MMOL/L 
93489994 Unilet Universal Comfortouchtype B 
86574994 U100single use 
87512994 Medisense Optium Plus 
90429994 U100single use 
94226994 Unilet Universal Comfortouchtype 
A&B 
88370994 Syringeord purp spec16[2A] 
98331994 Acetest 
89661994 MicroletType A ster sgle use 
96252998 GUAR GUM 
88371994 Syringeord purp spec16[2A] 
90148994 U100single use 
90274994 U100single use 
92813994 Ascensia Glucodisc 
90818994 BD Ultra Pen 
90169994 U100single use 
98332994 Clinistix 
97323994 Diabur Test 5000 
88523997 TROGLITAZONE 
93543992 LANCETS 
90109994 Glucotrendplus 
98219994 U100single use 
98227994 Micro-Fine 
90098994 Autopen 
89760994 U100single use 
85499994 Omnican 100 ins 
91179994 Pocket Scan 
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85546994 Medisense Optium Beta-Ketone test 
strips 
90232994 GlucoTip (Fine)type A 
88218994 One Touch Ultrasofttype A 
99336994 BM-Accutest 
87885994 U100single use 
98189994 Syringeord purp spec16[2A] 
99268994 BM-Test 1-44 
99733994 Syringeord purp spec16[2A] 
93067992 URINE GLUCOSE TEST STRIPS 
94201992 ZINC HUMAN INSULIN SUSPENSION 
98229994 Unilettype B 
94191994 Unilet G Superlitetype A 
85889994 U100 SINGLE USE INS SYR+8MM 
NDLE29G 1ML 
95084992 GUAR GUM 
98313994 GA 
87411994 mhi-5003 month 
90119994 GlucoMen Sensors 
97899998 GUAR GUM 
88474994 U100single use 
95693994 Supreme 
92949994 B-D U-100single use 
85558994 MHI-500 3 MONTH CONSUMABLE 
KIT SIZE 6 NOZZLE 
85497994 U100 SINGLE USE INS SYR+12MM 
NDL30G 
95186994 Medi-Test Glucose 
92925994 U100single use 
94225994 Unilet Universal Comfortouchtype A 
90163994 U100single use 
86020994 Softclix XLtype C 
87494994 GlucoMen (Fine)type A 
91326994 Fine Pointtype A 
90273994 U100single use 
89799994 Unilet General Purposetype A 
98334994 Albustix 
90444994 U100single use 
93836998 DEXTROSE 
87321994 mhi-500 
98993990 DEXTROSE 
91943994 U100single use 
90819994 Autopen 
90432994 U100single use 
90270994 U100single use 
95125994 Unilet G Superlitetype A 
90164994 U100single use 
98330994 Ketostix 
86086994 Ascensia Microfill 
93070992 BLOOD LANCETS 
85498994 Omnican 50 ins 
95377994 Monolettype A 
87909994 Unilet Comfortouchtype A&B 
87317994 Autopen 24 
94063994 Cleanlet 25 XLtype B 
90820994 Autopen 
97322994 Glucostix 
92627994 Glucotrend 
89842994 Prestige Smart System 
89800994 Unilet General Purposetype A 
89759994 U100single use 
95653992 REAGENT 
92924994 U100single use 
87412994 mhi-500needle free 
96251998 GUAR GUM 
90431994 U100single use 
90166994 U100single use 
92948994 B-D U-100single use 
94190994 Unilet G Superlitetype A 
98312994 ExacTech 
96920992 REAGENT STRIPS 
96051992 GUAR GUM 
88227994 Freestyletype A 
90272994 U100single use 
98237994 Hypoguard U100click/count 
96264998 GLYMIDINE SODIUM 
99391994 U100single use 
95305994 Diastix 
95413992 PHENFORMIN HYDROCHLORIDE 
85559994 MHI-500 
88278994 Compact Colorimetric 
90167994 U100single use 
90428994 U100single use 
87410994 mhi-5003 month 
85851994 TrueTrack Smart System biosensor 
strips 
95217994 Glucose VT 
90332994 Supreme Spectrum 
91778998 DEXTROSE 
INTRAVENOUSHUDDERSFIELD R.I. 
95124994 Unilet G Superlitetype A 
91942994 U100single use 
92950994 B-D U-100single use 
89801994 Unilet General PurposeSuperlite type 
A 
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90433994 U100single use 
99592994 One Touch 
90622994 Unilet GPtype A 
94193994 Unilet Superlitetype B 
98218994 U100single use 
90161994 Medisense Optium 
98803998 GUAR GUM 
93477994 Unilet Universal Comfortouchtype B 
96253996 GUAR GUM 
95185994 Medi-Test Glycaemie C 
90821994 Autopen 
89094994 Active 
90146994 U100single use 
95200994 Medisense G2 
95194994 Micro-Fine Plustype A 
87319994 Autopen 24 
 
10.8.3 AHD codes for Diabetes 
Mellitus 
Ahd code Description 
1009100000 Diabetes Annual Check 
 
10.8.4 Medical codes for 
Hypertension 
Medcode Description 
14A2.00 H/O: hypertension 
2126100 Hypertension resolved 
212K.00 Hypertension resolved 
246M.00 White coat hypertension 
6146200 Hypertension induced by oral 
contraceptive pill 
662..12 Hypertension monitoring 
6627 Good hypertension control 
6628 Poor hypertension control 
6629 Hypertension:follow-up default 
662b.00 Moderate hypertension control 
662c.00 Hypertension six month review 
662d.00 Hypertension annual review 
662F.00 Hypertension treatm. started 
662H.00 Hypertension treatm.stopped 
662O.00 On treatment for hypertension 
662P.00 Hypertension monitoring 
7Q01.00 High cost hypertension drugs 
7Q01000 Primary pulmonary hypertension 
drugs band 1 
7Q01100 Primary pulmonary hypertension 
drugs band 2 
7Q01200 Primary pulmonary hypertension 
drugs band 3 
7Q01300 Primary pulmonary hypertension 
drugs band 4 
7Q01y00 Other specified high cost 
hypertension drugs 
7Q01z00 High cost hypertension drugs NOS 
8CR4.00 Hypertension clinical management 
plan 
8HT5.00 Referral to hypertension clinic 
8I3N.00 Hypertension treatment refused 
9h3..00 Exception reporting: hypertension 
quality indicators 
9h31.00 Excepted from hypertension qual 
indicators: Patient unsuit 
9h32.00 Excepted from hypertension qual 
indicators: Informed dissent 
9N03.00 Seen in hypertension clinic 
9N1y200 Seen in hypertension clinic 
9N4L.00 DNA - Did not attend hypertension 
clinic 
9OD..00 Hypertension screen admin. 
9ODZ.00 Hypertension screen admin. NOS 
9OI..00 Hypertension monitoring admin. 
9OI..11 Hypertension clinic admin. 
9OI1.00 Attends hypertension monitor. 
9OI2.00 Refuses hypertension monitor. 
9OIA.00 Hypertension monitor.chck done 
9OIA.11 Hypertension monitored 
F450400 Ocular hypertension 
G20..00 Essential hypertension 
G200.00 Malignant essential hypertension 
G201.00 Benign essential hypertension 
G202.00 Systolic hypertension 
G203.00 Diastolic hypertension 
G20z.00 Essential hypertension NOS 
G20z.11 Hypertension NOS 
G22z.11 Renal hypertension 
G24..00 Secondary hypertension 
G240.00 Secondary malignant hypertension 
G240000 Secondary malignant renovascular 
hypertension 
G240z00 Secondary malignant hypertension 
NOS 
G241.00 Secondary benign hypertension 
G241000 Secondary benign renovascular 
hypertension 
G241z00 Secondary benign hypertension NOS 
G244.00 Hypertension secondary to endocrine 
disorders 
G24z.00 Secondary hypertension NOS 
G24z000 Secondary renovascular 
hypertension NOS 
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G24z100 Hypertension secondary to drug 
G24zz00 Secondary hypertension NOS 
G410.00 Primary pulmonary hypertension 
G41y000 Secondary pulmonary hypertension 
G8y3.00 Chronic peripheral venous 
hypertension 
Gyu2000 [X]Other secondary hypertension 
Gyu2100 [X]Hypertension secondary to other 
renal disorders 
J623.00 Portal hypertension 
L12..00 Hypertension complicating 
pregnancy/childbirth/puerperium 
L120.00 Benign essential hypertension in 
pregnancy/childbirth/puerp 
L120000 Benign essential hypertension in 
preg/childb/puerp unspec 
L120100 Benign essential hypertension in 
preg/childb/puerp - deliv 
L120300 Benign essential hypertension in 
preg/childb/puerp-not deliv 
L120400 Benign essential hypertension in 
preg/childb/puerp +p/n comp 
L120z00 Benign essential hypertension in 
preg/childb/puerp NOS 
L121.00 Renal hypertension in 
pregnancy/childbirth/puerperium 
L121000 Renal hypertension in 
pregnancy/childbirth/puerp 
unspecified 
L121100 Renal hypertension in 
pregnancy/childbirth/puerp - 
delivered 
L121200 Renal hypertension in 
preg/childb/puerp -deliv with p/n 
comp 
L121300 Renal hypertension in 
preg/childbirth/puerp - not delivered 
L121400 Renal hypertension in 
preg/childb/puerp + p/n 
complication 
L121z00 Renal hypertension in 
pregnancy/childbirth/puerperium 
NOS 
L122.00 Other pre-existing hypertension in 
preg/childbirth/puerp 
L122000 Other pre-existing hypertension in 
preg/childb/puerp unspec 
L122100 Other pre-existing hypertension in 
preg/childb/puerp - deliv 
L122300 Other pre-exist hypertension in 
preg/childb/puerp-not deliv 
L122400 Other pre-exist hypertension in 
preg/childb/puerp + p/n comp 
L122z00 Other pre-existing hypertension in 
preg/childb/puerp NOS 
L123.00 Transient hypertension of pregnancy 
L123000 Transient hypertension of pregnancy 
unspecified 
L123100 Transient hypertension of pregnancy 
- delivered 
L123200 Transient hypertension of pregnancy 
- deliv with p/n comp 
L123300 Transient hypertension of pregnancy 
- not delivered 
L123400 Transient hypertension of pregnancy 
+ postnatal complication 
L123500 Gestational hypertension 
L123600 Transient hypertension of pregnancy 
L123z00 Transient hypertension of pregnancy 
NOS 
L127.00 Pre-eclampsia or eclampsia with pre-
existing hypertension 
L127000 Pre-eclampsia or eclampsia with 
hypertension unspecified 
L127100 Pre-eclampsia or eclampsia with 
hypertension - delivered 
L127200 Pre-eclampsia or eclampsia with 
hypertension - del+p/n comp 
L127300 Pre-eclampsia or eclampsia with 
hypertension - not delivered 
L127400 Pre-eclampsia or eclampsia with 
hypertension + p/n comp 
L127z00 Pre-eclampsia or eclampsia + pre-
existing hypertension NOS 
L128.00 Pre-exist hypertension compl preg 
childbirth and puerperium 
L12B.00 Proteinuric hypertension of 
pregnancy 
L12z.00 Unspecified hypertension in 
pregnancy/childbirth/puerperium 
L12z000 Unspecified hypertension in 
preg/childb/puerp unspecified 
L12z100 Unspecified hypertension in 
preg/childb/puerp - delivered 
L12z200 Unspecified hypertension in 
preg/childb/puerp -del +p/n comp 
L12z300 Unspecified hypertension in 
preg/childb/puerp - not deliv 
L12z400 Unspecified hypertension in 
preg/childb/puerp with p/n comp 
L12zz00 Unspecified hypertension in 
preg/childb/puerp NOS 
 
10.8.5 AHD codes for hypertension 
Ahdcode Description 
1005010500 Blood Pressure 
1009315000 Target Blood pressure 
 
10.8.6 Medical Codes for BMI 
Medcode Description 
22K1.00 Body Mass Index normal K/M2 
22K2.00 Body Mass Index high K/M2 
22K3.00 Body Mass Index low K/M2 
22K4.00 Body mass index index 25-29 - overweight 
22K5.00 Body mass index 30+ - obesity 
22K6.00 Body mass index less than 20 
22K7.00 Body mass index 40+ - severely obese 
22K8.00 Body mass index 20-24 ± normal 
 
 
10.8.7 AHD codes for BMI 
1005010200 Weight 
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10.8.8 Medical codes for asthma 
Medcode Description 
14B4.00 H/O: asthma 
173A.00 Exercise induced asthma 
1780.00 Aspirin induced asthma 
1O2..00 Asthma confirmed 
2126200 Asthma resolved 
663..11 Asthma monitoring 
663N.00 Asthma disturbing sleep 
663N000 Asthma causing night waking 
663N100 Asthma disturbs sleep weekly 
663N200 Asthma disturbs sleep frequently 
663O.00 Asthma not disturbing sleep 
663O000 Asthma never disturbs sleep 
663P.00 Asthma limiting activities 
663Q.00 Asthma not limiting activities 
663U.00 Asthma management plan given 
663V.00 Asthma severity 
663V000 Occasional asthma 
663V100 Mild asthma 
663V200 Moderate asthma 
663V300 Severe asthma 
663W.00 Asthma prophylactic medication used 
663d.00 Emergency asthma admission since 
last appointment 
663e.00 Asthma restricts exercise 
663e000 Asthma sometimes restricts exercise 
663e100 Asthma severely restricts exercise 
663f.00 Asthma never restricts exercise 
663h.00 Asthma - currently dormant 
663j.00 Asthma - currently active 
663m.00 Asthma accident and emergency 
attendance since last visit 
663n.00 Asthma treatment compliance 
satisfactory 
663p.00 Asthma treatment compliance 
unsatisfactory 
663q.00 Asthma daytime symptoms 
663r.00 Asthma causes night symptoms 1 to 2 
times per month 
663s.00 Asthma never causes daytime 
symptoms 
663t.00 Asthma causes daytime symptoms 1 to 
2 times per month 
663u.00 Asthma causes daytime symptoms 1 to 
2 times per week 
663v.00 Asthma causes daytime symptoms 
most days 
663w.00 Asthma limits walking up hills or stairs 
663x.00 Asthma limits walking on the flat 
663y.00 Number of asthma exacerbations in 
past year 
66Y5.00 Change in asthma management plan 
66Y9.00 Step up change in asthma 
management plan 
66YA.00 Step down change in asthma 
management plan 
66YC.00 Absent from work or school due to 
asthma 
66YE.00 Asthma monitoring due 
66YJ.00 Asthma annual review 
66YK.00 Asthma follow-up 
66YP.00 Asthma night-time symptoms 
66YQ.00 Asthma monitoring by nurse 
66YR.00 Asthma monitoring by doctor 
8791.00 Further asthma - drug prevent. 
8793.00 Asthma control step 0 
8794.00 Asthma control step 1 
8795.00 Asthma control step 2 
8796.00 Asthma control step 3 
8797.00 Asthma control step 4 
8798.00 Asthma control step 5 
8B3j.00 Asthma medication review 
8H2P.00 Emergency admission, asthma 
9OJA.11 Asthma monitored 
H312000 Chronic asthmatic bronchitis 
H33..00 Asthma 
H33..11 Bronchial asthma 
H330.00 Extrinsic (atopic) asthma 
H330.11 Allergic asthma 
H330.12 Childhood asthma 
H330.13 Hay fever with asthma 
H330.14 Pollen asthma 
H330000 Extrinsic asthma without status 
asthmaticus 
H330011 Hay fever with asthma 
H330100 Extrinsic asthma with status 
asthmaticus 
H330111 Extrinsic asthma with asthma attack 
H330z00 Extrinsic asthma NOS 
H331.00 Intrinsic asthma 
H331.11 Late onset asthma 
H331000 Intrinsic asthma without status 
asthmaticus 
H331100 Intrinsic asthma with status 
asthmaticus 
H331111 Intrinsic asthma with asthma attack 
H331z00 Intrinsic asthma NOS 
H332.00 Mixed asthma 
H333.00 Acute exacerbation of asthma 
H33z.00 Asthma unspecified 
H33z000 Status asthmaticus NOS 
H33z011 Severe asthma attack 
H33z100 Asthma attack 
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H33z111 Asthma attack NOS 
H33z200 Late-onset asthma 
H33zz00 Asthma NOS 
H33zz11 Exercise induced asthma 
H33zz12 Allergic asthma NEC 
H35y600 Sequoiosis (red-cedar asthma) 
H35y700 Wood asthma 
H47y000 Detergent asthma 
 
10.8.9 Multilex drug codes for 
Asthma 
MULTILEX
EID 
GENERIC NAME 
87105998 IPRATROPIUM BROMIDE 
87107998 IPRATROPIUM BROMIDE 
87108998 IPRATROPIUM BROMIDE 
87109998 IPRATROPIUM BROMIDE 
87125998 IPRATROPIUM BROMIDE 
87126998 IPRATROPIUM BROMIDE 
87127998 IPRATROPIUM BROMIDE 
87128998 IPRATROPIUM BROMIDE 
87173998 BECLOMETASONE 
87174998 BECLOMETASONE 
87275998 SALBUTAMOL 
87276998 SALBUTAMOL 
87277998 SALBUTAMOL 
87438998 BUDESONIDE 
87439998 BUDESONIDE REFILLABLE 
87513998 IPRATROPIUM BROMIDE 
87514998 IPRATROPIUM BROMIDE 
87597998 MONTELUKAST(AS SODIUM SALT) 
87601998 MONTELUKAST(AS SODIUM SALT) 
87704998 CORTISONE ACETATE 
87878998 TERBUTALINE 
87928998 THEOPHYLLINE 
87929998 THEOPHYLLINE 
87930998 THEOPHYLLINE 
87950998 HYDROCORTISONE 
87979998 SALMETEROL+ FLUTICASONE 
87980996 SALMETEROL+ FLUTICASONE 
87980997 SALMETEROL+ FLUTICASONE 
87980998 SALMETEROL+ FLUTICASONE 
87986997 BECLOMETASONEEXTRAFINE PARTICLE 
87986998 BECLOMETASONEEXTRAFINE PARTICLE 
87988997 BECLOMETASONEEXTRAFINE PARTICLE 
87988998 BECLOMETASONEEXTRAFINE PARTICLE 
87990997 BECLOMETASONEEXTRAFINE PARTICLE 
87990998 BECLOMETASONEEXTRAFINE PARTICLE 
87991997 BECLOMETASONEEXTRAFINE PARTICLE 
87991998 BECLOMETASONEEXTRAFINE PARTICLE 
88004998 SALBUTAMOL 
88095998 ZAFIRLUKAST 
88102998 ZAFIRLUKAST 
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88156998 BUDESONIDE 
88262998 SALBUTAMOL 
88273998 IPRATROPIUM BROMIDE 
88299998 IPRATROPIUM BROMIDE 
88305997 BUDESONIDEWITH FORMOTEROL 
88305998 BUDESONIDEWITH FORMOTEROL 
88342998 MONTELUKAST(AS SODIUM SALT) 
88351996 MONTELUKAST(AS SODIUM SALT) 
88351997 MONTELUKAST(AS SODIUM SALT) 
88351998 MONTELUKAST(AS SODIUM SALT) 
88352997 MONTELUKAST(AS SODIUM SALT) 
88352998 MONTELUKAST(AS SODIUM SALT) 
88357998 SALBUTAMOL 
88434996 BECLOMETASONE 
88434997 BECLOMETASONE 
88434998 BECLOMETASONE 
88469996 BECLOMETASONE 
88469997 BECLOMETASONE 
88469998 BECLOMETASONE 
88470998 SALBUTAMOL 
88480997 SALBUTAMOL 
88480998 SALBUTAMOL 
88487998 FORMOTEROL FUMARATE 
88488998 FORMOTEROL FUMARATE 
88490997 FORMOTEROL FUMARATE 
88490998 FORMOTEROL FUMARATE 
88522998 SALMETEROL+ FLUTICASONE 
88524996 FLUTICASONE+ SALMETEROL 
88524997 FLUTICASONE+ SALMETEROL 
88524998 FLUTICASONE+ SALMETEROL 
88525996 SALMETEROL+ FLUTICASONE 
88525997 SALMETEROL+ FLUTICASONE 
88525998 SALMETEROL+ FLUTICASONE 
88706997 EPHEDRINE 
88706998 EPHEDRINE 
88727998 MOMETASONE FUROATE 
88832998 BECLOMETASONE 
88833997 BECLOMETASONE 
88833998 BECLOMETASONE 
88834998 SALBUTAMOL 
89060998 SALBUTAMOL 
89121998 BUDESONIDE 
89178998 SALBUTAMOL 
89229998 MOMETASONE FUROATE 
89235998 TIOTROPIUM 
89275998 SALBUTAMOL 
89276996 BECLOMETASONE 
89276997 BECLOMETASONE 
89276998 BECLOMETASONE 
89286998 SODIUM CROMOGLICATE 
89347998 SALBUTAMOL 
89443996 DEFLAZACORT 
89443997 DEFLAZACORT 
89443998 DEFLAZACORT 
89446996 DEFLAZACORT 
89446997 DEFLAZACORT 
89446998 DEFLAZACORT 
89862996 BECLOMETASONE 
89862997 BECLOMETASONE 
89862998 BECLOMETASONE 
90394997 BUDESONIDEWITH FORMOTEROL 
90394998 BUDESONIDEWITH FORMOTEROL 
90416996 BECLOMETASONE 
90416997 BECLOMETASONE 
90416998 BECLOMETASONE 
90417996 BECLOMETASONE 
90417997 BECLOMETASONE 
90417998 BECLOMETASONE 
90418998 SALBUTAMOL 
90419998 SALBUTAMOL 
90587998 SALBUTAMOL 
90588998 BECLOMETASONE 
90680998 SALBUTAMOL+ IPRATROPIUM BR 
90758998 MOMETASONE FUROATE 
90927998 THEOPHYLLINE+GUAIFEN &EPHEDRINE 
90929998 THEOPHYLLINE+GUAIFEN &EPHEDRINE 
90942998 FORMOTEROL FUMARATE 
90943998 FORMOTEROL FUMARATE 
90968998 MOMETASONE FUROATE 
91078998 FENOTEROL+ IPRATROPIUM BR 
91088996 BECLOMETASONE 
91088997 BECLOMETASONE 
91088998 BECLOMETASONE 
91107998 SALBUTAMOL+ IPRATROPIUM BR 
91272998 SALBUTAMOL 
91284997 SALBUTAMOL 
91284998 SALBUTAMOL 
91285998 AMINOPHYLLINE 
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91310998 IPRATROPIUM BROMIDE+ SALBUTAMOL 
91311998 IPRATROPIUM BROMIDE+ SALBUTAMOL 
91320998 SALBUTAMOL 
91322997 FLUTICASONE 
91322998 FLUTICASONE 
91334997 FLUTICASONE 
91334998 FLUTICASONE 
91335998 SALBUTAMOL 
91345998 SALBUTAMOL 
91348998 SALMETEROL+ FLUTICASONE 
91363996 BECLOMETASONE 
91363997 BECLOMETASONE 
91363998 BECLOMETASONE 
91387998 BECLOMETASONE 
91390997 AMINOPHYLLINE 
91390998 AMINOPHYLLINE 
91397998 SALBUTAMOL 
91403996 BECLOMETASONE 
91403997 BECLOMETASONE 
91403998 BECLOMETASONE 
91417998 SALBUTAMOL 
91493998 BUDESONIDEWITH FORMOTEROL 
91547998 SALMETEROL+ FLUTICASONE 
91570997 SALBUTAMOL 
91570998 SALBUTAMOL 
91619996 FLUTICASONE 
91619997 FLUTICASONE 
91619998 FLUTICASONE 
91646998 DEXAMETHASONE 
92199998 SALMETEROL+ FLUTICASONE 
92285996 BECLOMETASONE 
92285997 BECLOMETASONE 
92285998 BECLOMETASONE 
92411998 BUDESONIDEWITH FORMOTEROL 
92412998 HYDROCORTISONE 
92473996 FLUTICASONE 
92473997 FLUTICASONE 
92473998 FLUTICASONE 
92665998 IPRATROPIUM BROMIDE 
92755998 IPRATROPIUM BROMIDE+ SALBUTAMOL 
92756998 IPRATROPIUM BROMIDE+ SALBUTAMOL 
92810997 DEXAMETHASONE 
92810998 DEXAMETHASONE 
92842996 FLUTICASONE 
92842997 FLUTICASONE 
92842998 FLUTICASONE 
92843998 FLUTICASONE 
92844998 FLUTICASONE 
92845996 FLUTICASONE 
92845997 FLUTICASONE 
92845998 FLUTICASONE 
92861998 BETAMETHASONE SODIUM PHOSPHATE 
92894998 FENOTEROL+ IPRATROPIUM BR 
92895998 IPRATROPIUM BROMIDE 
92899996 FLUTICASONE 
92899997 FLUTICASONE 
92899998 FLUTICASONE 
92900996 FLUTICASONE 
92900997 FLUTICASONE 
92900998 FLUTICASONE 
93017992 SODIUM CROMOGLYCATE 
93035992 SODIUM CROMOGLYCATE NEBULISER 
SOLUTION 
93056996 FLUTICASONE 
93056997 FLUTICASONE 
93056998 FLUTICASONE 
93057996 FLUTICASONE 
93057997 FLUTICASONE 
93057998 FLUTICASONE 
93065998 SODIUM CROMOGLICATE 
93066996 BECLOMETASONE 
93066997 BECLOMETASONE 
93066998 BECLOMETASONE 
93075998 PREDNISOLONE SODIUM PHOSPHATE 
93083997 BAMBUTEROL 
93083998 BAMBUTEROL 
93084997 BAMBUTEROL 
93084998 BAMBUTEROL 
93086992 SALBUTAMOL (ALBUTEROL) 
93123992 SALBUTAMOL (ALBUTEROL) SULPHATE 
93154998 TERBUTALINE 
93181996 SALMETEROL 
93181997 SALMETEROL 
93181998 SALMETEROL 
93182996 SALMETEROL 
93182997 SALMETEROL 
93182998 SALMETEROL 
93264998 THEOPHYLLINE+ EPHEDRINE 
93302996 BUDESONIDE 
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93302997 BUDESONIDE 
93302998 BUDESONIDE 
93303996 BUDESONIDE 
93303997 BUDESONIDE 
93303998 BUDESONIDE 
93326992 BECLOMETHASONE/SALBUTAMOL(ALBU
T)100/400 
93350998 THEOPHYLLINE+ EPHEDRINE 
93411992 AMINOPHYLLINE 
93439998 TERBUTALINE 
93440998 TERBUTALINE 
93457998 TIOTROPIUM 
93584998 THEOPHYLLINE 
93588998 HYDROCORTISONE NA SUCCINATE 
93620992 BECLOMETHASONE DIPROPRIONATE 
CARTRIDGE 
93621992 BECLOMETHASONE DIPROPRIONATE 
CARTRIDGE 
93643992 BETAMETHASONE VALERATE 
93645992 BETAMETHASONE 
93646992 BETAMETHASONE 
93647992 BETAMETHASONE 
93650992 BETAMETHASONE VALERATE 
93684997 IPRATROPIUM BROMIDE 
93684998 IPRATROPIUM BROMIDE 
93685997 IPRATROPIUM BROMIDE 
93685998 IPRATROPIUM BROMIDE 
93697997 ORCIPRENALINE 
93697998 ORCIPRENALINE 
93731997 SODIUM CROMOGLICATE+ 
SALBUTAMOL 
93731998 SODIUM CROMOGLICATE+ 
SALBUTAMOL 
93732997 SODIUM CROMOGLICATE+ 
SALBUTAMOL 
93732998 SODIUM CROMOGLICATE+ 
SALBUTAMOL 
93754992 AMINOPHYLLINE 
93783998 EPHEDRINE 
93912996 PREDNISOLONE 
93912997 PREDNISOLONE 
93912998 PREDNISOLONE 
93941996 TERBUTALINE 
93941997 TERBUTALINE 
93941998 TERBUTALINE 
93983996 FLUTICASONE+ SALMETEROL 
93983997 FLUTICASONE+ SALMETEROL 
93983998 FLUTICASONE+ SALMETEROL 
94002992 TERBUTALINE SULPHATE NEBULE 
94023998 EPHEDRINE HYDROCHLORIDE 
94024996 EPHEDRINE HYDROCHLORIDE 
94024997 EPHEDRINE HYDROCHLORIDE 
94024998 EPHEDRINE HYDROCHLORIDE 
94027992 EPHEDRINE HCL/THEOPHYLLINE 
94041997 AMINOPHYLLINE 
94041998 AMINOPHYLLINE 
94063992 AMINOPHYLLINE 
94066992 AMINOPHYLLINE 
94134992 DEXAMETHASONE 
94199998 SALBUTAMOL 
94251994 Salbutamol Cyclohalertype 5 
94259998 SALBUTAMOL 
94260996 SALBUTAMOL 
94260997 SALBUTAMOL 
94260998 SALBUTAMOL 
94324992 BUDESONIDE REFILL 
94334992 CHOLINE THEOPHYLLINATE 
94343992 SODIUM CROMOGLYCATE 
94373992 TRIAMCINOLONE 
94383996 SALBUTAMOL 
94383997 SALBUTAMOL 
94383998 SALBUTAMOL 
94405992 AMINOPHYLLINE 
94406992 AMINOPHYLLINE 
94407997 SALBUTAMOL 
94407998 SALBUTAMOL 
94435998 AMINOPHYLLINE 
94442992 CORTISONE ACETATE 
94442996 SALBUTAMOL 
94442997 SALBUTAMOL 
94442998 SALBUTAMOL 
94455997 SALBUTAMOL 
94455998 SALBUTAMOL 
94456996 BECLOMETASONE 
94456997 BECLOMETASONE 
94456998 BECLOMETASONE 
94491997 IPRATROPIUM BROMIDE 
94491998 IPRATROPIUM BROMIDE 
94492997 IPRATROPIUM BROMIDE 
94492998 IPRATROPIUM BROMIDE 
94529998 SALBUTAMOL 
94532996 SALBUTAMOL 
94532997 SALBUTAMOL 
94532998 SALBUTAMOL 
94533996 SALBUTAMOL 
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94533997 SALBUTAMOL 
94533998 SALBUTAMOL 
94534998 SALBUTAMOLRONDO 
94544992 SALBUTAMOL (ALBUTEROL) INHALER 
94557996 BECLOMETASONE 
94557997 BECLOMETASONE 
94557998 BECLOMETASONE 
94558996 BECLOMETASONE 
94558997 BECLOMETASONE 
94558998 BECLOMETASONE 
94559996 BECLOMETASONE 
94559997 BECLOMETASONE 
94559998 BECLOMETASONE 
94585990 IPRATROPIUM BROMIDE 
94586990 IPRATROPIUM BROMIDE 
94587990 IPRATROPIUM BROMIDE 
94587992 SALBUTAMOL (ALBUTEROL) REFILL 
94588990 IPRATROPIUM BROMIDE 
94597992 SALBUTAMOL (ALBUTEROL) 
94624992 ORCIPRENALINE SULPHATE 
94624998 THEOPHYLLINE+ LYSINE 
94625998 SALMETEROL+ FLUTICASONE 
94627997 THEOPHYLLINE+ EPHEDRINE HCL 
94627998 THEOPHYLLINE+ EPHEDRINE HCL 
94628992 AMINOPHYLLINE/EPHEDRINE/AMYLOBA
RBITONE 
94628998 THEOPHYLLINE+ LYSINE 
94630992 AMINOPHYLLINE 
94632992 AMINOPHYLLINE 
94633992 AMINOPHYLLINE 
94634992 AMINOPHYLLINE 
94635992 AMINOPHYLLINE 
94658992 EPHEDRINE RESINATE/THEOPHYLLINE 
94736992 TERBUTALINE SULPHATE/GUAPHENESIN 
94833998 SALBUTAMOL 
94840997 SALBUTAMOL 
94840998 SALBUTAMOL 
94846997 SALBUTAMOL 
94846998 SALBUTAMOL 
94847996 BECLOMETASONE 
94847997 BECLOMETASONE 
94847998 BECLOMETASONE 
94849997 SALBUTAMOL+BECLOMETASONE 
94849998 SALBUTAMOL+BECLOMETASONE 
94853992 SALBUTAMOL (ALBUTEROL) 
94861997 SALBUTAMOL 
94861998 SALBUTAMOL 
94862998 SALBUTAMOL 
94870992 CORTISONE ACETATE 
94908992 DEXAMETHASONE 
94909992 DEXAMETHASONE 
94941996 SALBUTAMOL+BECLOMETASONE 
94941997 SALBUTAMOL+BECLOMETASONE 
94941998 SALBUTAMOL+BECLOMETASONE 
94943996 SALBUTAMOL 
94943997 SALBUTAMOL 
94943998 SALBUTAMOL 
94944997 SALBUTAMOL 
94944998 SALBUTAMOL 
94963992 EPHEDRINE HCL 24MG/THEOPHYLLINE 
120MG 
94969992 EPHEDRINE HCL/THEOPHYLLINE 
48/180MG S/R 
95036992 EPHEDRINE/THEOPHYLLINE 
95062998 AMINOPHYLLINE+DRIED AL HYDROX 
GEL 
95063997 AMINOPHYLLINE 
95063998 AMINOPHYLLINE 
95111998 BECLOMETASONE 
95124992 HYDROCORTISONE 
95139997 TRIAMCINOLONE 
95139998 TRIAMCINOLONE 
95140990 CORTISONE ACETATE 
95162990 BECLOMETASONE 
95163990 BECLOMETASONE 
95164990 BECLOMETASONE 
95179998 THEOPHYLLINE 
95180998 THEOPHYLLINE+PHENOBARB &GUAIFEN 
95181998 THEOPHYLLINE+ EPHEDRINE SULPHATE 
95182998 THEOPHYLLINE+ EPHEDRINE HCL 
95183998 THEOPHYLLINE 
95184996 THEOPHYLLINE 
95184997 THEOPHYLLINE 
95184998 THEOPHYLLINE 
95185996 THEOPHYLLINE 
95185997 THEOPHYLLINE 
95185998 THEOPHYLLINE 
95186996 THEOPHYLLINE 
95186997 THEOPHYLLINE 
95186998 THEOPHYLLINE 
95187996 THEOPHYLLINE 
95187997 THEOPHYLLINE 
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95187998 THEOPHYLLINE 
95188998 THEOPHYLLINE 
95195992 THEOPHYLLINE/ LYSINE 
95210998 TERBUTALINE 
95211997 TERBUTALINE+ GUAIFENESIN 
95211998 TERBUTALINE+ GUAIFENESIN 
95212997 TERBUTALINE 
95212998 TERBUTALINE 
95213997 TERBUTALINE 
95213998 TERBUTALINE 
95214996 TERBUTALINE 
95214997 TERBUTALINE 
95214998 TERBUTALINE 
95243990 SALBUTAMOL 
95306998 SALBUTAMOL 
95357992 DEXAMETHASONE 
95416998 PREDNISOLONESTEAGLATE 
95417996 PREDNISOLONE 
95417997 PREDNISOLONE 
95417998 PREDNISOLONE 
95441992 AMINOPHYLLINE 
95484992 PREDNISOLONE E/C 
95487992 PREDNISOLONE 
95492992 PREDNISOLONE 
95492997 BUDESONIDE 
95492998 BUDESONIDE 
95493992 PREDNISOLONE 
95493997 BUDESONIDE 
95493998 BUDESONIDE 
95526992 BUDESONIDE 
95527992 BUDESONIDE REFILL 
95528992 BUDESONIDE 
95536990 BECLOMETASONE 
95571990 IPRATROPIUM BROMIDE 
95593990 PREDNISOLONE 
95594990 PREDNISOLONE 
95651992 EPHEDRINE 
HC/THEOPHYLLINE/PHENOBARBITONE 
95652992 EPHEDRINE 
HYDROCHLORIDE/THEOPHYLLINE 
95658992 TERBUTALINE 
SULPHATE/GUAIPHENESIN 
95676998 ORCIPRENALINE 
95677997 ORCIPRENALINE 
95677998 ORCIPRENALINE 
95722992 SALBUTAMOL (ALBUTEROL) S/R 
95750998 NEDOCROMIL SODIUM 
95812992 SODIUM CROMOGLYCATE 
95847996 METHYLPREDNISOLONE 
95847997 METHYLPREDNISOLONE 
95847998 METHYLPREDNISOLONE 
95851996 METHYLPREDNISOLONE 
95851997 METHYLPREDNISOLONE 
95851998 METHYLPREDNISOLONE 
95912990 PREDNISOLONE 
95913990 CORTISONE ACETATE 
95938996 BUDESONIDE 
95938997 BUDESONIDE 
95938998 BUDESONIDE 
95967998 BETAMETHASONE 
95982990 BUDESONIDE 
95983990 BUDESONIDE 
95983996 BECLOMETASONE+ SALBUTAMOL 
95983997 BECLOMETASONE+ SALBUTAMOL 
95983998 BECLOMETASONE+ SALBUTAMOL 
95998992 SODIUM CROMOGLYCATE COMPLETE 
UNIT 
96025990 SALBUTAMOL 
96026990 SALBUTAMOL 
96027990 BECLOMETASONE 
96028990 BECLOMETASONE 
96029990 BECLOMETASONE 
96041992 FLUTICASONE PROPIONATE DISCS 
96089992 SALBUTAMOL (ALBUTEROL) 
96089998 ISOPRENALINE SULPHATE+SODIUM 
CROMOGLICATE 
96101992 EPHEDRINE HYDROCHLORIDE S/F 
96102990 SALBUTAMOL 
96108992 AMINOPHYLLINE 
96110997 IPRATROPIUM BROMIDE+FENOTEROL 
HYDROBROM 
96110998 IPRATROPIUM BROMIDE+FENOTEROL 
HYDROBROM 
96111996 IPRATROPIUM BROMIDE 
96111997 IPRATROPIUM BROMIDE 
96111998 IPRATROPIUM BROMIDE 
96112998 IPRATROPIUM BROMIDE 
96113997 IPRATROPIUM BROMIDE 
96113998 IPRATROPIUM BROMIDE 
96130990 BECLOMETASONE 
96131990 BECLOMETASONE 
96132990 BECLOMETASONE 
96143997 HYDROCORTISONE 
96143998 HYDROCORTISONE 
96146990 TERBUTALINE 
310 
 
96165990 SALBUTAMOL 
96177992 PREDNISONE 
96181992 DEXAMETHASONE 
96182992 DEXAMETHASONE 
96219992 EPHEDRINE 
96222992 EPHEDRINE 15MG/THEOPHYLLINE 
120MG 
96223992 EPHEDRINE HCL/AMINOPHYLLINE 
25/130/MG 
96224992 EPHEDRINE 
96226992 EPHEDRINE HCL 50MG/THEOPHYLLINE 
65MG 
96269992 HYDROCORTISONE PELLETS 
96361989 PREDNISOLONE 
96361990 PREDNISOLONE 
96372992 ORCIPRENALINE SULPHATE 
96402990 PREDNISOLONE 
96403997 AMINOPHYLLINE 
96403998 AMINOPHYLLINE 
96409992 PREDNISOLONE 
96410992 PREDNISONE 
96411992 PREDNISOLONE 
96425990 SALBUTAMOL 
96431997 DEXAMETHASONE 
96431998 DEXAMETHASONE 
96488992 THEOPHYLLINE 
96489992 THEOPHYLLINE 
96490992 THEOPHYLLINE 
96506992 SALBUTAMOL (ALBUTEROL) 
96507992 SALBUTAMOL (ALBUTEROL) 
96553997 FENOTEROL+ IPRATROPIUM BR 
96553998 FENOTEROL+ IPRATROPIUM BR 
96554996 FENOTEROL 
96554997 FENOTEROL 
96554998 FENOTEROL 
96557992 SALBUTAMOL (ALBUTEROL) 
96564990 SALBUTAMOL 
96577990 PREDNISOLONE SODIUM PHOSPHATE 
96578992 TRIAMCINOLONE ACETONIDE 
96580992 AMINOPHYLLINE 
96581992 AMINOPHYLLINE 
96603997 CORTISONE ACETATE 
96603998 CORTISONE ACETATE 
96626988 BECLOMETASONE 
96626989 BECLOMETASONE 
96626990 BECLOMETASONE 
96628990 SALBUTAMOL 
96629992 PREDNISOLONE 
96631992 PREDNISONE 
96642989 AMINOPHYLLINE 
96642990 AMINOPHYLLINE 
96675998 CHOLINE THEOPHYLLINATE 
96676998 CHOLINE THEOPHYLLINATE 
96677996 CHOLINE THEOPHYLLINATE 
96677997 CHOLINE THEOPHYLLINATE 
96677998 CHOLINE THEOPHYLLINATE 
96692990 SALBUTAMOL 
96733996 SODIUM CROMOGLICATE 
96733997 SODIUM CROMOGLICATE 
96733998 SODIUM CROMOGLICATE 
96734996 SODIUM CROMOGLICATE 
96734997 SODIUM CROMOGLICATE 
96734998 SODIUM CROMOGLICATE 
96735998 SODIUM CROMOGLICATE+ 
ISOPRENALINE 
96736998 SODIUM CROMOGLICATE 
96743992 PREDNISONE 
96744992 PREDNISOLONE 
96765990 IPRATROPIUM BROMIDE 
96766992 SODIUM CROMOGLYCATE INSUF 
CARTRIDGES 
96792990 SALBUTAMOL 
96798992 CHOLINE THEOPHYLLINATE 
96804992 TERBUTALINE RESPULES FOR 
NEBULISATION 
96835988 SALBUTAMOL 
96835989 SALBUTAMOL 
96835990 SALBUTAMOL 
96842992 SALBUTAMOL (ALBUTEROL) 
SULPHATE/NEB SOLN 
96884992 FLUTICASONE PROPIONATE DISCS 
96885990 IPRATROPIUM BROMIDE 
96885992 FLUTICASONE PROPIONATE DISCS 
96888992 SALBUTAMOL (ALBUTEROL) 
96926992 SODIUM CROMOGLYCATE/SPACER 
96935988 BECLOMETASONE 
96935989 BECLOMETASONE 
96935990 BECLOMETASONE 
96938990 AMINOPHYLLINE 
96940992 AMINOPHYLLINE 
96988992 TERBUTALINE SULPHATE 
96989992 TERBUTALINE SULPHATE RESPULES 
5MG/2ML 
97006988 BECLOMETASONE 
97006989 BECLOMETASONE 
97006990 BECLOMETASONE 
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97013992 CAFFEINE/EPHEDRINE 
97085997 SALBUTAMOL 
97085998 SALBUTAMOL 
97088998 EPHEDRINE 
97098989 SALBUTAMOL 
97098990 SALBUTAMOL 
97101989 PREDNISOLONE 
97101990 PREDNISOLONE 
97121997 SALBUTAMOL 
97121998 SALBUTAMOL 
97137992 CHOLINE THEOPHYLLINATE 
97147998 PREDNISOLONE 
97148997 PREDNISOLONE 
97148998 PREDNISOLONE 
97149997 PREDNISONE 
97149998 PREDNISONE 
97155997 PREDNISOLONE 
97155998 PREDNISOLONE 
97156997 PREDNISONE 
97156998 PREDNISONE 
97163997 AMINOPHYLLINE 
97163998 AMINOPHYLLINE 
97164997 AMINOPHYLLINE 
97164998 AMINOPHYLLINE 
97172996 NEDOCROMIL SODIUM 
97172997 NEDOCROMIL SODIUM 
97172998 NEDOCROMIL SODIUM 
97177990 TERBUTALINE 
97203992 CORTISONE ACETATE 
97237992 PREDNISOLONE ACETATE 
97238992 PREDNISOLONE ACETATE 
97240992 PREDNISOLONE 
97242998 TERBUTALINE 
97243992 DEXAMETHASONE 
97253996 THEOPHYLLINE 
97253997 THEOPHYLLINE 
97253998 THEOPHYLLINE 
97255988 BECLOMETASONE 
97255989 BECLOMETASONE 
97255990 BECLOMETASONE 
97334998 IPRATROPIUM BROMIDE 
97354992 EPHEDRINE HCL/BUTETHAMATE 
CITRATE 
97356992 EPHEDRINE 11MG/THEOPHYLLINE 
120MG 
97357992 EPHEDRINE/GUAIPHEN/PHENOBAR/THE
OPHYLLINE 
97358992 EPHEDRINE HCL/AMINOPHYLLINE E/C 
97359992 EPHEDRINE 
97391997 THEOPHYLLINE+ EPHEDRINE HCL 
97391998 THEOPHYLLINE+ EPHEDRINE HCL 
97418992 FENOTEROL HYDROBROMIDE 
97419992 FENOTEROL HYDROBROMIDE 
COMPLETE UNIT 
97436998 PREDNISOLONE 
97463998 SALBUTAMOL 
97484998 SALBUTAMOL 
97485997 SALBUTAMOL 
97485998 SALBUTAMOL 
97492997 HYDROCORTISONE 
97492998 HYDROCORTISONE 
97502998 DEXAMETHASONE 
97517997 BECLOMETASONE 
97517998 BECLOMETASONE 
97583992 HYDROCORTISONE 
97585998 SALBUTAMOL 
97586997 SALBUTAMOL 
97586998 SALBUTAMOL 
97672997 FLUTICASONE 
97672998 FLUTICASONE 
97680997 FLUTICASONE 
97680998 FLUTICASONE 
97698998 BECLOMETASONE 
97726990 PREDNISOLONE 
97740992 METHYLPREDNISOLONE 
97758997 SALBUTAMOL 
97758998 SALBUTAMOL 
97778997 SALBUTAMOL 
97778998 SALBUTAMOL 
97779998 SODIUM CROMOGLICATE 
97791990 AMINOPHYLLINE 
97822990 IPRATROPIUM BROMIDE 
97829998 METHYLPREDNISOLONE 
97832998 METHYLPREDNISOLONE 
97862998 SODIUM CROMOGLICATE 
97872996 BECLOMETASONE 
97872997 BECLOMETASONE 
97872998 BECLOMETASONE 
97929990 PREDNISOLONE 
97933990 TERBUTALINE 
97942992 PREDNISONE 
97943992 PREDNISONE 
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97950998 SODIUM CROMOGLICATE 
97967989 SALBUTAMOL 
97967990 SALBUTAMOL 
98046990 SALBUTAMOL 
98057996 EPHEDRINE 
98057997 EPHEDRINE 
98057998 EPHEDRINE 
98072990 DEXAMETHASONE 
98100990 THEOPHYLLINE 
98101996 AMINOPHYLLINE 
98101997 AMINOPHYLLINE 
98101998 AMINOPHYLLINE 
98107990 PREDNISOLONE 
98167988 SALBUTAMOL 
98167989 SALBUTAMOL 
98167990 SALBUTAMOL 
98169992 THEOPHYLLINE/NOSCAPINE 
98170992 THEOPHYLLINE 100MG/LYSINE 74MG 
98171992 THEOPHYLLINE 
98172992 THEOPHYLLINE 
98208990 AMINOPHYLLINE 
98219990 AMINOPHYLLINE 
98223996 SODIUM CROMOGLICATE 
98223997 SODIUM CROMOGLICATE 
98223998 SODIUM CROMOGLICATE 
98277998 IPRATROPIUM BROMIDE 
98288998 BECLOMETASONE 
98326997 TRIAMCINOLONE 
98326998 TRIAMCINOLONE 
98332996 BECLOMETASONE 
98332997 BECLOMETASONE 
98332998 BECLOMETASONE 
98333990 AMINOPHYLLINE 
98394998 BETAMETHASONE SODIUM PHOSPHATE 
98438990 SALBUTAMOL 
98439990 SALBUTAMOL 
98440990 SALBUTAMOL 
98441988 SALBUTAMOL 
98441989 SALBUTAMOL 
98441990 SALBUTAMOL 
98442990 SALBUTAMOL 
98455990 PREDNISOLONE 
98456988 PREDNISOLONE 
98456989 PREDNISOLONE 
98456990 PREDNISOLONE 
98514997 PREDNISOLONE 
98514998 PREDNISOLONE 
98561990 EPHEDRINE 
98562997 PREDNISOLONE 
98562998 PREDNISOLONE 
98580998 SALBUTAMOL+BECLOMETASONE 
98586998 SALBUTAMOL 
98588998 BECLOMETASONE 
98590996 BECLOMETASONE 
98590997 BECLOMETASONE 
98590998 BECLOMETASONE 
98595997 BUDESONIDE 
98595998 BUDESONIDE 
98596997 BUDESONIDE 
98596998 BUDESONIDE 
98601998 TERBUTALINE+ GUAIFENESIN 
98602998 TERBUTALINE 
98615998 THEOPHYLLINE 
98623998 THEOPHYLLINE 
98644989 DEXAMETHASONE 
98644990 DEXAMETHASONE 
98659996 SALBUTAMOL 
98659997 SALBUTAMOL 
98659998 SALBUTAMOL 
98718998 SODIUM CROMOGLICATE+ 
ISOPRENALINE 
98724997 DEXAMETHASONE 
98724998 DEXAMETHASONE 
98804998 SALBUTAMOL 
98805998 SALBUTAMOL 
98806996 SALBUTAMOL 
98806997 SALBUTAMOL 
98806998 SALBUTAMOL 
98808998 THEOPHYLLINE 
98809998 THEOPHYLLINE 
98810998 THEOPHYLLINE 
98887996 BUDESONIDE 
98887997 BUDESONIDE 
98887998 BUDESONIDE 
98934998 THEOPHYLLINE+ EPHEDRINE HCL 
98975997 SALBUTAMOL 
98975998 SALBUTAMOL 
98976998 SALBUTAMOL 
98977996 SALBUTAMOL 
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98977997 SALBUTAMOL 
98977998 SALBUTAMOL 
98978997 SALBUTAMOL 
98978998 SALBUTAMOL 
98979996 SALBUTAMOL 
98979997 SALBUTAMOL 
98979998 SALBUTAMOL 
98981996 SALBUTAMOL 
98981997 SALBUTAMOL 
98981998 SALBUTAMOL 
99003996 THEOPHYLLINE 
99003997 THEOPHYLLINE 
99003998 THEOPHYLLINE 
99013992 SALBUTAMOL (ALBUTEROL) 
99050997 THEOPHYLLINE 
99050998 THEOPHYLLINE 
99051998 AMINOPHYLLINE+DRIED AL HYDROX 
GEL 
99060989 PREDNISONE 
99060990 PREDNISONE 
99061989 PREDNISONE 
99061990 PREDNISONE 
99062990 PREDNISONE 
99098989 PREDNISONE 
99098990 PREDNISONE 
99099988 PREDNISOLONE 
99099989 PREDNISOLONE 
99099990 PREDNISOLONE 
99100989 PREDNISOLONE 
99100990 PREDNISOLONE 
99134996 THEOPHYLLINE 
99134997 THEOPHYLLINE 
99134998 THEOPHYLLINE 
99137998 PREDNISOLONESTEAGLATE 
99163998 AMINOPHYLLINE 
99214990 EPHEDRINE 
99226998 PREDNISOLONE SODIUM PHOSPHATE 
99228997 PREDNISOLONE 
99228998 PREDNISOLONE 
99254998 IPRATROPIUM BROMIDE+FENOTEROL 
HYDROBROM 
99256998 IPRATROPIUM BROMIDE+FENOTEROL 
HYDROBROM 
99326992 SODIUM CROMOGLYCATE 
99336998 THEOPHYLLINE 
99393988 SALBUTAMOL 
99393989 SALBUTAMOL 
99393990 SALBUTAMOL 
99394988 SALBUTAMOL 
99394989 SALBUTAMOL 
99394990 SALBUTAMOL 
99395988 SALBUTAMOL 
99395989 SALBUTAMOL 
99395990 SALBUTAMOL 
99396988 SALBUTAMOL 
99396989 SALBUTAMOL 
99396990 SALBUTAMOL 
99397988 SALBUTAMOL 
99397989 SALBUTAMOL 
99397990 SALBUTAMOL 
99423988 PREDNISOLONE 
99423989 PREDNISOLONE 
99423990 PREDNISOLONE 
99424989 PREDNISOLONE 
99424990 PREDNISOLONE 
99425988 PREDNISOLONE 
99425989 PREDNISOLONE 
99425990 PREDNISOLONE 
99531998 SODIUM CROMOGLICATE 
99550998 HYDROCORTISONE 
99609988 EPHEDRINE 
99609989 EPHEDRINE 
99609990 EPHEDRINE 
99624998 THEOPHYLLINE+PHENOBARB &GUAIFEN 
99626998 THEOPHYLLINE+ EPHEDRINE SULPHATE 
99718998 FENOTEROL+ IPRATROPIUM BR 
99781998 PREDNISONE 
99802998 CORTISONE ACETATE 
99803997 CORTISONE ACETATE 
99803998 CORTISONE ACETATE 
99804998 CORTISONE ACETATE 
99806998 HYDROCORTISONE 
99817992 AMINOPHYLLINE 
99818992 AMINOPHYLLINE 
99827992 AMINOPHYLLINE/ALUMINIUM 
HYDROXIDE DRIED 
99828992 AMINOPHYLLINE 
99829992 AMINOPHYLLINE 
99830992 AMINOPHYLLINE INTRAMUSCULAR 
99831992 AMINOPHYLLINE PAEDIATRIC 
99833996 CHOLINE THEOPHYLLINATE 
99833997 CHOLINE THEOPHYLLINATE 
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99833998 CHOLINE THEOPHYLLINATE 
99859998 EPHEDRINE 
99873989 AMINOPHYLLINE 
99873990 AMINOPHYLLINE 
99876998 TERBUTALINE+ GUAIFENESIN 
99877997 TERBUTALINE 
99877998 TERBUTALINE 
99878996 TERBUTALINE 
99878997 TERBUTALINE 
99878998 TERBUTALINE 
99879997 TERBUTALINE 
99879998 TERBUTALINE 
99890998 BETAMETHASONE 
99893996 FENOTEROL 
99893997 FENOTEROL 
99893998 FENOTEROL 
99896992 HYDROCORTISONE SODIUM 
PHOSPHATE 
99910998 BECLOMETASONE 
99914997 BECLOMETASONE 
99914998 BECLOMETASONE 
99922990 AMINOPHYLLINE 
99930998 IPRATROPIUM BROMIDE 
99965997 BECLOMETASONE 
99965998 BECLOMETASONE 
99966998 ORCIPRENALINE 
99967996 ORCIPRENALINE 
99967997 ORCIPRENALINE 
99967998 ORCIPRENALINE 
 
10.8.10  Medical codes for 
mental illnesses combined 
Medcode Description 
13Y3.00 Manic-depression association member 
1464.00 H/O: schizophrenia 
1465.00 H/O: depression 
1466.00 H/O: anxiety state 
146D.00 H/O: manic depressive disorder 
1B13.00 Anxiousness 
1B13.11 Anxiousness - symptom 
1B17.00 Depressed 
1B17.11 C/O - feeling depressed 
1B17.12 C/O - feeling unhappy 
1B1E.00 Hallucinations 
1B1N.00 Poor self esteem 
1B1U.00 Symptoms of depression 
1B1U.11 Depressive symptoms 
1B1V.00 C/O - panic attack 
1BH..00 Delusions 
1BH..11 Delusion 
1BI..00 Blunted affect 
1BO..00 Mood swings 
1BP..00 Loss of interest 
1BQ..00 Loss of capacity for enjoyment 
1BT..00 Depressed mood 
1BT..11 Low mood 
1BU..00 Loss of hope for the future 
1BY..00 Elevated mood 
1Ba0.00 Obsessional thoughts 
1P01.00 Psychomotor retardation 
2254.00 O/E - apathetic 
2257.00 O/E - depressed 
2258.00 O/E - anxious 
225C.00 O/E - elated 
62T1.00 Puerperal depression 
6G00.00 Postnatal depression counselling 
8BK0.00 Depression management programme 
8G94.00 Anxiety management training 
9HA0.00 On depression register 
E10..00 Schizophrenic disorders 
E100.00 Simple schizophrenia 
E100000 Unspecified schizophrenia 
E100200 Chronic schizophrenic 
E100400 Acute exacerbation of chronic 
schizophrenia 
E100500 Schizophrenia in remission 
E100z00 Simple schizophrenia NOS 
E101.00 Hebephrenic schizophrenia 
E101z00 Hebephrenic schizophrenia NOS 
E102.00 Catatonic schizophrenia 
E103.00 Paranoid schizophrenia 
E103000 Unspecified paranoid schizophrenia 
E103200 Chronic paranoid schizophrenia 
E103300 Acute exacerbation of subchronic 
paranoid schizophrenia 
E103400 Acute exacerbation of chronic paranoid 
schizophrenia 
E103500 Paranoid schizophrenia in remission 
E103z00 Paranoid schizophrenia NOS 
E104.00 Acute schizophrenic episode 
E106.00 Residual schizophrenia 
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E107.00 Schizo-affective schizophrenia 
E107000 Unspecified schizo-affective 
schizophrenia 
E107100 Subchronic schizo-affective 
schizophrenia 
E107200 Chronic schizo-affective schizophrenia 
E107300 Acute exacerbation subchronic schizo-
affective schizophrenia 
E107400 Acute exacerbation of chronic schizo-
affective schizophrenia 
E107z00 Schizo-affective schizophrenia NOS 
E10y000 Atypical schizophrenia 
E10yz00 Other schizophrenia NOS 
E10z.00 Schizophrenia NOS 
E11..12 Depressive psychoses 
E110.00 Manic disorder, single episode 
E110.11 Hypomanic psychoses 
E110000 Single manic episode, unspecified 
E110100 Single manic episode, mild 
E110200 Single manic episode, moderate 
E110300 Single manic episode, severe without 
mention of psychosis 
E110400 Single manic episode, severe, with 
psychosis 
E110z00 Manic disorder, single episode NOS 
E111.00 Recurrent manic episodes 
E111000 Recurrent manic episodes, unspecified 
E111100 Recurrent manic episodes, mild 
E111200 Recurrent manic episodes, moderate 
E111300 Recurrent manic episodes, severe 
without mention psychosis 
E111400 Recurrent manic episodes, severe, with 
psychosis 
E111600 Recurrent manic episodes, in full 
remission 
E111z00 Recurrent manic episode NOS 
E112.00 Single major depressive episode 
E112.11 Agitated depression 
E112.12 Endogenous depression first episode 
E112.13 Endogenous depression first episode 
E112.14 Endogenous depression 
E112000 Single major depressive episode, 
unspecified 
E112100 Single major depressive episode, mild 
E112200 Single major depressive episode, 
moderate 
E112300 Single major depressive episode, severe, 
without psychosis 
E112400 Single major depressive episode, severe, 
with psychosis 
E112500 Single major depressive episode, partial 
or unspec remission 
E112600 Single major depressive episode, in full 
remission 
E112z00 Single major depressive episode NOS 
E113.00 Recurrent major depressive episode 
E113.11 Endogenous depression - recurrent 
E113000 Recurrent major depressive episodes, 
unspecified 
E113100 Recurrent major depressive episodes, 
mild 
E113200 Recurrent major depressive episodes, 
moderate 
E113300 Recurrent major depressive episodes, 
severe, no psychosis 
E113400 Recurrent major depressive episodes, 
severe, with psychosis 
E113500 Recurrent major depressive 
episodes,partial/unspec remission 
E113600 Recurrent major depressive episodes, in 
full remission 
E113700 Recurrent depression 
E113z00 Recurrent major depressive episode NOS 
E114.00 Bipolar affective disorder, currently 
manic 
E114.11 Manic-depressive - now manic 
E114000 Bipolar affective disorder, currently 
manic, unspecified 
E114100 Bipolar affective disorder, currently 
manic, mild 
E114200 Bipolar affective disorder, currently 
manic, moderate 
E114300 Bipolar affect disord, currently manic, 
severe, no psychosis 
E114400 Bipolar affect disord, currently 
manic,severe with psychosis 
E115.00 Bipolar affective disorder, currently 
depressed 
E115.11 Manic-depressive - now depressed 
E115000 Bipolar affective disorder, currently 
depressed, unspecified 
E115100 Bipolar affective disorder, currently 
depressed, mild 
E115200 Bipolar affective disorder, currently 
depressed, moderate 
E115300 Bipolar affect disord, now depressed, 
severe, no psychosis 
E115500 Bipolar affect disord, now depressed, 
part/unspec remission 
E116.00 Mixed bipolar affective disorder 
E116000 Mixed bipolar affective disorder, 
unspecified 
E116200 Mixed bipolar affective disorder, 
moderate 
E116300 Mixed bipolar affective disorder, severe, 
without psychosis 
E116400 Mixed bipolar affective disorder, severe, 
with psychosis 
E116500 Mixed bipolar affective disorder, 
partial/unspec remission 
E116600 Mixed bipolar affective disorder, in full 
remission 
E116z00 Mixed bipolar affective disorder, NOS 
E117.00 Unspecified bipolar affective disorder 
E117000 Unspecified bipolar affective disorder, 
unspecified 
E117100 Unspecified bipolar affective disorder, 
mild 
E117200 Unspecified bipolar affective disorder, 
moderate 
E117400 Unspecified bipolar affective 
disorder,severe with psychosis 
E117500 Unspecified bipolar affect disord, 
partial/unspec remission 
E117600 Unspecified bipolar affective disorder, in 
full remission 
E117z00 Unspecified bipolar affective disorder, 
NOS 
E118.00 Seasonal affective disorder 
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E11y.00 Other and unspecified manic-depressive 
psychoses 
E11y000 Unspecified manic-depressive psychoses 
E11y200 Atypical depressive disorder 
E11yz00 Other and unspecified manic-depressive 
psychoses NOS 
E11z.00 Other and unspecified affective 
psychoses 
E11z000 Unspecified affective psychoses NOS 
E11z100 Rebound mood swings 
E11z200 Masked depression 
E11zz00 Other affective psychosis NOS 
E12..00 Paranoid states 
E120.00 Simple paranoid state 
E121.00 Chronic paranoid psychosis 
E122.00 Paraphrenia 
E123.11 Folie a deux 
E12y.00 Other paranoid states 
E12yz00 Other paranoid states NOS 
E12z.00 Paranoid psychosis NOS 
E13..00 Other nonorganic psychoses 
E13..11 Reactive psychoses 
E130.00 Reactive depressive psychosis 
E130.11 Psychotic reactive depression 
E131.00 Acute hysterical psychosis 
E132.00 Reactive confusion 
E133.00 Acute paranoid reaction 
E134.00 Psychogenic paranoid psychosis 
E135.00 Agitated depression 
E13y.00 Other reactive psychoses 
E13y000 Psychogenic stupor 
E13y100 Brief reactive psychosis 
E13yz00 Other reactive psychoses NOS 
E13z.00 Nonorganic psychosis NOS 
E13z.11 Psychotic episode NOS 
E1y..00 Other specified non-organic psychoses 
E200.00 Anxiety states 
E200000 Anxiety state unspecified 
E200100 Panic disorder 
E200111 Panic attack 
E200200 Generalised anxiety disorder 
E200300 Anxiety with depression 
E200400 Chronic anxiety 
E200500 Recurrent anxiety 
E200z00 Anxiety state NOS 
E203.00 Obsessive-compulsive disorders 
E203000 Compulsive neurosis 
E203100 Obsessional neurosis 
E203z00 Obsessive-compulsive disorder NOS 
E204.00 Neurotic depression reactive type 
E204.11 Postnatal depression 
E211100 Hypomanic personality disorder 
E211200 Depressive personality disorder 
E211300 Cyclothymic personality disorder 
E214.00 Compulsive personality disorders 
E214.11 Anancastic personality 
E275111 Compulsive eating disorder 
E275711 Compulsive water drinking 
E290.00 Brief depressive reaction 
E290z00 Brief depressive reaction NOS 
E291.00 Prolonged depressive reaction 
E2B..00 Depressive disorder NEC 
E2B0.00 Postviral depression 
E2B1.00 Chronic depression 
E2D0.00 Disturbance of anxiety and fearfulness 
childhood/adolescent 
E2D0000 Childhood and adolescent 
overanxiousness disturbance 
E2D0100 Childhood and adolescent fearfulness 
disturbance 
E2D0z00 Disturbance anxiety and fearfulness 
childhood/adolescent NOS 
Eu2..00 [X]Schizophrenia, schizotypal and 
delusional disorders 
Eu20.00 [X]Schizophrenia 
Eu20000 [X]Paranoid schizophrenia 
Eu20100 [X]Hebephrenic schizophrenia 
Eu20211 [X]Catatonic stupor 
Eu20213 [X]Schizophrenic catatonia 
Eu20214 [X]Schizophrenic flexibilatis cerea 
Eu20400 [X]Post-schizophrenic depression 
Eu20511 [X]Chronic undifferentiated 
schizophrenia 
Eu20600 [X]Simple schizophrenia 
Eu20y13 [X]Schizophrenifrm psychos NOS 
Eu20z00 [X]Schizophrenia, unspecified 
Eu21.00 [X]Schizotypal disorder 
Eu21.12 [X]Borderline schizophrenia 
Eu21.18 [X]Schizotypal personality disorder 
Eu22.00 [X]Persistent delusional disorders 
Eu22000 [X]Delusional disorder 
Eu22011 [X]Paranoid psychosis 
Eu22012 [X]Paranoid state 
Eu22015 [X]Paranoia 
Eu22y11 [X]Delusional dysmorphophobia 
Eu23.00 [X]Acute and transient psychotic 
disorders 
Eu23000 [X]Acute polymorphic psychot disord 
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without symp of schizoph 
Eu23012 [X]Cycloid psychosis 
Eu23100 [X]Acute polymorphic psychot disord 
with symp of schizophren 
Eu23112 [X]Cycloid psychosis with symptoms of 
schizophrenia 
Eu23200 [X]Acute schizophrenia-like psychotic 
disorder 
Eu23300 [X]Other acute predominantly delusional 
psychotic disorders 
Eu23312 [X]Psychogenic paranoid psychosis 
Eu23y00 [X]Other acute and transient psychotic 
disorders 
Eu23z00 [X]Acute and transient psychotic 
disorder, unspecified 
Eu23z11 [X]Brief reactive psychosis NOS 
Eu23z12 [X]Reactive psychosis 
Eu24.00 [X]Induced delusional disorder 
Eu24.12 [X]Induced paranoid disorder 
Eu24.13 [X]Induced psychotic disorder 
Eu25.00 [X]Schizoaffective disorders 
Eu25000 [X]Schizoaffective disorder, manic type 
Eu25011 [X]Schizoaffective psychosis, manic type 
Eu25012 [X]Schizophreniform psychosis, manic 
type 
Eu25100 [X]Schizoaffective disorder, depressive 
type 
Eu25111 [X]Schizoaffective psychosis, depressive 
type 
Eu25112 [X]Schizophreniform psychosis, 
depressive type 
Eu25200 [X]Schizoaffective disorder, mixed type 
Eu25212 [X]Mixed schizophrenic and affective 
psychosis 
Eu25z00 [X]Schizoaffective disorder, unspecified 
Eu25z11 [X]Schizoaffective psychosis NOS 
Eu2y.00 [X]Other nonorganic psychotic disorders 
Eu2y.11 [X]Chronic hallucinatory psychosis 
Eu2z.00 [X]Unspecified nonorganic psychosis 
Eu2z.11 [X]Psychosis NOS 
Eu30.00 [X]Manic episode 
Eu30.11 [X]Bipolar disorder, single manic episode 
Eu30000 [X]Hypomania 
Eu30100 [X]Mania without psychotic symptoms 
Eu30200 [X]Mania with psychotic symptoms 
Eu30212 [X]Mania with mood-incongruent 
psychotic symptoms 
Eu30y00 [X]Other manic episodes 
Eu30z11 [X]Mania NOS 
Eu31.00 [X]Bipolar affective disorder 
Eu31.11 [X]Manic-depressive illness 
Eu31.12 [X]Manic-depressive psychosis 
Eu31.13 [X]Manic-depressive reaction 
Eu31000 [X]Bipolar affective disorder, current 
episode hypomanic 
Eu31100 [X]Bipolar affect disorder cur epi manic 
wout psychotic symp 
Eu31200 [X]Bipolar affect disorder cur epi manic 
with psychotic symp 
Eu31300 [X]Bipolar affect disorder cur epi mild or 
moderate depressn 
Eu31400 [X]Bipol aff disord, curr epis sev 
depress, no psychot symp 
Eu31500 [X]Bipolar affect dis cur epi severe 
depres with psyc symp 
Eu31600 [X]Bipolar affective disorder, current 
episode mixed 
Eu31700 [X]Bipolar affective disorder, currently in 
remission 
Eu31y00 [X]Other bipolar affective disorders 
Eu31z00 [X]Bipolar affective disorder, unspecified 
Eu32.00 [X]Depressive episode 
Eu32.11 [X]Single episode of depressive reaction 
Eu32.12 [X]Single episode of psychogenic 
depression 
Eu32.13 [X]Single episode of reactive depression 
Eu32000 [X]Mild depressive episode 
Eu32100 [X]Moderate depressive episode 
Eu32200 [X]Severe depressive episode without 
psychotic symptoms 
Eu32211 [X]Single episode agitated depressn 
w'out psychotic symptoms 
Eu32212 [X]Single episode major depression 
w'out psychotic symptoms 
Eu32300 [X]Severe depressive episode with 
psychotic symptoms 
Eu32311 [X]Single episode of major depression 
and psychotic symptoms 
Eu32312 [X]Single episode of psychogenic 
depressive psychosis 
Eu32313 [X]Single episode of psychotic 
depression 
Eu32314 [X]Single episode of reactive depressive 
psychosis 
Eu32400 [X]Mild depression 
Eu32y00 [X]Other depressive episodes 
Eu32y11 [X]Atypical depression 
Eu32z00 [X]Depressive episode, unspecified 
Eu32z11 [X]Depression NOS 
Eu32z12 [X]Depressive disorder NOS 
Eu32z13 [X]Prolonged single episode of reactive 
depression 
Eu32z14 [X] Reactive depression NOS 
Eu33.00 [X]Recurrent depressive disorder 
Eu33.11 [X]Recurrent episodes of depressive 
reaction 
Eu33.12 [X]Recurrent episodes of psychogenic 
depression 
Eu33.13 [X]Recurrent episodes of reactive 
depression 
Eu33.14 [X]Seasonal depressive disorder 
Eu33.15 [X]SAD - Seasonal affective disorder 
Eu33000 [X]Recurrent depressive disorder, 
current episode mild 
Eu33100 [X]Recurrent depressive disorder, 
current episode moderate 
Eu33200 [X]Recurr depress disorder cur epi 
severe without psyc sympt 
Eu33211 [X]Endogenous depression without 
psychotic symptoms 
Eu33212 [X]Major depression, recurrent without 
psychotic symptoms 
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Eu33213 [X]Manic-depress psychosis,depressd,no 
psychotic symptoms 
Eu33300 [X]Recurrent depress disorder cur epi 
severe with psyc symp 
Eu33311 [X]Endogenous depression with 
psychotic symptoms 
Eu33312 [X]Manic-depress psychosis,depressed 
type+psychotic symptoms 
Eu33313 [X]Recurr severe episodes/major 
depression+psychotic symptom 
Eu33314 [X]Recurr severe episodes/psychogenic 
depressive psychosis 
Eu33315 [X]Recurrent severe episodes of 
psychotic depression 
Eu33316 [X]Recurrent severe episodes/reactive 
depressive psychosis 
Eu33400 [X]Recurrent depressive disorder, 
currently in remission 
Eu33y00 [X]Other recurrent depressive disorders 
Eu33z00 [X]Recurrent depressive disorder, 
unspecified 
Eu33z11 [X]Monopolar depression NOS 
Eu34000 [X]Cyclothymia 
Eu34012 [X]Cycloid personality 
Eu34013 [X]Cyclothymic personality 
Eu34100 [X]Dysthymia 
Eu34111 [X]Depressive neurosis 
Eu34112 [X]Depressive personality disorder 
Eu34113 [X]Neurotic depression 
Eu34114 [X]Persistant anxiety depression 
Eu3y011 [X]Mixed affective episode 
Eu3y111 [X]Recurrent brief depressive episodes 
Eu40012 [X]Panic disorder with agoraphobia 
Eu41.00 [X]Other anxiety disorders 
Eu41000 [X]Panic disorder [episodic paroxysmal 
anxiety] 
Eu41011 [X]Panic attack 
Eu41012 [X]Panic state 
Eu41100 [X]Generalized anxiety disorder 
Eu41111 [X]Anxiety neurosis 
Eu41112 [X]Anxiety reaction 
Eu41113 [X]Anxiety state 
Eu41200 [X]Mixed anxiety and depressive 
disorder 
Eu41211 [X]Mild anxiety depression 
Eu41300 [X]Other mixed anxiety disorders 
Eu41z00 [X]Anxiety disorder, unspecified 
Eu41z11 [X]Anxiety NOS 
Eu42.00 [X]Obsessive - compulsive disorder 
Eu42.12 [X]Obsessive-compulsive neurosis 
Eu42000 [X]Predominantly obsessional thoughts 
or ruminations 
Eu42100 [X]Predominantly compulsive acts 
[obsessional rituals] 
Eu42200 [X]Mixed obsessional thoughts and acts 
Eu42z00 [X]Obsessive-compulsive disorder, 
unspecified 
Eu51511 [X]Dream anxiety disorder 
Eu53011 [X]Postnatal depression NOS 
Eu53012 [X]Postpartum depression NOS 
Eu53111 [X]Puerperal psychosis NOS 
Eu60500 [X]Anankastic personality disorder 
Eu60511 [X]Compulsive personality disorder 
Eu60512 [X]Obsessional personality disorder 
Eu60513 [X]Obsessive-compulsive personality 
disorder 
Eu92000 [X]Depressive conduct disorder 
R001.00 [D]Hallucinations 
R001000 [D]Hallucinations, auditory 
R001100 [D]Hallucinations, gustatory 
R001200 [D]Hallucinations, olfactory 
R001300 [D]Hallucinations, tactile 
R001400 [D]Visual hallucinations 
R001z00 [D]Hallucinations NOS 
R007z13 [D]Postoperative depression 
R00z600 [D]Unhappiness 
Z4I7.00 Acknowledging anxiety 
Z4I7200 Alleviating anxiety 
Z4I7211 Reducing anxiety 
Z4L1.00 Anxiety counselling 
ZV11000 [V]Personal history of schizophrenia 
ZV11100 [V]Personal history of affective disorder 
ZV11111 [V]Personal history of manic-depressive 
psychosis 
ZV11112 [V]Personal history of manic-depressive 
psychosis 
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10.8.11  Medical codes for 
epilepsy 
Medcode Description 
R003100 [D]Convulsions, infantile 
R003z00 [D]Convulsion NOS 
F256000 Hypsarrhythmia 
Q480.11 Fits in newborn 
Q480.00 Convulsions in newborn 
F258.00 Post-ictal state 
1B64.00 Had a convulsion 
R003.00 [D]Convulsions 
282..11 O/E - a convulsion 
2825.00 O/E - psychomotor fit 
2824.11 O/E - Jacksonian fit 
R003y00 [D]Other specified convulsion 
6676.00 Last fit 
282..00 O/E - fit/convulsion 
282..12 O/E - a fit 
R003200 [D]Fit 
2822.00 O/E - grand mal fit 
F252.00 Petit mal status 
2824.12 O/E - focal fit 
Ryu7100 [X]Other and unspecified convulsions 
F253.00 Grand mal status 
282Z.00 O/E - fit/convulsion NOS 
1B63.11 Fit - had one, symptom 
6675.00 Fit frequency 
1B64.11 Convulsion - symptom 
2824.00 O/E - focal (Jacksonian) fit 
1B63.00 Had a fit 
2823.00 O/E - petit mal fit 
F25y500 Panayiotopoulos syndrome 
667N.00 Epilepsy severity 
667D.00 Epilepsy control poor 
667Z.00 Epilepsy monitoring NOS 
ZS82.00 Acquired epileptic aphasia 
F250100 Pykno-epilepsy 
F251.00 Generalised convulsive epilepsy 
F250000 Petit mal (minor) epilepsy 
667V.00 Many seizures a day 
667G.00 Epilepsy restricts employment 
F255600 Simple partial epileptic seizure 
F255500 Unilateral epilepsy 
667W.00 Emergency epilepsy treatment since last 
appointment 
F132z12 Myoclonic seizure 
667S.00 1 to 7 seizures a week 
F250011 Epileptic absences 
F25A.00 Juvenile myoclonic epilepsy 
F250z00 Generalised nonconvulsive epilepsy NOS 
F25y200 Locl-rlt(foc)(part)idiop epilep&epilptic 
syn seiz locl onset 
6678.00 Epilepsy treatment changed 
F25z.00 Epilepsy NOS 
667R.00 2 to 4 seizures a month 
Q480.12 Seizures in newborn 
282..13 O/E - a seizure 
667A.00 Epilepsy treatment stopped 
F254000 Temporal lobe epilepsy 
F250y00 Other specified generalised 
nonconvulsive epilepsy 
F256.12 West syndrome 
F255z00 Partial epilepsy without impairment of 
consciousness NOS 
9Of4.00 Epilepsy monitoring telephone invite 
F255200 Somatosensory epilepsy 
F256.00 Infantile spasms 
667K.00 Epilepsy limits activities 
F250500 Lennox-Gastaut syndrome 
1O30.00 Epilepsy confirmed 
667P.00 No seizures on treatment 
2126000 Epilepsy resolved 
667C.00 Epilepsy control good 
6672.00 Follow-up epilepsy assessment 
667X.00 No epilepsy drug side effects 
F251z00 Generalised convulsive epilepsy NOS 
667J.00 Epilepsy impairs education 
F256.11 Lightning spasms 
6677.00 Epilepsy drug side effects 
Fyu5000 [X]Other generalized epilepsy and 
epileptic syndromes 
667L.00 Epilepsy does not limit activities 
F253.11 Status epilepticus 
2828.00 Absence seizure 
8BIF.00 Epilepsy medication review 
667Q.00 1 to 12 seizures a year 
F255000 Jacksonian, focal or motor epilepsy 
212J.00 Epilepsy resolved 
F254100 Psychomotor epilepsy 
1B1W.00 Transient epileptic amnesia 
R003400 [D]Nocturnal seizure 
F254500 Complex partial epileptic seizure 
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F25X.00 Status epilepticus, unspecified 
F255012 Motor epilepsy 
F254400 Epileptic automatism 
F25y100 Gelastic epilepsy 
9Of3.00 Epilepsy monitoring verbal invite 
F251000 Grand mal (major) epilepsy 
F132100 Progressive myoclonic epilepsy 
6671.00 Initial epilepsy assessment 
F251500 Tonic-clonic epilepsy 
6679.00 Epilepsy treatment started 
667H.00 Epilepsy prevents employment 
F254.00 Partial epilepsy with impairment of 
consciousness 
F251400 Epileptic seizures - tonic 
F257.00 Kojevnikov's epilepsy 
F255311 Partial epilepsy with autonomic 
symptoms 
F251300 Epileptic seizures - myoclonic 
R003z11 [D]Seizure NOS 
F25y000 Cursive (running) epilepsy 
F132200 Myoclonic encephalopathy 
F256100 Salaam attacks 
F251011 Tonic-clonic epilepsy 
F251200 Epileptic seizures - clonic 
1473.00 H/O: epilepsy 
F25F.00 Photosensitive epilepsy 
F255.00 Partial epilepsy without impairment of 
consciousness 
F25y400 Benign Rolandic epilepsy 
F25C.00 Drug-induced epilepsy 
F25B.00 Alcohol-induced epilepsy 
667M.00 Epilepsy management plan given 
F259.11 Ohtahara syndrome 
F259.00 Early infant epileptic encephalopathy 
wth suppression bursts 
667..00 Epilepsy monitoring 
F256z00 Infantile spasms NOS 
F25..00 Epilepsy 
F255100 Sensory induced epilepsy 
SC20000 Traumatic epilepsy 
667B.00 Nocturnal epilepsy 
F25D.00 Menstrual epilepsy 
F254z00 Partial epilepsy with impairment of 
consciousness NOS 
6674.00 Epilepsy associated problems 
667T.00 Daily seizures 
F255400 Visual reflex epilepsy 
F251600 Grand mal seizure 
F255300 Visceral reflex epilepsy 
667F.00 Seizure free >12 months 
F250.00 Generalised nonconvulsive epilepsy 
Fyu5200 [X]Other status epilepticus 
F255011 Focal epilepsy 
F251111 Otohara syndrome 
F250300 Epileptic seizures - akinetic 
F25y.00 Other forms of epilepsy 
F25E.00 Stress-induced epilepsy 
F25z.11 Fit (in known epileptic) NOS 
Fyu5100 [X]Other epilepsy 
F251y00 Other specified generalised convulsive 
epilepsy 
8CE7.00 Epilepsy leaflet given 
F254300 Limbic system epilepsy 
F251100 Neonatal myoclonic epilepsy 
F250400 Juvenile absence epilepsy 
F254200 Psychosensory epilepsy 
F255y00 Partial epilepsy without impairment of 
consciousness OS 
F250200 Epileptic seizures - atonic 
F25yz00 Other forms of epilepsy NOS 
Fyu5900 [X]Status epilepticus, unspecified 
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10.8.12  Drug codes for 
epilepsy 
Multilexe 
id 
Genericname 
99332998 BECLAMIDE tabs 500mg 
96914998 BECLAMIDE tabs 500mg 
93771990 LAMOTRIGINE disp tab 25mg 
95532997 PHENYTOIN susp 30mg/5ml 
92200990 TOPIRAMATE tabs 25mg 
93016996 VALPROIC ACID ec soft gelatin ca 
500mg 
95186990 GABAPENTIN tabs 800mg 
96339990 PARALDEHYDE inj 
92332990 TOPIRAMATE tabs 50mg 
92735998 CARBAMAZEPINE supp 125mg 
92734997 CARBAMAZEPINE supp 250mg 
93934990 LAMOTRIGINE disp tab 25mg 
94409997 SODIUM VALPROATE ec tab 500mg 
94834996 GABAPENTIN caps 400mg 
94090990 LAMOTRIGINE tabs 200mg 
83946998 OXCARBAZEPINE oral liq 
87401998 PREGABALIN caps 25mg 
95409992 PHENOBARBITONE 10 MG PUL 
86843998 ZONISAMIDE caps 25mg 
92131997 CARBAMAZEPINE mr tab 400mg 
92969990 GABAPENTIN caps 100mg 
97955992 PRIMIDONE/PHENYTOIN SODIUM TAB 
91051997 TOPIRAMATE tabs 100mg 
96479992 TEGRETOL liq 100 MG/5ML LIQ 
94285992 PHENOBARBITONE 50 MG CAP 
84667998 SODIUM VALPROATE mr cap 150mg 
95216990 SODIUM VALPROATE + VALPROIC ACID 
mr tab 500mg 
94119990 LAMOTRIGINE tabs 50mg 
95417992 PHENOBARBITONE 5 MG ELI 
96446990 CARBAMAZEPINE mr tab 200mg 
94520992 PHENOBARBITONE 75 MG SUP 
96697990 CARBAMAZEPINE tabs 400mg 
98315996 PHENYTOIN SODIUM caps 100mg 
94116990 GABAPENTIN caps 300mg 
94282992 PHENOBARBITONE 15 MG CAP 
97884992 PHENOBARBITONE & PHENYTOIN 60 
MG CAP 
92291990 TOPIRAMATE caps 50mg 
96885998 CARBAMAZEPINE liq 100mg/5ml 
94049990 LAMOTRIGINE tabs 25mg 
94834997 GABAPENTIN caps 300mg 
94835996 GABAPENTIN caps 400mg 
99751990 CARBAMAZEPINE tabs 100mg 
99752988 CARBAMAZEPINE tabs 400mg 
92197990 TOPIRAMATE tabs 200mg 
91625997 OXCARBAZEPINE tabs 300mg 
94121990 GABAPENTIN caps 400mg 
94092990 LAMOTRIGINE tabs 50mg 
93806990 LAMOTRIGINE tabs 200mg 
94606997 SODIUM VALPROATE ec tab 500mg 
93939990 LAMOTRIGINE tabs 25mg 
94568997 SODIUM VALPROATE sf liq 200mg/5ml 
94010990 LAMOTRIGINE tabs 200mg 
93808990 LAMOTRIGINE tabs 50mg 
92700996 LAMOTRIGINE disp tab 100mg 
95187990 GABAPENTIN tabs 600mg 
94013990 LAMOTRIGINE tabs 25mg 
94428992 CANTIL + PHENOBARB TAB 
98049990 PHENOBARBITAL tabs 15mg 
92388990 OXCARBAZEPINE tabs 300mg 
99124989 PHENOBARBITAL tabs 30mg 
94166990 GABAPENTIN caps 300mg 
91596998 LAMOTRIGINE tabs 200mg 
94165990 GABAPENTIN caps 400mg 
92284990 TOPIRAMATE caps 25mg 
92297990 TOPIRAMATE tabs 50mg 
83511998 LACOSAMIDE tabs 150mg 
94283992 PHENOBARBITONE 15 MG SUP 
83518998 LACOSAMIDE soln for inf 200mg/20ml 
92734998 CARBAMAZEPINE supp 125mg 
92917997 SODIUM VALPROATE + VALPROIC ACID 
mr tab 300mg 
93769997 VIGABATRIN sf pwdr 500mg 
94409996 SODIUM VALPROATE crushable tab 
100mg 
99459989 PHENOBARBITAL tabs 30mg 
99176997 CLONAZEPAM tabs 2mg 
96676990 SODIUM VALPROATE crushable tab 
100mg 
97203997 PHENOBARBITAL tabs 30mg 
95444998 LAMOTRIGINE tabs 50mg 
97140990 PHENYTOIN SODIUM tabs 50mg 
94068998 VALPROIC ACID (AS SEMISODIUM 
SALT) ec tab 250mg 
98049989 PHENOBARBITAL tabs 30mg 
94093990 LAMOTRIGINE tabs 25mg 
83707998 SODIUM VALPROATE MR granules 
100mg 
95553998 PHENOBARBITAL SODIUM inj 
200mg/1ml 
84095998 STIRIPENTOL sach 500mg 
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94105990 LAMOTRIGINE tabs 25mg 
93493990 LAMOTRIGINE tabs 25mg 
99454990 PHENYTOIN SODIUM tabs 50mg 
95361992 OSPOLOT 50 MG TAB 
92802996 SODIUM VALPROATE sf liq 200mg/5ml 
83705998 SODIUM VALPROATE MR granules 
500mg 
93876990 LAMOTRIGINE disp tab 100mg 
93769998 VIGABATRIN tabs 500mg 
98111990 PHENOBARBITAL SODIUM inj 
200mg/1ml 
93460992 LAMICTAL NON-VALPROATE ADD-ON 
START PACK TAB 25 mg 
98658998 PHENYTOIN susp 30mg/5ml 
94120990 LAMOTRIGINE tabs 25mg 
82857998 SODIUM VALPROATE MR granules 
1000mg 
83790998 SODIUM VALPROATE + VALPROIC ACID 
MR granules 1000mg 
95161990 GABAPENTIN caps 100mg 
96916990 CARBAMAZEPINE tabs 100mg 
96536990 CARBAMAZEPINE mr tab 200mg 
92918997 SODIUM VALPROATE mr tab 300mg 
92389990 OXCARBAZEPINE tabs 150mg 
84097998 STIRIPENTOL caps 500mg 
97514997 PHENYTOIN paed tab 50mg 
98338988 CARBAMAZEPINE tabs 400mg 
96128990 CARBAMAZEPINE mr tab 200mg 
96159990 SODIUM VALPROATE sf liq 200mg/5ml 
84668998 SODIUM VALPROATE MR granules 
1000mg 
96195992 DIAZEPAM 10 MG INJ 
95444996 LAMOTRIGINE tabs 25mg 
92331990 TOPIRAMATE tabs 100mg 
93882990 LAMOTRIGINE tabs 25mg 
93769990 LAMOTRIGINE disp tab 5mg 
96407998 DIAZEPAM rectal tubes 5mg 
89210996 LEVETIRACETAM tabs 1000mg 
93530998 CARBAMAZEPINE chewable tab 100mg 
89408998 TIAGABINE tabs 5mg 
88868997 TOPIRAMATE caps 25mg 
93935990 LAMOTRIGINE disp tab 5mg 
98385989 SODIUM VALPROATE ec tab 500mg 
96536989 CARBAMAZEPINE mr tab 400mg 
94087990 LAMOTRIGINE disp tab 100mg 
86604998 CLONAZEPAM sf soln 
500micrograms/5ml 
93768992 PHENOBARBITONE 100 MG SPA 
96648997 CLOBAZAM tabs 10mg 
90776998 PHENYTOIN SODIUM caps 300mg 
87400998 PREGABALIN caps 50mg 
95852998 METHYLPHENOBARBITAL tabs 30mg 
96978990 PHENYTOIN SODIUM tabs 100mg 
95189990 GABAPENTIN caps 300mg 
93404992 PHENOBARBITONE 10 MG TAB 
96407997 DIAZEPAM rectal tubes 10mg 
83896998 PHENYTOIN SODIUM oral liq 
94047990 LAMOTRIGINE tabs 100mg 
92701990 PHENYTOIN SODIUM inj 250mg/5ml 
91050997 TOPIRAMATE tabs 100mg 
99110990 PHENOBARBITAL tabs 100mg 
99751989 CARBAMAZEPINE tabs 200mg 
87193998 LEVETIRACETAM oral soln 100mg/ml 
96767998 ETHOSUXIMIDE caps 250mg 
93443990 SODIUM VALPROATE ec tab 500mg 
93511990 LAMOTRIGINE disp tab 25mg 
93530997 CARBAMAZEPINE chewable tab 200mg 
97736997 PHENYTOIN SODIUM tabs 100mg 
83708998 SODIUM VALPROATE MR granules 
50mg 
91839998 OXCARBAZEPINE sf oral susp 60mg/ml 
87398998 PREGABALIN caps 100mg 
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10.9 DETAILED DESCRIPTION OF SURVEYS AND STUDIES CONDUCTED IN THE UK ON SMOKING DURING PREGNANCY 
Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
 Background: The first infant feeding survey took place in 
1975 as a result of recommendation from the Committee 
on Medical Aspects of Food and Nutrition Policy (COMA) 
working party to establish basic information about infant 
feeding practices. Information on smoking during 
pregnancy was asked for the first time in 1985. All infant 
feeding surveys were postal surveys, with three stages of 
each survey.  
Stage 1: when babies were approx. 6-8 weeks 
Stage 2: when babies were approx. 4-5 months 
Stage 3: when babies were approx. 8-10 months 
59,62,138,139,315,316 
Background: Health education 
authority commissioned these 
surveys of pregnant women to 
monitor the effectiveness of its 
smoking and pregnancy campaign 
targeted at women aged 15-24 
years in the social grade C2DE. The 
1992 survey was to provide the HEA 
with some baseline figures. All 9 
tracks of HEA survey were 
conducted in England, based on 
quota sampling techniques, where 
door-step screening was used to 
sample pregnant women, who were 
home-interviewed after press 
advertising aimed at reducing 
smoking during pregnancy each 
year. 63,64 
 
Smoking behaviour in pregnancy is collected at a 
woman's first antenatal booking appointment which 
usually takes place within the first three months of 
pregnancy. These booking appointments take place 
either at hospital or in the community and are 
recorded on the Scottish Woman Held Maternity 
Record, with data being subsequently transcribed onto 
the Scottish Morbidity Record (SMR02).  Estimates are 
based on financial year so each year ends on March 
31st. 
 
 
 
1984    This study was performed between 1st 
October 1982 and 31 March 1984 on 
patients attending the antenatal clinics 
at the Stobhill General Hospital , 
Glasgow. Total sample obtained: 
2,765.  
 
Results 
34.5% of pregnant women smoked 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
during pregnancy 317 
1985 Sample: Babies born between August to September 1985 
in Great Britain, chosen through systematic random 
sampling of births in a sample of 100 registration sub-
districts in England and Wales and birth registrations in 
Scotland. Social class V was oversampled. 
 
Sample size, response rate at each stage 
Stage 1: initial sample 8,154, response rate (90%), 
sample obtained 7,396 
Stage 2: response rate (81%), sample obtained 5,969 
Stage 3: response rate (83%) , sample obtained 4,946 
 
Results: 
39% of women smoked before pregnancy 
30% of women smoked during pregnancy 
24% gave up smoking during pregnancy62 
   
1986    Self-administered questionnaires given 
to 3882 pregnant women attending 
antenatal clinics at the Nottingham 
City Hospital and University Hospital 
Nottingham between July to August 
1986 for six weeks. Response rate 
90%, final study sample 3,483. 
 
Results 
31% of women smoked in pregnancy. 
36% never smoked, 26% stopped 
before getting pregnant, 7% stopped 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
on hearing about pregnancy, 21% 
reduced their smoking consumption 
while 2% increased their smoking. 
41% of women aged 14-20 smoked 
during pregnancy compared to 30% 
aged 21-30 and 22% aged 31 and 
over. 318 
1987     
1988     
1989     
1990 Sample: Babies born between August to October 1990, in 
the UK. Sampling methodology and frame same as the 
1985 survey except for the inclusion of births from 
Northern Ireland chosen randomly from birth registrations.  
 
Sample size, response rate at each stage 
Stage 1: initial sample 11,105, response rate (88%), 
sample obtained 9,778 
Stage 2: response rate (90%), sample obtained 8,793 
Stage 3: response rate (81%) , sample obtained 7,083 
 
Results: 
28% of women smoked before pregnancy 
30% of women smoked during pregnancy 
27% of women gave up smoking during pregnancy 316 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
1992  Track 1: Baseline measures ± 
January 1992. Sampled 625 
pregnant women. 
 
Results: 
40% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
27% were smoking during 
pregnancy 
44% women had never smoked 
36% in C2DE class smoked 
compared to 14% in ABC1. 64 
 A systematic random sample of 3200 
adults aged over 18 from each of the 
19 districts within the North Western 
Region of UK was taken from the 
Family Health Services Authority 
registers. The total sample was 60,800 
out of which 38,014 replied, in which 
513 women were pregnant. 
 
Results 
29% of pregnant women stated that 
they smoked and 8.4% smoked more 
than 15 cigarettes a day.  Pregnant 
smokers were more likely to be under 
25 years of age, tenants, and less 
likely to be engaged in any formal 
work or education. 319 
 
Track 2: March 1992 after the 
launch of HEA campaign, sampled 
606 women. 
 
Results: 
39% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
26% were smoking during 
pregnancy 
45% women had never smoked 
34% in C2DE class smoked 
compared to 14% in ABC1. 64 
1993  Track 3: March 1993.  Sample size 
= 526 pregnant women. 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
Results: 
37% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
27% were smoking during 
pregnancy 
44% women had never smoked 
36% in C2DE class smoked 
compared to 11% in ABC1. 64 
1994  Track 4: March 1994.  Sample size 
= 1,039 
 
Results: 
41% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
26% were smoking during 
pregnancy 
43% women had never smoked 
35% in C2DE class smoked 
compared to 14% in ABC1 64 
  
1995 Sample: Babies born between August to October 1995 in 
the UK chosen randomly from birth registers compiled by 
the General Register Offices in the UK. Social class V was 
oversampled. 
 
Sample size, response rate at each stage 
Initial sample 12,314, response rate (74%) sample 
obtained 9,130. 
Track 5: March 1995.  Sample size 
= 1,002 
 
Results: 
39% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
27% were smoking during 
Total women:59,862 
Current smokers : 29.0% 
Former smokers: 7.9% 
Never smokers: 58.1% 
Not known: 5.0% 320 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
 
Results: 
35% of women smoked before pregnancy 
23% of women smoked during pregnancy 
33% gave up smoking during pregnancy 315 
 
Smoking in pregnancy by social class 
social 
class 
Before 
pregnancy 
During 
pregnancy 
Gave up 
smoking 
I 14% 7% 50% 
II 22% 12% 44% 
IIINM 27% 14% 47% 
IIIM 35% 23% 33% 
IV 40% 28% 31% 
V 52% 37% 29% 
 
pregnancy 
46% women had never smoked 
41% in C2DE class smoked 
compared to  
11% in ABC1 64 
1996  Track 6: March 1996.  Sample size 
= 1,004 
 
Results: 
41% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
28% were smoking during 
pregnancy 
46% women had never smoked 
39% in C2DE class smoked 
compared to 15% in ABC1 64 
Total women: 58,478 
Current smokers: 28.8% 
Former smokers: 7.9% 
Never smokers: 58.2% 
Not known: 5.1% 320 
 
1997  Track 7: March 1997.  Sample size 
= 1,018 
Total women:57,500 
Current smokers: 29.4% 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
 
Results: 
38% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
26% were smoking during 
pregnancy 
47% women had never smoked 
37% in C2DE class smoked 
compared to 13% in ABC1 
 
64 
Former smokers: 8.0% 
Never smokers: 54.2% 
Not known: 8.5% 320 
 
 
1998  Track 8: March 1998.  Sample size 
= 1,019 
 
Results: 
38% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
22% were smoking during 
pregnancy 
46% women had never smoked 
32% in C2DE class smoked 
compared to 10% in ABC1 64 
Total women: 57,560 
Current smokers: 28.7% 
Former smokers: 8.2% 
Never smokers: 56.5% 
Not known: 6.6% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  47.8% 8.1% 40.% 4.2% 
SIMD2 34.3% 8.3% 51.3% 6.0% 
SIMD3 24.5% 8.4% 58.5% 8.5% 
SIMD4 17.1% 8.9% 66.7% 7.4% 
SIMD5 9.8% 7.3% 74.9% 7.9% 
NK 17.9% 6.0% 61.5% 14.7% 
 
Smoking by age 
Age  Current Former Never NK 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
<20 48.2% 10.2% 36.0% 5.6% 
20-24 42.0% 9.6% 42.3% 6.0% 
25-29 27.2% 8.3% 58.4% 6.0% 
30-34 20.4% 7.1% 65.2% 7.3% 
35.39 20.6% 7.1% 64.9% 7.5% 
40+ 21.2% 6.3% 63.2% 9.3% 
 
 
1999  Track 9: March 1999.  Sample size 
= 999 
 
Results: 
45% of the women in the sample 
were smoking in the 12 months 
before pregnancy 
30% were smoking during 
pregnancy 
42% women had never smoked 
43% in C2DE class smoked 
compared to 15% in ABC1 64 
Total women:55,776 
Current smokers: 27.6% 
Former smokers: 8.2% 
Never smokers: 57.0% 
Not known: 7.1% 320 
 
Smoking by SES  
SES Current Former Never NK 
SIMD1  45.9% 8.6% 40.6% 4.9% 
SIMD2 32.5% 9.0% 51.7% 6.7% 
SIMD3 24.9% 8.2% 57.9% 9.0% 
SIMD4 17.2% 7.8% 66.3% 8.6% 
SIMD5 9.1% 7.3% 76.7% 7.0% 
NK 18.5% 8.7% 54.4% 18.5% 
 
Smoking by age 
Age  Current Former Never NK 
<20 45.5% 11.5% 36.0% 7.0% 
20-24 39.9% 9.7% 43.6% 6.8% 
25-29 26.7% 8.5% 57.9% 7.0% 
30-34 19.8% 7.2% 66.0% 7.1% 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
35.39 20.2% 6.1% 66.0% 7.7% 
40+ 20.5% 6.2% 63.9% 9.4% 
 
 
2000 Sample: Babies born between August to October 2000 in 
the UK chosen randomly from birth registers compiled by 
the General Register Offices in the UK. In England and 
Wales a clustered sample within 100 registration districts 
was selected and Scotland and NI sample was chosen from 
all registration districts. Social class V was oversampled. 
 
Sample size, response rate at each stage 
Stage 1: initial sample 13,112, response rate (72%), 
sample obtained 9,492 
Stage 2: response rate (87%), sample obtained 8,299 
Stage 3: response rate (88%) , sample obtained 7,267 
 
Results: 
35% of women smoked before or during pregnancy 
20% of women smoked throughout pregnancy 
44% gave up smoking during or before pregnancy 138 
 
Smoking in pregnancy by social class 
NS-SEC Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
Higher  22% 8% 63% 
Intermediate 29% 13% 55% 
Lower 46% 29% 38% 
Never 50% 36% 29% 
 Total women: 53,355 
Current smokers: 26.6% 
Former smokers: 8.2% 
Never smokers: 57.3% 
Not known: 7.9% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  44.7% 8.5% 40.6% 6.1% 
SIMD2 31.7% 8.8% 52.0% 7.4% 
SIMD3 23.4% 8.4% 59.5% 8.7% 
SIMD4 16.2% 8.0% 66.9% 8.8% 
SIMD5 9.5% 7.1% 74.4% 9.0% 
NK 16.1% 4.0% 60.3% 19.6% 
 
Smoking by age 
Age  Current Former Never NK 
<20 44.5% 10.5% 37.0% 8.0% 
20-24 38.8% 10.5% 43.5% 7.2% 
25-29 25.8% 8.1% 58.4% 7.6% 
30-34 19.0% 7.1% 66.1% 7.8% 
35.39 19.0% 6.5% 65.3% 9.2% 
40+ 17.7% 6.6% 64.0% 11.7% 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
worked 
unclassified 38% 22% 44% 
 
6PRNLQJLQSUHJQDQF\E\PRWKHU¶VDJH 
age Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
< 20 65% 40% 38% 
20-24 53% 30% 43% 
25-29 36% 20% 45% 
30-34 25% 13% 48% 
35+ 24% 13% 45% 
 
 
2001    
Total women:51,791 
Current smokers: 25.4% 
Former smokers: 8.4% 
Never smokers: 52.8% 
Not known: 13.5% 320 
 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  43.5% 8.8% 38.9% 8.8% 
SIMD2 30.6% 9.3% 48.1% 12.0% 
SIMD3 21.8% 9.4% 54.8% 14.1% 
SIMD4 15.0% 8.2% 61.9% 14.9% 
SIMD5 8.0% 6.2% 66.3% 19.5% 
NK 19.9% 4.5% 54.7% 20.9% 
Millenium cohort study ± first 
survey 
 
The Millennium Cohort Study is a 
large-scale survey of the new 
FHQWXU\¶VEDELHVDQGWKH 
families who are bringing them up, for 
the four countries of the United 
Kingdom. Its first sweep was carried 
out during 2001-2002 and contains 
information about 18819 babies in 
18553 families, collected from parents 
when the babies were aged nine 
months. The sample design allowed 
for disproportionate representation of 
families living in areas of child poverty 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
 
Smoking by age 
Age  Current Former Never NK 
<20 42.4% 11.3% 34.7% 11.6% 
20-24 38.3% 10.7% 39.5% 11.6% 
25-29 24.8% 8.3% 54.4% 12.5% 
30-34 18.2% 7.2% 60.2% 14.4% 
35.39 16.9% 6.7% 60.6% 15.8% 
40+ 17.0% 7.3% 56.0% 19.7% 
 
 
in Northern Ireland, Scotland and 
Wales and in areas with high ethnic 
minority populations in England.  
 
Results 
35.3% of mothers reported smoking 
at some point during pregnancy while 
28.4% mothers reported smoking at 9 
month interview. Women who smoked 
during pregnancy were younger than 
non-smokers, and more likely to be 
single mothers 321 
2002   Total women:50,063 
Current smokers: 25.5% 
Former smokers: 8.6% 
Never smokers: 55.2% 
Not known: 10.7% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  7.5% 8.8% 40.8% 7.5% 
SIMD2 30.8% 9.7% 50.0% 9.5% 
SIMD3 22.4% 9.2% 56.8% 11.5% 
SIMD4 15.3% 8.6% 64.3% 11.8% 
SIMD5 8.5% 6.6% 70.5% 14.4% 
NK 21.8% 2.9% 59.2% 16.1% 
 
Smoking by age 
Age  Current Former Never NK 
Smoking status at time of delivery, 
England  
 
Since 2002/03, PCTs have been 
submitting data on smoking at 
delivery on a quarterly basis.  This 
provides more timely, frequent and 
local information on smoking among 
pregnant women than the Infant 
Feeding Survey and Health Survey for 
England. 
Collection was initially done via the 
Strategic Executive Information 
System (STEIS) and then via the DH 
data collection tool called Unify.  From 
2008/09 quarter 2 this information has 
EHHQFROOHFWHGXVLQJWKH,&¶V2PQLEXV
system, a web based system set up to 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
<20 44.2% 11.5% 34.5% 9.8% 
20-24 37.5% 10.3% 42.6% 9.5% 
25-29 24.6% 9.0% 56.4% 9.9% 
30-34 18.6% 7.6% 62.9% 10.9% 
35.39 17.3% 6.6% 63.2% 12.9% 
40+ 19.5% 6.4% 59.9% 14.1% 
 
 
collect performance and other central 
returns directly from the NHS. 
Each Primary Care Trust (PCT) is 
required to submit actual figures for 
the quarter and the year-to-date and 
forecasts for the year as a whole for 
the following three items: 
7KHQXPEer of maternities;  
7KHQXPEHURIPRWKHUVUHFRUGHGDV
smoking at delivery; and  
7KHQXPEHURIPRWKHUVUHFRUGHGDV
not smoking at delivery. 
 
'DWDIRUWKLV\HDUGLGQ¶WSDVVWKHGDWD
quality checks hence percentage not 
given 322 
2003   Total women:50,224 
Current smokers: 25.3% 
Former smokers: 9.0% 
Never smokers: 57.5% 
Not known: 8.1% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  42.7% 8.9% 41.7% 6.7% 
SIMD2 30.9% 10.3% 51.2% 7.6% 
SIMD3 22.4% 9.5% 58.9% 9.2% 
SIMD4 15.3% 9.2% 66.8% 8.8% 
SIMD5 8.4% 7.3% 75.6% 8.7% 
Smoking status at time of delivery, 
England  
'DWDIRUWKLV\HDUGLGQ¶WSDVVWKHGDWD
quality checks hence percentage not 
given 322 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
NK 14.6% 6.3% 58.7% 20.4% 
 
Smoking by age 
Age  Current Former Never NK 
<20 44.6% 10.7% 36.8% 7.9% 
20-24 37.0% 11.1% 44.4% 7.5% 
25-29 25.2% 9.4% 58.1% 7.3% 
30-34 17.8% 8.0% 65.6% 8.6% 
35.39 17.1% 7.3% 66.3% 9.2% 
40+ 18.5% 6.4% 65.6% 9.5% 
 
 
2004   Total women: 51,894 
Current smokers: 23.8% 
Former smokers: 9.1% 
Never smokers: 59.2% 
Not known: 7.9% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  40.0% 9.8% 42.0% 8.2% 
SIMD2 29.1% 9.7% 53.4% 7.9% 
SIMD3 20.7% 9.7% 60.0% 9.6% 
SIMD4 14.9% 9.3% 67.8% 8.0% 
SIMD5 8.0% 6.5% 79.6% 5.9% 
NK 20.1% 4.9% 60.4% 14.6% 
 
Smoking by age 
Age  Current Former Never NK 
Smoking status at time of delivery, 
England  
 
'DWDIRUWKLV\HDUGLGQ¶WSDVVWKHGDWD
quality checks hence percentage not 
given 322 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
<20 42.3% 11.1% 39.3% 7.4% 
20-24 35.2% 10.3% 45.7% 8.7% 
25-29 23.2% 10.1% 58.9% 7.8% 
30-34 17.1% 8.3% 67.1% 7.5% 
35.39 16.2% 7.1% 68.6% 8.1% 
40+ 17.4% 5.1% 68.0% 9.5% 
 
 
2005 Sample: A completely unclustered sample of 19,848 births 
selected from all births registered in the period August to 
October 2005. No oversampling of mothers from lower 
social class groups. Births with no partner oversampled. 
 
Sample size, response rate at each stage 
Stage 1: initial sample 19,848, response rate (62%), 
sample obtained 12,290 
Stage 2: response rate (88%), sample obtained 10,814 
Stage 3: response rate (87%) , sample obtained 9,416 
 
Results: 
33% of women smoked before or during pregnancy 
17% of women smoked throughout pregnancy 
48% gave up smoking during or before pregnancy 139 
 
Smoking in pregnancy by social class 
NS-SEC Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
Manag/prof. 22% 8% 63% 
Intermediate  29% 13% 55% 
 Total women:52,646 
Current smokers: 22.5% 
Former smokers: 9.3% 
Never smokers: 60.9% 
Not known: 7.3% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  38.5% 8.8% 44.1% 8.6% 
SIMD2 27.1% 10.6% 55.5% 6.7% 
SIMD3 19.8% 10.7% 61.9% 7.5% 
SIMD4 13.6% 9.2% 69.6% 7.6% 
SIMD5 7.1% 7.1% 80.4% 5.4% 
NK 18.0% 7.9% 64.0% 10.1% 
 
Smoking by age 
Age  Current Former Never NK 
<20 41.8% 10.3% 39.5% 8.3% 
20-24 34.3% 10.9% 47.5% 7.2% 
25-29 22.0% 10.6% 60.3% 7.2% 
30-34 15.4% 8.2% 69.4% 7.0% 
Smoking status at time of delivery, 
England  
 
'DWDIRUWKLV\HDUGLGQ¶WSDVVWKHGDWD
quality checks hence percentage not 
given 322 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
Rout./manual 46% 29% 38% 
Never 
worked 
50% 36% 29% 
Unclassified  38% 22% 44% 
 
6PRNLQJLQSUHJQDQF\E\PRWKHU¶VDJH 
age Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
< 20 65% 40% 38% 
20-24 53% 30% 43% 
25-29 36% 20% 45% 
30-34 25% 13% 48% 
35+ 24% 13% 45% 
 
35.39 14.9% 7.7% 70.0% 7.4% 
40+ 16.0% 6.1% 70.4% 7.6% 
 
 
2006   Total women:52,261 
Current smokers: 21.7% 
Former smokers: 8.5% 
Never smokers: 60.4% 
Not known: 9.4% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  35.7% 8.2% 43.9% 12.2% 
SIMD2 25.9% 10.1% 55.3% 8.7% 
SIMD3 19.3% 9.6% 62.7% 8.5% 
SIMD4 13.4% 8.1% 69.1% 9.4% 
SIMD5 7.6% 6.5% 78.9% 6.9% 
NK 15.1% 9.2% 61.6% 14.1% 
 
Smoking by age 
Smoking status at the time of 
delivery  
 
15.1% maternities smoking out of 
total 601,262 maternities (95% CI 
15.0-15.2%) 2006-07 322 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
Age  Current Former Never NK 
<20 39.8% 10.0% 40.2% 10.1% 
20-24 32.2% 10.2% 47.8% 9.8% 
25-29 21.3% 9.8% 59.5% 9.4% 
30-34 14.9% 7.5% 68.7% 8.9% 
35.39 14.8% 6.5% 69.2% 9.5% 
40+ 15.0% 5.2% 70.9% 8.9% 
 
2007   Total women:54,197 
Current smokers: 20.8% 
Former smokers: 9.4% 
Never smokers: 57.8% 
Not known: 12.0% 320 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  33.3% 8.3% 40.8% 17.7% 
SIMD2 26.1% 11.1% 51.6% 11.2% 
SIMD3 18.5% 10.6% 60.4% 10.5% 
SIMD4 12.7% 9.3% 67.7% 10.3% 
SIMD5 7.6% 7.6% 76.8% 8.0% 
NK 13.7% 7.3% 62.0% 17.1% 
 
Smoking by age 
Age  Current Former Never NK 
<20 40.4% 9.9% 36.2% 13.4% 
20-24 31.8% 10.8% 44.7% 12.8% 
25-29 20.3% 10.1% 57.4% 12.2% 
30-34 13.8% 8.9% 66.2% 11.1% 
35.39 13.6% 7.4% 67.1% 11.9% 
Smoking status at time of delivery, 
England 
 
14.4% (95% CI 14.4%-14.5%) 
maternities smoking out of total 
634,035 maternities  - 2007-08 322 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
40+ 13.6% 7.7% 67.6% 11.2% 
 
2008   Total women: 56,927 
Current smokers: 19.1% 
Former smokers: 9.0% 
Never smokers: 57.7% 
Not known: 14.2% 320 
 
 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  30.1% 8.2% 41.1% 20.6% 
SIMD2 24.2% 9.7% 52.8% 13.3% 
SIMD3 16.9% 10.7% 60.2% 12.1% 
SIMD4 11.8% 8.9% 67.5% 11.8% 
SIMD5 6.5% 7.6% 75.7% 10.2% 
NK 16.3% 6.4% 58.7% 18.6% 
 
Smoking by age 
Age  Current Former Never NK 
<20 37.9% 10.7% 36.1% 15.4% 
20-24 29.2% 10.5% 45.5% 14.7% 
25-29 18.7% 9.7% 57.2% 14.4% 
30-34 12.4% 8.1% 65.7% 13.9% 
35.39 12.2% 7.4% 66.8% 13.6% 
40+ 13.4% 6.1% 67.9% 12.6% 
 
Smoking status at time of delivery, 
England  
14.4%  (95% CI 14.3%-14.5%) 
maternities smoking out of a total 
640,681 maternities ± 2008-09 322 
 
2009   Total women: 57,338 
Current smokers: 18.1% 
Former smokers: 8.8% 
Smoking status at time of delivery, 
England 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
Never smokers: 58.9% 
Not known: 14.3% 323 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  29.4% 7.6% 44.2% 18.8% 
SIMD2 22.1% 9.8% 54.8% 13.3% 
SIMD3 15.9% 9.8% 62.4% 11.9% 
SIMD4 10.9% 9.5% 67.6% 12.0% 
SIMD5 5.8% 7.4% 73.6% 13.2% 
NK 8.9% 7.0% 51.4% 32.7% 
 
Smoking by age 
Age  Current Former Never NK 
<20 36.8% 11.2% 38.1% 13.9% 
20-24 27.8% 10.7% 47.0% 14.4% 
25-29 17.2% 9.4% 59.4% 13.9% 
30-34 11.7% 7.6% 66.3% 14.4% 
35.39 11.1% 6.8% 67.6% 14.5% 
40+ 13.4% 6.2% 65.8% 14.7% 
 
14.1% (14.0%-14.2%) maternities 
smoking out of a total 647,505 
maternities ± 2009-10 322 
2010 Sample: A sample of 22,400 births selected from all births 
registered in the period August to November 2010. All 
births in Wales and Northern Ireland were sampled and 
over-sampling of deprived mothers was done in England 
and Scotland. 
 
Sample size, response rate at each stage 
Stage 1: initial sample 22,400, response rate (52%), 
further 7,788 questionnaires sent 
 Total women: 57,398 
Current smokers: 18.8% 
Former smokers: 10% 
Never smokers: 60.6% 
Not known: 10.7% 203 
 
Smoking by SES 
SES Current Former Never NK 
SIMD1  30.6% 8.9% 50.7% 9.9% 
Smoking status at time of delivery, 
England 322 
 
13.5% (95% CI 13.4%-13.6%) 
maternities smoking out of a total 
659,763 maternities ± 2010-11 
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Year Infant Feeding Survey HEA/HDA survey* Scottish Morbidity Record Data Other studies 
 
Results: 
26% of women smoked before or during pregnancy 
12% of women smoked throughout pregnancy 
54% gave up smoking during or before pregnancy 59 
 
Smoking in pregnancy by social class 
NS-SEC Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
Manag/prof. 14% 4% 72% 
Intermediate  26% 10% 61% 
Rout./manual 40% 20% 50% 
Never 
worked 
30% 21% 29% 
Unclassified  29% 14% 53% 
 
Smoking in SUHJQDQF\E\PRWKHU¶VDJH 
age Before/during 
pregnancy 
Throughout 
pregnancy 
Gave up 
smoking 
< 20 57% 35% 38% 
20-24 44% 22% 50% 
25-29 26% 11% 58% 
30-34 17% 7% 62% 
35+ 15% 9% 58% 
 
SIMD2 22.0% 10.6% 56.8% 10.6% 
SIMD3 16.9% 11.0% 62.2% 9.9% 
SIMD4 11.3% 10.1% 69.3% 9.2% 
SIMD5 6.1% 9.6% 70.3% 14.0% 
NK 12.1% 6.9% 53.4% 27.6% 
 
Smoking by age 
Age  Current Former Never NK 
<20 38.2% 12.0% 40.0% 9.8% 
20-24 29.7% 10.8% 50.0% 9.5% 
25-29 17.9% 10.0% 61.8% 10.3% 
30-34 12.2% 9.6% 67.0% 11.2% 
35.39 11.5% 9.0% 67.5% 12.0% 
40+ 12.8% 8.6% 67.8% 10.8% 
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10.10 MEDICAL READ CODES FOR 
CONGENITAL ANOMALIES 
Med 
codes 
Description 
14H..00 H/O: congenital anomaly 
14H1.00 H/O: cardiac anomaly 
14H1.11 H/O: heart anomaly 
14H2.00 H/O: cleft palate 
14H3.00 H/O: cleft lip 
14H4.00 H/O: urinary anomaly 
14H5.00 H/O: cong. dislocation - hip 
14HZ.00 H/O: congenital anomaly NOS 
66g..00 Congenital heart condition monitoring 
7010111 Insertion of Halber valve for spina bifida 
7031000 Repair of meningoencephalocele 
7043.00 Repair of spina bifida 
7043000 Freeing of spinal tether 
7043100 Closure of spinal myelomeningocele 
7043200 Closure of spinal meningocele 
7043y00 Other specified repair of spina bifida 
7043z00 Repair of spina bifida NOS 
7406200 Correction of congenital atresia of choana 
7409.00 Correction of cleft lip nasal deformity 
7409000 Primary correction of cleft lip nasal 
deformity 
7409011 Primary correction of alar cartilage 
7409012 McComb primary correction of cleft nose 
7409013 Pigott alar leap-frog correction 
7409100 Secondary correction of cleft lip nasal 
deformity 
7409111 Secondary correction of alar slump 
7409112 Kernahan correction of alar slump 
7409113 Skoog correction of alar slump 
7409114 Dibbell correction of alar slump 
7409200 Correction of cleft lip nasal tip deformity 
7409211 Alar base advancement 
7409212 Kilner inroll 
7409300 Columella lengthening procedure 
unspecified 
7409400 Unilateral columella lengthening operation 
7409411 Tajima unilateral columella lengthening 
operation 
7409500 Rhinoplasty for cleft lip nasal deformity 
7409600 Septorhinoplasty for cleft lip nasal 
deformity 
7409700 Septoplasty for cleft lip nasal deformity 
7409800 Correction of nostril stenosis 
7409z00 Correction of nasal deformity NOS 
7502.00 Correction of deformity of lip 
7502.11 Repair of cleft lip operations 
7502000 Primary closure of cleft lip, unspecified 
7502011 Lemesurier cleft lip repair 
7502012 Millard cleft lip correction 
7502013 Randall cleft lip repair 
7502014 Tenison cleft lip repair 
7502100 Revision of primary closure of cleft lip 
7502200 Adjustment to vermilion border of lip NEC 
7502300 Unilateral lip adhesion 
7502400 Bilateral lip adhesion 
7502500 Repair of unilateral cleft lip using straight 
line technique 
7502511 Kilner repair unilateral cleft lip 
7502600 Repair unilat cleft lip - rotation 
advancement flp technique 
7502611 Millard repair unilateral cleft lip 
7502700 Repair of unilateral cleft lip with 
triangular flap 
7502711 Randall repair unilateral cleft lip 
7502712 Skoog repair unilateral cleft lip 
7502713 Tennyson repair unilateral cleft lip 
7502800 Repair unilateral cleft lip with 
quadrilateral flap 
7502811 Repair unilateral cleft lip with 
quadrilateral flap 
7502900 Repair of unilateral cleft lip unspecified 
7502A00 Repair bilateral cleft lip - rotation 
advancement flap tech 
7502A11 Rep bilat cleft lip Millard 
7502B00 Repair of bilateral cleft lip with 
quadrilateral flap 
7502B11 Barsky repair bilateral cleft lip 
7502C00 Repair of bilateral cleft lip using straight 
line technique 
7502C11 Manchester bilateral cleft lip repair 
7502C12 Veau type III bilateral cleft lip repair 
7502D00 Repair of bilateral cleft lip unspecified 
7502E00 Synchronous bilateral cleft lip repair 
7502F00 Asynchronous bilateral cleft lip repair 
7502y00 Other specified correction of deformity of 
lip 
7502z00 Correction of deformity of lip NOS 
7525.00 Correction of deformity of palate 
7525.11 Repair of deformity of palate 
7525.12 Repair of cleft palate 
7525000 Primary repair of cleft palate, unspecified 
7525011 Kilner repair of cleft palate 
7525012 Langenbeck repair of cleft palate 
7525013 Wardill repair of cleft palate 
7525100 Revision of repair of cleft palate 
7525200 Repair cleft hard palate post based axial 
transposition flap 
7525211 Repair cleft hard palate post based axial 
transposition flap 
343 
 
7525212 Wardill repair cleft palate 
7525213 Veau flap repair cleft palate 
7525300 Repair of cleft hard palate with bipedicled 
flaps 
7525311 Langenbeck repair cleft palate 
7525400 Repair of cleft soft palate with Z-plasty 
7525411 Furlow repair cleft palate 
7525500 Repair of anterior cleft palate with local 
flap 
7525600 Repair of anterior cleft palate with 
vomerine flap 
7525700 Repair of cleft soft palate with intra-velar 
veloplasty 
7525711 Rep anterior cleft palate local flap 
7525712 Plastic repair palate mucosal graft 
7525800 Repair cleft soft palate with other 
musculature correction 
7525y00 Other specified correction of deformity of 
palate 
7525z00 Correction of deformity of palate NOS 
7606000 Closure of tracheooesophageal fistula 
7606011 Excision of tracheooesophageal fistula 
7606200 Correction of congenital atresia of 
oesophagus 
761B100 Repair of congenital atresia of pylorus 
7902.00 Correction of tetralogy of Fallot 
7902000 Correct Fallot tetralogy- valved right 
ventr outflow conduit 
7902100 Correct Fallot tetralogy- right ventric 
outflow conduit NEC 
7902200 Correct Fallot tetralogy- right ventricular 
outflow patch 
7902300 Revision of correction of tetralogy of 
Fallot 
7902y00 Other specified correction of tetralogy of 
Fallot 
7902z00 Correction of tetralogy of Fallot NOS 
7903.00 Atrial inversion ops for transposition of 
great vessels 
7903.11 Mustard interatrial tr venous return 
7903.12 Senning correction for transposition of 
great vessels 
7903000 Atrium reconstruction atrial patch for 
transpos great vessel 
7903100 Atrium reconstruction atrial wall for 
transpos great vessels 
7903y00 Atrial inversion op for transposition of 
great vessels OS 
7903z00 Atrial inversion op for transposition of 
great vessels NOS 
7904.00 Other correction of transposition of great 
vessels 
7904000 Repositioning of transposed great vessels 
7904y00 Other correction of transposition of great 
vessels OS 
7904z00 Other correction of transposition of great 
vessels NOS 
7905.00 Correction of total anomalous pulmonary 
venous connection 
7905000 Correct total anomal pulm venous 
connect to supracard vessel 
7905100 Correct total anomal pulm venous 
connect to coronary sinus 
7905200 Correct total anomal pulm venous 
connect to infradiaph vess 
7905y00 Correction of total anomalous pulmonary 
venous connection OS 
7905z00 Correction total anomalous pulmonary 
venous connection NOS 
7906.00 Closure of defect of atrioventricular 
septum 
7906000 Close defect atrioventric septum using 
dual prosthetic patch 
7906100 Close defect atrioventric septum using 
prosthetic patch NEC 
7906200 Closure defect atrioventricular septum 
using tissue graft 
7906300 Closure of persistent ostium primum 
7906400 Primary closure of defect of 
atrioventricular septum NEC 
7906500 Revision of closure of defect of 
atrioventricular septum 
7906y00 Other specified closure of defect of 
atrioventricular septum 
7906z00 Closure of defect of atrioventricular 
septum NOS 
7907.00 Closure of defect of interatrial septum 
7907000 Closure defect of interatrial septum using 
prosthetic patch 
7907100 Closure defect of interatrial septum using 
pericardial patch 
7907200 Closure defect of interatrial septum using 
tissue graft NEC 
7907300 Primary closure of defect of interatrial 
septum NEC 
7907400 Revision of closure of defect of interatrial 
septum 
7907y00 Other specified closure of defect of 
interatrial septum 
7907z00 Closure of defect of interatrial septum 
NOS 
7908.00 Closure of defect of interventricular 
septum 
7908000 Close defect interventricular septum 
using prosthetic patch 
7908100 Close defect interventricular septum 
using pericardial patch 
7908200 Close defect interventricular septum 
using tissue graft NEC 
7908300 Primary closure of defect of 
interventricular septum NEC 
7908400 Revision of closure of defect of 
interventricular septum 
7908y00 Other specified closure of defect of 
interventricular septum 
7908z00 Closure of defect of interventricular 
septum NOS 
7909.00 Closure of defect of unspecified septum of 
heart 
7909000 Closure of defect of heart septum using 
prosthetic patch NEC 
7909100 Closure defect of heart septum using 
pericardial patch NEC 
7909200 Closure of defect of septum of heart using 
tissue graft NEC 
7909300 Primary closure of defect of septum of 
heart NEC 
7909400 Revision of closure of septum of heart 
NEC 
7909y00 Other specified closure of defect 
unspecified heart septum 
7909z00 Closure of defect of unspecified septum of 
heart NOS 
7A00.00 Open operations for combined 
abnormality of great vessels 
7A00000 Correction of persistent truncus arteriosus 
7A00100 Application of band to persistent truncus 
arteriosus 
7A00200 Repair of hemitruncus arteriosus 
7A00300 Closure of aortopulmonary window 
7A00y00 Open operation for combined abnormality 
of great vessels OS 
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7A00z00 Open operation for combined abnormality 
of great vessels NOS 
7A01.00 Open correction of patent ductus 
arteriosus 
7A01.11 Open correction of patent ductus 
arteriosus (PDA) 
7A01000 Division of patent ductus arteriosus 
7A01100 Ligation of patent ductus arteriosus 
7A01200 Closure of patent ductus arteriosus NEC 
7A01300 Revision of correction of patent ductus 
arteriosus 
7A01y00 Other specified open correction of patent 
ductus arteriosus 
7A01z00 Open correction of patent ductus 
arteriosus NOS 
7A02.00 Transluminal operations on abnormality 
of great vessel 
7A02000 Percut transluminal prosth occlusion 
patent ductus arterios 
7A02011 Percut translum prosth occlus patent 
ductus arteriosus (PDA) 
7A02y00 Transluminal operation on abnormality of 
great vessel OS 
7A02z00 Transluminal operation on abnormality of 
great vessel NOS 
7B41000 Other hypospadias repair 
7B41011 Byars hypospadias repair 
7B41012 Cecil reconstruction of urethra 
7B41013 Denis - Browne hypospadias repair 
7B41014 Ombredanne hypospadias repair 
7B41015 Van der Meulen hypospadias repair 
7B41016 Young hypospadias repair 
7B41017 First stage hypospadias repair 
7B41018 Second stage hypospadias repair 
7B41100 Epispadias repair 
7B41111 Browne-Denis epispadias repair 
7B41112 Denis-Browne epispadias repair 
7B41113 Young-Dees epispadias repair 
7B41700 MAGPI hypospadias repair 
7B41800 Duckett hypospadias repair 
7C04200 Excision of cyst of male hydatid of 
Morgagni 
7C09700 Excision of appendix of testis 
7C09711 Excision of male hydatid of Morgagni 
7F1A300 Drainage of hydrocephalus of fetus to 
facilitate delivery 
7H01000 Correction of pectus deformity of chest 
wall 
7H01011 Correction of pectus carinatum 
7H01012 Correction of pectus excavatum 
7H0D300 Repair of congenital diaphragmatic hernia 
7L0D.00 Correction of congenital deformity of 
shoulder or upper arm 
7L0E.00 Correction of congenital deformity of 
forearm 
7L0F.00 Correction of congenital deformity of 
hand 
7L0F000 Reduction of gigantism of hand 
7L0F100 Correction of mirror hand 
7L0F200 Correction of syndactyly of fingers using 
skin graft 
7L0F300 Correction of syndactyly of fingers using 
skin expander 
7L0F400 Amputation of duplicate thumb 
7L0F500 Amputation of supernumerary finger NEC 
7L0F600 Stabilisation of hypoplastic thumb 
7L0F700 Repositioning of thumb for cleft hand 
7L0F800 Correction of cleft hand 
7L0F900 Release of thumb-in-palm deformity 
7L0FA00 Realignment of congenital ulnar drift 
7L0FB00 Correction of camtodactyly 
7L0FC00 Correction of clinodactyly with osteotomy 
and bone graft 
7L0FD00 Correction of clinodactyly with closing 
wedge osteotomy 
7L0FE00 Correction of clinodactyly with reversed 
wedge osteotomy 
7L0FF00 Correction of radial polydactyly 
7L0FG00 Excision of radial digit & skeletal repair 
for polydactyly 
7L0FH00 Excision of ulnar digit and skeletal repair 
for polydactyly 
7L0FJ00 Correction of macrodactyly 
7L0Fy00 Other specified correction of congenital 
deformity of hand 
7L0Fz00 Correction of congenital deformity of 
hand NOS 
7L0G.00 Correction of congenital deformity of hip 
7L0G000 Open reduction of congenital dislocation 
of hip 
7L0G011 Ferguson open reduction of congenital 
deformity of hip 
7L0G012 Ludloff open reduction of congenital 
deformity of hip 
7L0G100 Primary osteotomy pelvis correction 
congenital deformity hip 
7L0G111 Albee osteotomy of pelvis 
7L0G112 Bosworth osteotomy of pelvis 
7L0G113 Chiari osteotomy of pelvis 
7L0G114 Dial osteotomy of pelvis 
7L0G115 Gill osteotomy of pelvis 
7L0G116 Pemberton osteotomy of ilium 
7L0G117 Salter osteotomy of pelvis 
7L0G118 Shelf procedure for stabilisation of hip 
joint 
7L0G119 Steez osteotomy of pelvis 
7L0G11A Sutherland osteotomy of pelvis 
7L0G200 Secndry arthroplasty hip for correctn 
congenital deformity 
7L0G211 Colonna arthroplasty of hip 
7L0G300 Intraartic soft tiss proced correct 
congenital deformity hip 
7L0G400 Extraarticular proced correction 
congenital deformity of hip 
7L0G500 Osteotomy of ilium correction of 
congenital deformity of hip 
7L0G600 Femoral osteotomy for correction 
congenital deformity of hip 
7L0G700 Pelvic osteotomy for congenital deformity 
of hip 
7L0G800 Salter osteotomy for congenital deformity 
of hip 
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7L0G900 Pemberton osteotomy for congenital 
deformity of hip 
7L0GA00 Chiari osteotomy for congenital deformity 
of hip 
7L0GB00 Colonna osteotomy for congenital 
deformity of hip 
7L0GC00 Shelf procedure for correction congenital 
deformity of hip 
7L0Gy00 Other specified correction of congenital 
deformity of hip 
7L0Gz00 Correction of congenital deformity of hip 
NOS 
7L0Gz11 Adams correction of congenital dislocation 
of hip 
7L0H.00 Correction of congenital deformity of leg 
7L0H000 Open reduction of congenital dislocation 
of knee 
7L0H100 Correction of pseudarthrosis of tibia 
7L0H111 Boyd bone graft pseudarthrosis of tibia 
7L0H112 McFarland bone graft pseudoarthrosis of 
tibia 
7L0H200 Excision of anlage of fibula 
7L0H300 Excision of anlage of tibia 
7L0H400 Centralisation tarsus correction congenital 
deformity of leg 
7L0H500 Reversal rotation plasty ankle correct 
congenital deform leg 
7L0H511 Van Nes rotationplasty for congenital 
deformity 
7L0H600 Coventry tibial osteotomy 
7L0H700 Gruca tibial bifurcation procedure 
7L0H800 Open reduction congenital dislocation of 
patella 
7L0H900 Tibiofibular synostosis for congenital 
deformity 
7L0Hy00 Other specified correction of congenital 
deformity of leg 
7L0Hz00 Correction of congenital deformity of leg 
NOS 
7L0J.00 Primary correction of congenital deformity 
of foot 
7L0J.11 Primary correction of club foot 
7L0J.12 Primary correction of talipes 
7L0J000 Release pantalar joints correction 
congenital deformity foot 
7L0J011 Turco soft tissue release for club foot 
7L0J100 Post release foot joints for correction 
congenital deformity 
7L0J200 Medial release foot joints- correction 
congenital deformity 
7L0J211 Dillwyn operation for club foot 
7L0J212 Evans operation for club foot 
7L0J213 Medial release of joints of foot for 
correction of club foot 
7L0J214 Perkins operation for club foot 
7L0J300 Anterior release foot joints correction 
congenital deformity 
7L0J400 Posteromedial release of clubfoot 
7L0J500 Combined posteromedial + posterolateral 
release of clubfoot 
7L0J600 Lateral release for congenital deformity of 
foot 
7L0J700 Correction of congenital vertical talus 
7L0J800 Complete subtalar release of clubfoot 
7L0Jy00 Primary correction of congenital deformity 
of foot OS 
7L0Jz00 Primary correction of congenital deformity 
of foot NOS 
7L0K.00 Other correction of congenital deformity 
of foot 
7L0K.11 Other operations for club foot 
7L0K.12 Other correction of talipes 
7L0K000 Osteotomy of body of os calcis 
7L0K011 Baker osteotomy of body of os calcis 
7L0K012 Dwyer osteotomy of body of os calcis 
7L0K100 Wedge tarsectomy for correction 
congenital deformity of foot 
7L0K111 Elmslie wedge tarsectomy 
7L0K200 Reduction of gigantism of foot 
7L0K300 Separation of tarsal coalition 
7L0K400 Triple arthrodesis for correction of 
congenital deformity 
7L0K500 Dilwyn Evans proc for correction of 
congenital deformity 
7L0K600 Metatarsal osteotomy for correction of 
congenital deformity 
7L0K700 Closure of cleft foot 
7L0Ky00 Other correction of congenital deformity 
of foot OS 
7L0Kz00 Other correction of congenital deformity 
of foot NOS 
7L0L.00 Correction of minor congenital deformity 
of foot 
7L0L000 Release of Streeter(constriction) band 
7L0L100 Release of syndactyly of toes 
7L0L200 Amputation of supernumerary toe 
7L0L300 Correction of curly fifth toe 
7L0L311 Lapidus transplantation of tendon of fifth 
toe 
7L0L400 Correction of congenital crossed toes 
7L0L500 Reduction of macrodactyly of toe 
7L0Ly00 Correction of minor congenital deformity 
of foot OS 
7L0Lz00 Correction of minor congenital deformity 
of foot NOS 
7L0N.00 Correction of complex craniofacial 
deformity 
7L0N000 Cranio-orbital remodelling for 
plagiocephaly 
7L0N100 Cranio-orbital remodelling for 
trigonocephaly 
7L0N200 Cranio-orbital remodelling, unspecified 
7L0N400 Frontal advancement - fixed 
7L0N500 Correction of oblique facial cleft 
7L0Nz00 Correction of complex craniofacial 
deformity NOS 
9RD0.00 Transfer of care from paediatric 
congenital heart service 
A560200 Rubella deafness 
AD00.00 Toxoplasma meningoencephalitis 
F030700 Encephalitis due to cytomegalovirus 
F030711 Cytomegaloviral encephalitis 
F033400 Encephalitis due to toxoplasmosis 
F033411 Toxoplasmosis encephalitis 
F113000 Normal pressure hydrocephalus 
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F113011 Low pressure hydrocephalus 
F115.00 Hydrocephalus 
F11x300 Cerebral degeneration due to congenital 
hydrocephalus 
F23y511 Congenital suprabulbar paresis 
F427J00 Leber's congenital amaurosis 
F480011 Congenital amblyopia 
F486300 Congenital night blindness NOS 
F4Gy011 Encephalocoele of orbit 
F4K5100 Congenital nystagmus 
F591800 Congenital prelingual deafness 
L236.00 Hydrocephalic disproportion 
L236000 Hydrocephalic disproportion unspecified 
L236200 Hydrocephalic disproportion with 
antenatal problem 
L236z00 Hydrocephalic disproportion NOS 
L253.11 Fetus with suspected rubella damage via 
mother 
L254.12 Suspect fetal damage from maternal 
toxoplasmosis 
P0...00 Anencephalus and similar anomalies 
P00..00 Anencephalus 
P00..11 Congenital absence of brain 
P000.00 Acrania 
P001.00 Amyelencephalus 
P002.00 Hemicephaly 
P002.11 Hemianencephaly 
P00y.00 Other specified anencephalus 
P00z.00 Anencephalus NOS 
P01..00 Craniorachischisis 
P02..00 Iniencephaly 
P020.00 Iniencephaly - closed 
P021.00 Open iniencephaly 
P02z.00 Iniencephaly NOS 
P0z..00 Anencephalus and similar anomalies NOS 
P1...00 Spina bifida 
P10..00 Spina bifida with hydrocephalus 
P10..11 Arnold - Chiari syndrome 
P100.00 Unspecified spina bifida with 
hydrocephalus 
P100000 Spina bifida with hydrocephalus, 
unspecified 
P100100 Cervical spina bifida with hydrocephalus 
P100200 Thoracic spina bifida with hydrocephalus 
P100300 Lumbar spina bifida with hydrocephalus 
P100z00 Spina bifida with hydrocephalus NOS 
P101.00 Arnold - Chiari syndrome 
P101.11 Closed spina bifida with Arnold-Chiari 
malformation 
P101000 Chiari malformation type I 
P101100 Chiari malformation type II 
P101200 Chiari malformation type III 
P101300 Chiari malformation type IV 
P102.00 Spina bifida with hydrocephalus - open 
P102.11 Fissured spine with hydrocephalus 
P102.12 Hydromyelocele with hydrocephalus 
P102.13 Myelocele with hydrocephalus 
P102.14 Rachischisis with hydrocephalus 
P102000 Unspecified spina bifida with 
hydrocephalus - open 
P102100 Cervical spina bifida with hydrocephalus - 
open 
P102200 Thoracic spina bifida with hydrocephalus - 
open 
P102300 Lumbar spina bifida with hydrocephalus - 
open 
P102400 Sacral spina bifida with hydrocephalus - 
open 
P102z00 Spina bifida with hydrocephalus - open 
NOS 
P103.00 Spina bifida with hydrocephalus - closed 
P103000 Unspecified spina bifida with 
hydrocephalus - closed 
P103100 Cervical spina bifida with hydrocephalus - 
closed 
P103200 Thoracic spina bifida with hydrocephalus - 
closed 
P103300 Lumbar spina bifida with hydrocephalus - 
closed 
P103400 Sacral spina bifida with hydrocephalus - 
closed 
P103z00 Spina bifida with hydrocephalus - closed 
NOS 
P103z11 Thoracolumbar spina bifida with 
hydrocephalus - closed 
P104.00 Spina bifida with hydrocephalus of late 
onset 
P105.00 Spina bifida with stenosis of aqueduct of 
Sylvius 
P10y.00 Other specified spina bifida with 
hydrocephalus 
P10y000 Dandy - Walker syndrome with spina 
bifida 
P10yz00 Other spina bifida with hydrocephalus 
NOS 
P10z.00 Spina bifida with hydrocephalus NOS 
P11..00 Spina bifida without mention of 
hydrocephalus 
P110.00 Spina bifida without mention of 
hydrocephalus, unspecified 
P110.11 Split notochord syndrome 
P110000 Spina bifida without hydrocephalus, site 
unspecified 
P110100 Cervical spina bifida without mention of 
hydrocephalus 
P110200 Thoracic spina bifida without mention of 
hydrocephalus 
P110300 Lumbar spina bifida without mention of 
hydrocephalus 
P110z00 Unspecified spina bifida without 
hydrocephalus NOS 
P111.00 Spinal hydromeningocele 
P111000 Spinal hydromeningocele, unspecified 
P111100 Cervical spinal hydromeningocele 
P111200 Thoracic spinal hydromeningocele 
P111z00 Spinal hydromeningocele NOS 
P112.00 Hydromyelocele 
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P112000 Hydromyelocele of unspecified site 
P112100 Cervical hydromyelocele 
P112200 Thoracic hydromyelocele 
P112300 Lumbar hydromyelocele 
P112z00 Hydromyelocele NOS 
P113.00 Spinal meningocele 
P113000 Spinal meningocele of unspecified site 
P113100 Cervical spinal meningocele 
P113200 Thoracic spinal meningocele 
P113300 Lumbar spinal meningocele 
P113z00 Spinal meningocele NOS 
P114.00 Meningomyelocele 
P114000 Meningomyelocele of unspecified site 
P114100 Cervical meningomyelocele 
P114200 Thoracic meningomyelocele 
P114300 Lumbar meningomyelocele 
P114z00 Meningomyelocele NOS 
P115.00 Myelocele 
P115000 Myelocele of unspecified site 
P115100 Cervical myelocele 
P115200 Thoracic myelocele 
P115300 Lumbar myelocele 
P115z00 Myelocele NOS 
P116.00 Myelocystocele 
P116000 Myelocystocele of unspecified site 
P116100 Cervical myelocystocele 
P116200 Thoracic myelocystocele 
P116300 Lumbar myelocystocele 
P116z00 Myelocystocele NOS 
P117.00 Spina bifida without hydrocephalus - open 
P117.11 Fissured spine 
P117.12 Rachischisis 
P117000 Unspecified spina bifida without 
hydrocephalus - open 
P117100 Cervical spina bifida without 
hydrocephalus - open 
P117200 Thoracic spina bifida without 
hydrocephalus - open 
P117300 Lumbar spina bifida without 
hydrocephalus - open 
P117400 Sacral spina bifida without hydrocephalus 
- open 
P117z00 Spina bifida without hydrocephalus - open 
NOS 
P118.00 Spina bifida without hydrocephalus - 
closed 
P118000 Unspecified spina bifida without 
hydrocephalus - closed 
P118100 Cervical spina bifida without 
hydrocephalus - closed 
P118200 Thoracic spina bifida without 
hydrocephalus - closed 
P118300 Lumbar spina bifida without 
hydrocephalus - closed 
P118400 Sacral spina bifida without hydrocephalus 
- closed 
P118z00 Spina bifida without hydrocephalus - 
closed NOS 
P118z11 Thoracolumbar spina bifida without 
hydrocephalus - closed 
P11y.00 Other specified spina bifida without 
hydrocephalus 
P11y.11 Syringomyelocele 
P11z.00 Spina bifida without mention of 
hydrocephalus NOS 
P11z.11 Rachischisis 
P11z.12 Syringomyelocele 
P11z.13 Billroth's disease 
P11z.14 Congenital hernia of dura mater 
P1z..00 Spina bifida NOS 
P2...00 Other nervous system congenital 
anomalies 
P20..00 Encephalocele 
P20..11 Hydroencephalocele 
P20..12 Cephalocele 
P20..13 Congenital cerebral hernia 
P20..14 Congenital endaural hernia 
P20..15 Sinus pericranii 
P20..16 Congenitalcerebral hernia 
P200.00 Encephalocystocele 
P201.00 Encephalomyelocele 
P202.00 Hydromeningocele - cranial 
P203.00 Meningocele - cerebral 
P203.11 Meningocele - cranial 
P204.00 Meningoencephalocele 
P205.00 Frontal encephalocele 
P206.00 Nasofrontal encephalocele 
P20z.00 Encephalocele NOS 
P20z000 Occipital encephalocele 
P20z100 Encephalocele of other specified site 
P20z111 Absence of roof of orbit 
P21..00 Microcephalus 
P210.00 Hydromicrocephaly 
P211.00 Micrencephaly 
P21z.00 Microcephalus NOS 
P22..00 Reduction deformities of brain 
P220.00 Agenesis of brain, part unspecified 
P221.00 Aplasia of brain, part unspecified 
P222.00 Hypoplasia of brain, part unspecified 
P223.00 Agyria 
P223.11 Lissencephaly 
P224.00 Arhinencephaly 
P225.00 Holoprosencephaly 
P226.00 Microgyria 
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P226.11 Hypoplasia of brain gyri 
P226000 Congenital bilateral perisylvian syndrome 
P227.00 Anomalies of cerebrum 
P227000 Agenesis of cerebrum 
P227100 Congenital hypoplasia of cerebrum 
P227z00 Anomaly of cerebrum NOS 
P228.00 Anomalies of corpus callosum 
P228000 Congenital absence of corpus callosum 
P228011 Agenesis of corpus callosum 
P228100 Hypoplasia of corpus callosum 
P228200 Aplasia of corpus callosum 
P228300 Aicardi syndrome 
P228z00 Anomaly of corpus callosum NOS 
P229.00 Anomalies of hypothalamus 
P22A.00 Anomalies of cerebellum 
P22A000 Congenital absence of cerebellum 
P22A011 Agenesis of cerebellum 
P22A100 Hypoplasia of cerebellum 
P22A200 Aplasia of cerebellum 
P22Az00 Anomaly of cerebellum NOS 
P22y.00 Other specified reduction deformities of 
brain 
P22y000 Cebocephaly 
P22y100 Familial aplasia of the vermis 
P22y111 Joubert syndrome 
P22y200 Gillespie syndrome 
P22y300 Partial absence of septum pellucidum 
P22yz00 Other reduction deformity of brain NOS 
P22z.00 Reduction deformities of brain NOS 
P22z.11 Cerebellar hypoplasia 
P22z.12 Agenesis of part of brain NEC 
P22z.13 Hypoplasia of part of brain NEC 
P22z.14 Aplasia of part of brain NEC 
P23..00 Congenital hydrocephalus 
P230.00 Aqueduct of Sylvius anomaly 
P230.11 Hydrocephauls with anomaly of aqueduct 
of Sylvius 
P230.12 Stenosis of aqueduct of Sylvius 
P230000 Aqueduct of Sylvius obstruction 
P230011 Aqueduct of Sylvius septum NEC 
P230100 Aqueduct of Sylvius stenosis 
P230200 Atresia of aqueduct of Sylvius NEC 
P230z00 Aqueduct of Sylvius anomaly NOS 
P231.00 Foramen of Magendie atresia 
P232.00 Foramen of Luschka atresia 
P233.00 Atresia of foramina of Magendie and 
Luschka 
P233.11 Dandy - Walker syndrome 
P233.12 Hydrocephalus with atresia of foramina of 
Magendie+Luschka 
P234.00 Hydranencephaly 
P23y.00 Other specified congenital hydrocephalus 
P23z.00 Congenital hydrocephalus NOS 
P24..00 Other specified brain anomalies 
P240.00 Congenital cerebral cyst 
P240.11 Congenital intracerebral cyst 
P240000 Single congenital cerebral cyst 
P240100 Multiple congenital cerebral cysts 
P240200 Schizencephaly 
P240z00 Congenital cerebral cyst NOS 
P241.00 Macroencephaly 
P241.11 Megalencephaly 
P241.12 Enlarged brain 
P241.13 Macrocephaly 
P242.00 Macrogyria 
P243.00 Porencephaly 
P244.00 Ulegyria 
P245.00 Congenital adhesions of cerebral 
meninges 
P246.00 Septo-optic dysplasia 
P247.00 Dysplasia of cerebral cortex 
P248.00 Congenital dilated lateral ventricles of 
brain 
P249.00 Megalencephaly 
P24A.00 Hemimegalencephaly 
P24x.00 Multiple brain anomalies 
P24z.00 Other specified brain anomalies NOS 
P25..00 Other specified spinal cord anomalies 
P250.00 Diastematomyelia 
P251.00 Hydromyelia 
P251.11 Hydrorachis 
P252.00 Congenital tethering of spinal cord 
P25y.00 Other specified anomalies of spinal cord 
P25y.11 Neuroenteric cyst 
P25y000 Amyelia 
P25y100 Atelomyelia 
P25y111 Myelatelia 
P25y112 Myelodysplasia of spinal cord 
P25y200 Congenital anomaly of spinal meninges 
P25y300 Defective development of the cauda 
equina 
P25y400 Spinal cord hypoplasia 
P25yz00 Other specified spinal cord anomalies 
NOS 
P25z.00 Spinal cord anomalies NOS 
P2x..00 Other specified nervous system 
anomalies 
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P2x0.00 Agenesis of nerve, unspecified 
P2x1.00 Brachial plexus displacement 
P2x2.00 Familial dysautonomia 
P2x3.00 Jaw-winking syndrome 
P2x4.00 Marcus - Gunn syndrome 
P2x5.00 Riley - Day syndrome 
P2x6.00 Chiari malformation type I 
P2x7.00 Congenital facial nerve palsy 
P2x8.00 Structural central nervous system 
abnormality 
P2xz.00 Other specified nervous system 
anomalies NOS 
P2xz000 Agenesis of nerve NEC 
P2xz100 Congenital optic atrophy 
P2y..00 Unspec nervous system anomaly of 
brain/cord/nervous system 
P2y0.00 Congenital brain anomaly 
P2y1.00 Congenital spinal cord anomaly 
P2yz.00 Unspecified nervous system anomaly NOS 
P2z..00 Nervous system anomalies NOS 
P3...00 Congenital eye anomalies 
P30..00 Anophthalmos 
P300.00 Clinical anophthalmos, unspecified 
P300100 Agenesis of eye 
P300200 Congenital absence of eye 
P300z00 Anophthalmos NOS 
P301.00 Congenital cystic eyeball 
P302.00 Cryptophthalmos syndrome 
P303.00 Congenital absence of eyes 
P30z.00 Anophthalmos NOS 
P31..00 Microphthalmos 
P310.00 Microphthalmos, unspecified 
P310000 Dysplasia of eye 
P310100 Hypoplasia of eye 
P310200 Rudimentary eye 
P310z00 Unspecified microphthalmos NOS 
P311.00 Simple microphthalmos 
P312.00 Microphthalmos with other eye anomaly 
P313.00 Lenz microphthalmia syndrome 
P31z.00 Microphthalmos NOS 
P32..00 Buphthalmos 
P320.00 Buphthalmos, unspecified 
P320000 Congenital glaucoma 
P320011 Newborn glaucoma 
P320100 Hydrophthalmos 
P320z00 Unspecified buphthalmos NOS 
P321.00 Simple buphthalmos 
P321.11 Enlarged eye NOS 
P322.00 Buphthalmos with other eye anomaly 
P322000 Congenital keratoglobus 
P322100 Congenital megalocornea 
P322111 Enlarged cornea 
P322112 Congenital macrocornea 
P322z00 Buphthalmos with other eye anomaly 
NOS 
P32z.00 Buphthalmos NOS 
P33..00 Congenital cataract and lens anomalies 
P33..11 Congenital lens anomaly 
P330.00 Congenital cataract, unspecified 
P331.00 Capsular and subcapsular cataract 
P331000 Capsular cataract 
P331100 Subcapsular cataract 
P331z00 Capsular or subcapsular cataract NOS 
P332.00 Cortical and zonular cataract 
P332000 Cortical cataract - congenital 
P332100 Zonular cataract 
P332z00 Cortical or zonular cataract NOS 
P333.00 Nuclear cataract - congenital 
P334.00 Total and subtotal congenital cataract 
P334000 Total congenital cataract 
P334100 Subtotal congenital cataract 
P334z00 Total or subtotal congenital cataract NOS 
P335.00 Congenital aphakia 
P335.11 Congenital absence of lens 
P335.12 Agenesis of lens 
P336.00 Anomalies of lens shape 
P336000 Microphakia 
P336100 Spherophakia 
P336111 Spherical lens 
P336200 Coloboma of lens 
P336z00 Anomalies of lens shape NOS 
P337.00 Congenital ectopic lens 
P337.11 Congenital displaced lens 
P337.12 Congenital dislocation of lens 
P33y.00 Other specified congenital cataract or lens 
anomaly 
P33y000 Blue dot cataract 
P33y100 Congenital membranous cataract 
P33yz00 Other congenital cataract or lens anomaly 
NOS 
P33z.00 Congenital cataract or lens anomaly NOS 
P34..00 Anterior chamber anomalies 
P340.00 Corneal size and shape anomalies 
P340000 Microcornea 
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P340100 Congenital keratoconus 
P340200 Cornea plana 
P340z00 Corneal size or shape anomalies NOS 
P341.00 Congenital corneal opacities 
P341.11 Arcus juvenilis 
P341000 Congenital corneal opacity with visual 
deficit 
P341100 Congenital corneal opacity without visual 
deficit 
P341z00 Congenital corneal opacities NOS 
P342.00 Specified anterior chamber anomalies 
P342000 Axenfield's anomaly 
P342100 Peter's anomaly 
P342200 Rieger's anomaly 
P342z00 Specified anterior chamber anomalies 
NOS 
P343.00 Aniridia 
P343.11 Congenital absence of iris 
P343.12 Agenesis of iris 
P344.00 Other iris and ciliary body anomalies 
P344.11 Goniodysgenesis 
P344000 Congenital anisocoria 
P344100 Atresia of pupil 
P344200 Coloboma of iris 
P344300 Corectopia 
P344311 Ectopic pupil 
P344400 Polycoria 
P344500 Hypoplasia of iris 
P344600 Aplasia of iris 
P344z00 Other iris or ciliary body anomalies NOS 
P345.00 Specified anomalies of sclera 
P345000 Blue sclera 
P345z00 Specified anomaly of sclera NOS 
P346.00 Multiple anterior segment anomalies 
P34y.00 Other specified anterior segment 
anomalies 
P34z.00 Anterior segment anomalies NOS 
P35..00 Posterior chamber congenital anomalies 
P350.00 Vitreous anomalies 
P350000 Congenital vitreous opacity 
P350z00 Vitreous anomalies NOS 
P351.00 Fundus coloboma 
P352.00 Congenital chorioretinal degeneration 
P353.00 Congenital folds and cysts of the posterior 
segment 
P353000 Congenital folds of the posterior segment 
P353100 Congenital cysts of the posterior segment 
P353z00 Congenital folds or cysts of the posterior 
segment NOS 
P354.00 Congenital macular changes 
P355.00 Other congenital retinal changes 
P355000 Coloboma of retina 
P355100 Congenital retinal fold 
P355200 Congenital hypertrophy of retinal pigment 
epithelium 
P355z00 Other congenital retinal changes NOS 
P356.00 Specified optic disc anomalies 
P356.11 Optic disc congenital anomalies 
P356000 Congenital optic disc coloboma 
P356z00 Specified optic disc anomaly NOS 
P357.00 Posterior chamber vascular anomalies 
P357000 Congenital retinal aneurysm 
P357100 Congenital arteriovenous malformation of 
retina 
P357200 Congenital stricture of retinal artery 
P357z00 Posterior chamber vascular anomalies 
NOS 
P358.00 Specified anomalies of choroid 
P358000 Coloboma of choroid 
P358z00 Specified anomaly of choroid NOS 
P35y.00 Other specified congenital anomalies of 
posterior chamber 
P35z.00 Congenital anomalies of posterior 
chamber NOS 
P36..00 Congenital anomalies of eyelid, lacrimal 
system and orbit 
P360.00 Congenital ptosis 
P360.11 Blepharoptosis 
P361.00 Congenital eyelid deformity 
P361000 Ablepharon -absent eyelids 
P361100 Accessory eyelid 
P361200 Congenital entropion 
P361300 Congenital ectropion 
P361400 Congenital blepharophimosis 
P361500 Coloboma of eyelids 
P361z00 Congenital eyelid deformity NOS 
P362.00 Other specified congenital eyelid 
anomalies 
P362000 Agenesis of cilia 
P362100 Agenesis of eyelid 
P362200 Fused eyelids 
P362300 Hypoplasia of eyelid 
P362z00 Other specified congenital eyelid 
anomalies NOS 
P363.00 Congenital lacrimal gland anomalies 
P364.00 Congenital lacrimal passage anomalies 
P364.11 Congenital blocked tear duct 
P364000 Agenesis of lacrimal apparatus 
P364011 Congenital absence of lacrimal apparatus 
P364100 Agenesis of punctum lacrimale 
P364111 Congenital absence of punctum lacrimale 
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P364200 Accessory lacrimal canal 
P364300 Stenosis or stricture of lacrimal duct 
P364400 Congenital blocked tear duct 
P364y00 Other specified congenital anomaly of 
lacrimal passages 
P364z00 Congenital anomaly of lacrimal passages 
NOS 
P365.00 Congenital orbit anomalies 
P36z.00 Other/unspecified anomalies of 
eyelid/lacrimal system/orbit 
P36z000 Accessory eye muscles 
P36z100 Hypoplasia of eye muscle 
P36zz00 Eyelid, lacrimal system and orbit 
congenital anomalies NOS 
P37..00 Macrophthalmos 
P3y..00 Other specified eye anomalies 
P3y0.00 Ocular albinism 
P3yz.00 Other eye anomalies NOS 
P3z..00 Congenital eye anomalies NOS 
P4...00 Ear, face and neck congenital anomalies 
P40..00 Ear anomalies with hearing impairment 
P400.00 Ear anomalies with hearing impaired, 
unspecified 
P401.00 Congenital absence of external ear 
P401000 Congenital absence of external ear, 
unspecified 
P401011 Absence of ear NOS 
P401100 Absence of external auditory canal 
P401200 Ear auricle and external auditory canal 
absent 
P401211 Congenital absence ear auricle 
P401300 Congenital absence of auricle 
P401z00 Absence of external ear NOS 
P402.00 Other external ear anomaly with hearing 
impairment 
P402000 Atresia of external auditory canal 
P402100 Stenosis of external auditory canal 
P402111 Congenital stricture of external auditory 
canal 
P402112 Congenital stricture of osseous meatus 
P402z00 Other external ear anomaly with hearing 
impairment NOS 
P403.00 Middle ear anomaly, excluding ossicles 
P403000 Ear osseous meatus atresia 
P403100 Ear osseous meatus stricture 
P403z00 Middle ear anomaly NEC NOS 
P404.00 Anomaly of ossicles 
P404000 Congenital fusion of ear ossicles 
P404z00 Anomaly of ossicles NOS 
P405.00 Inner ear anomalies 
P405000 Congenital anomaly of the membranous 
labyrinth 
P405100 Congenital anomaly of the organ of Corti 
P405z00 Inner ear anomalies NOS 
P40z.00 Other and unspecified ear anomaly with 
hearing impaired 
P40z.11 Deafness due to congenital anomaly NEC 
P40z000 Congenital absence of ear NOS 
P40zz00 Ear anomaly with hearing impaired NOS 
P41..00 Accessory ear auricle 
P41..11 Polyotia 
P410.00 Supernumerary ear 
P411.00 Accessory tragus 
P412.00 Supernumerary ear lobule 
P413.00 Preauricular appendage, tag or lobule 
P413.11 Preauricular appendage 
P413.12 Preauricular tag 
P413.13 Preauricular lobule 
P414.00 Other ear appendage or tag 
P414.11 Other ear appendage 
P414.12 Other ear tag 
P41z.00 Accessory ear auricle NOS 
P42..00 Other specified ear anomalies 
P420.00 Congenital ear lobe absence 
P421.00 Macrotia - abnormally big ears 
P421.11 Congenital big ears 
P422.00 Microtia - abnormally small ears 
P422.11 Congenital small ears 
P423.00 Eustachian tube anomalies 
P423000 Congenital absence of eustachian tube 
P423100 Congenital stenosis of eustachian tube 
P423z00 Eustachian tube anomalies NOS 
P42z.00 Other specified ear anomalies NOS 
P42z000 Congenital Bat ear 
P42z100 Darwin's tubercle 
P42z200 Congenital pointed ear 
P42z300 Congenital prominent auricle 
P42z400 Congenital ridge ear 
P42z500 Other mis-shapen ear 
P42z511 Aztec ear 
P42z512 Cat ear 
P42z513 Vulcan ear 
P42z600 Misplaced ears 
P42z611 Low-set ears 
P42zz00 Other ear anomalies NOS 
P43..00 Congenital ear anomaly NOS 
P44..00 Branchial cleft, cyst or fistula; 
preauricular sinus 
P440.00 Branchial cleft sinus and fistula 
P440.11 Branchial cleft 
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P440.12 Branchial cleft sinus 
P440000 Branchial cleft vestige, unspecified 
P440100 Branchial cleft external sinus 
P440200 Branchial cleft internal sinus 
P440300 Branchial cleft fistula 
P440z00 Branchial cleft vestige NOS 
P441.00 Branchial cleft cyst 
P442.00 Cervical auricle 
P443.00 Preauricular sinus and fistula 
P443000 Preauricular sinus 
P443100 Preauricular fistula 
P443z00 Preauricular sinus or fistula NOS 
P444.00 Preauricular cyst 
P44y.00 Other branchial cleft anomalies 
P44z.00 Branchial cleft,cyst,or fistula preauricular 
anomaly OS/NOS 
P44z000 Fistula of congenital auricle 
P44z100 Cervicoaural fistula 
P44zz00 Branchial cleft, cyst or fistula preauricular 
anomaly NOS 
P45..00 Congenital webbing of neck 
P450.00 Congenital neck webbing, unspecified 
P451.00 Pterygium colli 
P45z.00 Congenital webbing of neck NOS 
P4y..00 Other specified face and neck anomalies 
P4y0.00 Macrocheilia 
P4y0.11 Lip hypertrophy 
P4y1.00 Microcheilia 
P4y2.00 Macrostomia 
P4y2.11 Congenital hypertrophy of lip 
P4y3.00 Microstomia 
P4y4.00 Congenital absence of chin 
P4y5.00 Mid-facial hypoplasia 
P4yz.00 Other specified face and neck anomalies 
NOS 
P4z..00 Congenital face or neck anomaly NOS 
P4z0.00 Congenital anomaly of neck NOS 
P4z1.00 Congenital anomaly of face NOS 
P5...00 Bulbus cordis and cardiac septal closure 
anomalies 
P5...11 Cardiac septal defects 
P5...12 Congenital heart disease, septal and 
bulbar anomalies 
P5...13 Heart septal defects 
P50..00 Common aorto-pulmonary trunk 
P50..11 Aortic septal defect 
P50..12 Common truncus 
P50..13 Persistent truncus arteriosus 
P500.00 Absent septum between aorta and 
pulmonary artery 
P500.11 Persistent truncus arteriosus 
P500.12 Truncus arteriosus 
P501.00 Aortic septal defect 
P501.11 Aortopulmonary window 
P501.12 Aorticopulmonary septal defect 
P502.00 Persistent truncus arteriosus 
P502.11 Truncus arteriosus 
P50z.00 Common aorto-pulmonary trunk NOS 
P51..00 Transposition of great vessels 
P510.00 Total great vessel transposition 
P511.00 Double outlet right ventricle 
P511000 Double outlet right ventricle, unspecified 
P511100 Dextratransposition of aorta 
P511200 Incomplete great vessel transposition 
P511300 Taussig-Bing syndrome 
P511z00 Double outlet right ventricle NOS 
P512.00 Corrected great vessel transposition 
P51y.00 Other specified transposition of great 
vessels 
P51y.11 Transposition of aorta 
P51z.00 Great vessel transposition NOS 
P51z.11 Transposition of arterial trunk NEC 
P52..00 Tetralogy of Fallot 
P520.00 Tetralogy of Fallot, unspecified 
P520.11 Ventricular septal defect in Fallot's 
tetralogy 
P520.12 Dextraposition of aorta in Fallot's 
tetralogy 
P521.00 Pentalogy of Fallot 
P52z.00 Tetralogy of Fallot NOS 
P53..00 Common ventricle 
P54..00 Ventricular septal defect 
P540.00 Ventricular septal defect, unspecified 
P541.00 Interventricular septal defect 
P542.00 Left ventricle to right atrial 
communication 
P543.00 Eisenmenger's complex 
P544.00 Gerbode's defect 
P545.00 Roger's disease 
P54y.00 Other specified ventricular septal defect 
P54z.00 Ventricular septal defect NOS 
P55..00 Ostium secundum atrial septal defect 
P550.00 Atrial septal defect NOS 
P550.11 Auricular septal defect NOS 
P550.12 Interatrial septal defect NEC 
P550.13 Interauricular septal defect 
P551.00 Patent foramen ovale 
P552.00 Persistent ostium secundum 
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P552.11 Patent ostium secundum 
P553.00 Lutembacher's syndrome 
P55y.00 Other specified ostium secundum atrial 
septal defect 
P55y.11 Other specified atrial septal defect 
P55z.00 Ostium secundum atrial septal defect 
NOS 
P56..00 Endocardial cushion defects 
P560.00 Endocardial cushion defects, unspecified 
P561.00 Ostium primum defect 
P561.11 Persistent ostium primum 
P561.12 Ostium primum type interauricular septal 
defect 
P56y.00 Other specified endocardial cushion 
defects 
P56z.00 Endocardial cushion defects NOS 
P56z000 Common atrium 
P56z011 Cor triloculare biventriculare 
P56z100 Common atrioventricular canal 
P56z200 Common atrioventricular-type ventricular 
septal defect 
P56zz00 Endocardial cushion defects NOS 
P57..00 Cor biloculare 
P58..00 Double outlet left ventricle 
P59..00 Isomerism of atrial appendages 
P5X..00 Congenital malforms of cardiac 
chambers+connections unsp 
P5y..00 Other heart bulb and septal closure defect 
P5z..00 Heart bulb or septal closure defects NOS 
P6...00 Other congenital heart anomalies 
P60..00 Pulmonary valve anomalies 
P600.00 Pulmonary valve anomaly, unspecified 
P601.00 Congenital atresia of the pulmonary valve 
P601000 Hypoplasia of pulmonary valve 
P601z00 Congenital atresia of pulmonary valve 
NOS 
P602.00 Congenital pulmonary stenosis 
P602000 Congenital fusion of pulmonic cusps 
P602100 Congenital fusion of pulmonary valve 
segment 
P602z00 Congenital pulmonary stenosis NOS 
P603.00 Right hypoplastic heart syndrome 
P603.11 Pseudotruncus arteriosus 
P60z.00 Other pulmonary valve anomalies 
P60z000 Congenital insufficiency of the pulmonary 
valve 
P60z100 Fallot's trilogy 
P60z200 Supernumerary pulmonary valve cusps 
P60zz00 Other pulmonary valve anomaly NOS 
P61..00 Congenital tricuspid atresia and stenosis 
P610.00 Congenital tricuspid atresia 
P611.00 Congenital tricuspid stenosis 
P61z.00 Congenital tricuspid atresia or stenosis 
NOS 
P62..00 Ebstein's anomaly 
P63..00 Congenital aortic valve stenosis 
P64..00 Congenital aortic valve insufficiency 
P640.00 Congenital aortic valve insufficiency, 
unspecified 
P641.00 Bicuspid aortic valve 
P64z.00 Congenital aortic valve insufficiency NOS 
P65..00 Congenital mitral stenosis 
P65..11 Duroziez's disease 
P650.00 Congenital mitral stenosis, unspecified 
P651.00 Fused commissure of the mitral valve 
P652.00 Parachute deformity of the mitral valve 
P653.00 Supernumerary cusps of the mitral valve 
P65z.00 Congenital mitral stenosis NOS 
P66..00 Congenital mitral insufficiency 
P67..00 Hypoplastic left heart syndrome 
P68..00 Congenital heart disease 
P6W..00 Congenital malformation of aortic and 
mitral valves unsp 
P6X..00 Congenital malformation of tricuspid 
valve, unspecified 
P6y..00 Other specified heart anomalies 
P6y0.00 Subaortic stenosis 
P6y1.00 Cor triatriatum 
P6y2.00 Pulmonary infundibular stenosis 
P6y3.00 Obstructive heart anomaly NEC 
P6y3000 Uhl's disease 
P6y3z00 Obstructive heart anomaly NEC NOS 
P6y4.00 Coronary artery anomaly 
P6y4000 Congenital absence of coronary artery 
P6y4100 Single coronary artery 
P6y4200 Coronary artery from aorta 
P6y4300 Coronary artery from pulmonary trunk 
P6y4400 Anomalous coronary artery 
communication 
P6y4411 Congenital coronary arterio-venous fistula 
P6y4500 Congenital coronary aneurysm 
P6y4600 Congenital stricture of coronary artery 
P6y4z00 Coronary artery anomaly NOS 
P6y5.00 Congenital heart block 
P6y5000 Congenital heart block, unspecified 
P6y5100 Congenital complete atrio-ventricular 
heart block 
P6y5200 Congenital incomplete atrio-ventricular 
heart block 
P6y5z00 Congenital heart block NOS 
P6y6.00 Heart and cardiac apex malposition 
P6y6.11 Ectopic heart 
P6y6000 Dextrocardia 
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P6y6100 Levocardia 
P6y6111 Laevocardia 
P6y6200 Mesocardia 
P6y6300 Ectopia cordis 
P6y6400 Abdominal heart 
P6y6z00 Heart or cardiac apex malposition NOS 
P6y7.00 Myocardial bridge of coronary artery 
P6y8.00 Congenital dextroposition of heart 
P6yy.00 Other specified heart anomalies 
P6yy.11 Hypoplastic aortic orifice or valve 
P6yy.12 Hypoplasia of heart NOS 
P6yy.13 Congenital insufficiency of heart valve 
NEC 
P6yy000 Atresia of cardiac vein 
P6yy100 Hypoplasia of cardiac vein 
P6yy200 Congenital cardiomegaly 
P6yy300 Congenital left ventricular diverticulum 
P6yy400 Congenital pericardial defect 
P6yy411 Congenital absence of pericardium 
P6yy500 Congenital anomaly of myocardium 
P6yy600 Congenital aneurysm of heart 
P6yy700 Atresia of heart valve NEC 
P6yy800 Cor triloculare 
P6yy900 Congenital epicardial cyst 
P6yyA00 Hemicardia 
P6yyB00 Supernumerary heart valve cusps NEC 
P6yyC00 Fusion of mitral valve cusps 
P6yyD00 Fusion of heart valve cusps NEC 
P6yyD11 Fusion of tricuspid valve cusps NEC 
P6yyz00 Other specified heart anomalies NOS 
P6z..00 Congenital heart anomaly NOS 
P6z..11 Chiari's malformation 
P6z0.00 Unspecified anomaly of heart valve 
P6z1.00 Anomalous bands of heart 
P6z1000 Anomalous atrial bands 
P6z1100 Anomalous ventricular bands 
P6z1z00 Anomalous bands of heart NOS 
P6z2.00 Acyanotic congenital heart disease NOS 
P6z3.00 Cyanotic congenital heart disease NOS 
P6z3.11 Blue baby 
P6zz.00 Congenital heart anomaly NOS 
P7...00 Other congenital circulatory system 
anomalies 
P70..00 Patent ductus arteriosus 
P70..11 Botalli's patent ductus 
P71..00 Coarctation of aorta 
P710.00 Hypoplasia of aortic arch, unspecified 
P711.00 Preductal coarctation of aorta 
P711.11 Preductal hypoplasia of aorta 
P711.12 Preductal interruption of aorta 
P711.13 Preductal aortic stenosis 
P712.00 Postductal coarctation of aorta 
P712.11 Postductal hypoplasia of aorta 
P712.12 Postductal interruption of aorta 
P712.13 Postductal aortic stenosis 
P713.00 Interruption of aortic arch 
P713.11 Stenosis of aortic arch 
P71z.00 Coarctation of aorta NOS 
P72..00 Other anomalies of aorta 
P72..11 Anomalies of the aorta excluding 
coarction 
P720.00 Anomaly of aorta, unspecified 
P721.00 Aortic arch anomalies 
P721000 Anomalous origin of the aortic arch 
P721100 Dextraposition of aorta 
P721111 Overriding aorta 
P721200 Double aortic arch 
P721211 Vascular ring 
P721300 Kommerell's diverticulum 
P721400 Persistent aortic arch convolutions 
P721500 Persistent right aortic arch 
P721600 Vascular ring, aorta 
P721700 Overriding aorta 
P721z00 Aortic arch anomalies NOS 
P722.00 Atresia and stenosis of aorta 
P722000 Congenital absence of aorta 
P722100 Aplasia of aorta 
P722200 Hypoplasia of aorta 
P722211 Tubular hypoplasia of aorta 
P722300 Stricture of aorta 
P722400 Supra-valvular aortic stenosis 
P722411 Congenital stenosis of ascending aorta 
P722500 Atresia of aorta 
P722z00 Atresia or stenosis of aorta NOS 
P72z.00 Other anomalies of aorta NOS 
P72z000 Aneurysm of sinus of Valsalva 
P72z100 Congenital aneurysm of aorta 
P72z111 Congenital dilatation of aorta 
P72zz00 Other anomaly of aorta NOS 
P73..00 Pulmonary artery anomalies 
P730.00 Pulmonary artery anomaly, unspecified 
355 
 
P731.00 Pulmonary artery agenesis 
P731.11 Congenital absence of pulmonary artery 
P732.00 Pulmonary artery atresia 
P733.00 Coarctation of the pulmonary artery 
P734.00 Hypoplasia of the pulmonary artery 
P735.00 Stenosis of pulmonary artery 
P735.11 Congenital stricture of pulmonary artery 
P736.00 Pulmonary arterio-venous aneurysm 
P736.11 Pulmonary arterio-venous fistula 
P736.12 Pulmonary arterio-venous malformation 
P737.00 Pulmonary artery aneurysm 
P737.11 Dilatation of pulmonary artery 
P738.00 Atresia of pulmonary artery with septal 
defect 
P73y.00 Other specified anomaly of pulmonary 
artery 
P73z.00 Pulmonary artery anomaly NOS 
P74..00 Anomalies of great veins 
P740.00 Anomaly of great veins, unspecified 
P740000 Anomaly of the pulmonary veins, 
unspecified 
P740100 Anomaly of the vena cava, unspecified 
P740z00 Unspecified anomaly of the great veins, 
NOS 
P741.00 Total anomalous pulmonary venous 
return - TAPVR 
P741000 Subdiaphragmatic total anomalous 
pulmonary venous return 
P741100 Supradiaphragmatic total anomalous 
pulmonary venous return 
P741z00 Total anomalous pulmonary venous 
return NOS 
P742.00 Partial anomalous pulmonary venous 
return 
P742.11 Anomalous termination of right 
pulmonary vein 
P743.00 Anomalous portal vein termination 
P744.00 Portal vein - hepatic artery fistula 
P74z.00 Other great vein anomalies 
P74z.11 Persistent left posterior cardinal vein 
P74z000 Absence of inferior vena cava 
P74z100 Absence of superior vena cava 
P74z200 Stenosis of inferior vena cava 
P74z300 Stenosis of superior vena cava 
P74z400 Persistent left posterior cardinal vein 
P74z500 Persistent left superior vena cava 
P74z600 Scimitar syndrome 
P74z700 Transposition of pulmonary veins 
P74z800 Atresia of pulmonary vein 
P74zz00 Other great vein anomaly NOS 
P75..00 Absence or hypoplasia of the umbilical 
artery 
P750.00 Congenital absence of umbilical artery, 
unspecified 
P751.00 Umbilical artery hypoplasia, unspecified 
P752.00 Single umbilical artery 
P753.00 Two umbilical vessels 
P75z.00 Absence or hypoplasia of the umbilical 
artery NOS 
P76..00 Other peripheral vascular system 
anomalies 
P76..11 Other congenital anomalies of peripheral 
arteries 
P76..12 Other congenital anomalies of peripheral 
veins 
P760.00 Absence of artery NEC 
P761.00 Anomaly of artery NEC 
P762.00 Atresia of artery NEC 
P763.00 Absence of vein NEC 
P764.00 Anomaly of vein NEC 
P765.00 Atresia of vein NEC 
P766.00 Peripheral arterio-venous aneurysm 
P766.11 Peripheral arterio-venous malformation 
P767.00 Congenital peripheral aneurysm 
P767.11 Cirsoid aneurysm 
P768.00 Congenital phlebectasia 
P769.00 Congenital arterial stricture 
P769000 Renal artery stenosis 
P76A.00 Congenital varix 
P76B.00 Multiple renal arteries 
P76B.11 Accessory renal artery 
P76C.00 Anomalies of renal artery NEC 
P76C000 Aberrant main renal artery 
P76Cz00 Anomaly of renal artery NEC NOS 
P76D.00 Arteriovenous malformation 
P76E.00 Aber retro-oesophag subclavian artery 
causing dysphag lusori 
P76y.00 Congenital anomaly of peripheral vascular 
system OS 
P76y000 Hypoplasia of spinal vessel 
P76y100 Four vessels in umbilical cord 
P76yz00 Other congenital anomaly of peripheral 
vascular system NOS 
P76z.00 Peripheral vascular system anomaly NOS 
P77..00 Arteriovenous malformation of 
precerebral vessels 
P7W..00 Congenital malformation of circulatory 
system, unspecif 
P7X..00 Congenital malformation of great arteries, 
unspecified 
P7y..00 Other specified circulatory system 
anomalies 
P7y0.00 Cerebrovascular system anomalies 
P7y0000 Congenital anomaly of cerebral vessel, 
unspecified 
P7y0100 Congenital cerebral arteriovenous 
aneurysm 
P7y0111 Congenital arteriovenous fistula of brain 
P7y0112 Congenital cerebral arteriovenous 
malformation 
P7y0200 Congenital brain aneurysm NEC 
P7y0300 Congenital stricture of cerebral artery 
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P7y0400 Vein of Galen malformation 
P7y0y00 Other specified cerebrovascular anomaly 
P7y0z00 Cerebrovascular system anomaly NOS 
P7yz.00 Other cardiovascular system anomaly 
NOS 
P7yz000 Congenital aneurysm NEC 
P7yz100 Congenital chylothorax 
P7yzz00 Other cardiovascular system anomaly 
NOS 
P7z..00 Circulatory system anomaly NOS 
P7z..11 Fetal circulation 
P8...00 Respiratory system congenital anomalies 
P80..00 Choanal atresia 
P800.00 Choanal atresia, unspecified 
P801.00 Atresia of the anterior nares 
P802.00 Atresia of the posterior nares 
P803.00 Congenital stenosis of the anterior nares 
P804.00 Congenital stenosis of the posterior nares 
P80z.00 Choanal atresia NOS 
P81..00 Other anomalies of nose 
P810.00 Congenital nose deformity, unspecified 
P811.00 Absent nose 
P811.11 Agenesis of nose 
P811000 Agenesis of nose 
P811100 Underdevelopment of nose 
P811z00 Absent nose NOS 
P812.00 Accessory nose 
P813.00 Congenital cleft nose 
P814.00 Deformity of nasal sinus wall 
P815.00 Congenital notching of tip of nose 
P816.00 Congenital perforation of the nasal sinus 
wall 
P817.00 Perforated nasal septum 
P818.00 Congenital fissure of nose 
P819.00 Congenital hypoplastic nose 
P81z.00 Other anomalies of nose NOS 
P81z.11 Single nostril 
P82..00 Congenital web of larynx 
P820.00 Congenital web of larynx, unspecified 
P821.00 Congenital glottic web of larynx 
P822.00 Congenital subglottic web of larynx 
P82z.00 Congenital web of larynx NOS 
P83..00 Other anomalies of larynx, trachea and 
bronchus 
P830.00 Agenesis of larynx, trachea and bronchus 
P830000 Agenesis of bronchus 
P830100 Agenesis of larynx 
P830111 Congenital absence of larynx 
P830200 Agenesis of trachea 
P830211 Congenital absence of trachea 
P830z00 Agenesis of larynx, trachea or bronchus 
NOS 
P831.00 Anomaly of laryngeal and tracheal 
cartilage 
P831000 Anomaly of cricoid cartilage 
P831100 Anomaly of epiglottis 
P831200 Anomaly of thyroid cartilage 
P831300 Anomaly of tracheal cartilage 
P831400 Tracheomalacia 
P831500 Laryngeal hypoplasia 
P831600 Laryngomalacia 
P831z00 Anomaly of laryngeal or tracheal cartilage 
NOS 
P832.00 Atresia of larynx and trachea 
P832000 Atresia of epiglottis 
P832100 Atresia of glottis 
P832200 Atresia of larynx 
P832300 Atresia of trachea 
P832z00 Atresia of larynx or trachea NOS 
P833.00 Congenital stenosis of larynx, trachea and 
bronchus 
P833000 Congenital stenosis of larynx 
P833100 Congenital stenosis of trachea 
P833200 Congenital stenosis of bronchus 
P833300 Congenital subglottic stenosis 
P833400 Congenital supraglottic stenosis 
P833z00 Congenital stenosis of larynx or trachea 
NOS 
P83y.00 Other anomaly of larynx, trachea and 
bronchus 
P83y000 Congenital cleft thyroid cartilage 
P83y100 Congenital dilatation of trachea 
P83y200 Congenital tracheocele 
P83y300 Congenital laryngocele 
P83y400 Congenital diverticulum of bronchus 
P83y500 Congenital diverticulum of trachea 
P83y600 Congenital fissure of epiglottis 
P83y700 Congenital cleft of posterior cricoid 
cartilage 
P83y800 Rudimentary tracheal bronchus 
P83y900 Congenital laryngeal stridor 
P83yA00 Congenital fissure of larynx 
P83yB00 Congenital bronchomalacia 
P83yX00 Congenital malformation of larynx, 
unspecified 
P83yw00 Other anomaly of larynx 
P83yx00 Other anomaly of trachea 
P83yy00 Other anomaly of bronchus 
P83yz00 Other anomaly of larynx, trachea or 
bronchus NOS 
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P83z.00 Other anomalies of larynx, trachea or 
bronchus NOS 
P84..00 Congenital cystic lung 
P840.00 Congenital cystic lung disease, 
unspecified 
P841.00 Congenital polycystic lung 
P841.11 Multiple lung cysts 
P841.12 Multiple congenital bronchogenic cysts 
P842.00 Congenital honeycomb lung 
P843.00 Single lung cyst 
P843.11 Lung cyst 
P843.12 Congenital bronchogenic cyst 
P844.00 Congenital cystic adenomatoid 
malformation of the lung 
P84y.00 Other specified congenital cystic lung 
P84z.00 Congenital cystic lung NOS 
P85..00 Lung agenesis, hypoplasia and dysplasia 
P850.00 Aplasia of lung 
P851.00 Hypoplasia of lung 
P852.00 Sequestration of lung 
P853.00 Agenesis of lung 
P853.11 Congenital absence of lung 
P853000 Congenital absence of lung fissures 
P853100 Congenital absence of lobe of lung 
P853z00 Agenesis of lung NOS 
P85y.00 Other specified lung agenesis, hypoplasia 
or dysplasia 
P85y000 Fusion of lobes of lung 
P85yz00 Other lung agenesis, hypoplasia or 
dysplasia NOS 
P85z.00 Lung agenesis, hypoplasia or dysplasia 
NOS 
P86..00 Other lung anomalies 
P860.00 Anomaly of lung, unspecified 
P861.00 Congenital bronchiectasis 
P86y.00 Other lung anomaly 
P86y000 Accessory lung 
P86y100 Azygos lobe of lung 
P86y200 Accessory lobe of lung 
P86y300 Ectopic tissues in lung 
P86y311 Ectopic bone and cartilage in lung 
P86yz00 Other lung anomaly NOS 
P86z.00 Lung anomaly NOS 
P8y..00 Other specified respiratory system 
anomalies 
P8y0.00 Abnormal pericardio-pleural 
communication 
P8y1.00 Anomaly, pleural folds 
P8y2.00 Atresia of nasopharynx 
P8y3.00 Congenital cyst of mediastinum 
P8y4.00 Congenital pulmonary lymphangiectasis 
P8yz.00 Other specified respiratory system 
anomaly NOS 
P8z..00 Respiratory system anomaly NOS 
P9...00 Cleft palate and lip 
P90..00 Cleft palate 
P900.00 Cleft palate, unspecified 
P900.11 Palatoschisis 
P901.00 Unilateral complete cleft palate 
P901.11 Cleft hard palate, unilateral 
P902.00 Unilateral incomplete cleft palate 
P902.11 Cleft uvula 
P902.12 Cleft soft palate, unilateral 
P903.00 Bilateral complete cleft palate 
P903.11 Cleft hard palate, bilateral 
P904.00 Bilateral incomplete cleft palate 
P904.11 Cleft soft palate, bilateral 
P905.00 Central complete cleft palate 
P905.11 Cleft hard palate, central 
P906.00 Central incomplete cleft palate 
P906.11 Cleft soft palate, central 
P907.00 Complete cleft palate NOS 
P907.11 Cleft hard palate NOS 
P908.00 Incomplete cleft palate NOS 
P908.11 Cleft soft palate NOS 
P909.00 Cleft uvula 
P90A.00 Cleft soft palate, bilateral 
P90B.00 Cleft hard palate, bilateral 
P90C.00 Cleft hard palate, unilateral 
P90z.00 Cleft palate NOS 
P91..00 Cleft lip (harelip) 
P91..11 Cheiloschisis 
P91..12 Congenital fissure of lip 
P910.00 Cleft lip, unspecified 
P911.00 Unilateral complete cleft lip 
P912.00 Unilateral incomplete cleft lip 
P913.00 Bilateral complete cleft lip 
P914.00 Bilateral incomplete cleft lip 
P915.00 Central cleft lip 
P91z.00 Cleft lip NOS 
P92..00 Cleft palate with cleft lip 
P92..11 Cheilopalatoschisis 
P920.00 Cleft palate with cleft lip, unspecified 
P921.00 Unilateral complete cleft palate with cleft 
lip 
P922.00 Unilateral incomplete cleft palate with 
cleft lip 
P923.00 Bilateral complete cleft palate with cleft 
lip 
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P924.00 Bilateral incomplete cleft palate with cleft 
lip 
P925.00 Central complete cleft palate with cleft lip 
P926.00 Central incomplete cleft palate with cleft 
lip 
P927.00 Cleft hard palate with cleft soft palate, 
bilateral 
P928.00 Cleft hard palate with cleft soft palate, 
unilateral 
P92A.00 Cleft hard palate with cleft lip, bilateral 
P92B.00 Cleft hard palate with cleft lip, unilateral 
P92z.00 Cleft palate with cleft lip NOS 
P9z..00 Cleft palate or cleft lip NOS 
PA...00 Other congenital upper alimentary tract 
anomalies 
PA0..00 Tongue tie - ankyloglossia 
PA0..11 Ankyloglossia 
PA0..12 Tongue tie 
PA1..00 Other tongue anomalies 
PA10.00 Anomaly of tongue, unspecified 
PA11.00 Aglossia 
PA11.11 Congenital absence of tongue 
PA12.00 Congenital adhesions of tongue 
PA13.00 Fissure of tongue 
PA13.11 Bifid tongue 
PA13.12 Double tongue 
PA14.00 Macroglossia 
PA14.11 Congenital tongue hypertrophy 
PA15.00 Microglossia 
PA15.11 Hypoplasia of tongue 
PA15.12 Short tongue 
PA16.00 Dislocation of tongue 
PA16.11 Displacement of tongue 
PA17.00 Cleft tongue 
PA17.11 Whiteman's syndrome 
PA18.00 Congenital plicated tongue 
PA1z.00 Other tongue anomalies NOS 
PA2..00 Other specified mouth and pharynx 
anomalies 
PA20.00 Congenital absence of salivary gland 
PA21.00 Accessory salivary gland 
PA22.00 Atresia, salivary duct 
PA23.00 Congenital salivary gland fistula 
PA24.00 Congenital fistula of lip 
PA24.11 Congenital pits of lip 
PA25.00 Other mouth anomalies 
PA25.11 Fordyce's disease of mouth 
PA25000 Congenital absence of uvula 
PA25100 High arched palate 
PA25y00 Other congenital anomaly of palate 
PA25y11 Flat palate 
PA25z00 Other mouth anomalies NOS 
PA26.00 Diverticulum of pharynx 
PA26.11 Pharyngeal pouch 
PA27.00 Other pharynx anomalies 
PA27000 Imperforate pharynx 
PA27100 Congenital pharyngeal polyp 
PA27z00 Other pharynx anomalies NOS 
PA28.00 Ranula, congenital 
PA29.00 Other anomalies of salivary glands or 
ducts 
PA29.11 Displacement of Wharton's duct 
PA2A.00 Other anomalies of lip 
PA2A000 Congenital ectropion of lip 
PA2Az00 Other anomaly of lip NOS 
PA2z.00 Other mouth and pharynx anomalies NOS 
PA3..00 Oesophageal atresia, stenosis and fistula 
PA3..11 Congenital oesophageal ring 
PA30.00 Atresia of oesophagus 
PA31.00 Congenital oesophageal stricture 
PA31.11 Congenital oesophageal stenosis 
PA32.00 Congenital oesophageal fistula 
PA32000 Oesophagobronchial fistula 
PA32100 Oesophagotracheal fistula 
PA32111 Congenital tracheo-oesophageal fistula 
PA32z00 Congenital oesophageal fistula NOS 
PA33.00 Imperforate oesophagus 
PA34.00 Webbed oesophagus 
PA35.00 Congenital absence of oesophagus 
PA36.00 Cong.absence of oesophagus with 
tracheo-oesophageal fistula 
PA37.00 Atresia of oesophagus with tracheo-
oesophageal fistula 
PA3y.00 Other specified oesophageal atresia, 
stenosis or fistula 
PA3z.00 Oesophageal atresia, stenosis or fistula 
NOS 
PA4..00 Other specified oesophageal anomalies 
PA40.00 Congenital dilatation of oesophagus 
PA41.00 Congenital displacement of oesophagus 
PA42.00 Congenital diverticulum of oesophagus 
PA43.00 Congenital duplication of oesophagus 
PA44.00 Giant oesophagus 
PA45.00 Congenital oesophageal pouch 
PA4z.00 Other specified oesophageal anomaly 
NOS 
PA5..00 Congenital hypertrophic pyloric stenosis 
PA50.00 Congenital pyloric hypertrophy 
PA51.00 Congenital pyloric spasm 
PA51.11 Congenital pylorospasm 
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PA52.00 Congenital pyloric stenosis 
PA52.11 Congenital pyloric stricture 
PA5y.00 Other specified congenital pyloric 
obstruction 
PA5z.00 Congenital pyloric obstruction NOS 
PA6..00 Congenital hiatus hernia 
PA7..00 Other specified stomach anomalies 
PA70.00 Congenital cardiospasm 
PA70.11 Congenital achalasia of cardia 
PA71.00 Congenital hourglass stomach 
PA72.00 Congenital stomach displacement 
PA73.00 Congenital stomach diverticulum 
PA74.00 Duplication of stomach 
PA75.00 Megalogastria 
PA76.00 Microgastria 
PA77.00 Transposition of stomach 
PA78.00 Ectopic gastric mucosa 
PA7z.00 Other specified stomach anomaly NOS 
PA7z.11 Congenital displacement of gastric 
mucosa 
PAy..00 Other specified upper alimentary tract 
anomaly 
PAz..00 Upper alimentary tract anomalies NOS 
PAz0.00 Unspecified anomalies of mouth and 
pharynx 
PAz1.00 Unspecified anomalies of oesophagus 
PAz2.00 Unspecified anomalies of stomach 
PAzz.00 Anomalies of upper alimentary tract NOS 
PAzz.11 Malformation of throat 
PB...00 Other congenital digestive system 
anomaly 
PB0..00 Meckel's diverticulum 
PB0..11 Persistent omphalomesenteric duct 
PB0..12 Persistent vitelline duct 
PB00.00 Meckel's diverticulum, unspecified 
PB01.00 Displaced Meckel's diverticulum 
PB02.00 Hypertrophic Meckel's diverticulum 
PB03.00 Persistent omphalomesenteric duct 
PB03.11 Persistent vitelline duct 
PB0z.00 Meckel's diverticulum NOS 
PB1..00 Small intestine atresia and stenosis 
PB10.00 Atresia of small intestine 
PB10000 Atresia of small intestine, unspecified 
PB10100 Atresia of duodenum 
PB10200 Atresia of ileum 
PB10300 Atresia of jejunum 
PB10z00 Small intestine atresia NOS 
PB11.00 Congenital absence of small intestine 
PB11000 Congenital absence of duodenum 
PB11100 Congenital absence of jejunum 
PB11200 Congenital absence of ileum 
PB12.00 Congenital obstruction of small intestine 
PB13.00 Congenital stenosis of small intestine 
PB13000 Congenital stenosis of duodenum 
PB13100 Congenital stenosis of jejunum 
PB13200 Congenital stenosis of ileum 
PB13z00 Congenital stenosis of small intestine 
NOS 
PB13z11 Congenital stricture of small intestine 
PB14.00 Imperforate jejunum 
PB15.00 Imperforate small intestine NEC 
PB1z.00 Small intestine atresia or stenosis NOS 
PB2..00 Atresia and stenosis of large 
intestine/rectum/anal canal 
PB2..11 Atresia large intestine 
PB2..12 Stenosis large intestine 
PB20.00 Congenital absence of large intestine 
PB20000 Congenital absence of anus 
PB20100 Congenital absence of appendix 
PB20200 Congenital absence of rectum 
PB20211 Agenesis of rectum 
PB20300 Congenital absence of anus with fistula 
PB20400 Congenital absence of rectum with fistula 
PB20411 Agenesis of rectum with fistula 
PB20z00 Congenital absence of large intestine NOS 
PB21.00 Atresia of large intestine 
PB21000 Atresia of anus 
PB21100 Atresia of colon 
PB21200 Atresia of rectum 
PB21300 Atresia of appendix 
PB21400 Atresia of anus with fistula 
PB21500 Atresia of rectum with fistula 
PB21z00 Atresia of large intestine NOS 
PB22.00 Congenital obstruction of large intestine 
PB22.11 Congenital stenosis of large intestine 
PB22.12 Congenital stenosis of appendix 
PB23.00 Congenital occlusion of anus 
PB23.11 Anal septum 
PB23000 Congenital occlusion of anus with fistula 
PB23z00 Congenital occlusion of anus NOS 
PB24.00 Congenital stricture of anus 
PB24.11 Congenital anal stricture 
PB24000 Congenital stricture of anus with fistula 
PB24011 Congenital stenosis of anus with fistula 
PB24100 Congenital stricture of anus without 
mention of fistula 
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PB24111 Congenital stenosis of anus without 
mention of fistula 
PB24z00 Congenital stricture of anus NOS 
PB25.00 Congenital stricture of rectum 
PB25.11 Congenital rectal stricture 
PB25000 Congenital stricture of rectum with fistula 
PB25011 Congenital stenosis of rectum with fistula 
PB25100 Congenital stricture of rectum without 
mention of fistula 
PB25111 Congenital stenosis of rectum without 
mention of fistula 
PB25z00 Congenital stricture of rectum NOS 
PB26.00 Imperforate anus 
PB26000 Imperforate anus with fistula 
PB26z00 Imperforate anus NOS 
PB27.00 Imperforate rectum 
PB27000 Imperforate rectum with fistula 
PB27z00 Imperforate rectum NOS 
PB28.00 Imperforate large intestine 
PB2z.00 Atresia and stenosis of large 
intestine/rectum/anus NOS 
PB3..00 Hirschsprung's disease and allied 
congenital conditions 
PB3..11 Aganglionosis 
PB3..12 Congenital dilatation colon 
PB30.00 Hirschsprung's disease 
PB30000 Long segment Hirschsprung's disease 
PB30100 Short segment Hirschsprung's disease 
PB30z00 Hirschsprung's disease NOS 
PB31.00 Idiopathic congenital megacolon 
PB31.11 Congenital giant colon NEC 
PB32.00 Macrocolon 
PB33.00 Total intestinal aganglionosis 
PB33.11 Aganglionic macrocolon 
PB33.12 Congenital aganglionic megacolon 
PB3z.00 Hirschsprung's disease and allied 
congenital conditions NOS 
PB4..00 Intestinal fixation anomalies 
PB40.00 Congenital intestinal adhesions 
PB40000 Congenital omental adhesions 
PB40011 Congenital omental bands 
PB40100 Jackson's membrane 
PB40200 Congenital peritoneal adhesions 
PB40211 Congenital peritoneal bands 
PB40z00 Congenital intestinal adhesions NOS 
PB41.00 Malrotation of colon and caecum 
PB41000 Malrotation of colon 
PB41100 Malrotation of caecum 
PB41z00 Malrotation of colon or caecum NOS 
PB42.00 Universal mesentery 
PB43.00 Other anomalies of mesentery 
PB4y.00 Other specified intestinal fixation anomaly 
PB4z.00 Intestinal fixation anomaly NOS 
PB4z.11 Malfixation of gut NEC 
PB4z.12 Malrotation of gut 
PB4z.13 Malrotation of intestine 
PB5..00 Other anomalies of intestine 
PB50.00 Congenital diverticulum of colon 
PB51.00 Dolichocolon 
PB52.00 Duplication of intestine 
PB52000 Duplication of intestine, unspecified 
PB52100 Duplication of anus 
PB52200 Duplication of appendix 
PB52300 Duplication of caecum 
PB52z00 Duplication of intestine NOS 
PB52z11 Congenital redundant rectal mucosa 
PB52z12 Congenital redundant colon 
PB53.00 Transposition of intestine 
PB53000 Transposition of intestine, unspecified 
PB53100 Transposition of appendix 
PB53200 Transposition of caecum 
PB53300 Transposition of colon 
PB53z00 Transposition of intestine NOS 
PB54.00 Ectopic anus 
PB55.00 Megaloappendix 
PB56.00 Megaloduodenum 
PB57.00 Microcolon 
PB58.00 Persistent cloaca 
PB58.11 Anal fusion 
PB58.12 Anal and urogenital canal fusion 
PB59.00 Congenital anal fistula 
PB5A.00 Enterogenous cyst 
PB5B.00 Dysplasia of colon 
PB5X.00 Congenital malformation of intestine, 
unspecified 
PB5z.00 Other intestine anomalies NOS 
PB5z.11 Congenital volvulus 
PB5z.12 Short bowel syndrome 
PB5z000 Congenital faecal fistula 
PB6..00 Liver and biliary system anomalies 
PB6..11 Bile duct anomalies 
PB6..12 Biliary anomalies 
PB6..13 Gallbladder anomalies 
PB6..14 Liver anomalies 
PB60.00 Liver and biliary system anomalies, 
unspecified 
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PB60000 Liver anomaly, unspecified 
PB60100 Gallbladder anomaly, unspecified 
PB60200 Bile duct anomaly, unspecified 
PB60z00 Unspecified liver and biliary system 
anomaly NOS 
PB61.00 Biliary atresia 
PB61.11 Bile duct atresia 
PB61000 Congenital absence of bile duct 
PB61011 Agenesis of bile duct 
PB61100 Congenital hypoplasia of bile duct 
PB61200 Congenital obstruction of bile duct 
PB61300 Congenital stricture of bile duct 
PB61311 Congenital stricture of common bile duct 
PB61400 Atresia of bile duct 
PB61411 Intrahepatic atresia of bile duct 
PB61412 Extrahepatic atresia of bile duct 
PB61500 Congenital absence of hepatic ducts 
PB61511 Agenesis of hepatic ducts 
PB61600 Atresia of hepatic ducts 
PB61z00 Biliary atresia NOS 
PB62.00 Congenital cystic liver disease 
PB62.11 Congenital hepatic cyst 
PB62000 Congenital polycystic liver disease 
PB62100 Fibrocystic liver disease 
PB62z00 Congenital cystic liver disease NOS 
PB63.00 Congenital absence of liver and 
gallbladder 
PB63000 Congenital absence of gallbladder 
PB63011 Agenesis of gallbladder 
PB63100 Congenital absence of liver lobe 
PB63111 Congenital agenesis of liver lobe 
PB63200 Congenital small left lobe of liver 
PB63300 Riedel's lobe liver 
PB63400 Congenital absence of liver,total 
PB63411 Congenital agenesis liver,total 
PB63500 Alagille syndrome 
PB63z00 Absence of liver or gallbladder NOS 
PB64.00 Liver and biliary duplication 
PB64000 Duplication of biliary duct 
PB64100 Duplication of cystic duct 
PB64200 Duplication of gallbladder 
PB64300 Duplication of liver 
PB64311 Accessory liver 
PB64400 Accessory hepatic ducts 
PB64z00 Liver or biliary duplication NOS 
PB6y.00 Other liver and biliary anomalies 
PB6y000 Congenital choledochal cyst 
PB6y100 Congenital hepatomegaly 
PB6y200 Congenital floating gallbladder 
PB6y300 Congenital floating liver 
PB6y400 Intrahepatic gallbladder 
PB6y500 Hypoplasia of gallbladder 
PB6y600 Atrophy of left lobe of liver 
PB6y700 Congenital dilation of bile duct 
PB6y800 Congenital diverticulum of bile duct 
PB6y900 Liver hyperplasia 
PB6yw00 Other congenital anomaly of liver 
PB6yw11 Liver hamartoma 
PB6yw12 Abnormal liver lobulation 
PB6yw13 Trilobular liver 
PB6yx00 Other congenital anomaly of gallbladder 
PB6yy00 Other congenital anomaly of hepatic or 
bile ducts 
PB6yy11 Congenital kink of cystic duct 
PB6yz00 Other liver or biliary system anomalies 
NOS 
PB6z.00 Liver or biliary system anomalies NOS 
PB7..00 Anomalies of pancreas 
PB70.00 Congenital absence of pancreas 
PB71.00 Agenesis of pancreas 
PB72.00 Hypoplasia of pancreas 
PB73.00 Accessory pancreas 
PB74.00 Annular pancreas 
PB75.00 Ectopic pancreas 
PB76.00 Pancreatic heterotopia 
PB77.00 Pancreatic cyst, congenital 
PB7y.00 Other specified anomalies of pancreas 
PB7z.00 Anomalies of pancreas NOS 
PBy..00 Other specified digestive system 
anomalies 
PBy0.00 Congenital absence of digestive system 
NOS 
PBy0000 Complete absence of alimentary tract 
NOS 
PBy0100 Partial absence of alimentary tract NOS 
PBy0z00 Absence of digestive system NOS 
PBy1.00 Duplication of digestive system NOS 
PBy2.00 Congenital malposition of digestive 
system NOS 
PBy2.11 Ectopic digestive organs NOS 
PByz.00 Other specified digestive system 
anomalies NOS 
PBz..00 Digestive system anomalies NOS 
PC...00 Congenital genital organ anomalies 
PC0..00 Anomalies of ovaries 
PC00.00 Congenital absence of ovary 
PC00.11 Agenesis of ovary 
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PC01.00 Accessory ovary 
PC02.00 Ectopic ovary 
PC03.00 Streak ovary 
PC04.00 Developmental ovarian cyst 
PC05.00 Congenital torsion of ovary 
PC0y.00 Other specified congenital anomalies of 
ovaries 
PC0y.11 Congenital ovarian dysplasia 
PC0z.00 Congenital anomalies of ovaries NOS 
PC1..00 Fallopian tube and broad ligament 
anomalies 
PC10.00 Fallopian tube and broad ligament 
anomalies, unspecified 
PC11.00 Embryonic cyst of fallopian tube and 
broad ligament 
PC11.11 Cyst of mesenteric remnant 
PC11000 Epoophoron cyst 
PC11100 Fimbrial cyst 
PC11200 Gartner's duct cyst 
PC11211 Persistent Gartner's duct 
PC11300 Parovarian cyst 
PC11z00 Embryonic cyst of fallopian tube or broad 
ligament NOS 
PC1y.00 Other fallopian tube and broad ligament 
anomalies 
PC1y000 Congenital absence of fallopian tube 
PC1y011 Congenital absence of oviduct 
PC1y100 Accessory fallopian tube 
PC1y200 Atresia of fallopian tube 
PC1y300 Absent broad ligament 
PC1y400 Accessory broad ligament 
PC1y500 Atresia of broad ligament 
PC1yz00 Other fallopian tube or broad ligament 
anomalies NOS 
PC1z.00 Fallopian tube or broad ligament 
anomalies NOS 
PC2..00 Doubling of uterus 
PC20.00 Doubling of uterus, unspecified 
PC21.00 Didelphic uterus 
PC22.00 Doubling of uterus, including cervix and 
vagina 
PC2z.00 Doubling of uterus NOS 
PC3..00 Other anomalies of uterus 
PC30.00 Congenital absence of uterus 
PC31.00 Agenesis of uterus 
PC32.00 Aplasia of uterus 
PC33.00 Bicornuate uterus 
PC34.00 Uterus unicornis 
PC35.00 Displaced uterus 
PC35.11 Congenital prolapse of uterus 
PC36.00 Fistulae involving uterus with digestive or 
urinary tract 
PC36000 Uterointestinal fistula, congenital 
PC36100 Uterovesical fistula, congenital 
PC36z00 Fistula involving uterus with digestive or 
urinary tract NOS 
PC3y.00 Other specified anomalies of uterus 
PC3z.00 Anomalies of uterus NOS 
PC4..00 Cervical, vaginal and external female 
genital anomalies 
PC40.00 Cervical/vaginal/external female genital 
anomalies, unspec 
PC41.00 Embryonic cyst of cervix/vagina/external 
female genitalia 
PC41000 Congenital cyst of canal of Nuck 
PC41011 Patent canal of Nuck 
PC41100 Embryonal cyst of vagina 
PC41200 Congenital cyst of vulva 
PC41300 Embryonic cyst of cervix 
PC41z00 Embryonic cyst cervix/vagina/external 
female genitalia NOS 
PC42.00 Imperforate hymen 
PC43.00 Rectovaginal fistula, congenital 
PC4y.00 Other cervical, vaginal and external 
female genital anomaly 
PC4y000 Congenital absence of cervix 
PC4y100 Agenesis of cervix 
PC4y200 Congenital absence of clitoris 
PC4y300 Agenesis of clitoris 
PC4y400 Congenital absence of vagina 
PC4y411 Rudimentary vagina 
PC4y500 Agenesis of vagina 
PC4y600 Congenital absence of vulva 
PC4y611 Congenital absence of labium major 
PC4y612 Congenital absence of labium minor 
PC4y700 Agenesis of vulva 
PC4y800 Congenital stenosis of cervical canal 
PC4y900 Congenital stenosis of vagina 
PC4y911 Congenital stricture of vagina 
PC4yA00 Atresia of cervix 
PC4yB00 Atresia of vagina 
PC4yB11 Imperforate vagina 
PC4yC00 Congenital vaginal cyst NEC 
PC4yD00 Fusion of vulva 
PC4yD11 Fusion of labia 
PC4yE00 Congenital labial adhesions 
PC4yv00 Other congenital anomaly of cervix 
PC4yw00 Other congenital anomaly of vagina 
PC4yw11 Vaginal septum 
PC4yx00 Other congenital anomaly of vulva 
PC4yy00 Other congenital anomaly of clitoris 
PC4yy11 Hooded clitoris 
PC4yy12 Hypertrophy of clitoris 
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PC4yz00 Other cervical/vaginal/external female 
genital anomaly NOS 
PC4z.00 Cervical, vaginal and external female 
genital anomaly NOS 
PC5..00 Undescended testicle 
PC50.00 Cryptorchidism 
PC50000 Cryptorchidism, unilateral 
PC50100 Cryptorchidism, bilateral 
PC50z00 Cryptorchidism NOS 
PC51.00 Ectopic testis 
PC5z.00 Undescended testicle NOS 
PC5z.11 Retractile testis 
PC5z.12 Maldescent of testicle 
PC5z000 Undescended testis, unilateral 
PC5z011 Maldescent of testis, unilateral 
PC5z100 Undescended testis, bilateral 
PC5z111 Maldescent of testis, bilateral 
PC6..00 Hypospadias and epispadias 
PC60.00 Hypospadias 
PC60.11 Anaspadias 
PC60000 Hypospadias, penile 
PC60100 Hypospadias, penoscrotal 
PC60200 Hypospadias, perineal 
PC60300 Hypospadias, balanic 
PC60311 Hypospadias, glanular 
PC60312 Hypospadias, glandular 
PC61.00 Epispadias 
PC61.11 Anaspadias 
PC62.00 Congenital chordee 
PC6z.00 Hypospadias or epispadias NOS 
PC7..00 Indeterminate sex and 
pseudohermaphroditism 
PC7..11 Gynandrism 
PC70.00 True hermaphroditism 
PC70.11 Ovotestis 
PC71.00 Male pseudohermaphroditism 
PC72.00 Female pseudohermaphroditism 
PC73.00 Pure gonadal dysgenesis 
PC7z.00 Indeterminate sex or 
pseudohermaphroditism NOS 
PC7z000 Indeterminate sex NOS 
PC7z011 Intersex NEC 
PC7z100 Pseudohermaphrodite NOS 
PC7z111 False hermaphrodite 
PC8..00 Congenital anomaly of male genital 
system 
PC80.00 Other specified congenital anomaly of 
male genital system 
PCy..00 Other specified genital organ anomaly 
PCy0.00 Absence of genital organ NEC 
PCy0000 Congenital absence of penis 
PCy0100 Congenital absence of prostate 
PCy0200 Congenital absence of spermatic cord 
PCy0300 Congenital absence of vas deferens 
PCy0311 Congenital absence of seminal tract 
PCy0z00 Genital organ absence NEC NOS 
PCy1.00 Congenital aplasia of genital organ NEC 
PCy1000 Congenital aplasia of prostate 
PCy1100 Congenital aplasia of round ligament 
PCy1200 Congenital aplasia of testicle 
PCy1300 Congenital aplasia of scrotum 
PCy1400 Aplasia of penis 
PCy1z00 Congenital aplasia of genital organ NEC 
NOS 
PCy2.00 Hypoplasia of genital organ NEC 
PCy2000 Hypoplasia of penis 
PCy2100 Hypoplasia of testis 
PCy2200 Hypoplasia of scrotum 
PCy2z00 Hypoplasia of genital organ NEC NOS 
PCy3.00 Atresia of genital organ NEC 
PCy3000 Atresia of ejaculatory duct 
PCy3100 Atresia of vas deferens 
PCy3z00 Atresia of genital organ NEC NOS 
PCy4.00 Anorchism 
PCy4.11 Congenital absence of both testes 
PCy4.12 Testicular agenesis, bilateral 
PCy5.00 Monorchism 
PCy5.11 Congenital absence of testis, unilateral 
PCy5.12 Testicular agenesis, unilateral 
PCy6.00 Polyorchism 
PCy7.00 Congenital lateral curvature of penis 
PCy8.00 Fusion of testes 
PCy9.00 Paraspadias 
PCyA.00 Cysts of embryonic remnants NEC 
PCyA000 Hydatid cyst of Morgagni 
PCyA100 Wolffian duct cyst 
PCyA200 Hydatid cyst of Morgagni - male 
PCyA300 Hydatid cyst of Morgagni - female 
PCyA400 Wolffian duct cyst - male 
PCyA500 Wolffian duct cyst - female 
PCyA600 Cyst of embryonic remnant - male 
PCyA700 Cyst of embryonic remnant - female 
PCyAz00 Cyst of embryonic remnant NEC NOS 
PCyB.00 Doubling of vagina 
PCyw.00 Other congenital anomaly of testis or 
scrotum 
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PCyx.00 Other congenital anomaly of vas deferens 
or prostate 
PCyy.00 Other congenital anomaly of penis 
PCyy000 Hooded penis 
PCyy100 Webbed penis 
PCyyz00 Other congenital anomaly of penis NOS 
PCyz.00 Other specified genital organ anomaly 
NOS 
PCz..00 Genital organ anomaly NOS 
PD...00 Urinary system congenital anomalies 
PD0..00 Renal agenesis and dysgenesis 
PD00.00 Renal agenesis, unspecified 
PD00000 Bilateral renal agenesis 
PD00100 Unilateral renal agenesis 
PD00z00 Renal agenesis, unspecified NOS 
PD01.00 Congenital renal atrophy 
PD02.00 Congenital absence of kidney 
PD02000 Bilateral congenital absence of kidneys 
PD02100 Unilateral congenital absence of kidney 
PD02z00 Congenital absence of kidney NOS 
PD03.00 Hypoplasia of kidney 
PD03000 Bilateral renal hypoplasia 
PD03011 Potter's syndrome 
PD03100 Unilateral renal hypoplasia 
PD04.00 Dysplasia of kidney 
PD04000 Bilateral renal dysplasia 
PD04011 Bilateral renal dysgenesis 
PD04100 Unilateral renal dysplasia 
PD04111 Unilateral renal dysgenesis 
PD04z00 Dysplasia of kidney NOS 
PD0z.00 Renal agenesis or dysgenesis NOS 
PD1..00 Congenital cystic kidney disease 
PD1..11 Congenital cystic renal disease 
PD1..12 Fibrocystic kidney 
PD1..13 Polycystic kidney 
PD1..14 Sponge kidney 
PD10.00 Congenital renal cyst, single 
PD11.00 Polycystic kidney disease 
PD11000 Polycystic kidneys, infantile type 
PD11100 Polycystic kidneys, adult type 
PD11z00 Polycystic kidney disease NOS 
PD11z11 Cystic kidney disease NEC 
PD12.00 Medullary cystic disease 
PD12000 Medullary cystic disease, juvenile type 
PD12011 Nephronophthisis 
PD12100 Medullary cystic disease, adult type 
PD12111 Medullary sponge kidney 
PD12y00 Medullary cystic disease OS 
PD12z00 Medullary cystic disease NOS 
PD13.00 Multicystic renal dysplasia 
PD13.11 Multicystic kidney 
PD1y.00 Other specified congenital cystic kidney 
disease 
PD1y000 Fibrocystic kidney disease 
PD1y011 Fibrocystic renal degeneration 
PD1yz00 Other congenital cystic kidney disease 
NOS 
PD1z.00 Congenital cystic kidney disease NOS 
PD2..00 Renal pelvis and ureter obstructive 
defects 
PD20.00 Atresia of ureter 
PD21.00 Occlusion of ureter 
PD21.11 Congenital ureteric valves 
PD22.00 Congenital stricture of ureter 
PD22.11 Congenital stenosis of ureter 
PD22000 Congenital stricture of ureter, unspecified 
PD22100 Congenital stricture of ureteropelvic 
junction 
PD22200 Congenital stricture of ureterovesical 
orifice 
PD22z00 Congenital stricture of ureter NOS 
PD23.00 Congenital hydronephrosis 
PD23.11 Congenital dilated renal pelvis 
PD24.00 Congenital dilatation of ureter 
PD25.00 Hydroureter - congenital 
PD26.00 Megaloureter - congenital 
PD27.00 Ureterocele - congenital 
PD28.00 Impervious ureter 
PD2y.00 Other specified obstructive defect of renal 
pelvis or ureter 
PD2z.00 Obstructive defect of renal pelvis or 
ureter NOS 
PD3..00 Other specified renal anomaly 
PD30.00 Accessory kidney 
PD30.11 Duplication of kidney 
PD30.12 Renal duplication NEC 
PD30.13 Supernumerary kidney 
PD31.00 Congenital calculus of kidney 
PD32.00 Congenital displaced kidney 
PD33.00 Discoid kidney 
PD34.00 Double kidney with double pelvis 
PD34.11 Duplex kidneys 
PD34.12 Pyelon duplex 
PD35.00 Ectopic kidney 
PD35.11 Pelvic kidney 
PD36.00 Fusion of kidneys 
PD37.00 Giant kidney 
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PD38.00 Horseshoe kidney 
PD39.00 Hyperplasia of kidney 
PD3A.00 Lobulation of kidney 
PD3A.11 Ren arcuatus 
PD3A.12 Ren unguliformis 
PD3B.00 Malrotation of kidney 
PD3C.00 Triple kidney with triple pelvis 
PD3C.11 Trifid kidney 
PD3C.12 Pyelon triplex 
PD3D.00 Enlarged kidney 
PD3z.00 Other specified renal anomaly NOS 
PD4..00 Other specified ureter anomalies 
PD40.00 Absent ureter 
PD41.00 Accessory ureter 
PD42.00 Deviation of ureter 
PD43.00 Displaced ureteric orifice 
PD44.00 Double ureter 
PD44.11 Duplication of ureter 
PD45.00 Ectopic ureter 
PD45.11 Congenital displacement of opening of 
ureter 
PD45.12 Ectopic insertion of ureter 
PD46.00 Anomalous ureter implantation 
PD47.00 Congenital vesico-uretero-renal reflux 
PD4z.00 Other specified ureter anomaly NOS 
PD5..00 Exstrophy of urinary bladder 
PD5..11 Ectopia vesicae 
PD5..12 Ectopic bladder 
PD50.00 Ectopic bladder 
PD50.11 Ectopia vesicae 
PD5z.00 Exstrophy of urinary bladder NOS 
PD6..00 Urethra and bladder neck atresia and 
stenosis 
PD60.00 Congenital bladder neck obstruction 
PD60000 Atresia of bladder neck 
PD60100 Stenosis of bladder neck 
PD60z00 Congenital bladder neck obstruction NOS 
PD61.00 Congenital obstruction of urethra 
PD61000 Atresia of anterior urethra 
PD61100 Stenosis of anterior urethra 
PD61z00 Congenital obstruction of urethra NOS 
PD62.00 Congenital urethral valvular stricture 
PD62.11 Congenital posterior urethral valves 
PD62.12 Congenital urethral posterior valvular 
stricture 
PD63.00 Congenital urinary meatus stricture 
PD63.11 Congenital urinary meatus obstruction 
PD63.12 Congenital pinhole urinary meatus 
PD63000 Atresia of urinary meatus 
PD63100 Stenosis of urinary meatus 
PD63z00 Congenital urinary meatus stricture NOS 
PD64.00 Congenital vesicourethral orifice stricture 
PD65.00 Imperforate urinary meatus 
PD66.00 Impervious urethra 
PD67.00 Congenital posterior urethral valves 
PD6y.00 Other specified urethra or bladder neck 
atresia or stenosis 
PD6z.00 Urethra or bladder neck atresia or 
stenosis NOS 
PD7..00 Anomalies of urachus 
PD70.00 Cyst of urachus 
PD71.00 Fistula of urachus 
PD72.00 Patent urachus 
PD72.11 Persistent urachus 
PD73.00 Persistent umbilical sinus 
PD7y.00 Other specified anomalies of urachus 
PD7z.00 Anomalies of urachus NOS 
PDy..00 Other specified bladder and urethral 
anomalies 
PDy0.00 Congenital absence of bladder 
PDy1.00 Congenital absence of urethra 
PDy2.00 Accessory bladder 
PDy3.00 Accessory urethra 
PDy4.00 Congenital bladder diverticulum 
PDy5.00 Congenital bladder hernia 
PDy6.00 Congenital urethrorectal fistula 
PDy7.00 Congenital prolapse of bladder mucosa 
PDy8.00 Congenital prolapse of urethra 
PDy9.00 Double urethra 
PDyA.00 Double urinary meatus 
PDyB.00 Congenital hourglass bladder 
PDyz.00 Other bladder or urethral anomaly NOS 
PDyz000 Epispadias, female 
PDyz100 Hypospadias, female 
PDz..00 Urinary system anomalies NOS 
PDz0.00 Unspecified anomaly of kidney 
PDz1.00 Unspecified anomaly of ureter 
PDz2.00 Unspecified anomaly of bladder 
PDz3.00 Unspecified anomaly of urethra 
PE...00 Certain congenital musculoskeletal 
deformities 
PE...11 Congenital musculoskeletal deformities 
PE0..00 Skull, face and jaw congenital deformities 
PE0..11 Face congenital deformities 
PE0..12 Jaw congenital deformities 
366 
 
PE0..13 Skull congenital deformities 
PE00.00 Asymmetry of face 
PE00000 Hemifacial microsomia 
PE00100 Asymmetrical crying face syndrome 
PE01.00 Compression facies 
PE02.00 Potter's facies 
PE03.00 Depressions in skull 
PE04.00 Dolichocephaly 
PE05.00 Plagiocephaly 
PE05.11 Asymmetric head 
PE06.00 Congenital nasal septum deviation 
PE07.00 Congenital bent or squashed nose 
PE0z.00 Skull, face or jaw congenital deformities 
NOS 
PE1..00 Congenital sternomastoid torticollis 
PE1..11 Congenital wry neck 
PE1..12 Sternomastoid tumour 
PE2..00 Congenital spine deformity 
PE20.00 Congenital spine deformity, unspecified 
PE21.00 Congenital postural lordosis 
PE22.00 Congenital postural scoliosis 
PE23.00 Congenital scoliosis due to congenital 
bony malformation 
PE2z.00 Congenital spine deformity NOS 
PE2z.11 Congenital postural curvature of spine 
NOS 
PE3..00 Congenital dislocation and subluxation of 
the hip 
PE30.00 Congenital dislocation of hip 
PE30000 Unilateral congenital dislocation of hip 
PE30100 Bilateral congenital dislocation of hip 
PE30z00 Congenital dislocation of hip NOS 
PE31.00 Congenital subluxation of hip 
PE31000 Unilateral congenital subluxation of hip 
PE31011 Unstable hip 
PE31012 Preluxation of hip 
PE31013 Predislocation status of hip at birth 
PE31014 Congenital instability of hip joint 
PE31100 Bilateral congenital subluxation of hip 
PE31z00 Congenital subluxation of hip NOS 
PE32.00 Congenital dislocation one hip with 
subluxation other hip 
PE33.00 Congenital clicking hip 
PE33.11 Clicky hips - congenital 
PE34.00 Dysplastic hip 
PE34000 Unilateral dysplastic hip 
PE34100 Bilateral dysplastic hip 
PE35.00 Unstable hip 
PE35000 Unilateral unstable hip 
PE35100 Bilateral unstable hip 
PE3z.00 Congenital dislocation of hip NOS 
PE4..00 Genu recurvatum and long leg bone 
bowing 
PE4..11 Congenital leg bone bowing 
PE40.00 Congenital genu recurvatum 
PE41.00 Congenital dislocation of knee 
PE41000 Congenital dislocation of knee grade I 
PE41100 Congenital dislocation of knee grade II 
PE41200 Congenital dislocation of knee grade III 
PE41300 Congenital dislocation of patella 
PE42.00 Congenital bowing of femur 
PE43.00 Congenital bowing of tibia and fibula 
PE43000 Congenital bowing of tibia 
PE43100 Congenital bowing of fibula 
PE44.00 Congenital bowing of long leg bone, 
unspecified 
PE44.11 Bow legs NOS 
PE4z.00 Genu recurvatum and long leg bone 
bowing NOS 
PE5..00 Varus deformities of feet 
PE50.00 Congenital talipes varus 
PE50.11 Pes varus 
PE50.12 Congenital clubfoot - varus 
PE51.00 Congenital talipes equinovarus 
PE52.00 Metatarsus primus varus 
PE53.00 Congenital metatarsus varus 
PE54.00 Congenital metatarsus adductus 
PE5x.00 Complex varus foot deformities 
PE5y.00 Other specified varus feet deformity 
PE5y000 Congenital talipes calcaneovarus 
PE5yz00 Other specified varus foot deformity NOS 
PE5z.00 Varus foot deformity NOS 
PE6..00 Valgus deformities of feet 
PE60.00 Congenital talipes valgus 
PE60.11 Congenital clubfoot - valgus 
PE61.00 Congenital pes planus 
PE61.11 Congenital flat foot 
PE61.13 Rigid flat foot 
PE61.14 Spastic flat foot 
PE61000 Congenital vertical talus 
PE62.00 Congenital talipes calcaneovalgus 
PE6y.00 Other valgus foot deformities 
PE6y000 Congenital talipes equinovalgus 
PE6y100 Congenital planovalgus 
PE6yz00 Other valgus foot deformity NOS 
PE6z.00 Valgus foot deformity NOS 
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PE6z.11 Congenital metatarsus valgus 
PE7..00 Other deformities of feet 
PE70.00 Talipes, unspecified 
PE70.11 Clubfoot NOS 
PE71.00 Talipes cavus 
PE71.11 Congenital claw toe 
PE71.12 Pes cavus 
PE72.00 Congenital pes cavus 
PE73.00 Congenital claw foot 
PE74.00 Short Achilles tendon, congenital 
PE7y.00 Other specified foot deformity 
PE7y000 Asymmetric talipes 
PE7y100 Congenital talipes calcaneus 
PE7y200 Congenital talipes equinus 
PE7y300 Congenital positional talipes 
PE7yz00 Other specified foot deformity NOS 
PE7z.00 Feet deformities NOS 
PE8..00 Other specified nonteratogenic anomalies 
PE80.00 Pectus excavatum, congenital 
PE80.11 Congenital funnel chest 
PE81.00 Pectus carinatum, congenital 
PE81.11 Congenital pigeon chest 
PE8y.00 Other nonteratogenic anomalies OS 
PE8y000 Congenital club hand 
PE8y011 Congenital club fingers 
PE8y100 Congenital chest wall deformity NEC 
PE8y111 Congenital thoracic wall deformity NEC 
PE8y200 Congenital dislocation of elbow 
PE8y300 Congenital flexion contractures of leg 
PE8y400 Congenital spade-like hand 
PE8y500 Guerin - Stern syndrome 
PE8y600 Congenital flexion contracture of hip 
PE8y700 Congenital abduction contracture of hip 
PE8y800 Congenital flexion contracture of knee 
PE8y900 Congenital short quadriceps 
PE8yA00 Congenital dislocation of radial head 
PE8yB00 Discoid meniscus - congenital 
PE8yz00 Other nonteratogenic anomaly NOS 
PE8yz11 Specified intrauterine postural deformity 
NEC 
PE8yz12 Multiple congenital articular rigidities 
PE8z.00 Nonteratogenic anomalies NOS 
PE9..00 Other musc skeletal deformity 
PE9..11 Other congenital musculoskeletal 
deformity 
PEz..00 Congenital musculoskeletal deformity 
NOS 
PF...00 Other congenital limb anomalies 
PF0..00 Polydactyly - supernumerary digits 
PF00.00 Supernumerary digits, unspecified 
PF01.00 Accessory fingers 
PF01000 Radial polydactyly Wassel 1 
PF01100 Radial polydactyly Wassel 2 
PF01200 Radial polydactyly Wassel 3 
PF01300 Radial polydactyly Wassel 4 
PF01400 Radial polydactyly Wassel 5 
PF01500 Radial polydactyly Wassel 6 
PF01600 Radial polydactyly Wassel 7 
PF01700 Central polydactyly 
PF01800 Ulnar polydactyly 
PF02.00 Accessory toes 
PF02000 Accesory hallux 
PF02100 Accessory little toe 
PF02200 Other accessory toe 
PF03.00 Accessory thumbs 
PF0z.00 Polydactyly NOS 
PF1..00 Syndactyly - webbing of digits 
PF10.00 Syndactyly of multiple digits, unspecified 
PF11.00 Syndactyly of fingers without bone fusion 
PF11.11 Webbed fingers 
PF11000 Simple syndactyly - 1st web 
PF11100 Simple syndactyly - 2nd to 4th web 
PF12.00 Syndactyly of fingers with bone fusion 
PF12.11 Fused fingers 
PF12.12 Osseous syndactyly of fingers 
PF12000 Osseous syndactyly - 1st web 
PF12100 Osseous syndactyly - 2nd to 4th web 
PF13.00 Syndactyly of toes without bone fusion 
PF13.11 Webbed toes 
PF13000 Simple syndactyly of toes 1st web space 
PF13100 Simple syndactyly lesser toes 
PF14.00 Syndactyly of toes with bone fusion 
PF14.11 Fused toes 
PF14.12 Conjoined toes 
PF14.13 Syndactyly of toes with bone fusion 
PF14000 Osseous syndactyly of toes 1st web space 
PF14100 Osseous syndactyly lesser toes 
PF15.00 Polysyndactyly 
PF1z.00 Syndactyly NOS 
PF1z.11 Polysyndactyly 
PF1z.12 Symphalangism 
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PF2..00 Reduction deformity of upper limb 
PF2..11 Arm reduction deformity 
PF20.00 Congenital shortening of arm, unspecified 
PF20.11 Brachymelia of arm 
PF20100 Ectromelia of upper limb NOS 
PF20200 Hemimelia of upper limb NOS 
PF20z00 Unspecified congenital shortening of arm 
NOS 
PF21.00 Transverse deficiency of arm 
PF21.11 Congenital absence part of arm 
PF21000 Transverse deficiency of arm, unspecified 
PF21100 Transverse deficiency of arm, phalangeal 
level, all fingers 
PF21200 Transverse deficiency of arm, forearm 
level 
PF21300 Transverse deficiency of arm, shoulder 
level(amelia) 
PF21400 Congenital amputation of upper limb 
PF21500 Transverse deficiency of arm, elbow 
level(hemimelia) 
PF21600 Transverse deficiency of arm, wrist 
level(hemimelia) 
PF21611 Acheiria 
PF21612 Rudimentary hand 
PF21613 Congenital absence of hand 
PF21700 Transverse deficiency of arm, upper arm 
level-short 
PF21800 Transverse deficiency of arm, upper arm 
level-long 
PF21z00 Transverse deficiency of arm NOS 
PF21z11 Agenesis of hand 
PF22.00 Longitudinal deficiency of arm NEC 
PF22000 Phocomelia of upper limb NOS 
PF22100 Rudimentary arm 
PF22z00 Longitudinal deficiency of arm NEC NOS 
PF23.00 Congenital absence upper arm and 
forearm with hand present 
PF23.11 Complete phocomelia of upper limb 
PF24.00 Congenital absence of upper arm only 
PF24.11 Proximal phocomelia of upper limb 
PF25.00 Congenital absence of forearm only 
PF25.11 Distal phocomelia of upper limb 
PF26.00 Agenesis of radial ray 
PF26.11 Congenital absence of radius 
PF26000 Hypoplasia of radius 
PF26100 Partial radial absence 
PF26200 Total radial absence 
PF26300 Absent thumb 
PF26400 Hypoplastic thumb-Blauth 1 
PF26500 Hypoplastic thumb-Blauth 2 
PF26600 Hypoplastic thumb-Blauth 3 
PF26700 Hypoplastic thumb-Blauth 4 
PF26800 Hypoplastic thumb-Blauth 5 
PF27.00 Agenesis of ulna 
PF27000 Partial defect of ulna 
PF27100 Total absence of ulna 
PF27200 Ulnar and humeroulnar synostosis 
PF28.00 Agenesis of carpals and metacarpals 
PF28.11 Transverse arrest of carpals and 
metacarpals 
PF28000 Transverse arrest carpal level 
PF28100 Transverse arrest metacarpal 1st ray 
PF28200 Transverse arrest metacarpal other 
PF29.00 Congenital absence of finger 
PF29.11 Ectrodactyly of finger 
PF29.12 Transverse arrest of phalanges 
PF29000 Transverse arrest phalangeal level 1st ray 
PF29100 Transverse arrest phalangeal level 2nd 
ray 
PF29200 Transverse arrest phalangeal level 3rd 
ray 
PF29300 Transverse arrest phalangeal level 4th 
ray 
PF29400 Transverse arrest phalangeal level 5th 
ray 
PF29z00 Congenital absence finger NOS 
PF2y.00 Other specified reduction deformities of 
upper limb 
PF2z.00 Reduction deformity of upper limb NOS 
PF2z.11 Hypoplasia of upper limb 
PF3..00 Reduction deformity of lower limb 
PF3..11 Leg reduction deformity 
PF30.00 Congenital shortening of leg, unspecified 
PF30.11 Brachymelia of leg 
PF30000 Ectromelia of lower limb NOS 
PF30100 Hemimelia of lower limb NOS 
PF30z00 Unspecified congenital leg shortening 
NOS 
PF31.00 Transverse deficiency of leg 
PF31000 Transverse deficiency lower limb - 
unspecified 
PF31100 Transverse deficiency lower limb - ankle 
level 
PF31111 Apodia 
PF31112 Hemimelia - ankle level 
PF31200 Congenital absence of leg and foot 
PF31300 Transverse deficiency lower limb - hip 
level 
PF31311 Amelia - lower limb 
PF31400 Transverse deficiency lower limb - 
metatarsal level 
PF31500 Transverse deficiency lower limb - knee 
level 
PF31511 Hemimelia - knee level 
PF31600 Transverse deficiency lower limb - 
through femur 
PF31700 Transverse deficiency lower limb - 
through tibia/fibula 
PF31800 Absent pelvis and lower limb 
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PF31z00 Transverse deficiency of leg NOS 
PF32.00 Longitudinal reduction deformity of lower 
limb NEC 
PF32.11 Phocomelia of lower limb NOS 
PF33.00 Congenital absence of thigh and lower leg 
with foot present 
PF33.11 Complete phocomelia of lower limb 
PF34.00 Congenital absence of thigh only 
PF34.11 Proximal phocomelia of lower limb 
PF34000 Proximal femoral focal deficiency 
PF34100 Congenital short femur 
PF35.00 Congenital absence of lower leg only 
PF35.11 Distal phocomelia of lower limb 
PF36.00 Agenesis of tibia 
PF36000 Congenital tibial deficiency type I 
PF36100 Congenital tibial deficiency type II 
PF36200 Congenital tibial deficiency type III 
PF37.00 Agenesis of fibula 
PF37000 Congenital fibular deficiency type I 
PF37100 Congenital fibular deficiency type II 
PF37200 Congenital fibular deficiency type III 
PF38.00 Agenesis of tarsals and metatarsals 
PF38000 Agenesis of talus 
PF38100 Agenesis of calcaneum 
PF38200 Agenesis of other tarsal bone 
PF38300 Agenesis of multiple tarsal bones 
PF38400 Agenesis of 1st metatarsal 
PF38500 Agenesis of 5th metatarsal 
PF38600 Agenesis of other metatarsal 
PF38700 Agenesis of 4th and 5th metatarsals 
PF38800 Agenesis of other multiple metatarsal 
PF39.00 Congenital absence of toe 
PF39000 Congenital absence of great toe 
PF39100 Congenital absence of 5th toe 
PF39200 Congenital absence of other lesser toe 
PF39300 Congenital absence of 4th and 5th toes 
PF39400 Congenital absence of other multiple toes 
PF3A.00 Split foot 
PF3y.00 Other specified reduction deformities of 
lower limb 
PF3z.00 Reduction deformity of lower limb NOS 
PF3z.11 Hypoplasia of lower limb 
PF4..00 Reduction deformity of unspecified limb 
PF40.00 Congenital absence of limb NOS 
PF41.00 Amelia of unspecified limb 
PF42.00 Ectromelia of unspecified limb 
PF43.00 Hemimelia of unspecified limb 
PF44.00 Phocomelia of unspecified limb 
PF45.00 Congenital amputation of unspecified limb 
PF46.00 Longitudinal reduction deformity of 
unspecified limb 
PF47.00 Congenital absence of digits NOS 
PF47.11 Adactyly 
PF4y.00 Other specified reduction deformities of 
unspecified limb 
PF4y000 Brachymelia NOS 
PF4yz00 Other reduction deformity of unspecified 
limb NOS 
PF4z.00 Reduction deformity of unspecified limb 
NOS 
PF4z.11 Brachydactyly NOS 
PF4z.12 Withered limb 
PF4z.13 Hypoplasia of limb NOS 
PF5..00 Other upper limb and shoulder anomaly 
PF50.00 Upper limb anomaly, unspecified 
PF51.00 Congenital deformity of clavicle 
PF51.11 Clavicle agenesis 
PF52.00 Congenital elevation of scapula 
PF52.11 Sprengel's deformity 
PF52000 Undescended shoulder 
PF53.00 Radio-ulnar synostosis 
PF53000 Proximal radioulnar synostosis 
PF53100 Radioulnar synostosis and dislocation of 
radial head 
PF53200 Distal radioulnar synostosis 
PF54.00 Madelung's deformity 
PF55.00 Acrocephalosyndactyly 
PF55.11 Apert's syndrome 
PF55.12 Acrocephalopolysyndactyly 
PF55000 Acrocephalosyndactyly (Apert) 
PF55100 Acrocephalosyndactyly (Pfeiffer) 
PF55200 Acrocephalopolysyndactyly 
PF55300 Saethre-Chotzen syndrome 
PF56.00 Accessory carpal bones 
PF57.00 Macrodactylia (fingers) 
PF57000 Macrodactyly - simple 
PF57100 Macrodactyly - fatty nerve tumor 
PF58.00 Congenital cleft hand 
PF58.11 Lobster-claw hand 
PF58000 Cleft hand - first cleft 
PF58100 Cleft hand - central 
PF58200 Cleft hand with syndactyly 
PF58300 Cleft hand with polydactyly 
PF59.00 Other failure of differentiation of soft 
tissue of arm 
PF59000 Windblown hand 
PF59100 Aberrant forearm flexor muscle 
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PF59200 Aberrant forearm extensor muscle 
PF59300 Aberrant intrinsic muscles 
PF59400 Poland's syndrome 
PF59500 Thumb in palm deformity 
PF59600 Congenital trigger thumb 
PF5A.00 Other failure of differentiation, skeletal 
tissues of arm 
PF5A000 Lunate-triquetrum synostosis 
PF5A100 Capitate-hamate synostosis 
PF5A200 Scaphoid-lunate synostosis 
PF5A300 Other carpal synostosis 
PF5A400 PIP joint symphalangism 
PF5A500 DIP joint symphalangism 
PF5Az00 Other failure of differentiation skeletal 
tissues of arm NOS 
PF5B.00 Other duplication of limb 
PF5B000 Duplication of whole limb 
PF5B100 Duplication of humerus 
PF5B200 Duplication of radius 
PF5B300 Duplication of ulnar ray 
PF5B400 Duplication ulnar ray - mirror hand 
PF5B500 Duplication of whole hand 
PF5Bz00 Duplication of limb NOS 
PF5C.00 Other overgrowth of upper limb 
PF5C000 Overgrowth of whole upper limb 
PF5C100 Overgrowth of partial upper limb 
PF5Cz00 Other overgrowth of limb NOS 
PF5D.00 Other undergrowth of limb 
PF5D000 Undergrowth of whole limb 
PF5D100 Undergrowth of whole hand 
PF5D200 Brachymetacarpia 
PF5Dz00 Other undergrowth of limb NOS 
PF5E.00 Constriction ring syndrome of upper limb 
PF5E000 Constriction ring 
PF5E100 Constriction ring with lymphoedema 
PF5E200 Acrosyndactyly 
PF5E300 Intra-uterine amputation 
PF5E400 Constriction ring with acrosyndactyly and 
amputation 
PF5F.00 Congenital absence of both forearm and 
hand 
PF5G.00 Congenital complete absence of upper 
limb(s) 
PF5r.00 Other congenital anomalies of fingers 
PF5r000 Triphalangeal thumb 
PF5r100 Brachydactyly of fingers, unspecified 
PF5r200 Camptodactyly 
PF5r300 Clinodactyly 
PF5r400 Flexion deformity of fingers 
PF5r500 Brachydactyly-all 3 phalanges 
PF5r600 Brachydactyly-missing phalanx 
PF5r700 Symbrachydactyly 
PF5r800 Camptodactyly-little finger 
PF5r900 Camptodactyly-other or multiple 
PF5rA00 Clinodactyly with delta phalanx 
PF5rB00 Clinodactyly, no delta phalanx 
PF5rC00 Brachymesophalangia 
PF5rD00 Congenital malformation of thumb 
PF5rz00 Other anomaly of fingers NOS 
PF5s.00 Other congenital anomalies of hand 
PF5t.00 Other congenital anomalies of wrist 
PF5u.00 Other congenital anomalies of forearm 
PF5u000 Radio-ulnar dysostosis 
PF5uz00 Other congenital anomaly forearm NOS 
PF5v.00 Congenital anomalies of elbow and upper 
arm 
PF5v.11 Cubitus NOS 
PF5w.00 Other congenital anomalies of shoulder 
PF5w.11 Congenital deformity of scapula NEC 
PF5x.00 Other congenital anomalies of whole arm 
PF5y.00 Other upper limb and shoulder anomaly 
OS 
PF5y000 Cleidocranial dysostosis 
PF5y011 Cleidocranial dysplasia 
PF5y100 Congenital cubitus valgus 
PF5y200 Congenital cubitus varus 
PF5y300 Congenital humeral varus 
PF5y400 Humeroradial synostosis 
PF5y500 Humeroulnar synostosis 
PF5y600 Total elbow synostosis 
PF5yz00 Other upper limb and shoulder anomaly 
NOS 
PF5z.00 Upper limb or shoulder anomaly NOS 
PF6..00 Other lower limb and pelvic girdle 
anomalies 
PF60.00 Lower limb anomaly, unspecified 
PF61.00 Congenital coxa valga 
PF62.00 Congenital coxa vara 
PF63.00 Other congenital hip joint deformity 
PF63000 Congenital anteversion of femoral neck 
PF63100 Congenital hip dysplasia 
PF63111 Developmental dysplasia of the hip 
PF63200 Congenital acetabular dysplasia 
PF63X00 Congenital deformity of hip, unspecified 
PF63z00 Other congenital hip joint deformity NOS 
PF64.00 Congenital knee joint deformity 
PF64000 Congenital absence of patella 
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PF64100 Congenital genu valgum - knock-knee 
PF64200 Congenital genu varum - bowleg 
PF64300 Rudimentary patella 
PF64400 Congenital dislocation of patella 
PF64500 Bipartite patella 
PF64z00 Congenital knee joint deformity NOS 
PF65.00 Macrodactylia of toes 
PF65000 Macrodactyly of toes - simple 
PF65100 Macrodactyly of toes - fatty nerve tumor 
PF66.00 Other congenital anomalies of toe 
PF66000 Congenital hallux valgus 
PF66100 Congenital hallux varus 
PF66200 Congenital hammer toe 
PF66300 Brachydactyly of toes 
PF66400 Congenital crossed toes 
PF66411 Congenital overlapping toes 
PF66500 Congenital curly toes 
PF66600 Brachyphalangia of little toe 
PF66700 Brachyphalangia of other toes 
PF66800 Perodactylia of great toe 
PF66900 Perodactylia of lesser toe 
PF66A00 Perodactylia of multiple toes 
PF66B00 Triphalangeal great toe 
PF66z00 Other toe anomalies NOS 
PF67.00 Congenital anomalies of foot NEC 
PF67000 Astragaloscaphoid synostosis 
PF67100 Calcaneonavicular bar 
PF67200 Coalition of calcaneous 
PF67300 Talonavicular synostosis 
PF67400 Tarsal coalitions 
PF67500 Lobster claw foot 
PF67600 Rocker bottom foot 
PF67700 Accessory tarsal bones 
PF67800 Talocalcaneal bar 
PF67900 Naviculocuneiform bar 
PF67A00 Complex tarsal coalition 
PF67z00 Anomalies of foot NEC NOS 
PF68.00 Failure of soft tissue differentiation of 
lower limb 
PF68000 Aberrant muscle of lower limb 
PF69.00 Failure of differentiation of skeletal 
tissues of lower limb 
PF69000 Congenital synostosis of lower limb bones 
PF6A.00 Duplication of lower limb bone 
PF6B.00 Congenital overgrowth of lower limb 
PF6B000 Congenital overgrowth of proximal lower 
limb 
PF6B100 Congenital overgrowth of distal lower 
limb 
PF6B200 Congenital overgrowth of foot 
PF6B300 Congen overgrowth of whole lower limb 
PF6C.00 Congenital undergrowth of lower limb 
PF6C000 Congenital undergrowth of proximal part 
of limb 
PF6C100 Congenital undergrowth of distal part of 
limb 
PF6C200 Congenital undergrowth of foot 
PF6C300 Brachymetapodia of 1st metatarsal 
PF6C400 Brachymetapodia of 4th metatarsal 
PF6C500 Brachymetapodia of other metatarsal 
PF6C600 Congen undergrowth of whole lower limb 
PF6D.00 Constriction ring syndrome of lower limb 
PF6D000 Constriction ring of lower limb 
PF6D100 Constriction ring of lower limb with 
lymphoedema 
PF6D200 Intrauterine amputation of lower limb 
PF6D300 Constriction ring syndrome of lower limb 
with amputation 
PF6E.00 Congenital absence of thigh and lower leg 
with foot present 
PF6v.00 Other congenital anomalies of lower leg 
PF6w.00 Other congenital anomalies of upper leg 
PF6x.00 Other congenital anomalies of pelvis 
PF6x000 Congenital absence of pubis NEC 
PF6xz00 Other congenital anomalies of pelvis NOS 
PF6y.00 Other lower limb anomalies 
PF6y000 Congenital angulation of tibia 
PF6y100 Congenital deformity of ankle joint 
PF6y200 Congenital deformity of sacroiliac joint 
PF6y300 Congenital fusion of sacroiliac joint 
PF6y400 Congenital varus ankle 
PF6y500 Congenital valgus ankle 
PF6y600 Congenital pseudarthrosis of tibia 
PF6y700 Congenital ball-and-socket ankle 
PF6yz00 Other lower limb and pelvic girdle 
anomaly NOS 
PFy..00 Other specified anomalies of unspecified 
limb 
PFy0.00 Arthrogryposis multiplex congenita 
PFy1.00 Larsen's syndrome 
PFy2.00 Arthrogryposis, unspecified 
PFy3.00 Distal arthrogryposis syndrome 
PFy4.00 Other arthrogryposis syndromes 
PFyz.00 Other anomaly of unspecified limb NOS 
PFz..00 Congenital anomaly of unspecified limb 
NOS 
PG...00 Other congenital musculoskeletal 
anomalies 
PG0..00 Skull and face bone anomalies 
PG0..11 Face bone anomalies 
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PG0..12 Skull and face bone anomalies 
PG00.00 Congenital absence of skull bones 
PG01.00 Acrocephaly 
PG02.00 Congenital forehead deformity 
PG03.00 Craniosynostosis 
PG03.11 Scaphocephaly 
PG03000 Muenke syndrome 
PG04.00 Craniofacial dysostosis 
PG04.11 Crouzon's disease 
PG04.12 Trigorhinophalangeal dysplasia 
PG05.00 Hypertelorism 
PG06.00 Imperfect fusion of skull 
PG07.00 Oxycephaly 
PG08.00 Platybasia 
PG09.00 Premature cranial suture closure 
PG0A.00 Tower skull 
PG0B.00 Trigonocephaly 
PG0C.00 Pierre - Robin syndrome 
PG0D.00 Mandibulofacial dysostosis 
PG0D.11 Franceschetti syndrome 
PG0D.12 Treacher - Collins syndrome 
PG0E.00 Oculomandibular dysostosis 
PG0E.11 Hallerman - Streif syndrome 
PG0E.12 Oculomandibulofacial syndrome 
PG0F.00 Goldenhar's syndrome 
PG0G.00 Localised skull defects 
PG0G.11 Craniolacunia 
PG0G.12 Lacunar skull 
PG0G.13 Parietal foramina 
PG0H.00 Macrocephaly 
PG0J.00 Pierre Robin association 
PG0y.00 Other specified skull or face bone 
anomaly 
PG0y.11 Defect of skull ossification 
PG0y.12 Cranial dysostosis NEC 
PG0y000 Brachycephaly 
PG0yz00 Other anomaly of skull or face bone NOS 
PG0z.00 Skull or face bone anomaly NOS 
PG0z.11 Dysmorphic features 
PG1..00 Anomalies of spine 
PG10.00 Anomaly of spine, unspecified 
PG11.00 Congenital lumbosacral spondylolysis 
PG12.00 Congenital spondylolisthesis 
PG13.00 Congenital absence of vertebra 
PG13000 Congenital absence of cervical vertebra 
PG13100 Congenital absence of thoracic vertebra 
PG13200 Congenital absence of lumbar vertebra 
PG13300 Congenital absence of sacrum 
PG13311 Sacral agenesis 
PG13z00 Congenital absence of vertebra NOS 
PG14.00 Hemivertebra 
PG14000 Cervical hemivertebra 
PG14100 Thoracic hemivertebra 
PG14200 Lumbar hemivertebra 
PG14300 Cervical hemivertebra- balanced 
PG14400 Cervical hemivertebra - unbalanced 
PG14500 Thoracic hemivertebra- balanced 
PG14600 Thoracic hemivertebra - unbalanced 
PG14700 Lumbar hemivertebra - balanced 
PG14800 Lumbar hemivertebra - unbalanced 
PG14z00 Hemivertebra NOS 
PG15.00 Congenital fusion of spine 
PG15.11 Congenital lumbosacral fusion 
PG15000 Congenital complete fusion of spine 
PG15100 Congenital partial fusion of spine - 
balanced 
PG15200 Congenital partial fusion of spine - 
unbalanced 
PG15300 Congenital partial fusion spine with 
hemivertebra, balanced 
PG15400 Congenit partial fusion spine with 
hemivertebra, unbalanced 
PG16.00 Klippel-Feil syndrome 
PG16000 Wilderwanck's syndrome 
PG16z00 Klippel - Feil syndrome NOS 
PG17.00 Spina bifida occulta 
PG18.00 Congenital kyphosis 
PG18.11 Congenital kyphoscoliosis 
PG1u.00 Congenital anomalies of cervical 
vertebrae NEC 
PG1u000 Supernumerary cervical vertebra 
PG1uz00 Congenital anomaly of cervical vertebrae 
NEC NOS 
PG1v.00 Congenital anomalies of thoracic 
vertebrae NEC 
PG1v000 Supernumerary thoracic vertebra 
PG1vz00 Congenital anomaly of thoracic vertebrae 
NEC NOS 
PG1w.00 Congenital anomalies of lumbar vertebrae 
NEC 
PG1w000 Supernumerary lumbar vertebra 
PG1wz00 Congenital anomaly of lumbar vertebra 
NEC NOS 
PG1x.00 Congenital sacrococcygeal anomalies NEC 
PG1x000 Congenital absence of coccyx 
PG1x100 Congenital absence of sacrum 
PG1xz00 Congenital sacrococcygeal anomaly NOS 
PG1y.00 Other anomaly of spine 
373 
 
PG1y.11 Congenital deformity of lumbosacral joint 
PG1y.12 Congenital deformity of lumbosacral 
region 
PG1y000 Platyspondylia 
PG1y100 Supernumerary vertebra 
PG1y200 Congenital absence of spine NEC 
PG1y300 Defect of vertebral segmentation 
PG1y400 Hypoplasia of spine 
PG1yz00 Other anomaly of spine NOS 
PG1z.00 Anomalies of spine NOS 
PG2..00 Cervical rib 
PG3..00 Other rib and sternum anomalies 
PG30.00 Congenital absence of rib 
PG31.00 Congenital absence of sternum 
PG32.00 Congenital fissure of sternum 
PG33.00 Congenital fusion of ribs 
PG34.00 Sternum bifidum 
PG35.00 Mis-shapen ribs 
PG36.00 Extra ribs 
PG36.11 Supernumerary ribs 
PG37.00 Mis-shapen sternum 
PG3x.00 Other congenital anomalies of ribs 
PG3y.00 Other congenital anomalies of sternum 
PG3z.00 Other rib or sternum anomaly NOS 
PG3z.11 Anomalies of thoracic cage unspecified 
PG4..00 Chondrodysplasia 
PG40.00 Chondrodysplasia, unspecified 
PG41.00 Achondroplasia 
PG41.11 Dwarfism 
PG41.12 Achondrogenesis 
PG41.13 Achondroplastic dwarf 
PG41000 Hypochondroplasia 
PG42.00 Multiple enchondromata 
PG42.11 Enchondromatosis 
PG42.12 Ollier's disease 
PG42.13 Chondrodysplasia 
PG42.14 Chondrodystophy NEC 
PG42.15 Hypochondroplasia 
PG42.16 Osteopathia striata 
PG42.17 Pseudochondroplasia 
PG42.18 Dyschondroplasia 
PG42000 Multiple enchondromata with 
haemangioma 
PG42011 Kast's syndrome 
PG42012 Maffuci's syndrome 
PG42013 Chondrodysplasia with haemangioma 
PG42100 Myotonic chondrodysplasia 
PG42111 Catel-Schwartz-Jampel syndrome 
PG42z00 Dyschondroplasia NOS 
PG43.00 Asphyxiating thoracic dysplasia 
PG43.11 Jeune's syndrome 
PG44.00 Other specified dwarfing syndromes 
PG44000 Diastrophic dwarfism 
PG44011 Diastrophic dysplasia 
PG44100 Metatropic dwarfism 
PG44111 Metatropic dysplasia 
PG44200 Thanatophoric dwarfism 
PG44211 Thanatophoric dysplasia 
PG44300 Mesomelic dysplasia 
PG44400 Acromesomolic dysplasia 
PG44500 Kniest dysplasia 
PG44600 Pseudoachondroplasia 
PG44z00 Other dwarfing syndromes NOS 
PG45.00 Metaphyseal dysostosis 
PG45.11 Jansen's metaphyseal dysostosis 
PG45.12 Schmid's metaphyseal dysostosis 
PG45.13 Craniometaphyseal dysostosis 
PG45.14 Frontometaphyseal dysostosis 
PG45.15 Metaphyseal dysplasia 
PG46.00 Spondyloepiphyseal dysplasia 
PG46.11 Pseudoachondroplasia 
PG46000 Spondyloepiphyseal dysplasia congenita 
PG46100 Spondyloepiphyseal dysplasia tarda 
PG47.00 Congenital exostosis 
PG47.11 Multiple congenital exostosis 
PG48.00 Diaphyseal aclasis 
PG49.00 Dysplasia epiphysealis hemimelica 
PG4A.00 Metachondromatosis 
PG4B.00 Lethal retarded ossification syndromes 
PG4B000 Achondrogenesis 
PG4B100 Hypochondrogenesis 
PG4B200 Fibrochondrogenesis 
PG4B300 Short-rib/polydactyly syndrome 
PG4B400 Camptomelia dysplasia 
PG4By00 Other lethal retarded ossification 
syndromes 
PG4C.00 Chondrodysplasia punctata 
PG4D.00 Metaphyseal chondrodysplasia 
PG4E.00 Spondylometaphyseal dysplasia 
PG4F.00 Lei-Weill dyschondrosteosis 
PG4y.00 Chondrodysplasia OS 
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PG4z.00 Chondrodysplasia NOS 
PG5..00 Osteodysplasia 
PG5..11 Osteodystrophy 
PG50.00 Osteodysplasia, unspecified 
PG51.00 Osteogenesis imperfecta 
PG51.11 Vrolik's disease 
PG51.12 Eddowe's syndrome 
PG51.13 Adair-Dighton syndrome 
PG51.14 Lobstein's syndrome 
PG51.15 Van der Hoeve's syndrome 
PG51.16 Brittle bone disease 
PG51000 Fragilitas ossium 
PG51100 Osteopsathyrosis 
PG51200 Osteogenesis imperfecta - unclassifiable 
PG51300 Osteogenesis imperfecta type I 
PG51400 Osteogenesis imperfecta type II 
PG51500 Osteogenesis imperfecta type III 
PG51600 Osteogenesis imperfecta type IV 
PG51z00 Osteogenesis imperfecta NOS 
PG52.00 Osteopetrosis 
PG52.11 Albers - Schonberg syndrome 
PG52.12 Marble bones 
PG52000 Osteopetrosis - unclassified 
PG52100 Osteopetrosis - congenita type 
PG52200 Osteopetrosis - tarda type 
PG53.00 Osteopoikilosis 
PG53.11 Buschke-Ollendorff syndrome 
PG54.00 Polyostotic fibrous dysplasia 
PG55.00 Chondroectodermal dysplasia 
PG55.11 Ellis - Van Creveld syndrome 
PG56.00 Multiple epiphyseal dysplasia 
PG56000 Chondrodysplasia calcificans congenita 
PG56011 Chondrodysplasia calcificans congenita 
PG56012 Conradi - Hunermann syndrome 
PG56z00 Multiple epiphyseal dysplasia NOS 
PG57.00 Infantile cortical hyperostosis 
PG57.11 Caffey's syndrome 
PG58.00 Progressive diaphyseal dysplasia 
PG58.11 Engelmann's syndrome 
PG58.12 Camurati-Engelmann disease 
PG59.00 Pyknodysostosis 
PG59.11 Pycnodysostosis 
PG5A.00 Diaphyseal dysplasia 
PG5B.00 Multiple synostosis syndrome 
PG5C.00 Craniometaphyseal dysplasia 
PG5D.00 Craniodiaphyseal dysplasia 
PG5E.00 Frontometaphyseal dysplasia 
PG5y.00 Other specified osteodysplasia 
PG5y.11 Dyschondrosteosis 
PG5y.12 Furst-Ostrum syndrome 
PG5y000 Albright-Sternberg syndrome 
PG5y011 Albright-McCune-Sternberg syndrome 
PG5y012 Albright's polyostotic dysplasia 
PG5yz00 Other osteodysplasia NOS 
PG5z.00 Osteodysplasia NOS 
PG5z.11 Osteochondrodysplasia 
PG6..00 Anomalies of diaphragm 
PG60.00 Congenital absence of diaphragm 
PG61.00 Congenital diaphragmatic hernia 
PG61.11 Congenital defect of diaphragmatic NEC 
PG62.00 Congenital foramen Morgagni hernia 
PG63.00 Eventration of diaphragm 
PG6y.00 Other specified anomalies of diaphragm 
PG6z.00 Diaphragm anomalies NOS 
PG7..00 Abdominal wall anomalies 
PG70.00 Exomphalos 
PG71.00 Gastroschisis 
PG72.00 Prune belly syndrome 
PG7y.00 Other specified anomaly of abdominal 
wall 
PG7z.00 Abdominal wall anomaly NOS 
PG8..00 Congenital inguinal hernia 
PGW..00 Osteochondrodyspl with defct growth tub 
bone spine unspec 
PGX..00 Congenital malformation of bony thorax, 
unspecified 
PGy..00 Other specified muscle, tendon and fascia 
anomaly 
PGy0.00 Congenital absence of muscle and tendon 
PGy0000 Absent tendon 
PGy0100 Poland's syndrome 
PGy0200 Other absent muscle 
PGy0211 Muscle agenesis 
PGy0212 Orbinsky syndrome 
PGy0z00 Absent muscle or tendon NOS 
PGy1.00 Accessory muscle 
PGy2.00 Ehlers-Danlos syndrome 
PGy2000 Ehlers-Danlos syndrome type I 
PGy2100 Ehlers-Danlos syndrome type II 
PGy2200 Ehlers-Danlos syndrome type III 
PGy2300 Ehlers-Danlos syndrome type IV 
PGy2400 Ehlers-Danlos syndrome type V 
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PGy2500 Ehlers-Danlos syndrome type VI 
PGy2600 Ehlers-Danlos syndrome type VII 
PGy2700 Ehlers-Danlos syndrome type VIII 
PGy3.00 Nail-patella syndrome 
PGy3.11 Osteo-onychodysostosis 
PGy3.12 Onycho-osteodysplasia 
PGy4.00 Fibrodysplasia ossificans congenita 
PGyy.00 Other specified other anomalies of 
muscle, tendon and fascia 
PGyy.11 Ayala's disease 
PGyy000 Amyotrophica congenita 
PGyy100 Congenital shortening of tendon 
PGyy200 Hypoplasia of muscle 
PGyy300 Popliteal web syndrome 
PGyy400 Aplasia of muscle 
PGyyz00 Other anomaly of tendon, fascia or 
muscle NOS 
PGyz.00 Other muscle, tendon or fascia anomalies 
NOS 
PGz..00 Congenital musculoskeletal anomalies 
NOS 
PGz..11 Congenital deformity of musculoskeletal 
system NEC 
PGz0.00 Unspecified anomaly of muscle 
PGz1.00 Unspecified anomaly of tendon 
PGz2.00 Unspecified anomaly of bones 
PGz3.00 Unspecified anomaly of cartilage 
PGz4.00 Unspecified anomaly of connective tissue 
PH...00 Congenital integument anomalies 
PH...11 Congenital skin anomalies 
PH0..00 Hereditary oedema of legs 
PH00.00 Congenital lymphoedema 
PH01.00 Hereditary trophoedema 
PH02.00 Milroy's disease 
PH02.11 Meige's disease 
PH03.00 Congenital elephantiasis 
PH0z.00 Hereditary oedema of legs NOS 
PH1..00 Ichthyosis congenita 
PH10.00 Congenital ichthyosis, unspecified 
PH11.00 Harlequin fetus 
PH12.00 Ichthyosiform erythroderma 
PH12.11 Sjogren - Larsson syndrome 
PH13.00 Collodion baby 
PH14.00 Ichthyosis vulgaris 
PH15.00 X-linked ichthyosis 
PH1y.00 Other specified ichthyosis congenita 
PH1y000 Nethertons syndrome" 
PH1z.00 Ichthyosis congenita NOS 
PH1z.11 Congenital ichthyosiform erythroderma 
PH1z.12 Alligator skin 
PH2..00 Dermatoglyphic anomalies 
PH20.00 Abnormal palmar creases 
PH2z.00 Dermatoglyphic anomalies NOS 
PH3..00 Other specified skin anomalies 
PH30.00 Congenital ectodermal dysplasia 
PH31.00 Vascular hamartomas 
PH31.11 Vascular naevus 
PH31.12 Naevus flammeus 
PH31000 Birth mark, unspecified 
PH31100 Port wine stain 
PH31200 Strawberry naevus 
PH31300 Angiomatosis 
PH31z00 Vascular hamartoma NOS 
PH32.00 Congenital pigmentary skin anomalies 
PH32000 Congenital poikiloderma 
PH32100 Urticaria pigmentosa 
PH32111 Mast cell disease 
PH32112 Mastocytosis 
PH32113 Nettleship's syndrome 
PH32200 Xeroderma pigmentosum 
PH32211 Kaposi's xeroderma pigmentosum 
PH32300 Incontinentia pigmenti 
PH32311 Bloch - Sulzberger syndrome 
PH32z00 Congenital pigmentary skin anomaly NOS 
PH33.00 Specified syndromes NEC involving skin 
anomalies 
PH33000 Brugsch's syndrome 
PH33011 Acropachyderma 
PH33100 Hailey-Hailey disease 
PH33111 Benign familial chronic pemphigus 
PH33200 Mibelli's disease 
PH33300 Rothmund-Thomson syndrome 
PH33311 Atrophic heredofamilial dermatosis 
PH33312 Thomson's disease 
PH33400 Focal dermal hypoplasia 
PH33500 Pseudoxanthoma elasticum 
PH33511 Darier's disease - pseudoxanthoma 
elasticum 
PH33600 Siemen's syndrome 
PH33z00 Specified syndromes involving skin 
anomalies NEC NOS 
PH34.00 Other specified birthmark 
PH34.11 Naevus NEC 
PH34000 Naevus sebaceous 
PH35.00 Mongolian blue spot 
PH3y.00 Other congenital skin anomalies 
376 
 
PH3y.11 Keratosis palmaris 
PH3y000 Congenital accessory skin tags 
PH3y100 Congenital scar 
PH3y200 Epidermolysis bullosa 
PH3y211 Goldscheider's disease 
PH3y212 Koebner's disease 
PH3y213 Bullous eruption of hand 
PH3y300 Congenital keratoderma 
PH3y400 Congenital keratosis follicularis 
PH3y411 Darier's disease - keratosis follicularis 
PH3y500 Acanthosis nigricans, congenital 
PH3y600 Keratosis palmaris et plantaris 
PH3y611 Tylosis palmaris et plantaris 
PH3y700 Epidermolysis bullosa simplex 
PH3y800 Epidermolysis bullosa letalis 
PH3y900 Epidermolysis bullosa dystrophica 
PH3yA00 Bloom syndrome 
PH3yz00 Other congenital skin anomaly NOS 
PH3yz11 Lichen spinulosus 
PH3z.00 Integument anomalies NOS 
PH4..00 Specified hair anomalies 
PH40.00 Congenital alopecia 
PH40.11 Congenital atrichosis 
PH40000 Congenital alopecia, unspecified 
PH40100 Congenital localised alopecia 
PH40200 Congenital generalised alopecia 
PH40211 Atrichosis 
PH40z00 Congenital alopecia NOS 
PH41.00 Congenital monilethrix 
PH41.11 Beaded hair 
PH42.00 Congenital hypertrichosis 
PH43.00 Persistent lanugo 
PH43.11 Hypertrichosis lanuginosa 
PH44.00 Twisted hair 
PH44.11 Pili torti 
PH45.00 Taenzer's hair 
PH4z.00 Specified hair anomalies NOS 
PH5..00 Specified anomalies of nails 
PH50.00 Anonychia 
PH50.11 Congenital absence of nails 
PH51.00 Congenital clubnail 
PH52.00 Congenital koilonychia 
PH53.00 Congenital leukonychia 
PH54.00 Congenital onychauxis 
PH54.11 Enlarged nails 
PH55.00 Congenital pachyonychia 
PH55.11 Hypertrophic nails 
PH5z.00 Specified nail anomalies NOS 
PH6..00 Specified anomalies of breast 
PH60.00 Absent breast 
PH61.00 Absent nipple 
PH62.00 Accessory breast 
PH63.00 Accessory nipple 
PH64.00 Supernumerary breast 
PH65.00 Supernumerary nipple 
PH66.00 Hypoplasia of breast 
PH67.00 Small nipple 
PH67.11 Hypoplasia of nipple 
PH68.00 Ectopic breast tissue 
PH6X.00 Congenital malformation of breast, 
unspecified 
PH6z.00 Specified breast anomalies NOS 
PH7..00 Cutis marmorata telangiectasia congenita 
PHy..00 Other specified integument anomaly 
PHz..00 Integument anomalies NOS 
PHz..11 Congenital ectodermal defect 
PHz0.00 Unspecified congenital anomalies of skin 
PHz0.11 Congenital dermal defect 
PHz1.00 Unspecified congenital anomalies of hair 
PHz2.00 Unspecified congenital anomalies of nail 
PHz2.11 Congenital deformity of nail 
PJ...00 Chromosomal anomalies 
PJ0..00 Down's syndrome - trisomy 21 
PJ0..11 Mongolism 
PJ0..12 Trisomy 21 
PJ0..13 Trisomy 22 
PJ00.00 Trisomy 21, meiotic nondisjunction 
PJ01.00 Trisomy 21, mosaicism 
PJ01.11 Trisomy 21, mitotic nondisjunction 
PJ02.00 Trisomy 21, translocation 
PJ02.11 Partial trisomy 21 in Down's syndrome 
PJ0z.00 Down's syndrome NOS 
PJ0z.11 Trisomy 21 NOS 
PJ1..00 Patau's syndrome - trisomy 13 
PJ10.00 Trisomy 13, meiotic nondisjunction 
PJ11.00 Trisomy 13, mosaicism 
PJ11.11 Trisomy 13, mitotic nondisjunction 
PJ12.00 Trisomy 13, translocation 
PJ12.11 Partial trisomy 13 in Patau's syndrome 
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PJ1z.00 Patau's syndrome NOS 
PJ1z.11 Trisomy 13 NOS 
PJ2..00 Edward's syndrome - trisomy 18 
PJ20.00 Trisomy 18, meiotic nondisjunction 
PJ21.00 Trisomy 18, mosaicism 
PJ21.11 Trisomy 18, mitotic nondisjunction 
PJ22.00 Trisomy 18, translocation 
PJ22.11 Partial trisomy 18 in Edward's syndrome 
PJ2z.00 Edward's syndrome NOS 
PJ2z.11 TRISOMY 18 NOS 
PJ3..00 Monosomies and deletions from the 
autosomes 
PJ30.00 Antimongolism syndrome 
PJ30.11 Deletion of long arm of chromosome 21 
PJ31.00 Cri-du-chat syndrome 
PJ31.11 Deletion of short arm of chromosome 5 
PJ32.00 Deletion of short arm of chromosome 4 
PJ32.11 Wolff - Hirschorn syndrome 
PJ33.00 Other deletions of part of a chromosome 
PJ33000 Deletion of long arm of chromosome 13 
PJ33100 Deletion of long arm of chromosome 18 
PJ33111 18p- syndrome 
PJ33200 Deletion of short arm of chromosome 18 
PJ33211 18q- syndrome 
PJ33300 Smith-Magenis syndrome 
PJ33400 Jacobsen syndrome 
PJ33z00 Other deletion of part of a chromosome 
NOS 
PJ34.00 Deletions seen only at prometaphase 
PJ35.00 Deletions with other complex 
rearrangements 
PJ36.00 Whole chromosome monosomy, meiotic 
nondisjunction 
PJ37.00 Whole chromosome monosomy, 
mosaicism 
PJ37.11 Whole chromosome monosomy, mitotic 
nondisjunction 
PJ37.12 Autosomal deletion - mosaicism 
PJ37000 Monosomy 21, mosaicism 
PJ37z00 Whole chromosome monosomy, 
mosaicism NOS 
PJ38.00 Chromosome replaced with ring or 
dicentric 
PJ38.11 Chromosome replaced with dicentric 
PJ38.12 Chromosome replaced with ring 
PJ3y.00 Other deletions from the autosomes 
PJ3y000 Shprintzen syndrome 
PJ3y011 Velocardiofacial syndrome 
PJ3z.00 Monosomies and deletions from the 
autosomes NOS 
PJ4..00 Balanced autosomal translocation 
PJ5..00 Other condition due to autosomal 
anomaly 
PJ50.00 Whole chromosome trisomy syndromes 
PJ50000 Trisomy 6 
PJ50100 Trisomy 7 
PJ50200 Trisomy 8 
PJ50300 Trisomy 9 
PJ50400 Trisomy 10 
PJ50500 Trisomy 11 
PJ50600 Trisomy 12 
PJ50700 Other trisomy C syndromes 
PJ50800 Trisomy 22 
PJ50w00 Whole chromosome trisomy, meitotic 
nondisjunction 
PJ50x00 Whole chromosome trisomy, mosaicism 
PJ50x11 Whole chromosome trisomy, mitotic 
nondisjunction 
PJ50y00 Other specified whole chromosome 
trisomy syndrome 
PJ50z00 Whole chromosome trisomy syndrome 
NOS 
PJ51.00 Partial trisomy syndromes 
PJ51000 Major partial trisomy 
PJ51100 Minor partial trisomy 
PJ51z00 Partial trisomy syndrome NOS 
PJ52.00 Trisomies of autosomes NEC 
PJ52000 Duplications seen only at prometaphase 
PJ52100 Duplications with other complex 
rearrangements 
PJ52200 Extra marker chromosomes 
PJ52300 Triploidy 
PJ52400 Polyploidy 
PJ52z00 Trisomy of autosomes NEC NOS 
PJ53.00 Balanced rearrangements and structural 
markers NEC 
PJ53.11 Balanced translocations 
PJ53000 Chromosome inversion in normal 
individual 
PJ53100 Balanced autosomal rearrangement in 
abnormal individual 
PJ53200 Balanced sex/autosomal rearrangement 
in abnormal individual 
PJ53300 Individual with marker heterochromatin 
PJ53400 Individual with autosomal fragile site 
PJ53500 Shwachman-Diamond syndrome 
PJ53z00 Balanced rearrangement or structural 
marker NEC NOS 
PJ5y.00 Other specified conditions due to 
autosomal anomalies 
PJ5z.00 Unspecified conditions due to autosomal 
anomalies 
PJ5z.11 Aneuploidy NEC 
PJ6..00 Gonadal dysgenesis 
PJ60.00 Mixed gonadal dysgenesis 
PJ62.00 Ovarian dysgenesis 
PJ63.00 Turner's syndrome 
PJ63000 Turner's phenotype, karyotype normal 
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PJ63100 Turner's phenotype, karyotype 45X 
PJ63200 Turner's phenotype, karyotype 46X iso 
(Xq) 
PJ63300 Turner's,karyotype 46X + abnorm. sex 
chromosome,not iso(Xq) 
PJ63400 Turner's phenotype, mosaicism 45X/46XX 
or 45X/46XY 
PJ63500 Turner's,mosaic, 45X/other cell line with 
abn.sex chromosome 
PJ63600 Turner's phenotype, other variant 
karyotypes 
PJ63611 Turner's phenotype, ring chromosome 
karyotype 
PJ63612 Turner's phenotype, partial X deletion 
karyotype 
PJ63z00 Turner's syndrome NOS 
PJ63z11 Bonnevie-Ullrich syndrome NOS 
PJ63z12 Ovarian dwarfism NEC 
PJ64.00 Other gonadal dysgenesis phenotype 
PJ64000 XY, female phenotype 
PJ64z00 Other gonadal dysgenesis phenotype NOS 
PJ6z.00 Gonadal dysgenesis NOS 
PJ7..00 Klinefelter's syndrome 
PJ70.00 Klinefelter's phenotype, karyotype 47XXY 
PJ71.00 Klinefelter's syndrome,male with more 
than two X chromosomes 
PJ71.11 Klinefelter's syndrome, XXXY 
PJ71.12 Klinefelter's syndrome, XXXXY 
PJ72.00 Klinefelter's syndrome, male with 46XX 
karyotype 
PJ73.00 Klinefelter's syndrome, XXYY 
PJ74.00 Klinefelter's syndrome, XY/XXY mosaic 
PJ7z.00 Klinefelter's syndrome NOS 
PJ8..00 Balanced translocation and insertion in 
normal individual 
PJ9..00 Mowat-Wilson syndrome 
PJX..00 Sex chromosome abnormality, male 
phenotype, unspecified 
PJy..00 Other sex chromosome anomaly 
PJy0.00 Additional sex chromosome 
PJy1.00 Sex chromosome mosaicism 
PJy1000 Mosaic XO/XY 
PJy1100 Mosaic XO/XX 
PJy1200 Mosaic XY/XXY 
PJy1300 Mosaic including XXXXY 
PJy1z00 Sex chromosome mosaicism NOS 
PJy2.00 XXX syndrome 
PJy2.11 Triple X female 
PJy2.12 Karyotype 47, XXX 
PJy3.00 XXY syndrome 
PJy4.00 Female with more than three X 
chromosomes 
PJy5.00 Mosaicism, lines with various numbers of 
X chromosomes 
PJy6.00 Male with structurally abnormal sex 
chromosome 
PJyy.00 Other specified sex chromosome anomaly 
PJyy.11 Absence of sex chromosome 
PJyy000 Chimera 46XX/46XY 
PJyy011 Chimera 46XX/46XY, true hermaphrodite 
PJyy100 46XX true hermaphrodite 
PJyy200 Fragile X chromosome 
PJyy300 Karyotype 47,XYY 
PJyy400 Fragile X syndrome 
PJyyz00 Other sex chromosome abnormality NOS 
PJyz.00 Sex chromosome anomaly NOS 
PJz..00 Chromosomal anomalies NOS 
PJz0.00 Mosaicism NOS 
PJz1.00 Additional chromosome NOS 
PJz2.00 Deletion of chromosome NOS 
PJz3.00 Duplication of chromosome 
PJzz.00 Conditions due to anomaly of unspecified 
chromosome NOS 
PK...00 Other and unspecified congenital 
anomalies 
PK0..00 Anomalies of spleen 
PK00.00 Aberrant spleen 
PK01.00 Absent spleen 
PK01.11 Asplenia 
PK02.00 Accessory spleen 
PK03.00 Congenital splenomegaly 
PK03.11 Hyperplasia of spleen 
PK04.00 Ectopic spleen 
PK05.00 Congenital lobulation of spleen 
PK06.00 Hypoplasia of spleen 
PK07.00 Mis-shapen spleen 
PK0y.00 Other specified anomalies of spleen 
PK0z.00 Anomalies of spleen NOS 
PK1..00 Anomalies of adrenal gland 
PK10.00 Aberrant adrenal gland 
PK11.00 Absent adrenal gland 
PK12.00 Accessory adrenal gland 
PK13.00 Hypoplasia of adrenal gland 
PK14.00 Ectopic adrenal gland 
PK15.00 Aplasia of adrenal gland 
PK1y.00 Other specified anomalies of adrenal 
gland 
PK1y000 Congenital cyst of adrenal gland 
PK1yz00 Other congenital anomaly of adrenal 
gland NOS 
PK1z.00 Anomalies of adrenal gland NOS 
PK2..00 Other endocrine gland anomalies 
PK20.00 Absent parathyroid gland 
PK21.00 Accessory thyroid gland 
PK22.00 Persistent thyroglossal duct 
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PK22.11 Persistent thyrolingual duct 
PK23.00 Thyroglossal duct cyst 
PK24.00 Anomalies of pituitary gland 
PK24000 Aberrant pituitary gland 
PK24100 Congenital absence of pituitary gland 
PK24200 Accessory pituitary gland 
PK24z00 Anomaly of pituitary gland NOS 
PK25.00 Anomalies of thyroid gland NEC 
PK25000 Aberrant thyroid gland 
PK25011 Retrosternal thyroid gland 
PK25100 Congenital absence of thyroid gland 
PK25z00 Anomaly of thyroid gland NEC NOS 
PK26.00 Anomalies of thyroglossal duct NEC 
PK27.00 Anomalies of parathyroid gland NEC 
PK27000 Aberrant parathyroid gland 
PK27100 Accessory parathyroid gland 
PK27z00 Anomaly of parathyroid gland NEC NOS 
PK28.00 Anomalies of thymus 
PK28000 Aberrant thymus gland 
PK28100 Congenital absence of thymus 
PK28200 Accessory thymus gland 
PK28z00 Anomaly of thymus gland NOS 
PK2y.00 Other specified endocrine gland anomaly 
PK2z.00 Endocrine gland anomaly NOS 
PK3..00 Situs inversus 
PK30.00 Situs inversus, unspecified 
PK30.11 Transposition of viscera unspecified 
PK31.00 Situs inversus abdominalis 
PK31.11 Transposition of abdominal viscera 
PK32.00 Situs inversus thoracis 
PK32.11 Transposition of thoracic viscera 
PK33.00 Complete situs inversus with dextrocardia 
PK34.00 Situs inversus with levocardia 
PK35.00 Kartagener's syndrome 
PK3z.00 Situs inversus NOS 
PK4..00 Conjoined twins 
PK40.00 Craniopagus 
PK40.11 Head-joined twins 
PK40000 Craniopagus frontalis 
PK40100 Craniopagus occipitalis 
PK40200 Craniopagus parietalis 
PK40300 Craniopagus parasiticus 
PK40z00 Craniopagus NOS 
PK41.00 Dicephalus 
PK41.11 Conjoined twins with two heads 
PK42.00 Pygopagus 
PK42.11 Buttock-joined twins 
PK43.00 Thoracopagus 
PK43.11 Thorax-joined twins 
PK44.00 Xiphopagus 
PK44.11 Xiphoid- and pelvis-joined twins 
PK45.00 Diaxial (double) monster 
PK4y.00 Other specified conjoined twins 
PK4z.00 Conjoined twins NOS 
PK5..00 Tuberous sclerosis 
PK5..11 Bourneville's disease 
PK5..12 Epiloia 
PK6..00 Other hamartoses NEC 
PK60.00 Peutz - Jegher's syndrome 
PK61.00 Sturge-Weber syndrome 
PK61.11 Kalischer's disease 
PK61.12 Encephalocutaneous angiomatosis 
PK62.00 Von Hippel-Lindau syndrome 
PK62.11 Lindau's disease 
PK63.00 Gardner's syndrome 
PK64.00 Proteus syndrome 
PK6y.00 Other specified hamartoses NEC 
PK6z.00 Hamartoses NOS 
PK7..00 Multiple congenital anomalies NOS 
PK70.00 Monster NOS 
PK7z.00 Multiple congenital anomalies NOS 
PK8..00 Congenital malformation syndromes due 
to known exogen causes 
PK80.00 Fetal alcohol syndrome 
PK81.00 Fetal hydantoin syndrome 
PK82.00 Dysmorphism due to warfarin 
PK83.00 Fetus and newborn affected by maternal 
use of alcohol 
PK84.00 Fetal valproate syndrome 
PKy..00 Other specified anomalies 
PKy0.00 Multiple system congenital anomalies NEC 
PKy0.11 Prader-Willi Syndrome 
PKy0.12 Prader-Willi syndrome 
PKy0.13 Noonan's syndrome 
PKy0000 Bannayan-Riley-Ruvalcaba syndrome 
PKy0100 Currarino triad 
PKy0200 Adams-Oliver syndrome 
PKy0300 Weaver syndrome 
PKy1.00 Laurence-Moon-Biedl syndrome 
PKy1.11 Biedl-Bardet syndrome 
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PKy2.00 Marfan's syndrome 
PKy3.00 Single monster, specified type 
PKy4.00 William syndrome 
PKy5.00 Congen malformation syndromes 
affecting facial appearance 
PKy5000 Oral - facial - digital syndrome 
PKy5011 Papillon-Leage-Psaume syndrome 
PKy5100 Mohr's syndrome 
PKy5200 Cyclops 
PKy5300 Whistling face syndrome 
PKy5311 Freeman Sheldon syndrome 
PKy5400 Waardenburg's syndrome 
PKy5500 Gorlin-Chaudhry-Moss syndrome 
PKy5600 Marchesani syndrome 
PKy5611 Weill-Marchesani syndrome 
PKy5612 Spherophakia-brachymorphia syndrome 
PKy5700 Otopalatodigital syndrome 
PKy5800 Usher's syndrome 
PKy5900 Oculo-palato-digital syndrome 
PKy5A00 Trichorhinophalangeal syndrome 
PKy5B00 Costello syndrome 
PKy5C00 Treacher Collins syndrome 
PKy5D00 Kabuki make-up syndrome 
PKy5E00 Branchio-otorenal dysplasia 
PKy5F00 Coffin-Lowry syndrome 
PKy5G00 Carey Fineman Ziter syndrome 
PKy5H00 Simpson-Golabi-Behmel syndrome 
PKy5z00 Congenital malform syndrome affecting 
facial appearance NOS 
PKy6.00 Congenital malformation syndromes with 
short stature 
PKy6000 Amsterdam dwarf 
PKy6011 Cornelia de Lange syndrome 
PKy6012 Bruck-de Lange syndrome 
PKy6013 Degenerative amsterodamensis typus 
PKy6100 Cockayne syndrome 
PKy6200 Russell - Silver syndrome 
PKy6300 Smith - Lemli - Opitz syndrome 
PKy6400 Seckel syndrome 
PKy6500 Aarskog syndrome 
PKy6600 Dubowitz syndrome 
PKy6700 Robinow syndrome 
PKy6800 Floating-Harbor syndrome 
PKy6z00 Congenital malformation syndrome with 
short stature NOS 
PKy7.00 Congenital malformation syndromes 
involving limbs 
PKy7000 Carpenter's syndrome 
PKy7100 Holt - Oram syndrome 
PKy7200 Klippel - Trenaunay - Weber syndrome 
PKy7300 Rubenstein - Tayi syndrome 
PKy7400 Sirenomelia 
PKy7411 Sympus 
PKy7412 Mermaid sirenomelia 
PKy7500 Arachnodactyly 
PKy7600 Aglossia - adactyly syndrome 
PKy7611 Hanhart syndrome 
PKy7700 Caudal dysplasia sequence 
PKy7800 Multiple pterygium syndrome 
PKy7900 Popliteal pterygium syndrome 
PKy7A00 Congenital contractural arachnodactyly 
PKy7A11 Beals syndrome 
PKy7B00 Stickler syndrome 
PKy7z00 Congenital malformation syndrome 
involving limbs NOS 
PKy8.00 Congenital malformation syndromes with 
other skeletal change 
PKy8000 Noonan's syndrome 
PKy8z00 Congenital malformation syndrome+other 
skeletal changes NOS 
PKy9.00 Congenital malformation syndromes with 
metabolic disturbance 
PKy9000 Alport's syndrome 
PKy9100 Beckwith's syndrome 
PKy9111 Wiedemann - Beckwith syndrome 
PKy9200 Menke's syndrome 
PKy9211 Kinky hair syndrome 
PKy9212 Congenital kinking hair 
PKy9300 Prader - Willi syndrome 
PKy9400 Zellweger's syndrome 
PKy9500 Biemond's syndrome 
PKy9600 VATER association 
PKy9z00 Congenital malformation syndrome + 
metabolic disturbance NOS 
PKyA.00 Cloacal exstrophy 
PKyB.00 CHARGE association 
PKyC.00 Pena-Shokeir syndrome type I 
PKyD.00 Nicolaides-Baraitser syndrome 
PKyE.00 Barber-Say syndrome 
PKyF.00 Alstrom syndrome 
PKyG.00 Men ret congen heart dis blepharophim 
blepharop hypopl teeth 
PKyG.11 Ohdo blepharophimosis syndrome 
PKyH.00 Moulded baby syndrome 
PKyJ.00 Lujan-Fryns syndrome 
PKyK.00 Loeys-Dietz syndrome 
PKyz.00 Other specified anomalies NOS 
PKyz.11 Cockayne's syndrome 
PKyz.12 Local gigantism NEC 
381 
 
PKyz000 Ullrich - Feichtiger syndrome, chimaera 
PKyz100 Acardia 
PKyz200 Acephalobrachius 
PKyz300 Acephalogaster 
PKyz400 Acephalothorax 
PKyz500 Happy puppet syndrome 
PKyz511 Angelman syndrome 
PKyz600 Congenital hemihypertrophy 
PKyz700 Angelman's syndrome 
PKyz711 Angelman syndrome 
PKyz800 DOOR - Deafness, triphalangeal thumbs, 
onychodystrophy 
PKz..00 Other anomalies NOS 
PKz0.00 Anomalies of umbilicus 
PKz1.00 Embropathia NEC 
PKzz.00 Congenital anomaly NOS 
Pyu0.00 [X]Congenital malformations of the 
nervous system 
Pyu0000 [X]Encephalocele of other sites 
Pyu0100 [X]Other congenital hydrocephalus 
Pyu0200 [X]Other reduction deformities of brain 
Pyu0300 [X]Other specified congenital 
malformations of brain 
Pyu0400 [X]Unspecified spina bifida with 
hydrocephalus 
Pyu0500 [X]Other congenital cauda equina 
malformations 
Pyu0600 [X]Other specified congenital 
malformations of spinal cord 
Pyu0700 [X]Other specif congenital malformations 
of nervous system 
Pyu1.00 [X]Congenital malformations of eye, ear, 
face and neck 
Pyu1000 [X]Other congenital malformations of 
eyelid 
Pyu1100 [X]Other congenital malformations of 
lacrimal apparatus 
Pyu1200 [X]Other anophthalmos 
Pyu1300 [X]Other congenital lens malformations 
Pyu1400 [X]Other congenital malformations of iris 
Pyu1500 [X]Other congenital corneal 
malformations 
Pyu1600 [X]Other congenital malforms of anterior 
segment of eye 
Pyu1700 [X]Other cong malformations of posterior 
segment of eye 
Pyu1800 [X]Other specified congenital 
malformations of eye 
Pyu1900 [X]Other congenital malformations of 
middle ear 
Pyu1A00 [X]Congenital malformation of inner ear 
Pyu1B00 [X]Malformation of ear with impairment 
of hearing, unspec 
Pyu1C00 [X]Other misshapen ear 
Pyu1D00 [X]Other specified congenital 
malformations of ear 
Pyu1E00 [X]Other branchial cleft malformations 
Pyu1F00 [X]Other specified congenital 
malformations of face & neck 
Pyu2.00 [X]Congenital malformations of the 
circulatory system 
Pyu2000 [X]Other cong malformatn of cardiac 
chambers & connections 
Pyu2100 [X]Other congenital malformations of 
cardiac septa 
Pyu2200 [X]Other congenital malformations of 
pulmonary valve 
Pyu2300 [X]Other congenital malformations of 
tricuspid valve 
Pyu2400 [X]Other congenital malformations of 
aortic & mitral valves 
Pyu2500 [X]Other specified congenital 
malformations of the heart 
Pyu2600 [X]Other congenital malformations of 
aorta 
Pyu2700 [X]Other congenital malformations of 
pulmonary artery 
Pyu2800 [X]Other congenital malformations of 
great arteries 
Pyu2900 [X]Other congenital malformations of 
great veins 
Pyu2A00 [X]Other congenital malformations of 
renal artery 
Pyu2B00 [X]Oth specified cong malform of 
peripheral vascular system 
Pyu2C00 [X]Other malformations of precerebral 
vessels 
Pyu2D00 [X]Other malformations of cerebral 
vessels 
Pyu2E00 [X]Other specified cong malformations of 
circulatory system 
Pyu2F00 [X]Congenital malforms of cardiac 
chambers+connections unsp 
Pyu2G00 [X]Congenital malformation of tricuspid 
valve, unspecified 
Pyu2H00 [X]Congenital malformation of aortic and 
mitral valves unsp 
Pyu2J00 [X]Congenital malformation of great 
arteries, unspecified 
Pyu2K00 [X]Congenital malformation of circulatory 
system, unspecif 
Pyu3.00 [X]Congenital malformations of the 
respiratory system 
Pyu3000 [X]Other congenital malformations of 
nose 
Pyu3100 [X]Other congenital malformations of 
larynx 
Pyu3200 [X]Other congenital malformations of 
trachea 
Pyu3300 [X]Other congenital malformations of 
bronchus 
Pyu3400 [X]Other congenital malformations of 
lung 
Pyu3500 [X]Other specified congen malformation 
respiratory system 
Pyu3600 [X]Congenital malformation of larynx, 
unspecified 
Pyu4.00 [X]Cleft lip and cleft palate 
Pyu4000 [X]Cleft palate, unspecified, bilateral 
Pyu4100 [X]Unspecified cleft palate with cleft lip, 
bilateral 
Pyu5.00 [X]Other congenital malformations of the 
digestive system 
Pyu5000 [X]Other congenital malformations of 
tongue 
Pyu5100 [X]Congenital malformations of palate, 
NEC 
Pyu5200 [X]Other congenital malformations of 
mouth 
Pyu5300 [X]Other congenital malformations of 
pharynx 
Pyu5400 [X]Other congenital malformations of 
oesophagus 
Pyu5500 [X]Other specified congenital 
malformations of stomach 
Pyu5600 [X]Other specif congen malformations 
upper alimentary tract 
Pyu5700 [X]Cong absence/atresia/stenos oth spec 
parts small intest 
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Pyu5800 [X]Cong absence/atresia/stenos of other 
parts large intest 
Pyu5900 [X]Cong abs, atresia & stenosis of large 
intest, part unsp 
Pyu5A00 [X]Other congenital functional disorders 
of colon 
Pyu5B00 [X]Other specified congenital 
malformations of intestine 
Pyu5C00 [X]Other congenital malformations of 
gallbladder 
Pyu5D00 [X]Other congenital malformations of bile 
ducts 
Pyu5E00 [X]Other congenital malformations of 
liver 
Pyu5F00 [X]Other congen malformation of 
pancreas & pancreatic duct 
Pyu5G00 [X]Other specified congen malformation 
of digestive system 
Pyu5H00 [X]Congenital malformation of intestine, 
unspecified 
Pyu6.00 [X]Congenital malformations of genital 
organs 
Pyu6000 [X]Other congenital malformations of 
ovary 
Pyu6100 [X]Other congen malform of fallopian 
tube & broad ligament 
Pyu6200 [X]Other doubling of uterus 
Pyu6300 [X]Other congenital malformations of 
uterus and cervix 
Pyu6400 [X]Other congenital malformations of 
vagina 
Pyu6500 [X]Other congenital malformations of 
vulva 
Pyu6600 [X]Other specified congenital malform of 
female genitalia 
Pyu6700 [X]Other specified hypospadias 
Pyu6800 [X]Other congenital malformations of 
testis and scrotum 
Pyu6900 [X]Oth cong malform vas 
def/epidid/semin vesicles/prostate 
Pyu6A00 [X]Other congenital malformations of 
penis 
Pyu6B00 [X]Other specified congenit malform of 
male genital organs 
Pyu7.00 [X]Congenital malformations of the 
urinary system 
Pyu7000 [X]Other cystic kidney diseases 
Pyu7100 [X]Other obstructive defects of renal 
pelvis and ureter 
Pyu7200 [X]Other congenital malformations of 
ureter 
Pyu7300 [X]Other specified congenital 
malformations of kidney 
Pyu7400 [X]Other atresia and stenosis of urethra 
and bladder neck 
Pyu7500 [X]Other congenital malformations of 
bladder and urethra 
Pyu7600 [X]Other specified congenital malform of 
urinary system 
Pyu8.00 [X]Congenital 
malformations+deformations 
musculoskeletal sys 
Pyu8000 [X]Other congenital deformities of hip 
Pyu8100 [X]Other congenital varus deformities of 
feet 
Pyu8200 [X]Other congenital valgus deformities of 
feet 
Pyu8300 [X]Other congenital deformities of feet 
Pyu8400 [X]Other congenital deformities of skull, 
face and jaw 
Pyu8500 [X]Other congenital deformities of chest 
Pyu8600 [X]Other specified congenital 
musculoskeletal deformities 
Pyu8700 [X]Other reduction defects of upper 
limb(s) 
Pyu8800 [X]Other reduction defects of lower 
limb(s) 
Pyu8900 [X]Other reduction defects of unspecified 
limb(s) 
Pyu8A00 [X]Other congen malform upper limb(s), 
incl shoulder girdle 
Pyu8B00 [X]Other congen malform lower limb(s), 
includ pelvic girdle 
Pyu8C00 [X]Other specified congenital 
malformations of limb(s) 
Pyu8D00 [X]Other specified congenit malformation 
skull & face bones 
Pyu8E00 [X]Other congen malform of spine, not 
assoc with scoliosis 
Pyu8F00 [X]Other congenital malformations of ribs 
Pyu8G00 [X]Other congenital malformations of 
bony thorax 
Pyu8H00 [X]Oth osteochondrodyspl with def 
growth tub bones & spine 
Pyu8J00 [X]Other specified 
osteochondrodysplasias 
Pyu8K00 [X]Other congenital malformations of 
diaphragm 
Pyu8L00 [X]Other congenital malformations of 
abdominal wall 
Pyu8M00 [X]Other congenital malforms of the 
musculoskeletal system 
Pyu8N00 [X]Congenital deformity of hip, 
unspecified 
Pyu8P00 [X]Congenital malformation of bony 
thorax, unspecified 
Pyu8Q00 [X]Osteochondrodyspl with defct growth 
tub bone spine unspec 
Pyu9.00 [X]Other congenital malformations 
Pyu9000 [X]Other congenital ichthyosis 
Pyu9100 [X]Other epidermolysis bullosa 
Pyu9200 [X]Other specified congenital 
malformations of skin 
Pyu9300 [X]Other congenital malformations of 
breast 
Pyu9400 [X]Other congenital malformations of hair 
Pyu9500 [X]Other congenital malformations of 
nails 
Pyu9600 [X]Other specified congenital 
malformations of integument 
Pyu9700 [X]Other phakomatoses, not elsewhere 
classified 
Pyu9800 [X]Other cong malformat syndr due to 
known exogenous causes 
Pyu9900 [X]Other congen malform syndromes with 
other skelet changes 
Pyu9A00 [X]Other specified congenital 
malformation syndromes, NEC 
Pyu9B00 [X]Other specified congenital 
malformations 
Pyu9C00 [X]Congenital malformation of breast, 
unspecified 
Pyu9D00 [X]Primary ciliary dyskinesia 
PyuA.00 [X]Chromosomal abnormalities, not 
elswhere classified 
PyuA000 [X]Oth specif trisomies & partial trisomies 
of autosomes 
PyuA100 [X]Other deletions of part of a 
chromosome 
PyuA200 [X]Other deletions from the autosomes 
PyuA300 [X]Other balanced rearrangements and 
structural markers 
PyuA400 [X]Balanced rearrangement & structural 
marker, unspecified 
PyuA500 [X]Other variants of Turner's syndrome 
PyuA600 [X]Other specif sex chromosome 
abnormalit, female phenotype 
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PyuA700 [X]Other male with 46,XX karyotype 
PyuA800 [X]Other specif sex chromosome 
abnormalit, male phenotype 
PyuA900 [X]Other specified chromosome 
abnormalities 
PyuAA00 [X]Sex chromosome abnormality, male 
phenotype, unspecified 
PyuAB00 [X]Pallister-Killian syndrome 
PyuAC00 [X]Townes-Brocks syndrome 
Pz...00 Congenital anomaly NOS 
Q400.00 Congenital rubella 
Q400.11 Extended rubella syndrome 
Q48y500 Megalencephaly 
ZV13600 [V]Personal history of congenital 
malformations 
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10.11 DETAILED DESCRIPTION OF MATERNAL NRT USE AND CORRESPONDING ANOMALIES IN EACH MOTHER-CHILD PAIR 
  NRT FORM TIME TOT PRSC. WEEKS CONGENITAL ANOMALY 
1 inhalation cartridge 10mg month 2 1 day congenital dislocation of hip 
2 sublingual tablet 2mg month 2 2 days congenital dilated renal pelvis 
        enlarged kidney 
3 nicotine patch 21mg month 1 4 weeks Unilateral congenital dislocation of hip 
  nicotine patch 21mg month 2 2 weeks   
4 nicotine patch 5mg month 3 2 weeks thyroglossal duct cyst 
5 nicotine patch 5mg month 1 2 weeks patent ductus arteriosis 
6 nicotine patch 21mg month 1 2 weeks polycystic kidneys, infantile type 
  nicotine patch 21mg at sp 2 weeks 
   nicotine patch 7mg month 2 4 weeks 
   nicotine patch 14mg month 1 4 weeks   
7 nicotine patch 15mg month 2 8 weeks ankyloglossia 
8 nicotine patch 15mg month 1 1 week ventricular septal defect 
  nicotine patch 21mg month 2 1 week 
   nicotine patch 15mg month 1 1 week 
   nicotine patch 21mg month 1 1 week 
   nicotine patch 21mg month 2 1 week 
   nicotine patch 7mg month 2 2 weeks 
   nicotine patch 10mg month 2 1 week 
   nicotine patch 15mg month 2 1 week 
   nicotine patch 7mg month 2 2 weeks   
9 nicotine chewing gum 2mg month 3 1 week patent ductus arteriosis 
10 inhalation cartridge 10mg month 3 1 week atrial septal defect NOS 
11 nicotine patch 21mg 14 days before 6 weeks talipes, unspecified 
  nicotine patch 14mg month 3 2 weeks congenital absence of toe 
12 nicotine patch 14mg first week preg   ventricular septal defect 
  nicotine patch 7mg month 1 
    nicotine patch 14mg 21 days before      
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  NRT FORM TIME TOT PRSC. WEEKS CONGENITAL ANOMALY 
13 nicotine patch 21mg month 1 2 weeks hypospadias 
  nicotine patch 21mg month 1 2 weeks 
   nicotine chewing gum 2mg month 2 1 week 
   nicotine patch 21mg month 2 2 weeks 
   nicotine patch 21mg month 1 1 week   
14 nicotine ptch 14mg month 2 2 weeks undescended testicle 
        hirschprung's disease 
15 inhalation cartridge 10mg month 1 1 day congenital dilated renal pelvis 
16 nicotine patch 15mg month 3 2 weeks other lung anomaly NOS 
17 nicotine patch 10mg month 1 2 weeks congenital bowing of long leg bone, unspecified 
        hypospadias 
18 nicotine lozenges 2mg month 3 2 days patent ductus arteriosis 
19 nicotine patch 21mg month 3 2 weeks dandy-Walker syndrome 
  nicotine patch 14mg month 3 2 weeks coloboma of retina 
  inhalation cartridge 10mg month 2 4 days cleft palate and lip 
  
   
other musculoskeletal deformity 
        coloboma of iris 
20 nicotine patch 15mg month 3 2 weeks hirschprung's disease 
21 nicotine patch 10mg month 1 2 weeks other lung anomalies 
22 nicotine patch 15mg first week preg  1 week balanced translocations 
  nicotine patch 15mg month 1 1 week 
   nicotine patch 15mg month 1 4 weeks   
23 nicotine patch 21mg 25 days before 3 weeks congenital dislocation and subluxation of the hip 
  nicotine patch 14mg month 1 2 weeks   
24 nicotine patch 15mg month 3 1 week fragile X chromosome 
25 nicotine patch 15mg month 2 4 weeks congenital cystic adenomatoid malformation of the lung 
        bow legs NOS 
26 nicotine patch 21mg month 3 1 week multicystic kidney 
27 nicotine patch 15mg at sp 2 weeks hypospadias, glandular 
28 nicotine patch 10mg month 3 2 weeks supernumerary finger NEC 
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  NRT FORM TIME TOT PRSC. WEEKS CONGENITAL ANOMALY 
  nicotine patch 10mg month 3 2 weeks   
29 nicotine lozenges 2mg month 3 4 days stenosis of pulmonary atrety 
        pulmonary artery anomalies 
30 nicotine patch 10mg month 3 2 weeks Poland's syndrome 
31 nicotine patch 7mg month 2 1 week ventricular septal defect 
        hypospadias 
32 nicotine patch 21mg month 3 4 weeks patent ductus arteriosis 
33 inhalation cartridge 10mg month 3 1 day craniosynostosis 
  
   
undescended testis, bilateral 
        plagiocephaly 
34 nicotine patch 21mg month 2 2 weeks pulmonary infundibular stenosis 
  nicotine patch 21mg month 3 2 weeks   
35 nicotine chewing gum 2mg month 1 2 days undescended testes 
  nicotine chewing gum 2mg month 3 2 days congenital dislocation and subluxation of the hip 
36 nicotine lozenges 2mg month 3 2 days congenital hypertrophic pyloric stenosis 
        ventricular septal defect 
37 nicotine patch 14mg month 2 2 weeks congenital posterior urethral valves 
38 nicotine nasal spray 10mg/ml at sp 1 day choanal atresia 
  nicotine patch 21mg month 1 4 weeks hypoplasia of upper limb 
  
   
aplasia of muscle 
        congenial club hand 
39 nicotine sublingual tab 2mg month 1 1 week congenital dislocation and subluxation of the hip 
        primary ciliary dyskinesia 
  nicotine patch 10mg   2 weeks   
40 nicotine patch 21mg month 2 2 weeks Lissencephaly 
  nicotine patch 21mg month 3 2 weeks 
   nicotine patch 14mg month 3 2 weeks   
41 nicotine patch 21mg 28 days before 2 weeks undescended testes, unilateral 
        congenital posterior urethral valves 
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  NRT FORM TIME TOT PRSC. WEEKS CONGENITAL ANOMALY 
42 nicotine lozenges 2mg month 3 5 days congenital bronchomalacia 
  nicotine chewing gum 2mg month 3 6 days laryngeomalacia 
43 nicotine patch 21mg month 1 3 weeks congenital cleft nose 
        cleft lip 
44 nicotine patch 5mg month 3 2 weeks plagiocephaly 
  nicotine patch 5mg month 3 4 weeks craniosynostosis 
45 inhalation cartridge 10mg month 3 4 days congenital laryngeal stridor 
  inhalation cartridge 10mg month 3 1 day   
46 nicotine patch 15mg month 3 1 week hypospadias 
  nicotine patch 10mg month 3 1 week   
47 nicotine patch 7mg month 3 2 weeks congenital laryngeal stridor 
  nicotine patch 21mg month 3 2 weeks   
48 nicotine patch 7mg month 1 2 weeks patent ductus arteriosis 
  nicotine patch 14mg month 1 2 weeks patent foramen ovale 
  nicotine patch 21mg month 2 2 weeks   
49 nicotine patch 10mg month 2 2 weeks hypospadias 
  nicotine patch 5mg month 3 2 weeks   
50 nicotine patch 21mg month 3 2 weeks undescended testes, bilateral 
  
   
congenital talipes varus 
        Down's syndrome 
51 nicotine patch 15mg month 2 2 weeks ankyloglossia 
52 nicotine patch 15mg month 2  2 weeks microcephalus 
53 inhalation cartridge 10mg month 1 4 days hypospadias 
  inhalation cartridge 10mg month 2 1 day 
   nicotine patch 15mg month 2 2 weeks   
54 nicotine patch 14mg month 1 4 weeks patent ductus arteriosis 
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  NRT FORM TIME TOT PRSC. WEEKS CONGENITAL ANOMALY 
55 nicotine chewing gum 2mg month 2 3 days ventricular septal defect 
56 nicotine patch 21mg month 3 1 week multicystic kidney 
57 nicotine patch 21mg month 2 2 weeks ventricular septal defect 
        patent ductus arteriosis 
58 nicotine patch 10mg month 1 2 weeks other lung anomalies 
* Prescription days not recorded in more than 95% of the prescriptions, therefore the duration of prescription was recalculated by 
approximating the average daily dose according to the British National Formulary and then dividing the total dose prescribed by the 
average daily dose.  
 
